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Abstract 
 
This Thesis explores aspects of disease pathogenesis in Crohn’s disease (CD) 
and ulcerative colitis (UC), investigates mechanisms of responsiveness to 
biologic treatment in inflammatory bowel disease (IBD), and describes the clinical 
and immunologic phenotype associated with a homozygous deletion in a 
disintegrin and a metalloproteinase (ADAM)17 gene. 
 
The role of interleukin (IL)-17A, IL-17E and IL-13 in human intestinal 
inflammation is not clear. IL-13 plays an important role in experimental colitis and 
in intestinal experimental fibrosis. However, contrasting observations exist on the 
levels and the role of IL-13 in inflamed IBD mucosa, and limited information is 
available on the role of IL-13 in CD intestinal fibrosis. We observed that IL-13 is 
not up-regulated in UC intestinal mucosa, and that it is unlikely to play a 
functional role in the mucosal pro-inflammatory response in the majority of 
patients with UC. Conversely, IL-17A is up-regulated in fibrostenosing CD 
intestine, and may contribute to intestinal fibrosis in CD. Our results indicate that 
IL-17E and IL-13 are not up-regulated in CD intestinal strictures, and are unlikely 
to play a role in intestinal fibrosis in CD. 
 
A considerable proportion of IBD patients do not respond to anti-tumour necrosis 
factor (TNF)- agents. Anti-TNF- agents exert their action in inflamed tissues, 
rich in matrix metalloproteinase (MMP)-3 and MMP-12, which in turn can 
degrade immunoglobulin (Ig)G1. We observed that MMP-3, MMP-12, and protein 
extracts from inflamed IBD mucosa, but not MMP-9, degrade the anti-TNF- 
agents infliximab, adalimumab and etanercept, however etanercept shows a 
higher susceptibility than infliximab and adalimumab. We also observed that a 
subgroup of IBD patients who did not respond to anti-TNF- agents have 
particularly high serum levels of MMP-3-/MMP-12-cleaved endogenous IgG and 
anti-hinge autoantibodies compared to IBD patients who subsequently 
responded to biologic therapy. 
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Finally, we observed that homozygous deletion in ADAM17 in humans is 
associated with a complex, neonatal-onset, multi-organ syndrome affecting 
mainly the skin, the intestine, and the cardiovascular system. In this condition, 
ADAM17 expression is down-regulated in the skin and in the duodenum, and 
soluble TNF- release by peripheral blood mononuclear cells (PBMCs) is 
substantially impaired. 
 
These results underline the heterogeneity characterising chronic intestinal 
inflammation, and may form the basis for subsequent studies with the aim to 
identify accurate serum biomarkers of disease progression and responsiveness 
to biologic therapy, and ultimately to develop effective strategies of patient 
stratification in IBD. 
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CRP  C reactive protein 
CT  Computed tomography 
CTLA  Cytotoxic T lymphocyte antigen 
CXCL  Chemokine (C-X-C motif) ligand 
DC  Dendritic cell 
DMEM  Dulbecco’s modified Eagle’s medium 
DSG  Desmoglein 
DSS  Dextran sulfate sodium 
EAEC  Enteroaggregative Escherichia coli 
ECM  Extracellular matrix 
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EDTA  Ethylenediaminetetraacetic acid 
EGF  Epidermal growth factor 
EGFR  Epidermal growth factor receptor 
EHEC  Enterohaemorrhagic Escherichia coli 
EIEC  Adherent-invasive Escherichia coli 
ELISA  Enzyme-linked immunosorbent assay 
EPEC  Enteropathogenic Escherichia coli 
ESR  Erythrocyte sedimentation rate 
FAE  Follicle-associated epithelium 
FasL  Fas ligand 
FBS  Foetal bovine serum 
FcR  Fc receptor
FcRn  Neonatal Fc receptor 
GALT  Gut-associated lymphoid tissue 
GAPDH  Glyceraldehyde 3-phosphate dehydrogenase 
GWAS  Genome-wide association studies 
HLA  Human leukocyte antigen 
HSP  Heat shock protein 
IBD  Inflammatory bowel disease 
IBDU  IBD, type unclassified 
ICAM  Intercellular adhesion molecule 
IEC  Intestinal epithelial cells 
IEL  Intraepithelial lymphocytes 
IFN  Interferon 
Ig  Immunoglobulin 
IL  Interleukin 
IL-4R  Interleukin-4 receptor 
IL-6R  Interleukin-6 receptor 
IL-7R  IInterleukin-7 receptor 
IL-13R  Interleukin-13 receptor 
IL-17R  Interleukin-17 receptor 
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IL23R  Interleukin-23 receptor (gene) 
IL-23R  Interleukin-23 receptor (protein) 
ILC  Innate lymphoid cell 
ILC2  Type 2 innate lymphoid cells 
ILF  Isolated lymphoid follicle 
iNKT  Invariant natural killer T 
IRF  Interferon regulatory factor 
iRhom  inactive Rhomboid 
JAK  Janus kinase 
JAM  Junctional adhesion molecule 
KLH  Keyhole limpet haemocyanin 
LPMC  Lamina propria mononuclear cell 
LPS  Lipopolysaccharide 
LTi  Lymphoid tissue inducer 
MAdCAM  Mucosal addressin cell adhesion molecule 
MALT  Mucosa-associated lymphoid tissue 
MAPK  Mitogen-activated protein kinase 
MDP  Muramyl dipeptide 
MDR1  Multi-drug resistance type 1 
MHC  Major histocompatibility complex 
MLCK  Myosin light chain kinase 
MLN  Mesenteric lymph node 
MMP  Matrix metalloproteinase 
MRI  Magnetic resonance imaging 
MT  Transmembrane domain 
MyD88  Myeloid differentiation primary response gene 88 
NF  Nuclear factor 
NK  Natural killer
NKT  Natural killer T 
NLR  Nucleotide-binding domain and leucine-rich repeat containing 
receptor 
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NOD2  Nucleotide-binding oligomerisation domain containing 2 
OR  Odds ratio 
p-ANCA  Perinuclear anti-neutrophil cytoplasmic serum autoantibodies 
PBMC  Peripheral blood mononuclear cell 
PCR  Polymerase chain reaction 
PDAI  Perianal disease activity index 
PGP  Proline-glycine-proline 
PI3K  Phosphatidylinositol 3-kinase 
pIgA  Immunoglobulin A polymers 
pIgR  Polymeric Ig receptor 
PMA  Phorbol 12-myristate 13-acetate 
PP  Peyer’s patch 
PPAR  Peroxisome proliferator-activated receptor 
PRR  Pattern recognition receptor 
PUFA  Polyunsaturated fatty acid 
qRT  Quantitative reverse transcription 
RELM/FIZZ Resistin-like molecule /found in inflammatory zone
rh  Recombinant human 
RIPK  Receptor-interacting protein kinase 
ROR  Retinoic acid receptor-related orphan nuclear receptor 
SC  Secretory component 
SES-CD  Simple Endoscopic Score in Crohn’s Disease 
SFB  Segmented filamentous bacterium 
SIg  Secretory immunoglobulin 
SNP  Single nucleotide polymorphism 
STAT  Signal transducer and activator of transcription 
TCNB  50 mM Tris, 10 mM CaCl2, 150 mM NaCl, 0.05% Brij 35 
T-LPL  Lamina propria T lymphocyte 
TACE  Tumour necrosis factor- converting enzyme 
TR  Transforming growth factor- receptor 
TCR  T cell receptor 
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TGF  Transforming growth factor 
Th  T helper 
TIMP  Tissue inhibitor of metalloproteinase 
TL1A  Tumour necrosis factor-like ligand 1A 
TLR  Toll-like receptor 
TNBS  Trinitrobenzenesulfonic acid 
TNF  Tumour necrosis factor 
TNFR  Tumour necrosis factor- receptor 
Treg  Regulatory T cell 
TRUC  Tbx21-/-Rag2-/- ulcerative colitis 
TSLP  Thymic stromal lymphopoietin 
UC  Ulcerative colitis 
UCEIS  Ulcerative Colitis Endoscopic Index of Severity 
VCAM  Vascular cell adhesion molecule 
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Chapter 1: General Introduction – Hypotheses 
 
This Thesis explores aspects of disease pathogenesis and responsiveness to 
treatment in chronic inflammation in the human intestine. The following 
introductory Chapter provides an overview of the components and functional 
properties of the intestinal mucosal immune system, particularly regarding the 
intestinal barrier, mucosal T cells, and proteases, and outlines clinical and 
immunologic aspects of inflammatory bowel disease (IBD). In the last part of the 
Introduction, the background and hypotheses of the Results Chapters are 
described. Subsequently, after a general description of the Methods, the 
individual Results Chapters are focused on the involvement of cytokines 
produced by mucosal T cells in mechanisms of intestinal inflammation, on the 
effects of proteases on biologic agents, and on the immunologic consequences 
of a mutation in a particular protease gene. 
 
1.1 The intestinal mucosal immune system 
 
1.1.1 Constituents, organisation and development 
 
The intestinal mucosal immune system is divided into two compartments, namely 
inductive sites and effector sites. Inductive sites comprise the mucosa-associated 
lymphoid tissue (MALT), or gut-associated lymphoid tissue (GALT) in the 
intestine, and the mucosa-draining mesenteric lymph nodes (MLNs). Effector 
sites comprise the epithelium, the lamina propria and the stroma of exocrine 
glands (Brandtzaeg et al. 2004; Brandtzaeg et al. 2008). 
 
GALT and induction of the mucosal immune response 
 
GALT, which comprises Peyer’s patches (PPs), caecal and colonic patches, 
isolated lymphoid follicles (ILFs), and the appendix, is at the forefront of 
interaction between the immune system, food antigens and the intestinal 
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microbiota, and is important in controlling the intensity of immune response 
(Brandtzaeg et al. 2013). Similar to lymph nodes, GALT contains B cell follicles, 
interfollicular T cell areas, efferent lymphatics and antigen-presenting cells 
(APCs), but has neither capsule nor afferent lymphatics. PPs contain by 
definition between 5 and 200 aggregated lymphoid follicles, and can be 
considered immune sensors in the intestine and are important inductive sites for 
both antigen-specific humoral and cell-mediated immunity (Cornes 1965; Jung et 
al. 2010). PPs contain multiple B cell follicles with germinal centres, where 
isotype switching to immunoglobulin (Ig)A occurs, surrounded by the mantle zone 
filled with naïve B cells (Brandtzaeg 2010; Macpherson et al. 2012). Caecal and 
colonic patches are similar to PPs. ILFs are in close proximity to the intestinal 
epithelium, sample antigens through M cells, and contain germinal centers; 
however, ILFs contain relatively few T cells and no distinct T cell zones (Eberl et 
al. 2009). 
 
Dome-shaped PPs are covered by follicle-associated epithelium (FAE), which 
lacks villi and contains M cells, a particular type of epithelial cells that are 
effective in antigen uptake from the mucosal surface (Brandtzaeg et al. 2013). 
Dendritic cells (DCs) are localised underneath the FAE for capture, processing 
and presentation of antigens delivered by M cells, and subsequent initiation of 
antigen-specific immune responses (Fujihashi et al. 2013). Luminal antigen 
sampling can take place also outside inductive sites, in which case it is typically 
operated by lamina propria DCs, extending their dendrites between epithelial 
cells to reach the antigens, without compromising the integrity of the epithelial 
barrier (Rescigno et al. 2001). The interaction between antigens sampled from 
mucosal surfaces with naïve B and T cells can take place both in GALT and 
MLNs, and leads to the differentiation of memory and effector cells, which may 
first enter lymphatic, then peripheral blood circulation, then extravasate at 
mucosal effector sites. This process, named “homing”, is directed by tissue 
expression of vascular adhesion molecules and chemokines, and by the 
expression of integrins and chemokine receptors on the surface of B and T cells 
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(Brandtzaeg et al. 2008). It has been shown that DCs in PPs can educate 
antigen-specific T cells to acquire intestinal homing molecules, such as C-C 
chemokine receptor (CCR)9 and 47 integrin, via vitamin A and retinoic acid 
(Mora et al. 2003; Fujihashi et al. 2013). 
 
Development of the mucosal immune system 
 
Organogenesis of PPs, MLNs and ILFs is not synchronous. It has been shown 
that both PPs and MLNs are programmed to start developing in the sterile foetal 
environment (Eberl et al. 2009). Organogenesis of PPs and MLNs in mice 
requires the expression of lymphotoxin-12 on the surface of retinoic acid 
receptor-related orphan nuclear receptor (ROR)t-expressing CD3-CD4+ 
interleukin (IL)-7 receptor (IL-7R)+ lymphoid tissue inducer (LTi) cells, of 
haemopoietic origin (Eberl et al. 2003; van de Pavert et al. 2010). As a 
consequence, LTi cells can interact with lymphotoxin- receptor expressing 
stromal organiser cells, of mesenchymal lineage, and this is a pivotal event 
driving secondary lymphoid tissue development (van de Pavert et al. 2010). 
Whether similar processes occur in humans is difficult to determine, however a 
LTi cell which expresses IL-7R and RORc (the human orthologue of mouse 
RORt), but is CD4-, has been described in foetal human tissue (Cupedo et al. 
2009). In humans, PP precursors begin to form at 11 weeks of pregnancy, and at 
19 weeks of gestation organised small PPs with a FAE, primary B cell follicles, T 
cell areas and a population of CD11c+ DCs below the FAE can be distinguished. 
Soon after birth, presumably as a result of colonisation by the intestinal 
microbiota, early secondary follicles in developing germinal centres appear, and 
PPs enlarge to become macroscopically visible (Brandtzaeg et al. 2008). 
Approximately, there are 50 PPs at the beginning of the last trimester, 100 at 
birth, 250 at 15 years, and then the number of PPs progressively decreases to 
become approximately 100 between 70 and 95 years of age (Cornes 1965).  
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Unlike PPs and MLNs, organogenesis of other human GALT structures, including 
ILFs, commences only after birth upon bacterial colonisation of the intestine 
(Eberl et al. 2009). The different timings of appearance of intestinal lymphoid 
tissues strongly suggest that development is programmed in the case of MLNs 
and PPs, and environment-induced in the case of ILFs (Eberl et al. 2009). In 
germ-free mice, ILFs do not develop, and a comparable amount of small clusters 
of LTi cells, named cryptopatches, are present instead (Eberl et al. 2004; 
Bouskra et al. 2008). It has been suggested that cryptopatches are clusters of 
LTi cells that induce the formation of ILFs during bacterial colonisation (Bouskra 
et al. 2008). The size and number of ILFs depends on the levels of intestinal 
bacteria, and, during early life, microbial colonisation induces substantial 
changes in the epithelium, with important consequences on barrier integrity and 
function. In particular, the intestinal microbiota exerts an important influence on 
the maturation of the mucosal immune system by driving the development of 
secondary lymphoid follicles, induction of secretory Ig (SIg)A, differentiation of 
innate immune cells, and shaping of T cell subsets (Hooper et al. 2012). 
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1.1.2 The intestinal epithelium 
 
The intestinal epithelium is formed by a single layer of columnar and cuboidal 
intestinal epithelial cells (IECs) and a number of specialised epithelial cells, 
including mucus-releasing goblet cells, enteroendocrine cells, tuft cells and, in 
the small intestine, Paneth cells. M cells are one further type of specialised 
epithelial cells, which ensure controlled interaction between luminal antigens and 
cells of the intestinal mucosal immune system (Pickard et al. 2010). Furthermore, 
interspersed between IECs are intraepithelial lymphocytes (IELs). 
 
With a surface of approximately 300 m2, the intestinal epithelium is the largest 
interface between the body and the external environment, and is exposed to food 
components and to the luminal microbiota (Turner 2009; Barmeyer et al. 2015). 
The intestinal epithelium absorbs nutrients and water, but does so in an 
environment containing a high density of dietary and microbial antigens 
(Rescigno 2011). Hence, the integrity of the intestinal epithelium is critical for 
immune homoeostasis and its disruption may result in uncontrolled antigen 
ingress into the mucosa and the subsequent development of inflammatory 
reactions. The impermeability of the intestinal epithelium is regulated by 
intercellular junctions between IECs which, from the luminal to the baso-lateral 
side, are represented by the tight junctions (formed mainly by claudins and 
zonula occludens proteins), the adherens junctions (formed mainly by homotypic 
interactions involving E-cadherin) and the desmosomes (formed by interactions 
between desmoglein (DSG), desmocollin, desmoplakin and keratin filaments) 
(Turner 2009). 
 
IECs – Protein expression profile  
 
IECs express a wide range of receptors for cytokines, including pro-inflammatory 
tumour necrosis factor (TNF)-, IL-1, IFN-, and regulatory IL-22, as well as the 
common  chain, which is required for IL-2, IL-4, IL-7, IL-9 and IL-15 signalling 
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(Reinecker et al. 1995). In particular, TNF-, IL-1, IFN- and lipopolysaccharide 
(LPS) impair tight junction impermeability, thus accelerating the onset of 
experimental colitis (Moriez et al. 2005; Wang et al. 2005; Al-Sadi et al. 2008). IL-
13 can alter claudin expression and composition in the tight junctions, hence 
promoting intestinal barrier dysfunction. In particular, IL-13 up-regulates the 
expression of claudin 2 in monolayers of T84 and HT-29 cells, with consequent 
reduction of transepithelial resistance and up-regulation of paracellular 
permeability (Heller et al. 2005; Prasad et al. 2005; Weber et al. 2010). IL-22, 
produced by T helper (Th)17 cells and natural killer (NK) cells, plays an important 
role in intestinal wound healing by inducing the activation of signal transducer 
and activator of transcription (STAT)3 in IECs and consequently orchestrating a 
pro-regenerative, wound healing programme (Pickert et al. 2009). Moreover, IL-
17A enhances tight junction function between polarised IECs (Kinugasa et al. 
2000). 
 
IECs constitutively express major histocompatibility complex (MHC) class I 
molecules and, upon stimulation with pro-inflammatory molecules such as 
interferon (IFN)-, murine IECs can also express MHC class II, particularly in the 
small intestine (Thelemann et al. 2014). Moreover, on the surface of IECs there 
are non-classical MHC class I molecules, including CD1d and human leukocyte 
antigen (HLA)-E (Perera et al. 2007).IECs also express receptors called pattern 
recognition receptors (PRRs), that recognise structures common to both 
pathogens and commensal microorganisms, such as LPS, peptidoglycan, 
flagellin and lipoteichoic acid (Gewirtz et al. 2001; Lavelle et al. 2010; Fukata et 
al. 2013). In particular, PRRs include membrane-associated toll-like receptors 
(TLRs) and intracellular nucleotide-binding domain and leucine-rich repeat 
containing receptors (NLRs) (Lavelle et al. 2010). After ligand binding, 
intracellular signalling of most TLRs, except for TLR3, is dependent on myeloid 
differentiation primary response gene 88 (MyD88) (Fukata et al. 2013). Both 
MyD88 signalling and muramyl dipeptide (MDP)-sensing by the nucleotide-
binding oligomerisation domain containing 2 (NOD2) NLR induce nuclear factor 
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(NF)-B activation, whereas MyD88-independent TLR3 and TLR5 activation 
leads to caspase activation and type I IFN production (Baumgart et al. 2007a; 
Fukata et al. 2013). While IECs express only TLR2, TLR3, TLR4, TLR5 and 
TLR9, professional APCs express the full spectrum of PRRs (Iwasaki et al. 2003; 
Fukata et al. 2013). NOD2 is mainly expressed by Paneth cells (Lala et al. 2003).
 
Particularly in response to interaction with luminal pathogens, IECs can release a 
variety of cytokines and chemokines with chemoattracting effects on neutrophils, 
such as IL-8, also known as chemokine (C-X-C motif) ligand (CXCL)8, on 
macrophages and DCs, such as C-C chemokine ligand (CCL)2, and on 47 T 
cells, such as CCL25 (Kagnoff 2014). IEC expression of the carcinoembryonic 
antigen-related cell adhesion molecule (CEACAM)1 and CEACAM20, two Ig 
superfamily members which are important in the epithelial-lymphoid cell cross-
talk process, is regulated by the intestinal commensal microbiota (Kitamura et al. 
2015). At the steady state, IECs release regulatory molecules, including 
transforming growth factor (TGF)-, retinoic acid and thymic stromal 
lymphopoietin (TSLP), which have been shown to be essential in driving the 
development of CD103+ DCs in mice (Iliev et al. 2009). Moreover, epithelial-
derived TSLP plays an important role in immunologic tolerance by inhibiting IL-12 
release by DCs in response to bacteria (Rescigno et al. 2009).
 
Specialised epithelial cells in the intestine 
 
Goblet cells produce the mucin glycoproteins forming the mucus layers covering 
the epithelium (Birchenough et al. 2015). This provides both anchorage and 
nutrients to the intestinal microbiota, however it also minimises and regulates 
direct interaction of bacteria with the intestinal mucosa (Rescigno 2011). Tuft 
cells have been identified in the human intestine, however their function is still 
largely unknown (Gerbe et al. 2012). In the small intestine, an important action 
against bacterial invasion across the epithelium is provided by Paneth cells, 
specialised cells at the base of the crypts of the small intestine which produce 
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anti-microbial peptides such as defensins and lysozyme (Bevins et al. 2011). The 
mediators released by Paneth cells play an important role in shaping the 
composition of the intestinal microbiota, in controlling microbial growth, and in 
protecting against pathogens (Lai et al. 2009; Salzman et al. 2013). 
Enteroendocrine cells, which comprise at least 14 different cytotypes depending 
on their specific secretion profile, are considered chemosensors of the luminal 
intestinal content (Gribble et al. 2016). Serotonin-producing cells, also known as 
enterochromaffin cells, are the predominant enteroendocrine cell type and are 
situated among crypt and villous enterocytes throughout the entire intestinal 
mucosa, with maximum distribution in the small bowel (Sjölund et al. 1983). 
Serotonin exerts important immunologic effects, including stimulation of T cell 
recruitment and proliferation, DC activation, and pro-inflammatory cytokine 
production (Shajib et al. 2015). 
 
Development of the intestinal epithelium 
 
All throughout the intestine, the epithelium is continuously renewed every 4-5 
days by stem cells arising from the crypts of Lieberkühn. Stem cells localised at 
the base of the crypts give rise to the three cell types that move toward the 
luminal side during their differentiation (IECs, enteroendocrine cells, and goblet 
cells), and, in the small intestine, to the only cell type that stays at the base of the 
crypt, Paneth cells (Mowat et al. 2014). Crypt base columnar cells were 
confirmed to be long-lived, multipotent stem cells, characterised by the 
expression of the R-spondin receptor Lgr5, which enhances Wnt signalling 
strength (Barker et al. 2007; Koo et al. 2014). Paneth cells constitute the ideal 
niche for Lgr5+ stem cells in intestinal crypts by expressing epidermal growth 
factor (EGF), TGF- and Wnt3, all essential signals for stem cells maintenance in 
culture (Sato et al. 2011). 
 
The Wnt pathway is the major driver of epithelial cell renewal, and Wnt-mediated 
activation of the bipartite transcription factor -catenin/TCF is the central event in 
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establishing migratory pathways of cells in development, as well as in 
maintaining cellular boundaries in the intestinal epithelium (Batlle et al. 2002; Koo 
et al. 2014). Also Notch ligands are essential for the homoeostasis of intestinal 
stem cells, and Notch signalling promotes the preferential development of IECs 
and inhibition of secretory cell lineage differentiation (Koo et al. 2009). 
Conversely, inhibition of Notch signalling leads to the conversion of all epithelial 
cells into goblet cells (van Es et al. 2005). Neurogenin 3 promotes the 
development of a bipotential secretory progenitor to enteroendocrine cell rather 
than goblet cell fate (López-Díaz et al. 2007). Paneth cells appear and begin to 
express -defensins in the first trimester of gestation in humans and, after birth, 
the gene products of murine Paneth cells and the intestinal microbiota exert a 
reciprocal influence on each other. Wnt signalling is required for Paneth cell 
maturation and expression of anti-microbial peptides (McGuckin et al. 2013). It 
has been shown that crypt base columnar stem cells can be grown into budding 
cysts containing crypt- and villus-like domains, and harboring all 4 common 
lineages (IECs, enteroendocrine cells, goblet cells and Paneth cells), and these 
epithelial cysts can be expanded in culture over years (Sato et al. 2009). These 
structures, called intestinal organoids, can also be established from human Lgr5+ 
cells (Jung et al. 2011). 
 
IELs – Phenotype, functions and development 
 
IELs can be divided into “conventional” or “type A” IELs, which express a T cell 
receptor (TCR) in addition to the co-receptors CD8 or, less frequently, CD4, 
and are thought to derive from naïve T cells that have been activated in 
secondary lymph nodes; and “unconventional” or “type B” IELs, which lack 
CD8 and CD4, express either a TCR or a TCR, and typically express the 
activation marker CD8, thought to derive from agonist-selected autoreactive 
thymocytes (Mowat et al. 2014). 
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IELs share functional and phenotypical characteristics that distinguish them from 
lymphocytes present at other sites. In particular, IELs are almost exclusively T 
cells, and comprise a high proportion of  T cells. IELs are antigen-experienced, 
however they do not express the activation marker CD25. IELs are largely 
cytotoxic and display constitutive cytolytic activity driven by various pathways, 
including serine proteases, perforin release, and Fas-Fas ligand (FasL)-mediated 
programmed cell death, but they release only small amounts of cytokines 
(Cheroutre et al. 2013). CD8+TCR+ IELs, which represent the majority of 
IELs in the small intestine, can be rapidly activated and provide immediate 
cytotoxic function. CD4+TCR+ IELs include the classical Th1, Th2, Th17 and 
regulatory T cell (Treg) subsets. Treg IELs are particularly enriched in the small 
intestine, and can suppress other IEL subtypes (Cheroutre et al. 2013).

 IELs play an important role in preserving epithelial integrity, as suggested by 
the observations that  IEL-deficient mice have a defective expression of claudin 
3 and zonula occludens-1 in tight junction complexes and are more susceptible 
to epithelial transmigration of Salmonella typhimurium (Dalton et al. 2006), and 
are more susceptible to dextran sulfate sodium (DSS)-induced colitis due to lack 
of keratinocyte growth factor (Chen et al. 2002). Moreover,  IELs migrate close 
to IECs in direct contact with bacteria and limit the possible penetration of luminal 
microorganisms by releasing anti-microbial peptides (Ismail et al. 2009; Edelblum 
et al. 2015). It has been shown that, upon exposure to Salmonella or to 
commensals, IECs release IL-23, which in turn stimulates  IELs to produce IL-
22, and this latter triggers the synthesis of angiogenin 4 by Paneth cells (Walker 
et al. 2013). Among unconventional IELs, one subset has been identified which 
displays a repertoire of TCRs with a pattern of MHC restriction that does not 
overlap with that of CD4+ or CD8+ T cells, indicating that these IELs sense 
antigens that are not recognised by conventional T cell subsets (Mayans et al. 
2014). 
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Differently from the steady state, under inflammatory conditions, IELs may 
disrupt the epithelial integrity, and the close proximity of IELs with IECs may 
become a detrimental factor. Indeed, IELs can also produce IFN- and TNF-, 
and, in active coeliac disease, NKG2D receptors expressed by IELs may trigger 
potent cytotoxicity upon binding MHC class I polypeptide-related sequence 
(MIC)A on IECs (Hue et al. 2004). 
 
In the human intestinal epithelium, infiltration of T cells occurs from 12 to 14 
weeks of gestation, then IELs continue to rise. IEL distribution depends partly on 
age, species and environmental conditions. Germ-free mice have a markedly 
reduced number of IELs, and conventional IELs are especially depleted (Round 
et al. 2009). After birth, the increase in TCR IELs is not seen in germ-free 
conditions, indicating that their accumulation depends on the intestinal microbiota. 
Neonatal or foetal thymus grafting studies have demonstrated that all IELs are 
thymus-derived, but further maturation occurs in the intestine (McGuckin et al. 
2013). 
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1.1.3 The intestinal barrier 
 
The intestinal barrier is formed by the intestinal epithelium, by the mucus system, 
and by anti-microbial peptides released by IECs and Paneth cells (McGuckin et 
al. 2013). The tight junctions between IECs are another important component of 
the intestinal barrier, as they are rate-limiting for paracellular absorption of 
luminal contents (Watson 2015). 
 
The intestinal barrier protects against physical, chemical and biological insults, is 
selectively permeable at homoeostasis, prevents the direct contact between the 
luminal contents and the mucosal immune system, and regulates the interactions 
between microbial and dietary antigens and the different cell types populating the 
intestinal mucosa (Turner 2009). Although the large absorptive area of the 
intestinal epithelium could favour the persistence of microorganisms, the low 
bacterial concentration in the small intestine suggests that there are efficient 
mechanisms in place to prevent extensive bacterial colonisation of the epithelium. 
In particular, the physical separation and the tightly regulated interaction between 
the intestinal microorganisms and the epithelial surface, ensured by the intestinal 
barrier, have emerged as important factors for maintaining host-intestinal 
microbiota homoeostasis (Johansson et al. 2011). 
 
Tight junction and paracellular flux regulation 
 
There are at least two distinct pathways of paracellular flux, the so-called “leak 
pathway” and “pore pathway”, that depend on the regulation of tight junction 
protein expression by different cytokines (Turner et al. 2014). The main 
determinant of paracellular permeability is the expression of claudin family 
members and occludin within the tight junctions. In particular, it was originally 
observed in a murine model of T cell-mediated acute diarrhoea that TNF- 
activates myosin light chain kinase (MLCK), which in turn promotes endocytosis 
of the tight junction protein occludin within IECs, thereby enhancing the 
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paracellular permeability via the leak pathway (Clayburgh et al. 2005). On the 
other hand, IL-13 increases paracellular permeability via the pore pathway in 
intestinal epithelial monolayers in vitro by up-regulating claudin 2 expression 
within the tight junctions (Weber et al. 2010). 
 
Goblet cells and the intestinal mucus system 
 
Mucus is a highly hydrated viscous secretion released by goblet cells and 
permeable to macromolecules, and its main components are polymeric mucin 
glycoproteins. Goblet cells store large amounts of mucin granules which can be 
rapidly released in response to microbial or inflammatory signals (Birchenough et 
al. 2015). 
 
The main constituent of intestinal mucus is the MUC2 mucin, which needs to be 
appropriately folded in the endoplasmic reticulum before release, and is present 
in a polymeric form, resulting in the formation of enormous net-like polymeric 
sheets (Ambort et al. 2012). Other typical mucus components are FCGBP, 
CLCA1, ZG16, and AGR2 (Birchenough et al. 2015). It has been shown that 
mutated MUC2 accumulates into the endoplasmic reticulum as a result of 
misfolding, and this process leads to the development of experimental colitis 
(Heazlewood et al. 2008). The regulatory cytokine IL-10 can reduce protein 
misfolding and endoplasmic reticulum stress and promotes intestinal mucin 
production (Hasnain et al. 2013). MUC2 is synthesised as a transmembrane 
protein, and in the small intestine it is cleaved by meprin , which, in turn, is 
anchored to IEC membrane and needs to be cleaved by bacteria in order to be 
able to access MUC2. This is in keeping with the observation that, while in 
normal conditions mucus can be removed easily from the surface of the small 
intestine, in germ-free mice MUC2 mucin remains anchored to the goblet cells 
(Schütte et al. 2014). Moreover, germ-free mice have a decreased number of 
goblet cells and a reduced size of goblet cell granules, together with a 
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paradoxically thicker mucus layer, possibly due to reduced mucin degradation 
(Kandori et al. 1996; McGuckin et al. 2013). 
 
While in the small intestine there is a single layer of mucus, in the colon the 
mucus system is composed of an outer, looser layer, which can be easily 
removed and is highly populated by microorganisms, and of a dense inner layer, 
which is attached to goblet cells and is largely void of bacteria (Johansson et al. 
2008; Ermund et al. 2013). The pore size of the inner mucus layer hampers 
penetration of bacteria and luminal content, and endogenous proteases are 
responsible for the conversion of the inner layer into the outer one (Johansson et 
al. 2008). It has been shown that the outer mucus layer hosts a distinct microbial 
niche, including bacteria without specialised mucolytic capacity (Li et al. 2015). 
Mucus is continuously renewed by goblet cells, and this pushes microorganisms 
away from the epithelial surface toward the intestinal lumen. Moreover, without 
the mucus the anti-microbial peptides released by Paneth cells and IECs would 
be quickly diluted in the luminal content and would not be able to maintain 
microorganisms away from the epithelium (McGuckin et al. 2011). 
 
In addition to structural mucus components, goblet cells also release resistin-like 
molecule /found in inflammatory zone (RELM/FIZZ)2, which is also induced by 
IL-13 and plays an important effector role in counteracting nematode infections 
(Artis et al. 2003). Parasitic helminth infections trigger marked goblet cell 
hyperplasia and mucus hypersecretion via a Th2 response. In particular, IL-13 
has been shown to directly induce goblet cell hyperplasia and release of 
RELM/FIZZ2 via STAT6 signalling (Oeser et al. 2015). In addition, both IL-9 and 
IL-17E, also known as IL-25, promote goblet cell hyperplasia and mucus 
hypersecretion via IL-13-dependent pathways (Steenwinckel et al. 2009). Finally, 
IL-22-deficient mice show that goblet cell hyperplasia observed in response to 
parasitic infection is defective despite high levels of IL-4 and IL-13 (Turner et al. 
2013). 
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Intestinal anti-microbial peptides 
 
Intestinal anti-microbial peptides may be expressed constitutively or may be 
induced by exposure to microbial antigens, are typically activated by proteolysis, 
and in humans include defensins, cathelicidin LL-37, lysozyme C, 
phospholipases, and C-type lectins (Bevins et al. 2011). 
 
Defensins comprise - and -defensins, are major constituents of Paneth cells 
granules, and are present at high concentration at the point of release. Human 
Paneth cell -defensins comprise human -defensin 5 and human -defensin 6, 
and are expressed constitutively in the small intestine, whereas human -
defensins, which are expressed ubiquitously by several different cell types, 
including colonic IECs, are mostly inducible (Bevins et al. 2011). In addition to 
their disruptive effect on the microbial wall, defensins can exert other actions, as 
displayed by the chemoattractant activity of human -defensin 1 and human -
defensin 2 for cells expressing CCR6 (Yang et al. 1999). While pro--defensins 
in mouse small intestine are activated intracellularly by matrix metalloproteinase 
(MMP)-7 cleavage, human Paneth cells store unprocessed pro--defensin which 
is activated after secretion by trypsin (Ghosh et al. 2002). It has been shown that 
mouse pro--defensin can also be activated in the intestinal lumen by host and 
microbial proteases (Mastroianni et al. 2012).

Human cathelicidin LL-37 is expressed by neutrophils and IECs mainly in the 
small intestine, is activated by proteinase 3, prevents LPS from binding TLR4, 
and exerts a variety of immune effects, including chemotactic action on 
neutrophils and stimulation of the inflammasome activation (Vandamme et al. 
2012; Kahlenberg et al. 2013). Lysozyme C, which can specifically hydrolyse 
peptidoglycan, and phospholipases, which degrade both 
phosphatidylethanolamine and phosphatidylglycerol in the bacterial wall, are 
expressed mainly by Paneth cells and macrophages (Bevins et al. 2011). The 
main lectin in human Paneth cells is Reg3, which is under the control of MyD88 
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and, after activation by trypsin, can bind to peptidoglycan and is bactericidal 
against Gram-positive species (Salzman et al. 2013). A reduction of the intestinal 
microbiota following antibiotic treatment down-regulates IEC expression of Reg3, 
the mouse orthologue of Reg3 (Brandl et al. 2008). 
 
Th17-associated cytokines, such as IL-17A, IL-17F and IL-22 enhance the 
production of the anti-microbial molecules lipocalin-2 and calprotectin by IECs, 
and both IL-17A and IL-17F stimulate intestinal production of -defensins (Aujla 
et al. 2008; Ishigame et al. 2009; Raffatellu et al. 2009). These mechanisms 
potentially prevent bacterial dissemination from the intestinal mucosa, as 
suggested by the increased translocation of S. typhimurium to MLNs and spleen 
in mice lacking IL-17 receptor (IL-17R)A (Raffatellu et al. 2008). Interestingly, IL-
13, but not IFN-, has been shown to induce Paneth cell degranulation and 
release of anti-microbial peptides, suggesting that IL-13 may contribute to host 
defense and host-microbial homoeostasis (Stockinger et al. 2014). 
 
Anti-microbial peptides play an important role in defense from pathogens, as 
exemplified by the observation that transgenic mice expressing human -
defensin 5 or human -defensin 6 show enhanced survival upon challenge with S. 
typhimurium via the formation of nanonets, which bind to the surface proteins 
and entangle the bacteria (Chu et al. 2012; Salzman et al. 2013). Anti-microbial 
peptides exert an important influence on the composition of the intestinal 
microbiota, as shown by the observations of SFB depletion in the small intestine 
of transgenic mice expressing human -defensin 5, and of increased bacterial 
colonisation of the epithelial surface, with consequent humoral and Th1 response 
activation, in Reg3-deficient mice (Salzman et al. 2010; Vaishnava et al. 2011). 
Moreover, in the intestinal microbiota of MMP-7-/- mice, which lack mature -
defensins, the relative abundance of Firmicutes is increased and Bacteroidetes 
are depleted, whereas transgenic mice expressing human -defensin 5 show the 
reciprocal change in intestinal microbiota composition (Salzman et al. 2010). 
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1.1.4 T cell populations in the intestinal lamina propria during 
homoeostasis 
 
In the normal intestine, T cells constitute one third of the cells present in the 
lamina propria and in the GALT, and TCR T cells are predominant 
(MacDonald et al. 2011). Unlike in the epithelium, in the lamina propria CD4+ and 
CD8+ T cells are present at a ratio of approximately 2:1, and are thought to 
derive mainly from T cells that have been primed in secondary lymphoid organs 
(Mowat et al. 2014). The number and activity of lamina propria T lymphocytes (T-
LPLs) is regulated in order to ensure that intestinal homoeostasis is the default 
pathway and that the onset of spontaneous inflammation is prevented (Maynard 
et al. 2009). The various T cell phenotypes, including Tregs, Th1, Th2 and Th17 
cells, are differentially represented in the intestinal lamina propria during 
homoeostasis. 
 
The expression of 47 integrin on the cell surface provides T-LPLs with the 
ability to bind to mucosal addressin cell adhesion molecule (MAdCAM)-1, 
expressed on endothelial cells of the lamina propria microvasculature 
(MacDonald et al. 2013). The vitamin A metabolite all-trans retinoic acid drives 
intestinal homing of T cells present in PPs by inducing 47 integrin and CCR9 
expression on their cell surface (Iwata et al. 2004). 
 
Intestinal lamina propria Tregs – Phenotype and differentiation 
 
The normal lamina propria and the GALT are home to a relatively high number of 
Tregs (Maynard et al. 2009). Tregs are CD4+ T cells characterised by the 
expression of Foxp3, and can be defined as T cells able to suppress naïve T cell 
proliferation both in vitro and in vivo (O'Garra et al. 2004; Izcue et al. 2009). Two 
major Treg populations have been described, which have been designated as 
naturally occurring and induced Tregs (O’Garra et al. 2004; Barnes et al. 2009). 
Naturally occurring Tregs originate in the thymus, whereas naïve CD4+ T cells 
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can differentiate into induced Tregs when activated by TCR stimulation in the 
presence of TGF- and IL-2 (Chen et al. 2003; Barnes et al. 2009). TGF- plays 
an important role in the differentiation of naïve T cells into Tregs. Mice lacking the 
binding site for Smad3 on the Foxp3 locus, with consequently impaired TGF- 
signalling, have a decreased number of Tregs selectively in the intestine 
(Schlenner et al. 2012). Treg differentiation is promoted by the release of TGF- 
and retinoic acid by CD103+ DCs (Mangan et al. 2006; Coombes et al. 2007; 
Mucida et al. 2007; Sun et al. 2007; Li et al. 2008). These latter, in turn, develop 
upon the action of epithelium-derived TGF-, retinoic acid and TSLP (Rescigno 
et al. 2009), and have the ability to release TGF- upon in vitro stimulation with 
Lactobacillus paracasei and with Bifidobacterium breve culture supernatants 
(Bermudez-Brito et al. 2012; Bermudez-Brito et al. 2013). 
 
Effector T-LPLs – Phenotype and differentiation 
 
A substantial proportion of CD4+ T-LPLs at the steady state have the phenotype 
of effector-memory T cells, being CD45RO+, CD62lo, CD69hi, CD25+, Fas+ and 
FasL+ (MacDonald et al. 2013). Effector T-LPLs can be classified into Th cell 
types according to their expression of specific transcription factors and cytokines.  
 
Th1 cells are characterised by the expression of the transcription factor T-bet and 
the release of IFN- (Neurath et al. 2002). IL-12 is an important factor driving the 
development of Th1 cells, however it is mainly expressed by DCs in peripheral 
lymphoid tissue (Hue et al. 2006). IL-23 can induce IFN- release by memory 
CD4+ T cells, hence it has been suggested that during homoeostasis lamina 
propria Th1 cells are induced by an IL-23-dependent pathway or migrate to the 
lamina propria following induction in the periphery (Maynard et al. 2009). 
 
Th2 cells are characterised by the expression of the transcription factor GATA3 
and the release of IL-4, IL-5 and IL-13 (Neurath et al. 2002). Epithelium-derived 
IL-17E, also known as IL-25, is a major driver of Th2 differentiation (Fort et al. 
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2001). The main mechanism driving Th2 cell development is IL-4-mediated 
STAT6 activation, however Th2 cell differentiation may also occur in the absence 
of the IL-4/STAT6 pathway (Zhu 2015). 
 
Th17 cells are characterised by the expression of IL-23 receptor (IL-23R), CCR6 
and the transcription factor RORc, and by the release of IL-17A, IL-17F, IL-21 
and IL-22 (Zhou et al. 2007; Korn et al. 2009). Th17 cells are induced by a 
combination of IL-6 and TGF-, and their expansion is promoted by IL-23 (Zhou 
et al. 2007). IL-21 produced by Th17 cells, in turn, stimulates their expression of 
the IL-23R, further expanding this cell subtype by a positive autoregulatory 
feedback loop (Sarra et al. 2010). 
 
One further type of effector T cells has been reported, namely Th9 cells, which 
are characterised by the production of IL-9 and can be induced by antigenic 
stimulation of naïve T cells in the presence of TGF- and IL-4 (Dardalhon et al. 
2008), however their presence and function in the intestinal lamina propria at 
homoeostasis is currently unclear. 
 
Finally, natural killer T (NKT) cells are non-conventional T cells which express 
CD161 and recognise endogenous and/or exogenous glycolipid antigens when 
presented by the MHC class I-like molecule CD1d (Middendorp et al. 2009). NKT 
cells may express an invariant TCR chain which pairs with multiple TCR 
chains and responds to -galactosylceramide, hence these are called invariant 
NKT (iNKT) cells. Alternatively, NKT cells may express a diverse set of TCR 
chains, responding to a less well characterised group of lipid antigens, and are 
therefore named non-invariant NKT cells (Middendorp et al. 2009). NKT cells are 
present in the lamina propria at homoeostasis, however their precise function in 
this condition is unclear (O'Keeffe et al. 2004). 
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Functional properties of T-LPLs 
 
In the normal intestinal lamina propria, Tregs and effector T-LPLs are in close 
proximity to each other, suggesting that Tregs may exert a dominant suppressive 
action on effector T-LPL development (Maynard et al. 2009). Tregs exert their 
function by producing the anti-inflammatory cytokines IL-10 and TGF-, and by 
preventing both the activation and the effector function of T-LPLs that have 
escaped other mechanisms of tolerance (Valencia et al. 2006). 
 
In the intestinal lamina propria, Th1 cells are essential in the elimination of 
intracellular pathogens and viruses, whereas Th2 cells are protective against 
parasites (Neurath et al. 2002). Th1 cells are normally present in the intestinal 
lamina propria, whereas Th2 cells are rare or absent in the normal uninfected 
intestine, and this is likely to reflect the relative scarcity of parasites in the 
intestinal microbiota of humans living in countries with good hygienic conditions 
(Maynard et al. 2009). Th17 cells are well represented in the normal intestinal 
lamina propria, where they promote IL-17A-mediated neutrophil recruitment and 
play an important role in defense against extracellular bacteria and fungi (Korn et 
al. 2009). Moreover, Th17-associated cytokines, such as IL-17A, IL-17F and IL-
22, play an important role in mucosal immune responses to bacteria and favour 
epithelial barrier restitution and repair during resolution of inflammation (Maloy et 
al. 2008; Blaschitz et al. 2010). 
 
T cell phenotype plasticity 
 
It has been observed that T cells polarised towards a Th17 phenotype can shift 
toward a Th1-like phenotype in response to IL-12 (Xu et al. 2007). Th1/Th17 cells, 
which release both IFN- and IL-17A, have also been identified (Harrington et al. 
2005; Annunziato et al. 2007). Along a similar line, T cells cultured under mixed 
Th1 and Th2 conditions display a continuum of cytokine expression, with some 
IFN-+, some CD4+, and some double positive cells (Antebi et al. 2013).  
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Moreover, numerous data indicate that Tregs are characterised by substantial 
instability, especially when exposed to pro-inflammatory cytokines. It has been 
reported that Tregs stimulated with IL-6 can repress the expression of Foxp3 and 
express IL-17A, thereby acquiring the phenotype of Th17-like cells, which 
suggests that mature Tregs can become Th-like cells (Lee et al. 2009a). It has 
also been observed that, following peroxisome proliferator-activated receptor 
(PPAR), Th17 cells undergo phenotype switch and become Tregs (Carbo et al. 
2013). Furthermore, it has been observed using human naïve T cells that the 
addition of TGF- to IL-1, IL-6 and IL-23 leads to the differentiation of Th17 cells 
with immunosuppressive properties (Chalmin et al. 2012). 
 
Very little is known about the mechanisms underlying CD4+ T cell plasticity in the 
intestinal mucosa, however both microbial and dietary factors are likely to play an 
important role in this process, and the immunologic milieu surrounding a 
particular T cell appears to be an essential determinant for its phenotype 
(Brucklacher-Waldert et al. 2014). 
 
Effects of TGF- on T cell differentiation 
 
TGF- exerts important effects on T-LPLs. In addition to its role in Treg 
differentiation, TGF- inhibits the development of intestinal Th1 cells. This is 
indicated by the increased frequency of colonic Th1 cells in mice with a T cell-
specific deletion of Tgfb1 gene (Li et al. 2007). TGF- is essential for the 
prevention of Th1-mediated colitis following adoptive naïve T cell transfer in 
immunodeficient mice (Powrie et al. 1996). Culture of biopsies and lamina 
propria mononuclear cells (LPMCs) from human normal colon and ileum with an 
anti-TGF- neutralising antibody up-regulates IFN- production and T-bet 
expression (Di Sabatino et al. 2008). It has been observed that TGF- induces 
overexpression of micro-RNA-155 in human T-LPLs, and that this is associated 
with down-regulation of IL-2 and IFN- expression (Das et al. 2013). 
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The role of TGF- on Th17 cell differentiation is controversial, and has been 
studied mainly in other tissues and organs than the intestine. In the presence of 
IL-6, TGF- promotes the development of Th17 cells from murine naïve splenic T 
cells (Mangan et al. 2006; Yang et al. 2008) by inducing the expression of 
transcription factors RORt and ROR (Yang et al. 2008). Moreover, in the 
absence of TGF-, murine Th17 cells from the spleen and lymph nodes cultured 
with IL-12 and IL-23 start producing IFN- and stop releasing IL-17A and IL-17F 
(Lee et al. 2009b). However, TGF- blockade increases the production of IL-17A 
by both biopsies and LPMCs from human normal ileum and colon, which 
indirectly suggests an inhibitory effect of TGF- on Th17 differentiation (Di 
Sabatino et al. 2008). It has also been hypothesised that the gene expression 
profile of Th17 cells may be influenced by the presence or absence of TGF-. 
Indeed, stimulation of murine myelin-reactive Th17 cells with TGF- and IL-6 
abrogates their pathogenic function by inducing the production of the anti-
inflammatory IL-10 despite up-regulation of IL-17A (McGeachy et al. 2007). 
 
Effects of the intestinal microbiota on T-LPL differentiation 
 
Both the presence and the composition of the intestinal microbiota exert an 
important influence on the number and maturation of T-LPLs. Germ-free mice 
have fewer T-LPLs and impaired T cell homing and, following microbial 
colonisation, T-LPLs return to normal levels (Round et al. 2009). Colonisation of 
germ-free mice with human intestinal microbiota restores mucosal T cell numbers 
only partially, and mouse intestinal microbiota is required for full immune 
maturation and optimal protection from Salmonella infection (Chung et al. 2012).  
 
The symbiont Clostridia-related microorganism segmented filamentous bacterium 
(SFB) has the ability to potently induce Th17 cell differentiation in the small 
intestine, however SFB colonisation has protective effects on the host (Ivanov et 
al. 2009). SFB appear to colonise preferentially the surface of PPs, where they 
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can orchestrate mucosal T cell immunity at the inductive site. It has been shown 
using a bacterium-host cell co-culturing system that SFB growth in vitro induces 
a strong inflammatory and anti-microbial host response, with the transcription of 
TNF- and IL-1 and lactoferrin, and promotes an immunological environment 
that favours recruitment of neutrophils, T and B cells, and the transmigration of 
IgA (Schnupf et al. 2015). Colonisation of mice by a defined mix of Clostridium 
strains enhances colonic Treg number and function (Atarashi et al. 2011). Finally, 
short-chain fatty acids, such as butyrate, produced by bacteria in the large 
intestine, promote the development of colonic Tregs (Furusawa et al. 2013; 
Smith et al. 2013). 
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1.1.5 The humoral intestinal mucosal immune response 
 
The humoral immune response in the intestinal mucosa is mainly characterised 
by the production of antigen-specific SIgA by lamina propria plasma cells, and 
plays an important role in maintaining mucosal immune homoeostasis 
(Macpherson et al. 2005).  
 
Differentiation of intestinal lamina propria plasma cells 
 
Plasma cells are relatively abundant in the healthy intestinal lamina propria, and 
derive from B cells primed by luminal antigens in the GALT, a process which 
triggers B cell proliferation and differentiation, somatic hypermutation with 
commitment to IgA production by class switch recombination, and induction of 
regional homing molecules to specific parts of the intestine (Brandtzaeg et al. 
2008). During this process, activated B cells gradually lose CD19, CD20 and B 
cell receptor (BCR) expression (Brandtzaeg et al. 2013). B cells then enter 
lymphatic and blood vessels and, after about 14 days since antigen exposure, 
enter the intestinal lamina propria and differentiate into long-lived plasma cells 
that release IgA (Hapfelmeier et al. 2010). 
 
Interaction with the intestinal microbiota plays an important role in early B cell 
development in the lamina propria, in shaping the BCR repertoire, and in 
determining SIgA induction and composition (Hapfelmeier et al. 2010; 
Wesemann et al. 2013). Mucosal SIgA is nearly absent from germ-free mice 
(Benveniste et al. 1971). Upon colonisation, mice develop a long-lasting SIgA 
response, which is specific for the introduced species. In response to 
colonisation, SIgA induction occurs as a stepwise rather than a prime-boost 
response, and introduction of other microbial species shifts the specificity of the 
SIgA response against the new microbiota (Hapfelmeier et al. 2010). 
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IgA – Synthesis and release as SIgA in the intestinal lumen 
 
Humans have two IgA subclasses (IgA1 and IgA2), encoded by two distinct 
constant region genes. While plasma IgA occurs in a monomeric, four chain form, 
with two heavy  chains and two light  or  chains, in the intestinal lumen the 
most abundant form of IgA is SIgA, formed by two (IgA dimers) or four (IgA 
polymers, pIgA) monomeric IgA, one molecule of J chain and an additional 
glycoprotein, the secretory component (SC), acquired during transcytosis through 
IECs (Kaetzel et al. 2013). The daily production of IgA exceeds that of all other Ig 
types, and more than 50% of the total IgA in the human body is synthesised in 
the intestinal lamina propria and actively released as SIgA in the lumen. 
 
IgA are released in the intestinal lumen as SIgA via transcytosis through IECs. 
The model for the common epithelial transcytosis of IgA dimers and pIgA was 
proposed in 1974 (Brandtzaeg 1974). In particular, once released in the lamina 
propria, IgA dimers and pIgA bind to the polymeric Ig receptor (pIgR) on the 
basolateral surface of IECs. The pIgR-bound IgA is subsequently translocated 
via transcytotic vesicles to the luminal surface of IECs, where the pIgR is cleaved 
from the cell membrane and becomes the SC of SIgA, and ultimately the pIgR-
IgA complex is released in the intestinal lumen as SIgA (Brandtzaeg 1974; 
Mostov et al. 2003). Normally, pIgR expression by IECs is high in order to 
maintain an adequate release of IgA in the lumen, and is regulated by both 
microbial and host factors. The expression of pIgR is reduced in IECs of germ-
free mice, and is up-regulated by bacterial-derived butyrate and by pro-
inflammatory cytokines, including IFN-and TNF-, produced in response to 
bacterial antigens (Schneeman et al. 2005). 
 
Effects of TGF- on the induction of SIgA  
 
TGF- plays an important role in inducing the production of SIgA (Cerutti et al. 
2008; Cong et al. 2009). This has been demonstrated in different experimental 
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models: mice deficient for the inhibitory protein Smad7 show enhanced isotype 
switch to IgA (Li et al. 2006), and this process, conversely, is impaired in Smad2-
/- mice (Klein et al. 2006). Accordingly, TGF- receptor (TR)II-/- mice exhibit 
impaired SIgA responses both at the steady state and upon antigen stimulation, 
both systemically and in the intestine (Cazac et al. 2000). TGF- induces IgA 
class switch in cooperation with B cell activating-factor of the TNF family (BAFF), 
a proliferation-inducing ligand (APRIL), and IL-10 (Cerutti et al. 2008). Moreover, 
TGF- has a synergistic effect with retinoic acid, leading to enhanced IgA switch 
(Watanabe et al. 2010; Seo et al. 2013). DCs promote TGF--mediated induction 
of IgA class switch by up-regulating TRII expression on B cells through the 
production of inducible nitric oxide synthase (Tezuka et al. 2007). 
 
Functional properties of intestinal SIgA 
 
Intestinal SIgA reduce absorption of antigens from mucosal surfaces, a process 
called immune exclusion (Macpherson et al. 2015). In particular, SIgA can 
prevent microorganisms from gaining access to the epithelium by a sequential 
process involving formation of microbial aggregates (agglutination) through 
binding and cross-linking, entrapment in mucus, and clearance through 
peristalsis (Mantis et al. 2010). Of note, IL-21 produced by from microbiota-
specific Th17 promotes B cell trafficking to the intestine and SIgA production 
(Cao et al. 2015). On the other hand, certain pathogens can target SIgA to evade 
host defense. Despite the SC provides relative protection from proteolytic 
degradation and, unlike in peripheral blood, SIgA have a longer half-life 
compared to IgG in the protease-rich intestinal environment (Kaetzel et al. 2013), 
particular strains of Neisseria gonorrhoeae, Haemophilus influenzae and 
Streptococcus pneumoniae can secrete proteolytic enzymes that cleave specific 
post-proline peptide bonds within the extended hinge region of IgA1 (Senior et al. 
2000). The ability to release IgA-cleaving proteases is associated with virulence, 
as non-pathogenic strains are unable to produce proteolytic enzymes. 
Conversely, IgA2 lacks the susceptible aminoacid sequence, hence it is resistant 
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to proteolysis (Senior et al. 2000; Bonner et al. 2009). Moreover, IgA-cleaving 
proteases can inhibit phagocytic killing of S. pneumoniae by IgA1, but not IgA2, 
human anti-capsule monoclonal antibodies (Janoff et al. 2014). 
 
IgG transport and function in the intestinal mucosa 
 
While SIgA transport is unidirectional, the neonatal Fc receptor (FcRn), which is 
expressed in IECs throughout life, is responsible for the bidirectional transport of 
IgG between the lamina propria and the intestinal lumen (Pyzik et al. 2015). 
FcRn is expressed mostly in endosomes, and protects internalised IgG from 
degradation by diverting it away from lysosomes, thereby increasing half-life of 
circulating IgG (Akilesh et al. 2007). Unlike pIgR, FcRn is not cleaved once IgG is 
released, hence every FcRn molecule can mediate transport of multiple IgG. 
FcRn-mediated IgG transport is an important mechanism of antigen delivery to 
the mucosal immune system (Pyzik et al. 2015), and on the other hand it has 
been shown that pathogen-specific IgG are transported into the intestinal lumen 
by the FcRn (Yoshida et al. 2006). 
 
B cells, but not SIgA, are required for clearance of Citrobacter rodentium, a 
Gram-negative pathogenic bacterium widely used to model human infections with 
the attaching-and-effacing (A/E) human pathogens enteropathogenic Escherichia 
coli (EPEC) and enterohaemorrhagic E. coli (EHEC) (Maaser et al. 2004; Collins 
et al. 2014). The importance of mucosal IgG in the clearance of pathogens is 
illustrated by the observation that IgG specific for a virulence factor mediating 
epithelial attachment is released in the intestinal lumen of mice infected with C. 
rodentium, promoting engulfment and elimination by neutrophils. Conversely, 
phenotypically avirulent pathogens, which are unable to adhere to the epithelium, 
are eventually outcompeted by the intestinal microbiota (Kamada et al. 2015). 
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1.1.6 Oral tolerance to food and microbial antigens 
 
Oral tolerance can be defined as a state of both local and systemic 
unresponsiveness to orally administered and luminal antigens, such as dietary 
and microbial components (Brandtzaeg 2011; Pabst et al. 2012). The two main 
mechanisms by which oral tolerance is induced are the generation of Tregs, and 
the clonal deletion and anergy of T cells, depending on the dose of antigen 
administered. 
 
Main mechanisms of oral tolerance 
 
In human healthy volunteers, feeding with keyhole limpet haemocyanin (KLH), an 
antigen used in earlier studies of oral tolerance, has been shown to suppress the 
antigen-specific Th1 response of subsequent parenteral immunisation (Kapp et al. 
2010). The first event in the induction of oral tolerance is the antigen uptake from 
the intestinal lumen. This occurs not only in GALT, but also in the epithelium 
overlying effector sites, and it has been observed that antigen-loaded CD11c+ 
DCs are present in mouse lamina propria within minutes from dextran or 
ovalbumin feeding (Chirdo et al. 2005). Subsequently, antigens disseminate via 
lymph or blood and generate systemic tolerance, and the key event for this is 
antigen transport by CD103+ DCs to the MLNs, where Treg generation occurs 
(Pabst et al. 2012). CD103+ DCs are particularly potent in inducing the 
development of Tregs and in promoting the expression of intestinal homing 
molecules on T cells (Sun et al. 2007; Jaensson et al. 2008). Upon generation in 
the MLNs, Tregs can then enter the systemic circulation via lymphatic vessels, 
and ultimately home to the intestinal mucosa where they exert their suppressive 
function on effector T cells. Oral tolerance requires both the generation of Tregs 
in MLNs and 7-dependent ability of Tregs to home to the intestinal lamina 
propria (Hadis et al. 2011). Accordingly, CCR9-deficient mice display impaired 
oral tolerance, which can be restored upon transfer of wild-type T cells (Cassani 
et al. 2011). Within the lamina propria, Tregs undergo secondary expansion, and 
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local IL-10 is needed to maintain mucosal Treg function, both in the small bowel 
and in the colon (Murai et al. 2009; Hadis et al. 2011). 
 
Exposure to a high dose of antigen is considered to induce oral tolerance via 
another mechanism, namely clonal deletion and anergy of T cells (Weiner et al. 
2011), however it has been observed that Tregs can also be generated when 
using high doses of antigen (Siewert et al. 2008). 
 
Oral tolerance to the intestinal microbiota 
 
While oral tolerance to dietary components occurs in the small intestine, immune 
tolerance to the intestinal microbiota is mainly induced in the colon (Pabst et al. 
2012). Upon recognition of the intestinal microbiota, the mucosal immune system 
should trigger a stimulatory response in the case of pathogens, and a tolerogenic 
response in the case of commensal species (Chistiakov et al. 2015). Colonisation 
of germ-free mice with Bacteroides fragilis promotes the conversion of CD4+ T 
cells into IL-10-producing Tregs (Round et al. 2010). Similarly, colonisation of 
germ-free mice with Clostridium-containing human microbiota promotes the 
differentiation of mucosal IL-10-producing Tregs, thereby ameliorating 
trinitrobenzenesulfonic acid (TNBS)-induced colitis (Atarashi et al. 2011; Atarashi 
et al. 2013). Interaction with the colonic commensal microbiota results in the 
preferential generation of antigen-specific Tregs rather than effector T cells, and 
the TCR repertoire of colonic Tregs is influenced by the composition of the 
intestinal microbiota (Lathrop et al. 2011; Cebula et al. 2013). Regular stimulation 
by microbial antigens contributes to maintaining Tregs in the lamina propria, as 
suggested by the decrease in Treg proliferation in MLNs and GALT of mice 
treated with long-term antibiotics; however, this mechanism does not appear to 
be dependent on TLR stimulation, since mice deficient for various TLRs show 
normal, or even enhanced, Treg development (Atarashi et al. 2011; Cording et al. 
2013). 
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Additional mechanisms contributing to oral tolerance 
 
During homoeostasis, a number of mechanisms are in place to prevent abnormal 
intestinal immune activation following the interaction with the components of the 
luminal content. Colonic IECs discriminate between different commensal bacteria 
by producing different cytokine patterns, and the probiotic Lactobacillus 
rhamnosus can suppress pro-inflammatory cytokine production induced by other 
commensals (Lan et al. 2005). Moreover, colonic IECs have the ability to 
suppress the proliferation and to prevent activation of T cells (Cruickshank et al. 
2004). In the normal intestinal epithelium, TLR2 and TLR4 are expressed at low 
levels on the apical surface of IECs, thereby limiting the interaction with the 
intestinal microbiota and consequent possibility of an aberrant stimulatory 
immune response (Abreu et al. 2003). TLR5 is expressed only on the basolateral 
colonic IEC membrane, in the optimal position to detect flagellin and trigger an 
immune response only in case of epithelial injury (Gewirtz et al. 2001). Moreover, 
differentiated IECs have the ability to dampen the potential pro-inflammatory 
effects of PRR-mediated signals received from the apical side, whereas PRR 
signalling from the basolateral side stimulates the release of defensins in order to 
combat the infection (Artis 2008).  
 
Extraintestinal effects of oral tolerance 
 
Oral tolerance exerts an important influence on immune response not only in the 
intestinal mucosa, but also systemically and in other organs. Oral administration 
of polysaccharide A from B. fragilis protects mice from experimental autoimmune 
encephalomyelitis, with a process mediated by the induction of IL-10-producing 
Tregs in GALT (Ochoa-Repáraz et al. 2010). B. fragilis polysaccharide A has 
also been shown to enhance the development and the suppressive action of 
human Tregs in vitro (Telesford et al. 2015). Induction of oral tolerance to the 
triggering autoantigen has proved to be effective in the prevention of both 
experimental autoimmune encephalomyelitis, induced by immunisation with 
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myelin basic protein, and experimental arthritis, induced by collagen type II (Faria 
et al. 2006). However, autoimmune disease in humans is typically characterised 
by response to multiple autoantigens. This potential limitation to the application of 
oral tolerance is circumvented by the bystander suppression of Tregs, which, 
despite bearing an antigen-specific TCR, can inhibit local T cells in an antigen 
non-specific manner (Elson et al. 2013). 
 
Another important limitation to the application of oral tolerance in human 
autoimmune disease is that the immune response to the autoantigen has already 
been established. It has however been shown that KLH feeding in previously 
immunised humans decreases the proportion of IL-17A+ antigen-specific T cells 
at the end of the feeding, and increases IL-10+ T cells after re-immunisation 
(Hostmann et al. 2015). The mechanisms underlying the extraintestinal effects of 
oral tolerance are not entirely clear, however it has been speculated that they 
may be mediated by a fraction of the Tregs that have expanded in the lamina 
propria and have then entered the systemic circulation via the draining 
lymphatics or via the bloodstream (Pabst et al. 2012). 
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1.1.7 Compartmentalisation of the intestinal mucosal immune system 
 
Both the constituents and the organisation of the mucosal immune system 
display important distinctions between the different compartments of the gastro-
intestinal tract. The largest amount of lymphoid tissue in the gastro-intestinal tract 
is contained in the small intestine and in the colon, which constitute structurally, 
immunologically and functionally distinct compartments (Bowcutt et al. 2014). 
 
Structural differences between small and large intestine 
 
The small intestine is specialised for the digestion and absorption of food, 
whereas the primary function of the colon is water re-absorption and elimination 
of undigested luminal content. The mucosa of the small intestine is organised 
into multiple finger-like villi, and the luminal side of epithelial cells is shaped into 
an extensive brush border of microvilli that contain digestive enzymes, hence 
having an optimal structural organisation for nutrient absorption. Villi become 
shorter progressing through the small intestine, and are absent in the colon. In 
the small intestine, crypts contain undifferentiated proliferating progenitor cells, 
whereas villi are populated by differentiated non proliferating cells. A similar 
organisation exists in the colon, with proliferating cells localised in the lower part 
of the crypt, and differentiated cells found at the epithelial surface. Compared to 
those present in the small intestine, colonic crypts are smaller (Mowat et al. 
2014). 
 
Compartmentalisation of intestinal lymphoid structures  
 
PPs are localised on the antimesenteric side of the small intestine and increase 
in size and density from the jejunum to the ileum. PPs are particularly 
concentrated in the distal ileum, are rare in the duodenum (Cornes 1965), and 
are likely to be the main source of IgA-producing plasma cells that migrate to the 
small intestine (Masahata et al. 2014). Conversely, caecal and colonic patches 
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are important in the generation of IgA-producing plasma cells that migrate to the 
colon in response to the local intestinal microbiota (Masahata et al. 2014). The 
human small intestine contains at least 30,000 ILFs, increasing in density distally. 
In particular, in the healthy jejunum and ileum there is on average 1 ILF per 269 
villi and 1 ILF per 28 villi, respectively. The density of ILFs increases distally also 
in the colon (Brandtzaeg et al. 2008). Also MLNs draining the small intestine and 
the colon have been shown to be anatomically and functionally separate, and the 
DCs that migrate to either ileal or colonic MLNs are immunologically different 
(Houston et al. 2015). 
 
Compartmentalisation of intestinal specialised epithelial cells 
 
Paneth cells are only present in the small intestine, and they are particularly 
concentrated in the ileum. In the small intestine, -defensins secreted by Paneth 
cells are the major anti-microbial peptides, whereas -defensin 2 is highly 
expressed in the colon during inflammation and infections (O’Neil et al. 1999). 
The frequency of goblet cells increases progressively through the gastro-
intestinal tract, with goblet cells being 25% of all epithelial cells in the colon, and 
10% or less in the upper small intestine. In addition to the different organisation 
into a single layer and a double layer, also mucus composition differs 
substantially between the small and large intestine, however at both sites it is 
built on MUC2 mucin polymers (Birchenough et al. 2015). The mucus system is 
thickest in the colon, where the bacterial load is particularly abundant 
(Macpherson et al. 2013). 
 
Compartmentalisation of intestinal mucosal T cells and plasma cells 
 
IELs are progressively less frequent in the small intestine and relatively rare in 
the colon. Most IELs in the jejunum are TCR+CD8+ tissue-resident effector 
memory IELs, whereas the ileum and colon contain proportionally more 
TCR+CD4-CD8- IELs (Lundqvist et al. 1995). In the lamina propria, there are 
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marked differences in the distribution and function of CD4+ T cells along the 
intestine, and this may be due, at least in part, to variations in luminal content 
(Sathaliyawala et al. 2013). An inverse correlation between lamina propria Th17 
cells and Tregs has been reported in mice, with Th17 cell number progressively 
decreasing from the duodenum to the colon, and Treg number being highest in 
the colon (Denning et al. 2011). Conversely, in humans, a higher proportion of 
Th17 cells has been reported in the colon and ileum compared to the jejunum 
(Sathaliyawala et al. 2013). The frequencies of lamina propria Th1 and Th2 cells 
do not seem to vary significantly along the human intestine (Wolff et al. 2012). 
The density of plasma cells is highest at the most proximal and distal ends of the 
gastro-intestinal tract (Brandtzaeg 2010). Most of the plasma cells in the 
duodenum and jejunum produce IgA1, whereas the proportion of IgA2 increases 
from approximately 25% in the small intestine to >60% in the distal colon (Lin et 
al. 2014).
 
Compartmentalisation of PRR and adhesion molecule expression in the intestine 
 
Also the expression of PRRs varies throughout the intestine, and these 
differences are likely to be driven by the intestinal microbiota (Mowat et al. 2014). 
In particular, in mice TLR2 is highly expressed on IECs of the proximal colon, 
whereas it is present at low levels distally (Wang et al. 2010). Conversely, murine 
TLR4 and its co-receptor CD14 are expressed at higher levels in the colon than 
in the small intestine (Ortega-Cava et al. 2003).  
 
Several adhesion molecules and chemokines play an important role in immune 
cell compartmentalisation within the intestine. In particular, CCL25 is expressed 
by IECs in the small intestine, and its interaction with CCR9 is important in 
driving immune cell homing to the small intestine, but not the colon (Stenstad et 
al. 2007). Conversely, CCL28, which interacts with CCR10, is mostly expressed 
by colonic and rectal IECs (Pan et al. 2000). CCL20 and CCL9 are constitutively 
expressed by the FAE overlying PPs in the small intestine (Mowat et al. 2012).  
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1.2 Proteases and their inhibitors 
 
According to their mechanisms of action and their three-dimensional structure, 
proteases can be classified into metalloproteinases, serine proteases, cysteine 
proteases and aspartic proteases (Table 1.1). 
 
Metalloproteinases – MMPs and Adamalysins 
 
Metalloproteinases are a group of enzymes that exert an important role in tissue 
remodelling through their ability to digest the ECM (Sorokin 2010). Amongst the 
most important enzymes in this group are MMPs and adamalysins (Huxley-Jones 
et al. 2007). 
 
MMPs require Ca2+ for stability, cleave specific peptide bonds via a functional 
domain at neutral or near neutral pH, and contain both a catalytic domain with a 
highly conserved zinc-binding sequence essential for their action and a pro-
domain which maintains the enzyme in inactive form and is cleaved by trypsin, 
plasmin, plasminogen or active MMPs during the activation process (Nagase et 
al. 2006). Currently, 24 different mammalian MMPs have been identified, and can 
be subdivided into MMPs that are secreted in the ECM and those that are 
anchored to the cell surface by a transmembrane domain (MT), such as MMP-14, 
also known as MT1-MMP (Parks et al. 2004). Another subdivision of MMPs can 
be made, based on their primary substrate specificity, such as collagenases 
(MMP-1, MMP-8, MMP-13), gelatinases (MMP-2 and MMP-9), stromelysins 
(MMP-3, MMP-10, MMP-11), matrilysin (MMP-7) and elastase (MMP-12).  
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Table 1.1. Characteristics of the four major classes of mammalian proteases 
 
  Protease class 
 
Main members 
 
Alternative name 
 
Main (matrix; non-matrix) substrates 
 
Metalloproteinases 
 
        MMPs 
 
 
 
MMP-1 
 
MMP-2 
 
MMP-3 
 
MMP-7 
 
MMP-8 
 
MMP-9 
 
MMP-10 
 
MMP-11 
 
MMP-12 
 
 
MMP-13 
 
MMP-14 
 
MMP-15 
 
MMP-16 
 
MMP-17 
 
MMP-20 
 
 
 
Collagenase 1 
 
Gelatinase A
 
Stromelysin 1 
 
Matrilysin 
 
Collagenase 2 
 
Gelatinase B 
 
Stromelysin 2 
 
Stromelysin 3 
 
Macrophage 
metalloelastase 
 
Collagenase 3 
 
MT1-MMP 
 
MT2-MMP 
 
MT3-MMP 
 
MT4-MMP 
 
Enamelysin 
 
 
 
Collagen  (types I-V, IX) 
 
Gelatin, laminin, elastin, fibronectin; CCL7, CXCL12, pro-IL-1
 
Collagen (types IV, V, IX, X), laminin; IgG1, pro-IL-1, IL-1
 
Elastin, laminin: E-cadherin, tmTNF-, IgG1 
 
Collagen  (types I-V, IX) 
 
Gelatin, laminin; 1-antiproteinase, pro-TGF-, pro-IL-1
 
Gelatin, fibronectin 
 
Unknown 
 
Elastin, collagen type IV; IgG1, tmTNF-
 
 
Collagen  (types I-V, IX), gelatin 
 
Collagen (types I-III), gelatin, fibronectin, syndecan-1 
 
Fibrin 
 
Fibrin, syndecan-1 
 
Unknown 
 
Amelogenin 
 
        Adamalysins  
 
ADAM8 
 
ADAM9 
 
ADAM10 
 
ADAM15 
 
ADAM17 
 
 
ADAM19 
 
 
 
 
 
CD156c 
 
 
 
TNF- converting 
enzyme
 
 
Unknown; L-selectin 
 
Unknown; pro-EGF 
 
Unknown; E-cadherin, tmTNF-, pro-TGF-, DSGs, HER2 
 
Unknown; E-cadherin 
 
Unknown; tmTNF-, pro-TGF-, pro-EGF, DSGs, IL-6R, L-
selectin 
 
Unknown; tmTNF-
 
 
Serine proteases  
 
 
Plasminogen 
activators 
 
Trypsin 
 
 
Chymotrypsin 
 
 
Cathepsin G  
 
 
Neutrophil 
elastase 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
ELA2 
 
 
 
Aggrecan, syndecan, fibronectin, laminin; plasminogen, 
trypsinogen, HGF, pro-TGF-
 
Unknown; trypsinogen, lysine-, arginine-containing proteins, -
defensin 
 
Unknown; tryptophan-, tyrosine-, phenylalanine-, leucine-
containing proteins 
 
Unknown; lysine-, arginine-, tryptophan-, tyrosine-, 
phenylalanine-, leucine-containing proteins 
 
Elastin 
 
 
Cysteine proteases  
 
 
Cathepsin B 
 
 
Cathepsin L 
 
Cathepsin N 
 
Cathepsin S  
 
Calpains 
 
Caspases 
 
 
 
 
 
 
 
 
 
  
 
 
-amyloid precursor protein, proteoglycans, collagen, 
connective tissue proteins 
 
Collagen type I 
 
-amyloid precursor protein 
 
Elastin 
 
Unknown; STIM1 
 
Unknown; Bax, Bcl-2, pro-IL-1, procaspases 1-14 
 
Aspartic proteases  
 
Pepsin 
 
Cathepsin D 
 
Renin 
 
 
 
 
 
 
 
-amyloid invariant chain, IgG 
 
MHC class II 
 
Unknown; angiotensinogen 
HER, human epidermal growth factor receptor; HGF, hepatocyte growth factor; IL-6R, IL-6 receptor; MT, transmembrane 
domain; tm, membrane-bound. 
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Most MMPs are released as inactive zymogens by epithelial cells and 
mesenchymal cells, monocytes, macrophages, neutrophils and T cells. MMP 
activation occurs in the extracellular space and is mediated by the cleavage of 
the pro-domain that maintains the molecule in its inactive form. This process is 
amplified by a cascade of autocatalytic reactions and cleavage processes by 
which MMPs can activate each other (Fig. 1.1) (Knäuper et al. 1993; Fridman et 
al. 1995; Knäuper et al. 1996; Makowski et al. 2005). 
 
 
 
Figure 1.1. Representative example of MMP activation process. Pro-MMPs 
are converted to the active form via proteolytic removal of their pro-domain. 
Active MMP-3 can amplify its own activation via autocatalytic cleavage, or 
alternatively can remove the pro-domain from pro-MMP-7, pro-MMP-9 and MMP-
13. Active MMP-7, in turn, exerts an activating action on pro-MMP-2, and active 
MMP-13 can activate both MMP-2 and MMP-9. Moreover, active MMP-2 can 
cleave MMP-13 and MMP-9 pro-domain. As shown in this example, proteolytic 
enzymes can therefore auto-activate themselves, mutually activate each other 
and trigger a cascade of protease activation processes. All these mechanisms 
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can lead to a broad proteolytic activation in diseased tissues. C, catalytic domain; 
F, fibronectin repeat; H, haemopexin-like domain; P, pro-domain. (From 
Biancheri et al. 2013). 
 
 
MMP proteolytic activity is regulated by differential transcription, activation, 
substrate availability and inhibition (Di Girolamo et al. 2006; Sorokin 2010). The 
latter is mediated by the four tissue inhibitors of metalloproteinases (TIMP)1-4, 
whereas the major endogenous serum MMP inhibitor is 2-macroglobulin 
(Sorokin 2010). ECM degradation and regulation of tissue turnover are not the 
only important functions of MMPs, which also exert their proteolytic action on 
non-structural molecules embedded within the matrix, leading to their activation 
or facilitating their catabolism (Parks et al. 2004). In particular, MMPs can act on 
intercellular junction proteins, chemokines, cytokines, IgG1 and microorganisms, 
potentiating or inhibiting their activity (Table 1.2). The effect of MMPs on 
cytokines is diverse. For example, MMP-2, MMP-3 and MMP-9 can cleave and 
activate the IL-1 precursor, however MMP-3 can also degrade the active form of 
this cytokine (Ito et al. 1997; Schönbeck et al. 1998). 
 
Adamalysins are a family of transmembrane proteinases crucially involved in 
ectodomain shedding of growth factors, cytokines, membrane receptors and 
adhesion molecules (Edwards et al. 2008). One of the most studied adamalysins 
is a disintegrin and a metalloproteinase (ADAM)17, also known as TNF- 
converting enzyme (TACE), a membrane-bound enzyme which cleaves the 
transmembrane form of TNF- to generate soluble TNF-, and which is also 
essential for the shedding of other cell surface proteins such as TGF-, IL-6 
receptor and L-selectin (Scheller et al. 2011), thus playing an important role in 
the control of inflammatory and regenerative responses. 
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Table 1.2. Main substrates of MMPs 
    
Type of substrate Molecule/species MMPs Effect 
    
    
ECM components Collagen I-IV MMP-1, MMP-3, MMP-7, MMP-8, 
MMP-10, MMP-12, MMP-13, MT1-
MMP 
Degradation 
    
 Collagen V MMP-1, MMP-3, MMP-8, MMP-13 Degradation 
    
 Collagen IX MMP-1, MMP-3, MMP-8, MMP-13 Degradation 
    
 Collagen X MMP-3 Degradation 
    
 Elastin MMP-2, MMP-7, MMP-12 Degradation 
    
 Laminin MMP-2, MMP-3, MMP-7, MMP-9, 
MMP-10, MMP-12 
Degradation 
    
 Fibronectin MMP-2, MMP-3, MMP-7, MMP-10, 
MMP-12, MT-MMP-1 
Degradation 
    
 Gelatin MMP-2, MMP-9, MMP-10, MMP-
13, MT1-MMP 
Degradation 
    
 Proteoglycan MMP-3, MMP-7, MMP-10 Degradation 
    
 Chondroitin sulfate MMP-12 Degradation 
    
 Aggrecan MMP-2, MT1-MMP Degradation 
    
    
Intercellular junction proteins E-cadherin MMP-7, enterotoxin, gelatinase E Degradation 
    
    
Cytokines/chemokines Pro-IL-1 MMP-2, MMP-3, MMP-9 Activation (by cleavage) 
    
 IL-1 MMP-3 Inactivation (by cleavage) 
    
 tmTNF- MMP-7, MMP-12, MMP-13 Conversion into soluble TNF-
    
 CXCL5/CXCL6 MMP-8 Activation (by cleavage) 
    
 CXCL8 (IL-8) MMP-9 Activation (by cleavage) 
    
 CCL7 MMP-2 Inactivation (by cleavage) 
    
 CXCL1 MMP-7 Generation of a chemotactic gradient 
by cleavage of CXCL1 ligand 
syndecan-1 
    
    
Antibodies IgG1 MMP-3, MMP-7, MMP-12 Cleavage 
    
    
Bacteria Staphylococcus aureus MMP-12 Inhibition 
    
 E. coli MMP-12 Inhibition 
    
 C. rodentium MMP-3 Increased clearance via regulation of T 
cell migration 
    
tm, membrane-bound. 
 
Serine proteases 
 
Another class of proteases is represented by serine proteases, which exert their 
action at neutral pH. Mammalian serine proteases include plasminogen 
activators, chymotrypsin, trypsin, and proteolytic enzymes produced by 
granulocytes and mast cells, such as cathepsin G and neutrophil elastase. 
Bacteria also produce serine proteases, such as subtilisin (Hedstrom 2002). 
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Cathepsin G and neutrophil elastase are stored in granules as inactive 
precursors and released as active forms in response to inflammatory or allergic 
reactions. Serine protease inhibitors, also known as serpins, include 1-
antitrypsin, 1-antichymotrypsin, antithrombin III, elafin, protease-nexin and the 
universal protease inhibitor 2-macroglobulin (Silverman et al. 2001). 
 
Cysteine proteases 
 
Cysteine proteases include mammalian lysosomal cathepsins B, K, L, N and S, 
which can degrade connective tissue proteins in vitro, and cytosolic calcium-
activated proteases, also known as calpains (Zavasnik-Bergant et al. 2006). 
These proteases are inhibited by cystatins, a superfamily including stefins, 
cystatin C and S and kininogens (Abrahamson et al. 2003). Caspases are 
intracellular cysteine-aspartic proteases involved in apoptosis, necrosis, and 
inflammation. Caspases, such as caspase-3, cleave a wide range of intracellular 
proteins, thereby inducing apoptotic cell death. Caspases are specifically 
associated with receptor-activated apoptosis, for example Fas/FasL-mediated 
programmed cell death. Finally, caspases, such as caspase-9, initiate a cascade 
of cleavage of other caspases, thereby activating them (Becker et al. 2013). 
 
Aspartic proteases 
 
Finally, aspartic proteases include bacterial penicillopepsin and mammalian 
pepsin, cathepsin D, and renin (Tang et al. 1997). Cathepsin D is involved in the 
enzymatic removal of invariant chain from class II MHC molecule during antigen 
processing and in the production of antigenic peptides in the phagolysosome of 
APCs (Villadangos et al. 1999). Both cysteine proteases and aspartic proteases 
exert their action at low pH values and are therefore often referred to as acidic 
proteases. 
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1.2.1 Proteases in intestinal homoeostasis and wound healing 
 
Proteases are constitutively expressed in the healthy human intestine, where 
they are produced mainly by IECs and by goblet cells in the epithelium, by 
immune and mesenchymal cells in the lamina propria, and by bacteria in the 
lumen (Ravi et al. 2007; Steck et al. 2012). Proteases are essential to preserve 
mucosal homoeostasis and physiologic tissue turnover, and are central players in 
the process of wound healing and re-epithelisation after injury. Moreover, 
proteases may exert important effects on the epithelial barrier (Fig. 1.2). 
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Figure 1.2 (see previous page). Effects of intestinal proteases on proteins 
forming intercellular junctions in the intestinal epithelium. Proteases can 
exert their actions on several elements of the intercellular junctions between 
IECs. In particular, matriptase, a trypsin-like transmembrane serine protease, co-
localises with E-cadherin in the adherens junction and is also present on the 
basolateral side of IECs. Matriptase regulates the expression of epithelial claudin 
2, a junctional protein which increases epithelial permeability. Another 
transmembrane protease, ADAM19, co-localises with zonula occludens-1 (Zo-1), 
a tight junction-associated protein. Goblet cells release the cysteine protease 
cathepsin K, which regulates E-cadherin and occludin expression, and protects 
from colitis by means of its potent anti-microbial activity. Activated mast cells in 
the lamina propria release the proteolytic enzyme tryptase, which decreases 
epithelial barrier function by reducing the expression of the tight junction protein 
junctional adhesion molecule (JAM)-A. Pathogenic bacteria (red), as well as 
opportunistic pathogens (yellow) and commensal bacteria (green) can release 
proteases which have important effects on components of the intercellular 
junctions. Vibrio cholerae produces haemagglutinin/protease, which can degrade 
occluding. Moreover, both the metalloproteinase gelatinase E, produced by the 
commensal bacterium Enterococcus faecalis, and the MMP fragilysin, released 
by B. fragilis, are capable of cleaving E-cadherin in the adherens junction. 
(Adapted from Giuffrida et al. 2014). 
 
 
Proteases produced by IECs 
 
Constitutive epithelial expression of matrilysin (MMP-7) has been shown to 
mediate defense against luminal bacteria in mice. In particular, mouse MMP-7 
activates intestinal pro--defensins, needed for the clearance of pathogenic E. 
coli and S. typhimurium (Wilson et al. 1999). MMP-7 can cleave transmembrane 
FasL, which induces apoptosis of target cells by binding to Fas receptor 
expressed on IEC surface (Powell et al. 1999). Epithelial MMP-7 expression is 
dependent on the exposure to intestinal bacteria (López-Boado et al. 2000; 
Salmela et al. 2004), essentially priming the epithelium for anti-bacterial activity. 
Moreover, IECs constitutively express high levels of meprin, a metalloproteinase 
which counteracts bacterial adhesion and invasion, thus representing an 
important host defense mechanism against pathogenic strains of E. coli (Vazeille 
et al. 2011). 
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After injury, collagenase 1 (MMP-1), MMP-7 and stromelysin 2 (MMP-10) are 
expressed by migrating IECs and promote re-epithelisation by facilitating the 
migration of IECs toward the wound edge (Salmela et al. 2004). MMP-7-/- mice 
show a complete lack of re-epithelisation after wounding (Parks et al. 2004). 
During lung injury, MMP-7 has been shown to degrade E-cadherin from 
adherens junctions, consequently promoting cell migration and tissue remodeling, 
however these findings have not been replicated in the intestine (McGuire et al. 
2003). Epithelium-derived MMP-7 can generate a chemotactic gradient by 
cleaving from the epithelial cell surface the proteoglycan syndecan-1, the ligand 
for the neutrophil chemoattractant CXCL1 (Li et al. 2002). MMP-1, MMP-7 and 
MMP-10 expression by IEC cell lines is up-regulated by EGF, TGF- and IL-1 
(Salmela et al. 2004).  
 
Matriptase is an epithelial trypsin-like transmembrane serine protease that co-
localises with E-cadherin in the apical junctional complex, is also present on the 
basolateral aspect of the cell, and is activated by a glycosylphosphatidylinositol-
anchored serine protease, prostasin (Buzza et al. 2010; Buzza et al. 2013). In 
mice, matriptase is encoded by St14 gene, and it has been shown that IEC-
specific St14-/- mice develop diarrhoea from birth, show megacolon and colitis 
and die early in life, however the small intestine is normal (List et al. 2009). 
Tamoxifen-inducible IEC-specific St14-/- mice become moribund 9-10 days after 
tamoxifen treatment. These animals show severe oedema and dissolution of the 
colonic mucosa and regenerative crypt hyperplasia, but the small intestine is 
normal (List et al. 2009). Mice hypomorphic for the St14 gene are viable but 
show increased permeability in the small intestinal barrier (Buzza et al. 2010). 
The addition of exogenous matriptase to the basolateral side of Caco-2 cells 
markedly increases transepithelial resistance, whereas when matriptase is 
knocked down in Caco-2 cells there is a decrease in transepithelial resistance 
and an increase in paracellular permeability (Buzza et al. 2010; Buzza et al. 
2013). Interestingly, knock-down of matriptase results in an increase in epithelial 
claudin 2, a tight junction protein known to enhance epithelial permeability 
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(Prasad et al. 2005; Buzza et al. 2010). Matriptase-hypomorphic mice are also 
particularly susceptible to DSS-induced colitis (Netzel-Arnett et al. 2012). 
 
Proteases produced by intestinal specialised epithelial cells 
 
Intestinal goblet cells produce the acidic cysteine protease cathepsin K, which 
has activity also at neutral pH and can degrade elastin, collagen, and gelatin. 
Cathepsin K-/- mice have increased amounts of type IV collagen in the intestinal 
epithelial basement membrane, increased E-cadherin at the apical junctions and 
disrupted expression of occludin (Arampatzidou et al. 2012). Cathepsin K-/- mice 
are significantly more susceptible to DSS colitis, possibly because cathepsin K 
has potent anti-microbial activity, and intrarectal administration of cathepsin K 
ameliorates DSS colitis (Sina et al. 2013). 
 
In the normal small bowel, Paneth cells activate caspase-8 to prevent IEC 
necroptosis (Becker et al. 2013). Mice with a conditional deletion of caspase-8 in 
intestinal cells of epithelial lineage show increased TNF--induced necroptosis 
and death of IECs and Paneth cells, spontaneously develop an inflammatory 
response in the terminal ileum and are highly susceptible to experimental colitis 
(Günther et al. 2011). Loss of Paneth cells, in turn, impairs anti-microbial defense 
and intestinal barrier function, potentially leading to the abnormal ingress of 
bacteria and, subsequently, immune activation (Becker et al. 2013). 
 
Proteases produced in the intestinal lamina propria 
 
During homoeostasis, mesenchymal cells and immune cells in the lamina propria 
release small, detectable amounts of stromelysin 1 (MMP-3) (Ravi et al. 2007). 
MMP-3 seems to be involved in T cell migration, as shown by the observation 
that MMP-3-/- mice infected with C. rodentium show an impaired migration of 
CD4+ cells in the lamina propria and a delayed bacterial clearance (Li et al. 2004). 
Macrophage metalloelastase (MMP-12) exerts a direct bactericidal effect on 
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Staphylococcus aureus and E. coli by disrupting bacterial cell wall, and MMP-12-/- 
mice have impaired survival to intraperitoneal E. coli administration (Houghton et 
al. 2009). 
 
Mast cell secretory granules contain large amounts of the cell-specific serine 
proteases chymases, tryptases and carboxypeptidase A (Douaiher et al. 2014). 
Mice lacking mast cells or mast cell chymase Mcpt4 have significantly reduced 
basal small intestinal permeability compared to wild-type mice (Groschwitz et al. 
2009). Upon performing kinetic analysis of IEC renewal in mast cell-deficient 
mice and Mcpt4-null mice, the reduced intestinal permeability has been found to 
be associated to defective IEC migration along the villus/crypt axis, altered 
intestinal morphology, and dysregulated claudin 3 crypt expression (Groschwitz 
et al. 2009). Studies on murine chymases are of limited applicability in humans, 
as there are 10 chymases in mice and only one chymase in humans (Douaiher et 
al. 2014). The addition of human chymase to Caco-2 cell monolayers in vitro 
down-regulates transepithelial resistance (Groschwitz et al. 2013). The increase 
in epithelial permeability induced by human mast cell chymase does not result 
from a direct effect on adherens junctions. Instead, chymase activates protease-
activated receptor-2 and induces the expression of gelatinase A (MMP-2), which 
mediates tight junction protein claudin 2 degradation (Groschwitz et al. 2013). 
Overall, however, MMP-2 appears to have a protective effect on the epithelial 
barrier, since MMP-2-/- mice show a higher susceptibility to experimental colitis 
and an increase in intestinal permeability (Garg et al. 2006). Tryptase is another 
mast cell-derived protease. When added to Caco-2 cell monolayers, tryptase 
decreases transepithelial resistance (Wilcz-Villega et al. 2013). This appears to 
be due to a reduction in the expression of tight junction protein junctional 
adhesion molecule-A (JAM-A) (Wilcz-Villega et al. 2013). 
 
After injury, MMPs promote leukocyte recruitment to the site of lesion, an 
important process in order to clear infection and damaged tissue. In particular, 
collagenase 2 (MMP-8) and gelatinase B (MMP-9) activate by cleavage the 
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chemokines CXCL5/CXCL6 and CXCL8 (IL-8) respectively, thereby promoting 
leukocyte recruitment at the site of damage (Van Den Steen et al. 2003). It has 
also been shown that the combined action of MMP-8, MMP-9 and prolyl-
endopeptidase generates collagen cleavage products, such as the tripeptide 
proline-glycine-proline (PGP) and its acetylated form N-acetyl-PGP, with 
chemoattractive effects on neutrophils (Koelink et al. 2014). MMPs produced in 
the lamina propria are involved also in the subsequent phases of tissue repair 
and wound healing. Upon activation, myofibroblasts express high amounts of 
MT1-MMP (MMP-14) and MMP-2, which increase their migration through 
synthetic matrix and therefore may enhance their wound healing potential 
(Pender et al. 2000). Moreover, it has been shown that MMP-14 promotes airway 
epithelial cell proliferation after injury (Atkinson et al. 2007). MMP-10, which is 
normally produced by stromal cells in the intestinal lamina propria, appears to be 
involved in wound healing and co-localises with MMP-1 at the migrating epithelial 
front (Ravi et al. 2007). 
 
Proteases produced by the intestinal microbiota 
 
The intestinal microbiota is an important source of proteases. In particular, both 
commensal and pathogenic bacteria can produce a wide range of proteolytic 
enzymes such as serine and aspartic proteases and metalloproteinases, which 
can exert profound effects on the integrity and the functions of the intestinal 
barrier (Steck et al. 2012). 
 
It has been shown that the commensal bacterium Enterococcus faecalis 
produces the metalloproteinase gelatinase E, which can degrade the junctional 
proteins occludin and E-cadherin (Steck et al. 2011). IL-10-/- mice mono-
associated with gelatinase E-producing E. faecalis develop colitis, whereas 
colonic inflammation is significantly reduced in the absence of bacteria-derived 
gelatinase E (Steck et al. 2011). Disruption of the intestinal epithelial barrier by 
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gelatinase E-producing E. faecalis occurs only in genetically susceptible hosts, 
before the onset of intestinal inflammation (Steck et al. 2011). 
 
Proteases can also be produced by opportunistic pathogens. Clostridium 
perfringens can produce collagenase A, which degrades mucus and collagen 
types I and IV (Pruteanu et al. 2011). The ability of B. fragilis to induce 
inflammatory diarrhoea depends on the production of the MMP fragilysin, also 
known as B. fragilis toxin, which can cleave E-cadherin from the surface of HT-29 
cells, and can mediate the pathogenic effects of B. fragilis by binding to a specific 
receptor expressed on colonic IECs (Wu et al. 2007; Sears et al. 2014). 
 
Both non-invasive and invasive pathogens release a wide range of proteases, 
which can exert important effects on the intestinal barrier and may be relevant for 
evading host defense mechanisms. Vibrio cholerae haemagglutinin/protease can 
degrade mucin and occludin, and thereby disrupt the intestinal barrier (Wu et al. 
2000). The protease domain in lymphostatin released by C. rodentium disrupts 
the integrity of epithelial barrier in the intestine of infected mice (Babbin et al. 
2009). Moreover, C. rodentium outer membrane protease (CroP) cleaves the 
murine cathelicidin-related antimicrobial peptide (CRAMP) (Brannon et al. 2015). 
The A/E human pathogens EPEC and EHEC, major causes of diarrhoeal disease 
worldwide, can inject into IECs the effector protein NleC, which degrades the p65 
subunit of NF-B (Shames et al. 2011). EHEC produces also the 
metalloproteinase StcE, which can cleave MUC7 mucin and potentially facilitate 
adherence to IECs (Grys et al. 2005). It has been shown that the OmpT outer 
membrane protease of EHEC and, to a lesser extent, EPEC degrades the human 
anti-microbial cathelicidin LL-37 (Thomassin et al. 2012). Pic, a secreted 
protease released by enteroaggregative E. coli (EAEC) and Shigella flexnerii, 
has the ability to degrade gelatin (Henderson et al. 1999). Adherent-invasive E. 
coli (AIEC) produces a protease called Vat-AIEC, which facilitates crossing of the 
intestinal mucus layer (Gibold et al. 2015). 
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Also parasites may release proteases affecting the intestinal barrier. Entamoeba 
histolytica also secretes a cysteine protease, which dissolves the intestinal 
mucus layer (Lidell et al. 2006). The nematode Trichuris muris secretes a 
number of proteases as excretory/secretory products. Excretory/secretory 
products can degrade the N-terminus of MUC2 mucin, thus reducing mucus 
viscosity, and since this property is inhibited by chymostatin but not inhibitors of 
other classes of proteases it is assumed that the proteolytic activity is due to a 
serine protease (Hasnain et al. 2012). Interestingly, serpins, natural inhibitors of 
serine proteases, are increased in the mucus layer during worm expulsion, 
suggesting a role in protective immunity (Hasnain et al. 2012). 
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1.3 IBD – Clinical aspects 
 
1.3.1 Definition and history 
 
IBD, including Crohn’s disease (CD) and ulcerative colitis (UC), is a group of 
chronic, inflammatory, spontaneously relapsing disorders of the gastrointestinal 
tract (Baumgart et al. 2012; Ordás et al. 2012). CD had been first observed by 
the German surgeon Wilhelm Fabry (aka Guilhelmus Fabricius Hildanus) in 1623 
(Anonymous 1964). In 1761 Giovanni Battista Morgagni, in his “De Sedibus et 
Causis Morborum”, gave the clinical description of a probable case of CD 
(Kirsner 1988). CD has been subsequently described in 1913 in six cases in 
which tuberculosis was excluded by careful bacteriological studies, and defined 
as “chronic interstitial enteritis” by the Scottish surgeon Thomas Kennedy Dalziel 
(Dalziel 1913), and has been later named after the US physician Burril B Crohn 
(Crohn et al. 1984). UC was first described in 1859 by the London physician Sir 
Samuel Wilks, who reported the case of a 42 year old woman who died after 
several months of diarrhoea and fever (Wilks 1859). Autopsy demonstrated 
ulcerative inflammation of the colon and terminal ileum which was designated as 
“simple UC”. Later on, in 1875, Wilks and Moxon described ulcerative 
inflammation in the entire colon in a young lady who died after severe bloody 
diarrhoea (Wilks et al. 1875). 
 
CD and UC have traditionally been considered a disease of developed Western 
countries, with the highest incidence in North America, Western Europe and 
Australia (Cosnes et al. 2011). However, since 1990 IBD have emerged in newly 
industrialised countries, and their prevalence is now rising in every continent 
(Kaplan 2015). Interestingly, the rise in UC incidence in developing countries 
often precedes that of CD by approximately one decade (Ananthakrishnan 2015). 
 
Both CD and UC have a fluctuating clinical course, with periods of remission 
alternating to flares of disease, and are characterised by a wide clinical 
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heterogeneity (Cosnes et al. 2011; Baumgart et al. 2012; Ordás et al. 2012). 
Extraintestinal manifestations are present in up to 40% of patients with IBD, 
involve mainly the joints, the eyes and the skin, and include peripheral 
seronegative arthritis, sacroileitis, ankylosing spondylitis, erythema nodosum, 
Pyoderma gangrenosum, episcleritis and uveitis (Williams et al. 2008; Ott et al. 
2013). By definition, CD can potentially affect any part of the gastrointestinal tract, 
from the mouth to the anus, however in three quarters of CD patients the lesions 
are localised in the terminal ileum and/or in the ascending colon. Inflammation in 
CD is usually patchy and transmural, as lesions can involve all the layers of the 
intestinal wall. Conversely, UC is a mucosal disease which always affects the 
rectum and can spread proximally up to the caecum with a continuous retrograde 
distribution, without patchiness or skip lesions (Baumgart et al. 2007b). The main 
clinical and pathological characteristics distinguishing CD and UC are 
summarised in Table 1.3. In approximately 5% of patients with colitis it is not 
possible to formulate a conclusive diagnosis or CD or UC, and this condition is 
termed IBD, type unclassified (IBDU) (Mowat et al. 2011). 
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Table 1.3. Clinical and pathological features of CD and UC 
 CD UC 
   
Clinical presentation    
 
 
 
 
 
 
 
 
 
 
 
Complications  
 
 
 
 
 
Endoscopic features 
 
 
 
 
 
 
 
 
 
Histologic features 
 
Severe abdominal pain, 
mainly in right iliac fossa 
 
Diarrhoea  
 
Possible abdominal mass in 
the right iliac fossa (inflamed 
or strictured ileum) 
 
Possible obstructive symptoms 
(intestinal stricture) 
 
Abscesses 
 
Intestinal strictures 
 
Fistulae 
 
Discontinuous, “patchy” 
distribution of lesions 
 
Ileal involvement 
 
Linear and serpiginous deep 
ulcers  
 
“Cobblestone” appearance 
 
Epithelioid granulomas 
 
Mucin preservation at active 
sites 
 
 
Transmural involvement 
 
Cramping abdominal pain, 
mainly in left iliac fossa 
 
Bloody diarrhoea 
 
Abdominal mass in the left 
iliac fossa (inflamed sigma) – 
Rare 
 
Rectal tenesmus, urgency 
 
 
Colorectal cancer 
 
Primary sclerosing 
cholangitis 
 
 
Continuous distribution of 
lesions 
 
Rectal involvement 
 
Superficial and diffuse ulcers  
 
 
Mucosal oedema 
 
Crypt architectural distortion 
 
Mucin depletion 
 
Basal cell plasmacytosis 
 
Mucosal involvement 
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1.3.2  CD 
 
1.3.2.1 Epidemiology 
 
The annual incidence of adult CD is up to 20.2 per 100,000 inhabitants in North 
America and up to 12.7 per 100,000 inhabitants in Europe, depending on 
different geographical areas (Ananthakrishnan 2015). In the UK, CD affects at 
least 115,000 patients, with a prevalence of approximately 200 in 100,000 
inhabitants (Mayberry et al. 2013). CD has its main peak of incidence between 
the second and third decade, and it is 20-30% more frequent in women than in 
men (Cosnes et al. 2011; www.crohnsandcolitis.org.uk). The incidence of adult 
CD in the UK has been rising markedly between the 1950s and the 1980s, 
whereas in the subsequent decades the rate of increase has been slower (Mowat 
et al. 2011). Conversely, from 1988 to 2007 the incidence of CD in Northern 
France has increased by 29% in the overall population and by 71% in the 10-19 
year-old age group (Chouraki et al. 2011), suggesting that the recent increase in 
incidence is primarily attributable to paediatric cases. Paediatric CD is more 
frequent in males than in females (Cosnes et al. 2011). 
 
1.3.2.2 Diagnosis 
 
The diagnosis of CD is based on a thorough clinical evaluation and a 
combination of endoscopic, histologic, laboratory and radiologic test results 
(Mowat et al. 2011). 
 
Clinical manifestations and laboratory investigations 
 
Clinical manifestations of CD are heterogeneous; however, they commonly 
include diarrhoea for more than six weeks, abdominal pain and/or weight loss 
(Van Assche et al. 2010a). In a subject with suspect CD, initial laboratory tests 
should include full blood count, urea and electrolytes, liver function tests, 
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erythrocyte sedimentation rate (ESR) and/or C reactive protein (CRP), ferritin, 
vitamin B12 and folate (Mowat et al. 2011). Faecal calprotectin, an anti-bacterial 
protein produced by neutrophils and activated macrophages, is a reliable marker 
of active colonic inflammation both in CD and UC (Mosli et al. 2015), and can be 
a useful marker in distinguishing IBD from functional diarrhoea (Mowat et al. 
2011). Anti-Saccharomyces cerevisiae serum antibodies (ASCA) are present in a 
significant proportion of CD patients and are very rare in UC, however there is no 
evidence base to recommend their routine use in clinical practice (Mowat et al. 
2011). 
 
Endoscopic, histologic and radiologic findings 
 
Pancolonoscopy with retrograde ileoscopy and multiple biopsies is the gold 
standard confirmatory exam for the diagnosis of ileo-colonic CD (Van Assche et 
al. 2010a). Typical endoscopic lesions in active CD are areas with aphtous 
ulcerations alternated with unaffected areas. This patchy discontinuity of lesions 
leads, in the most severe cases, to the development of a “cobblestone” pattern. 
Discontinuous distribution of the lesions, ileal involvement, and deep ulcerations 
are important endoscopic features in the differential diagnosis with UC. 
According to the guidelines of the British Society of Gastroenterology (Mowat et 
al. 2011), perendoscopic biopsy sampling (two biopsies from at least five 
intestinal segments including the ileum and the rectum) and histologic analysis 
should be performed and the differential diagnosis with UC should be attempted.  
 
The presence of non-caseating granulomas, focal or patchy lamina proprial 
chronic inflammation, conserved crypt architecture and a normal number of 
goblet cells (mucin depletion and crypt distortion are typical in UC) help confirm 
the diagnosis of CD (Baumgart et al. 2012; Feakins 2013). 
 
Radiological investigations are particularly useful to study the extent and 
complications in CD (Van Assche et al. 2010a). Magnetic resonance imaging 
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(MRI) allows rapid and accurate assessment of small bowel extent and activity of 
disease in CD, and may be useful in differentiating between inflammatory and 
fibrotic intestinal strictures (Mowat et al. 2011). Computed tomography (CT) 
enteroclysis and CT enterography provide similar information to MRI, are the 
gold standard for the study of abscesses, and are usually available out of hours; 
however, CT has the major disadvantage of high radiation exposure (Mowat et al. 
2011). 
 
Complications 
 
Especially in case of clinical manifestations such as fever, tenesmus, perianal 
pain and subocclusive symptoms, particular attention should be dedicated to the 
investigation of possible complications of CD. These include intra-abdominal or 
intraparietal perianal abscesses, fistulae – which abnormally connect the 
intestinal lumen with another part of the gastro-intestinal tract, or with a 
contiguous organ (e.g. bladder, ureter, vagina), or with the skin – and intestinal 
strictures, which are caused by intestinal inflammation and/or fibrosis and lead to 
the subsequent development of pre-stenotic dilatations (Van Assche et al. 
2010a). 
 
1.3.2.3 Classification 
 
According to the Montreal classification (Silverberg et al. 2005; Satsangi et al. 
2006), CD can be classified in clinical phenotypes depending on the age of onset 
(Montreal A-category), the localisation of intestinal lesions (Montreal L-category), 
and the disease behaviour (Montreal B-category). In particular, A1 indicates 
diagnosis < 16 years of age, A2 17-40 years and A3 > 40 years. L1 indicates 
lesions localised only in the ileum, L2 only in the colon, L3 ileo-colonic disease, 
L4 disease in the upper gastrointestinal tract, L4+L3 upper gastrointestinal tract + 
distal disease. Finally, B1 indicates non-stricturing non penetrating (also known 
as luminal) disease, B2 stricturing (also known as fibrostenosing) disease, B3 
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penetrating (also known as fistulising) disease, B3p perianally penetrating 
disease. The Montreal classification is useful for patient stratification, as different 
clinical phenotypes have different treatment options (Van Assche et al. 2010b). 
While disease localisation is usually stable, the behaviour tends to change over 
time. In particular, the large majority of patients have luminal disease at 
diagnosis, whereas after 25 years of follow-up most of CD patients evolve 
towards a B2 or B3 disease phenotype (Cosnes et al. 2011). 
 
1.3.2.4 Disease activity indices 
 
Several clinical, laboratory, endoscopic and radiologic indices of disease activity 
in CD have been developed as a means to objectively evaluate, particularly in 
the research and clinical trial settings, the response to treatment, and with a view 
to ultimately stratify patients according to their predicted disease course. 
However, none of the disease activity indices in CD has been formally validated 
according to the guidance of the US Food and Drug Administration for the 
development of patient-reported or clinician-reported outcomes (Levesque et al. 
2015). 
 
Crohn’s Disease Activity Index (CDAI) and Harvey-Bradshaw Index (HBI)  
 
The CDAI has been widely used as outcome measure in clinical trials since the 
publication of the National Crohn’s Disease Study trial in 1979 (Best et al. 1976). 
CDAI ranges from 0 to 600 according to the presence and severity of eight 
independent predictors (seven clinical manifestations and haematocrit). CDAI < 
150 indicates disease remission; between 150 and 219, mildly active disease; 
between 220 and 449, moderately active disease; > 450, severely active disease 
(Best et al. 1976). CDAI correlates poorly with endoscopic inflammation, serum 
CRP and faecal calprotectin, as symptoms of active CD overlap with conditions 
such as irritable bowel syndrome, small bowel bacterial overgrowth or bile salt 
malabsorption (Jones et al. 2008). 
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The HBI can be described as a simplified version of CDAI, and consists of five 
clinical predictors (which is a useful feature when laboratory test results are not 
available). Remission is defined as a score < 5 (Harvey et al. 1980). A 3-point 
change in HBI corresponds with a 100-point change in CDAI, and an HBI ≤ 4 
corresponds with a CDAI < 150 (Vermeire et al. 2010).  
 
Endoscopic disease activity indices 
 
In 1989 the Crohn’s Disease Endoscopic Index of Severity (CDEIS) was 
developed based on colonoscopy findings in 75 CD patients, and showed a 
remarkable interobserver agreement (Mary et al. 1989). The CDEIS considers 
five intestinal segments (ileum, right colon, transverse colon, left colon/sigmoid, 
rectum). For each of them four parameters are evaluated and graded from 0 to 3 
based on severity, namely the presence and size of ulcerations, the percentage 
of ulcerated surface, the percentage of inflamed surface, and the presence of 
strictures. The cut-off points for CDEIS have been different among different 
investigators. Complete endoscopic remission was subsequently defined by the 
same group as a score of < 3, endoscopic remission as a score of < 6, and 
endoscopic response as a decrease of > 5 points, whereas other studies have 
used different cut-off points (Rutgeerts et al. 2012; Hébuterne et al. 2013). In 
particular, mild, moderate and severe CD have been described as CDEIS < 5, 5 
to 15, and > 15, respectively (Geboes et al. 2005). 
 
In 2004, the Simple Endoscopic Score in Crohn’s Disease (SES-CD) was 
developed in order to make objective endoscopic assessment and grading of 
disease severity in CD easier and more applicable to clinical practice (Daperno et 
al. 2004). The five intestinal segments considered in the SES-CD are the same 
as in CDEIS, however the descriptors (presence/absence of deep ulcerations, 
presence/absence of superficial ulcerations, surface involved by disease and 
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surface involved by ulcerations, with an additional score for the presence of a 
stricture) are more immediate to determine than those of the CDEIS. 
 
Endoscopic mucosal healing in CD has been defined as the absence of intestinal 
ulcerations among patients with ulcerations at baseline (Hanauer et al. 2002; 
Colombel et al. 2010), and has been used as primary end point in the 
adalimumab EXTEND trial (Rutgeerts et al. 2012). The major limitation of using 
mucosal healing as an outcome measure is that partial resolution of ulcers is not 
considered (Levesque et al. 2015). However, a post-hoc analysis of the SONIC 
trial showed that both a 50% decrease in endoscopic activity indices (CDEIS and 
SES-CD) and mucosal healing are the most robust predictors of steroid-free 
remission at week 50 from the treatment start (Ferrante et al. 2013). 
 
The Lémann index 
 
In order to evaluate disease progression in CD, the Lémann index has been 
developed based on a comprehensive evaluation of cumulative structural 
intestinal damage, including strictures, fistulae, and surgical resections, using 
clinical, upper and lower endoscopic and abdominal and pelvic MRI assessment 
(Pariente et al. 2015). Using the Lémann index it has been reported that 62% of 
patients have substantial intestinal damage from 2 to 10 years from the diagnosis, 
and that high Lémann index scores at the first evaluation, time, persistent clinical 
activity, and intestinal resection are associated with damage (Gilletta et al. 2015). 
 
1.3.2.5 Treatment 
 
The key points in the therapeutic management of adult CD patients are the 
induction of remission during active disease and the maintenance of remission in 
order to prevent disease progression and development of complications. One of 
the most important measures to adopt in CD is to strongly recommend the 
patient to stop smoking, as this is associated with a 65% reduction in relapse risk 
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(Johnson et al. 2005). Treatment options for active CD include nutritional support 
and nutritional therapy, an expanding range of anti-inflammatory drugs and 
immunomodulators with considerable variability in specificity and targets, and 
surgery (Mowat et al. 2011). 
 
Nutritional support and nutritional therapy 
 
Malnutrition is a common feature in CD, and particular attention should be paid to 
the correction of micronutrient deficiencies such as calcium, vitamin B12, folate, 
iron and zinc (Mowat et al. 2011). Total parenteral nutrition may be required in 
CD patients who develop short bowel syndrome after surgical resection of 
affected intestine, or in the perioperative care of patients with significant weight 
loss (Mowat et al. 2011). Exclusive enteral nutrition is effective in inducing 
remission both in small bowel and colonic disease in 60-80% children with active 
CD, with no difference between elemental and polymeric diet. Liquid feeding has 
the great advantages of ensuring optimal growth and avoiding toxicity of 
corticosteroids in children with CD (Zachos et al. 2007; Mowat et al. 2011). A 
retrospective study showed that the combination of partial enteral nutrition and 
exclusion diet induces clinical remission in children and young adults with mildly 
and moderately active luminal CD (Sigall-Boneh et al. 2014). However, exclusive 
enteral nutrition is more effective than partial enteral nutrition in reducing 
mucosal inflammation in children with active CD (Lee et al. 2015b). It has been 
proposed that dietary intervention could be used as an adjunct therapy in specific 
subsets of patients in order to reduce the risk of relapse or the degree of 
immunosuppression necessary to control the disease (Lee et al. 2015a). 
 
Medical therapy 
 
The majority of patients with active CD are treated with anti-inflammatory drugs 
such as corticosteroids, immunosuppressive agents such as thiopurines and 
methotrexate, and biologic drugs with a specific target such as anti-TNF- and 
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anti-integrin agents (Danese 2012). While 5-aminosalicylates have limited 
efficacy in CD, corticosteroids such as prednisone have been used as first-line 
therapy in most patients with active CD (Dignass et al. 2010). Thiopurines, which 
include azathioprine and 6-mercaptopurine, are effective in inducing and 
maintaining remission and are associated with a 40% reduction of surgical 
resections in CD, however they have a slow onset of action and patients must be 
carefully monitored for the risk of haepatotoxicity, pancreatitis and leucopaenia 
(Chatu et al. 2014; Goel et al. 2015). Methotrexate is very appropriate in CD 
patients with arthropathy, as both disorders can benefit from this drug (Baumgart 
et al. 2012). Patients with perianal CD benefit from treatment courses with 
antibiotics such as metronidazole and ciprofloxacin, which are also used for the 
treatment of complications such as abscesses (Mowat et al. 2011). 
 
The management of active CD has been revolutionised by anti-TNF- agents, 
such as the chimaeric murine-human monoclonal antibody infliximab and the fully 
human monoclonal antibody adalimumab, which can induce both clinical 
remission and mucosal healing in luminal CD, as shown in the SONIC and 
EXTEND trials, and are also effective in fistulising CD (Colombel et al. 2010; 
Mowat et al. 2011; Rutgeerts et al. 2012). It has been shown that dose 
adjustment of infliximab based on serum trough level measurement is associated 
with fewer flares of CD during the course of treatment compared to clinically-
based dosing (Vande Casteele et al. 2015). In particular, the Authors recommend 
continued concentration-based infliximab dosing, aiming for serum trough levels 
≥3 and ≤7 g/ml, which maximise response to treatment and minimise costs and 
potential side effects (Vande Casteele et al. 2015). A relevant limitation in the 
use of anti-TNF- agents resides in their high cost. However, after the patent for 
infliximab has expired, the biosimilar infliximab has been developed and 
approved in Europe, UK and US. The cheaper price of biosimilars will enable 
access to anti-TNF- treatment to a wider population of patients, and this may 
have a substantial impact on therapeutic paradigms in CD (Schreiber 2015).  
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Other biologic agents with alternative mechanisms of action have also been 
successful in randomised clinical trials in CD. In particular, both ustekinumab, a 
fully human monoclonal antibody specific for IL-12 and IL-23 p40 subunit, and 
vedolizumab, an anti-47 integrin monoclonal antibody, have shown clinical 
efficacy in CD (Sandborn et al. 2012b; Sandborn et al. 2013b; Wils et al. 2016). 
Finally, mongersen, an oral antisense oligonucleotide targeting the inhibitor of 
TGF- signalling Smad7, has been shown to induce significantly higher clinical 
response and remission rates compared with placebo (Monteleone et al. 2015).
 
Surgical options 
 
When the outcome of medical therapy is not satisfactory and in case of 
complications such as internal or complicated perianal fistulae and fibrotic 
strictures, surgical management of CD should be considered. However, surgery 
is not curative in CD, and, rather than extensive destructive intestinal resections, 
the current trend is to resect or treat the segment responsible for the main 
symptoms and leave the rest of the affected intestine in place (Dignass et al. 
2010). The cumulative incidence of abdominal surgery in CD is 33% at 5 years 
and 47% at 10 years from the diagnosis (Frolkis et al. 2013). When the extent of 
CD lesions is very limited, such as in ileocaecal CD, surgical resection of the 
affected tract is a valid option. Typically, fibrotic strictures causing intestinal 
occlusive symptoms in the jejunum and ileum may be treated with stricturoplasty. 
Conversely, stricturoplasty in the colon is not recommended (Dignass et al. 2010). 
Seton drainage is commonly performed in perianal CD, whereas advancement 
flaps and fistula plugs may be appropriate for persistent or complex fistulae in 
combination with medical treatment. 
 
Unfortunately, most patients develop recurrence of CD lesions in the neo-
terminal ileum or at the anastomosis after surgical intestinal resection, however 
smoking cessation substantially reduces post-operative relapse (Mowat et al. 
2011). Macroscopic recurrence of lesions after surgery in CD can be graded 
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endoscopically according to the Rutgeerts’ score (Rutgeerts et al. 1990). In 
particular, 0 indicates absence of lesions; 1: less than 5 aphthous lesions; 2: 
more than 5 aphthous lesions with normal mucosa between the lesions, or skip 
areas of larger lesions, or lesions confined to the ileo-colonic anastomotic lining 
(< 1cm); 3: diffuse aphthous ileitis with diffusely inflamed mucosa; 4: diffuse ileal 
inflammation with larger ulcers, nodules, or narrowing. Hyperaemia and oedema 
alone are not considered as signs of recurrence (Rutgeerts et al. 1990). The 
POCER trial explored the optimal approach to prevent post-operative disease 
recurrence, and established that, after surgery, a strategy based on treatment 
with thiopurine or adalimumab in case of high clinical risk of recurrence (smoking 
and/or penetrating disease and/or previous resection) followed by colonoscopy 
after 6 months and treatment step-up in case of recurrence of lesions is more 
effective than conventional step-up management for the prevention of post-
operative recurrence in CD (De Cruz et al. 2015). 

Management strategies in CD – “Step-up”, “top down” and “treat-to-target”

The traditional way to treat active CD has been following the so-called “step-up” 
approach, with step-wise therapy intensification and change in drug class 
according to the response to treatment and to the frequency and severity of 
subsequent relapses (Fig. 1.3A). However, the decision to escalate treatment is 
often based on clinical assessment, and it is well known that there is poor 
correlation between clinical and endoscopic activity (Peyrin-Biroulet et al. 2011). 
Moreover, as a result of the incremental step-up approach, the decision to start 
immunosuppression or biologic therapy in the most aggressive cases of CD is 
delayed, with potential negative consequences on disease progression. It has 
been demonstrated that early combined immunosuppression with infliximab and 
azathioprine has superior efficacy compared with step-up therapy and to 
monotherapy with either infliximab or thiopurines in CD, and leads to sustained, 
steroid-free remission (D’Haens et al. 2008; Colombel et al. 2010). 
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Figure 1.3. Possible treatment strategies in CD. (A) The “step-up” treatment 
approach has been traditionally followed in order to induce remission in patients 
with active CD. Treatment is decided based on disease activity, and escalation to 
a more aggressive and/or effective treatment is dictated by non-responsiveness 
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or subsequent relapse. (B) Following the observation that early combined 
immunosuppression with infliximab and azathioprine has superior long-term 
efficacy compared with step-up therapy and to monotherapy with either infliximab 
or thiopurines, the alternative “top down” approach has been proposed for CD, 
with the idea that using a combination of biologic and immunosuppressant early 
in the disease may reduce the need for hospitalisation and surgery. (C) The 
“treat-to-target” approach in CD is based on the definition of a specific 
therapeutic target and the subsequent selection of the most appropriate 
treatment depending on the risk of disease progression. The achievement of the 
selected target is evaluated by regularly assessing response to treatment, and 
therapy adjustment is performed accordingly. In particular, assessment of 
response can be performed by clinical examination in case patient-reported 
outcomes such as clinical response and remission have been chosen as targets; 
by blood and stool tests in order to evaluate serologic (CRP) and biochemical 
(faecal calprotectin) remission; by ileocolonoscopy to assess endoscopic 
remission and mucosal healing. (Original Figure). 
 
 
Therefore, the alternative “top down” approach has been proposed, with the idea 
that starting with a combination of biologic and immunosuppressant and de-
escalate if possible may improve disease course and reduce the need for 
hospitalisation and surgery in CD (Fig. 1.3B). However, CD is a heterogeneous 
disease, and the top down strategy may lead to overtreatment in a substantial 
proportion of patients. One way to avoid this is to stratify CD patients at diagnosis 
according to the presence of risk factors for disease progression. In particular, 
age < 40 years at diagnosis, rectal or small bowel lesions, perianal disease, deep 
ulcerations and need for steroids to treat the first flare are all associated with 
disabling disease course in CD (Beaugerie et al. 2012). In the REACT trial, CD 
patients who failed to achieve clinical remission with a course of steroids were 
randomised to receive either conventional step-up therapy or early combined 
immunosuppression (Khanna et al. 2015). The rate of steroid-free clinical 
remission at 12 months did not differ between the two groups, however at 24 
months patients assigned to early combined immunosuppression had 
significantly lower rates of intestinal resections and CD complications such as 
fistulae and strictures, supporting the concept that management based on risk 
stratification may improve natural history in CD. 
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Clinical experience in rheumatoid arthritis has shown that management based on 
the regular assessment of pre-defined therapeutic targets with objective 
measures and consequent treatment adjustment leads to optimal outcomes for 
patients (Schipper et al. 2010). These considerations prompted the formulation of 
the “treat-to-target” approach for CD, in which the desired target is specified 
before starting the treatment, and the intervention is decided upon careful risk 
assessment, with a view to start early immunosuppression in high-risk patients 
(Fig. 1.3C) (Bouguen et al. 2015). Response to treatment is then assessed 
regularly until the target is reached, and drug therapy is adjusted accordingly. 
Consensus-based recommendations of therapeutic targets for CD have been 
formulated, and include both the patient-reported outcome of clinical remission, 
defined as resolution of abdominal pain and diarrhea/altered bowel habit, and 
endoscopic remission, defined as resolution of ulceration at ileocolonoscopy, or 
resolution of findings of inflammation on cross-sectional imaging in patients who 
cannot be adequately assessed with ileocolonoscopy, whereas serologic 
(CRP)/biochemical (faecal calprotectin) remission has been considered as an 
adjunctive target (Peyrin-Biroulet et al. 2015). It has been suggested that in a 
clinical setting the “treat-to-target” approach may be realistically feasible by 
performing a first endoscopic assessment every six months after the treatment 
start until disappearance of intestinal ulcers, then every 1-2 years thereafter 
(Bouguen et al. 2015). 
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1.3.3 UC 
 
1.3.3.1 Epidemiology 
 
The annual incidence of UC is up to 19.2 per 100,000 inhabitants in North 
America and up to 24.3 per 100,000 inhabitants in Europe, depending on 
different geographical areas (Ananthakrishnan 2015). In the UK, UC affects at 
least 146,000 patients, with a prevalence of approximately 240 in 100,000 
inhabitants (NICE 2013; www.crohnsandcolitis.org.uk). UC occurs at 
approximately the same rate in men and women (www.crohnsandcolitis.org.uk). 
The main peak of incidence in UC is between the ages of 15 and 25, with a 
second, smaller peak between 55 and 65 years, although this latter has not been 
conclusively demonstrated (NICE 2013). 
 
1.3.3.2 Diagnosis 
 
The diagnosis of UC is based on the presence of clinical symptoms confirmed by 
endoscopic and histologic findings (Dignass et al. 2012a). 
 
Clinical manifestations and laboratory investigations 
 
Typical manifestations of UC are rectal bleeding and diarrhoea, urgency and 
tenesmus. In severe cases, fever and tachycardia may be present. In a subject 
with suspect UC, initial laboratory tests should include full blood count, ESR 
and/or CRP, urea and electrolytes, liver function tests and ferritin (Dignass et al. 
2012a). Infectious colitis needs to be ruled out by performing stool cultures and 
by testing for Clostridium difficile toxin A and B (Dignass et al. 2012a). Faecal 
calprotectin is an accurate marker of colonic inflammation, it is more sensitive 
than CRP as a biomarker of endoscopic inflammation, and it may be useful in 
monitoring disease activity or response to therapy (Lewis et al. 2011; Mosli et al. 
2015). Serum perinuclear anti-neutrophil cytoplasmic antibodies (pANCA) are 
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present in up to 65% UC patients and in less than 10% CD patients, however 
their use in clinical practice is currently not recommended (Dignass et al. 2012a). 
 
Endoscopic and histologic findings 
 
Pancolonoscopy with retrograde ileoscopy and segmental biopsies including the 
rectum are the preferred procedures to establish the diagnosis of UC (Dignass et 
al. 2012a). In UC, colonoscopy reveals signs of inflammation such as mucosal 
erhytema and hyperemia on friable mucosa and multiple ulcerations, however no 
endoscopic feature is specific for UC (Dignass et al. 2012a). The continuous 
damage-regeneration process occurring in inflamed areas leads to the growth of 
pseudopolyps. The most indicative endoscopic signs of UC (as opposed to CD) 
are rectal involvement with a caudo-cranial extension and a continuous 
distribution (Dignass et al. 2012a). Disease extent should be assessed at 
diagnosis, because of prognostic and therapeutic implications. 
 
A reliable diagnosis of UC requires the histologic analysis of at least two biopsies 
from at least five intestinal segments, including the ileum and the rectum 
(Dignass et al. 2012a). Microscopically, crypt abscesses, crypt architectural 
distortion with branching and atrophy, mucin depletion, and basal cell 
plasmacytosis (presence of plasma cells around or below the crypts) are typical 
features of UC (Dignass et al. 2012a; Feakins 2013). 
 
Complications 
 
UC can be associated with primary sclerosing cholangitis, a chronic cholestatic 
liver disease characterised by a fibrosing inflammatory destruction of intrahepatic 
and extrahepatic bile ducts, which occurs in up to 3% of patients (Rothfuss et al. 
2006). The presence of primary sclerosing cholangitis increases the risk of both 
cholangiocarcinoma and colo-rectal cancer (CRC) (Van Assche et al. 2013). 
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Importantly, the risk of thromboembolism is doubled in patients with UC 
compared with control subjects (Van Assche et al. 2013). 
 
Patients with UC have a higher risk of CRC compared with the general 
population, and this is correlated with disease extent and duration (Van Assche 
et al. 2013). Indeed, it has been reported that the cumulative probability of CRC 
development is estimated at 2%, 8% and 18% respectively after 10, 20 and 30 
years of disease duration (Lakatos et al. 2008). The presence of severe and 
persistent disease activity, colonic pseudopolyps, primary sclerosing cholangitis 
and positive family history for CRC confer an additional risk for CRC in UC 
patients (Baars et al. 2011; Van Assche et al. 2013). Colon carcinogenesis in UC 
is characterised by a multi-step process from low-grade dysplasia (with stratified, 
bottom-placed, elongated, hyperchromatic nuclei and increased number of 
mitoses) to high-grade dysplasia (marked nuclear atypia, loss of cell polarisation, 
branched crypts) and finally to adenocarcinoma (Triantafillidis et al. 2009). 
Colonic stenosis seen endoscopically in UC should raise the suspicion of CRC, 
and prompt radiologic imaging in case intubation is not possible (Dignass et al. 
2012a). 
 
1.3.3.3 Classification 
 
According to the Montreal classification (Silverberg et al. 2005; Satsangi et al. 
2006), UC can be classified into different clinical phenotypes depending on the 
maximal extent of intestinal inflammation observed at colonoscopy (Montreal E-
category). In particular, E1 indicates proctitis, when only the rectum is involved; 
E2, left-sided colitis, extending up to splenic flexure; E3, more extensive disease, 
which can be defined as pancolitis when all the colon is involved (Silverberg et al. 
2005). At diagnosis, UC is limited to the rectum in approximately one third of 
patients, it extends up to the splenic flexure in another third, and proximally to the 
splenic flexure in another third, with 20-25% of patients having pancolitis. 
Disease extent tends to change over the course of UC: distal colitis progresses 
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proximally in about 50% of patients, whereas in more than 2/3 of pancolitic 
patients the extent of colonic involvement decreases over time (Cosnes et al. 
2011). Disease extent is an important predictor of colectomy and CRC (Ordás et 
al. 2012). 
 
1.3.3.4 Disease activity indices 
 
Since the first randomised controlled trial in UC (Truelove et al. 1955), several 
indices of disease activity based on clinical, laboratory, endoscopic or histologic 
variables have been developed in clinical trial design in UC. However, none of 
them has been formally and completely validated according to the guidance of 
the US Food and Drug Administration for the development of patient-reported or 
clinician-reported outcomes (Levesque et al. 2015). 
 
Truelove and Witts’ criteria 
 
The Truelove and Witts’ criteria (Truelove et al. 1955), which are derived from the 
Truelove and Witts Severity Index (Truelove et al. 1955), are the only disease 
activity index to be used routinely in clinical practice in UC, and define acute 
severe UC (ASUC) as the passage of six or more stools with blood per day 
associated with one or more signs of systemic toxicity (temperature > 37.8°C; 
tachycardia > 90 bpm; haemoglobin < 105 g/L; ESR > 30 mm/h; CRP > 30 mg/L). 
In particular, the Truelove and Witts’ criteria are used to identify UC patients in 
need of hospital admission and intensive treatment (Macken et al. 2015). 
 
Powell-Tuck Index, Clinical Activity Index (CAI) and Lichtiger score 
 
Other clinical indices of disease activity in UC include the Powell-Tuck Index 
(also known as St Mark’s Index) (Powell-Tuck et al. 1978), which considers 10 
gastrointestinal and systemic clinical variables and was subsequently modified to 
include macroscopic appearance at sigmoidoscopy (Powell-Tuck et al. 1982), 
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and the CAI (or Rachmilewitz Index) (Rachmilewitz 1989). This latter is 
composed of seven clinical variables (number of stools, blood in stools, 
investigator’s global assessment of symptomatic state, abdominal pain or cramps, 
temperature due to colitis, extraintestinal manifestations, and laboratory findings) 
and ranges from 0 to 29 points, with remission bein defined as a score ≤ 4. 
 
In the first pilot trial on the use of intravenous ciclosporin in ASUC, a modified 
Truelove and Witts Severity Index, also known as the Lichtiger score (Lichtiger et 
al. 1994), was used to assess response to treatment. The Lichtiger Score 
includes seven clinical variables and ranges from 0 to 21 points, ASUC is defined 
as a score > 10 points, and remission has been defined as a score ≤ 3 points 
(D’Haens et al. 2007; Laharie et al. 2012). 
 
Endoscopic or composite clinical and endoscopic disease activity indices 
 
In addition to clinical indices, multiple endoscopic or composite clinical and 
endoscopic indices of disease activity have been developed in UC. 
 
The Baron Score was developed to assess interobserver variability in describing 
rectosigmoid mucosa using a rigid proctoscope (Baron et al. 1964), and 
considered eight endoscopic descriptors such as friability, vascular pattern and 
spontaneous bleeding. The Modified Baron Score removed qualitative 
assessment of different levels of bleeding (moderately, severely), established five 
grades by categorical variables (0, normal; 1, granular; 2, friable; 3, bleeding; 4, 
ulcerated), and defined endoscopic response as an improvement of 2 grades and 
endoscopic remission as a score of 0 (Feagan et al. 2005). 
 
The Mayo Score (also known as Disease Activity Index) is a composite index that 
includes three clinical variables (stool frequency, rectal bleeding, physician’s 
global assessment) and endoscopic severity at flexible sigmoidoscopy, each one 
ranging from 0 to 3 (Schroeder et al. 1987). Complete remission is defined as a 
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subscore of 0 in all variables. The main limitation of the Mayo Score is that it 
assimilates symptoms and endoscopic variables that are not logically combinable 
and are difficult to appropriately weight, with consequent detrimental effect on 
measurement variability and statistical efficiency. A possible approach to 
overcome this limitation has been to independently assess endoscopic 
inflammation and clinical variables of the Mayo Score, using a 3-item (stool 
frequency, rectal bleeding and physician’s global assessment) or a 2-item (stool 
frequency, rectal bleeding) clinical Mayo score, and an endoscopic Mayo 
subscore (Levesque et al. 2015). In particular, in the endoscopic Mayo subscore, 
0 indicates normal or inactive disease; 1, mild disease with erythema, decreased 
vascular pattern, mild friability; 2, moderate disease with marked erythema, 
absent vascular pattern, friability, erosions; 3, severe disease with spontaneous 
bleeding and/or ulceration. 
 
Mucosal healing in UC has been classically defined as an endoscopic Mayo 
subscore 0 or 1 (Colombel et al. 2011). It has been shown that UC patients with 
an endoscopic Mayo subscore of 1 have a significantly higher risk of clinical 
relapse (defined as the need for therapy to induce remission, any treatment 
escalation, hospitalisation or colectomy) in the following 6-12 months compared 
with those with subscore of 0 (Barreiro-de Acosta et al. 2016; Boal Carvalho et al. 
2016), suggesting that the definition of mucosal healing should be limited to 
endoscopic Mayo subscore of 0. 
 
In contrast to the empirically developed endoscopic scoring systems described 
so far, the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) has been 
developed upon the analysis of 630 assessments of 60 endoscopic videos by 10 
specialists (Travis et al. 2012b). Initially defined as an 11-point score, the UCEIS 
has been subsequently simplified to an 8-point score with the following variables: 
erosions and ulcers (score 0-3), vascular pattern (score 0-2) and bleeding (score 
0-3), and has shown high correlation with overall endoscopic assessment of 
severity (Travis et al. 2013). 
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Histologic disease activity indices 
 
Several histologic indices of activity have also been developed in UC, in most 
cases empirically (Mosli et al. 2014). The first one to be described was the 3-
grade (mild, moderate and severe) Truelove and Richards Index (Truelove et al. 
1956), which was used in a study showing that microscopic inflammation can be 
present in UC patients with macroscopically normal mucosa and predicts a 
higher risk of relapse. 
 
Originally developed as a 5-point scale evaluating the degree of chronic 
inflammatory infiltrate and tissue destruction (Riley et al. 1988), the Riley Score 
was subsequently designed as a 4-point scale (normal, mild, moderate, severe) 
assessment of six independent variables (neutrophil infiltrate, crypt abscesses, 
mucin depletion, surface epithelial integrity, chronic inflammatory cell infiltrate 
and crypt architectural irregularities) (Riley et al. 1991). Unlike endoscopic 
evidence of erythema, histologic inflammation, graded using the Riley Score, was 
shown to predict relapse of UC in patients with clinically quiescent disease and 
normal or erythematous rectal mucosa (Riley et al. 1991). The Modified Riley 
Score ranked the degree of inflammation hierarchically according to the presence 
of neutrophils in the epithelium (mild), neutrophil infiltration in the lamina propria 
(moderate), erosions or ulceration (severe) (Feagan et al. 2005). 
 
Finally, the more comprehensive Geboes Score incorporated a number of 
previously reported variables, including architectural changes, epithelial and 
lamina propria neutrophils, crypt destruction, erosion or ulceration (Geboes et al. 
2000). The Geboes Score showed a good interobserver agreement between 
pathologists for biopsies collected from endoscopically inflamed mucosa of UC 
patients (Geboes et al. 2000). Both the Modified Riley Score and the Geboes 
Score show a highly significant correlation with the Mayo endoscopic subscore in 
case of both severely active and inactive disease, however there is high diversity 
in mildly and moderately active disease (Lemmens et al. 2013). 
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1.3.3.5 Treatment 
 
The treatment goals in UC are to induce remission during a disease flare and to 
maintain remission in order to prevent complications and colectomy. Several anti-
inflammatory agents, immunosuppressants and immunomodulators may be used 
in active UC, however the choice of a specific agent and its way of administration 
depend on the different features of disease in a particular patient. The key 
aspects to consider when making therapeutic decisions in active UC are disease 
extent and severity, and outcomes of previous treatments (Mowat et al. 2011; 
Dignass et al. 2012b). 
 
Medical therapy for the induction of remission 
 
5-aminosalicylates such as mesalazine are the first-line therapy for patients with 
mild to moderate UC and can be administered topically (suppositories in case of 
proctitis or aenemas in case of more extensive disease) and/or orally (in case of 
left-sided colitis or pancolitis), depending on disease extent (Dignass et al. 
2012b). Addition oral mesalazine or topical steroids to topical mesalazine should 
be considered for escalation of treatment in proctitis (Dignass et al. 2012b). 
Topical steroids may be added to topical mesalazine, however they are less 
effective than mesalazine (Marshall et al. 2010). In left-sided colitis and more 
extensive mild to moderate UC, the first-line treatment is combined oral and 
topical mesalazine (Dignass et al. 2012b). 
 
If mesalazine fails to induce improvement in 2-4 weeks, oral corticosteroids 
should be started (Mowat et al. 2011; Dignass et al. 2012b; Ordás et al. 2012). 
While 70% patients respond to steroids, the remaining 30% do not respond or 
develop steroid-dependence and should be switched to thiopurines and/or anti-
TNF-agents (Ordás et al. 2012). Azathioprine is moderately effective in 
inducing clinical and endoscopic remission in steroid-dependent UC (Ardizzone 
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et al. 2006; Leung et al. 2008; Louis et al. 2014). Both infliximab and adalimumab 
have shown good ability to induce mucosal healing, defined as endoscopic Mayo 
subscore  1, in patients with moderate to severe chronically active UC 
(Rutgeerts et al. 2005; Reinisch et al. 2013). It has been shown that combination 
of infliximab and azathioprine is superior to either drug as monotherapy in 
moderate to severe chronically active UC (Panaccione et al. 2014), however 
further studies are needed before combination therapy can be conclusively 
recommended in UC, and an individualised approach appears currently 
preferable (Lee et al. 2014). 
 
Other therapeutic agents or interventions have been tested, and in certain cases 
approved, for the treatment of active UC. In particular, the fully human 
monoclonal anti-TNF- antibody golimumab was effective in inducing clinical 
remission and mucosal healing (endoscopic Mayo subscore  1) in patients with 
moderately to severely active UC (Sandborn et al. 2014). In the UK, golimumab 
has been recommended as an alternative to infliximab and adalimumab for UC 
patients with moderately or severely active disease who did not respond to or 
could not tolerate corticosteroids or thiopurines (NICE 2015a). The anti-47 
integrin humanised monoclonal antibody vedolizumab is significantly more 
effective than placebo in inducing clinical remission and mucosal healing 
(endoscopic Mayo subscore  1) in UC (Feagan et al. 2013), and in the UK 
vedolizumab has been recommended for moderately to severely active UC 
patients who failed therapy with conventional therapy or with an anti-TNF- agent 
(NICE 2015b). The oral Janus kinase (JAK) inhibitor tofacitinib induced clinical 
remission and mucosal healing (endoscopic Mayo subscore 0) in a dose-
dependent manner in moderately or severely active UC (Sandborn et al. 2012c), 
however its safety profile needs to be carefully evaluated before recommending 
its use in clinical practice to treat UC (Peyrin-Biroulet et al. 2013). 
 
Finally, faecal microbiota transplantation has given contrasting results in two 
randomised controlled clinical trials in mild to moderate UC, possibly due to 
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different route and frequency of administration (Moayyedi et al. 2015; Rossen et 
al. 2015). In particular, duodenal infusion of donor faeces, which is significantly 
more effective than vancomycin for recurrent C. difficile infection (van Nood et al. 
2013), had no significant effect on mild to moderate UC (Rossen et al. 2015). 
Conversely, weekly faecal microbiota transplantation via retention enema for six 
weeks induced endoscopic remission in a significantly higher proportion than 
placebo in patients with mild to moderate UC (Moayyedi et al. 2015), however 
this was achieved only in 24% of randomised patients. 
 
Management of ASUC 
 
The management of ASUC follows a different algorithm from chronically active 
UC. ASUC is a medical emergency which requires admission and intravenous 
hydrocortisone administration due to the high risk of colectomy (Macken et al. 
2015). A plain abdomen radiograph is required to exclude the presence of toxic 
megacolon or perforation, and an unprepared flexible sigmoidoscopy with 
biopsies may be important for the diagnosis and management, however it should 
not delay the treatment start (Macken et al. 2015). Moreover, patients admitted 
for ASUC require venous thromboembolism prophylaxis and fluid/electrolyte 
balance correction (Macken et al. 2015). Nutritional support is important in 
malnourished patients with ASUC (Dignass et al. 2012b). There is not sufficient 
evidence to recommend total parenteral nutrition with bowel rest in ASUC, 
whereas in this condition enteral nutrition is most appropriate and associated with 
significantly fewer complications than parenteral nutrition (Van Gossum et al. 
2009). 
 
Intravenous hydrocortisone induces remission in 70% patients with ASUC. 
However, failure of steroids by day 3, defined according to the Oxford criteria as 
stool frequency > 8/day, or stool frequency 3-8/day and a CRP > 45mg/L, 
predicts an 85% likelihood of requiring a colectomy, and prompts escalation to 
rescue therapy with infliximab or ciclosporin or tacrolimus, or referral for 
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colectomy (Dignass et al. 2012b; Macken et al. 2015). It has been shown that 
ciclosporin has equivalent efficacy to infliximab in steroid-resistant ASUC, with no 
significant difference between the two treatments in the rate or time to colectomy 
(Laharie et al. 2012). Colectomy should be considered in patients who do not 
respond to rescue therapy within 7 days from initiation (Macken et al. 2015). A 
retrospective study showed that patients with ASUC who were given an 
accelerated induction with three doses of infliximab within a median of 24 days 
had a significantly lower rate of colectomy at 3 months as compared with the 
standard 0, 2 and 6 week induction regimen (Gibson et al. 2015). 
 
Approximately 5% patients with ASUC develop toxic megacolon, which can be 
defined as a total or segmental non-obstructive dilatation of the colon (≥ 5.5 cm) 
on plain abdominal X-ray, associated with systemic toxicity (Gan et al. 2003). 
Hypomagnesaemia, hypokalaemia and anti-diarroheal medications are risk 
factors for toxic megacolon (Dignass et al. 2012b). In case of toxic megacolon, in 
addition to intravenous hydrocortisone, empirical treatment with oral vancomycin 
should be considered until stool is confirmed negative for C. difficile toxin, and 
surgical opinion should be seeked, as an early colectomy may be necessary 
(Dignass et al. 2012b). 
 
Medical therapy for the maintenance of remission 
 
Once active UC has been successfully treated, the therapeutic goal is to maintain 
steroid-free clinical and endoscopic remission. Oral mesalazine is the first-line 
therapy for maintenance of remission in UC patients (Mowat et al. 2011). MMX-
mesalazine administered once daily represents a valid alternative to traditional 
mesalazine and allows better patients’ compliance (Yang et al. 2011). 
Azathioprine and 6-mercaptopurine are effective for maintaining remission in UC 
(Timmer et al. 2012), and are recommended as maintenance therapy for patients 
who are intolerant to 5-aminosalicylates, ASUC patients responding to 
ciclosporin or tacrolimus for induction of remission, and as steroid-sparing agents 
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in steroid-dependent UC (Dignass et al. 2012b; Goel et al. 2015). Anti-TNF- 
therapy may also be continued as maintenance therapy in patients who initially 
respond to treatment (Dignass et al. 2012b), however this is not recommended in 
the UK (Mowat et al. 2011). 
 
CRC prevention strategies in UC 
 
Strategies to prevent CRC in UC include long-term treatment with mesalazine, 
which has an established chemopreventive effect, and colonoscopy surveillance 
with dye spray (chromoendoscopy) and targeted biopsies (Van Assche et al. 
2013). It has been shown that prolonged administration of mesalazine can 
reduce the risk of UC-associated CRC (Velayos et al. 2005), whereas 
maintenance with thiopurines does not have a significant protective effect on the 
development of CRC (Jess et al. 2014). Patients with CD colitis are now 
considered to have a similar risk of CRC as UC patients. 
 
According to the British Society of Gastroenterology guidelines (Cairns et al. 
2010), patients with colitis should have a screening chromoendoscopy with 
targeted biopsies 10 years after diagnosis. The subsequent follow-up is decided 
based on the endoscopic and histologic findings. In particular, in patients with 
dysplasia, colectomy should be considered; patients with extensive moderately 
or severely active colitis, or family history of CRC in first-degree relatives aged < 
50 years, or primary sclerosing cholangitis, or previous evidence of dysplasia and 
declining surgery should undergo yearly encdoscopic surveillance; patients with 
mildly active colitis, or family history of CRC in first-degree relatives aged < 50 
years, or pseudopolyps should undergo endoscopic surveillance every 3 years; 
patients with no evidence of inflammation should undergo surveillance 
colonoscopy every 5 years (Cairns et al. 2010). In the last decade the rate of 
CRC and colectomy in UC patients has decreased, likely due to surveillance 
programs and to the more widespread use of chemoprevention with mesalazine 
(Van Assche et al. 2013; Vester-Andersen et al. 2014). 
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Surgical options and pouchitis 
 
Unlike in CD, surgery can be curative in UC. Emergency surgery is indicated in 
ASUC and toxic megacolon not responsive to medical management, whereas 
elective surgery is mainly indicated in patients with dysplasia or CRC, and 
resistance or contraindication to medical management in active UC (Mowat et al. 
2011). The most frequently performed surgical technique is total proctocolectomy 
with ileal J-pouch-anal anastomosis that usually requires a temporary diverting 
ileostomy (Ordás et al. 2012). The cumulative probability of colectomy in UC is 
20-30% after 25 years, with disease extent and severity of symptoms at 
diagnosis being the most accurate predictors (Cosnes et al. 2011). 
 
Surgery may be complicated by the development of pouchitis, characterised by 
high stool frequency and faecal incontinence, which can be acute or chronic if 
symptoms last less or more than 4 weeks, respectively (Van Assche et al. 2013). 
The first-line treatment of acute pouchitis is metronidazole or ciprofloxacin, 
whereas chronic pouchitis can be treated with antibiotic combination or 
budesonide or, in refractory cases, infliximab (Van Assche et al. 2013). The best 
option both for maintaining antibiotic-induced remission and for preventing 
recurrences of pouchitis is represented by the probiotic preparation VSL#3 
(Holubar et al. 2010; Van Assche et al. 2013). 
 
Management strategies in UC – “Step-up” and “treat-to-target” 
 
The management of chronically active UC still largely relies on a “step-up” 
approach, with decisions on treatment escalation being guided by outcomes of 
previous therapy (Mowat et al. 2011; Dignass et al. 2012b) (Fig. 1.4A). 
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Figure 1.4. Possible treatment strategies in chronically active UC. (A) The 
management of UC in the outpatients setting still largely follows a “step-up” 
approach, with decisions on treatment escalation being guided by outcomes of 
previous therapy. (B) The “treat-to-target” approach in UC is based on the 
definition of a specific therapeutic target and the subsequent selection of the 
appropriate treatment depending on disease activity. Assessment of disease 
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activity is repeated at a pre-specified time point, and therapy adjustment is 
performed accordingly, with the view of leaving the therapeutic target unchanged. 
(Original Figure). 
 
 
Conversely, the management of ASUC, based on the application of the Truelove 
and Witts’ criteria to decide which patients need aggressive treatment in order to 
prevent colectomy, is a good example of patient stratification based on predicted 
risk of subsequent complications. 
 
Similarly to CD, the “treat-to-target” approach is emerging as a valuable strategy 
also in the medical management of chronically active UC, however the proposed 
algorithm in UC is based on disease activity assessment rather than on risk 
evaluation (Fig. 1.4B) (Levesque et al. 2015). The choice of the appropriate 
target is important in order to prevent long-term negative outcomes in UC, and, 
as a therapeutic goal, clinical remission has been surpassed by mucosal healing. 
Failure to achieve mucosal healing after the first course of steroids for newly 
diagnosed UC predicts a more aggressive disease course at 5 years (Ardizzone 
et al. 2011). Conversely, patients who achieve early mucosal healing 
(endoscopic Mayo subscore ≤1 at week 8 after treatment start) after infliximab 
induction are less likely to undergo hospitalisation and colectomy at one year 
compared with those with higher scores (Colombel et al. 2011). Histologic 
healing, which can be defined as the complete resolution of histologic 
abnormalities, is becoming a potential target not only for assessing disease, but 
also for predicting disease evolution and consequently for therapeutic decision 
making in UC (Peyrin-Biroulet et al. 2014; Marchal Bressenot et al. 2015). 
 
The feasibility of the “treat-to-target” approach in clinical practice was tested in a 
pilot study in which 60 UC patients were followed-up for 18 months by means of 
an endoscopic test and therapeutic adjustment within six months from treatment 
start/change until achievement of the pre-specified targets (mucosal healing – 
endoscopic Mayo subscore ≤1; and histologic healing). Most of the patients 
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underwent two or three endoscopic tests in 18 months, and high cumulative rates 
of mucosal and histologic healing were observed (60% and 50%, respectively) 
(Bouguen et al. 2014). 
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1.4 IBD – Aetiopathogenesis 
 
There is evidence that IBD arises as an inappropriate inflammatory reaction to 
stimuli including the intestinal microbiota in genetically susceptible individuals in 
response to environmental triggers. 
 
1.4.1 Genetic susceptibility in IBD 
 
A number of epidemiologic observations support an important role for genetic 
susceptibility in the development of IBD. Jewish populations have a higher 
prevalence compared with non-Jewish population living in the same area 
(Ananthakrishnan 2015). Additionally, studies on migrant populations showed 
that, with time, the risk of developing IBD tends to become similar to that of the 
general population living in the same geographical area. This is more evident 
particularly from the second generation after the migration, supporting the view 
that CD and UC arise from a combination of genetic and environmental factors 
(Cosnes et al. 2011). Studies on familial aggregation showed that 5-15% patients 
with IBD have a positive family history for IBD, and in case both parents are 
affected, the risk of developing IBD before the age of 30 is 33% (Halme et al. 
2006). The concordance rate in monozygotic twins is 20-50% for CD and 
approximately 15% for UC, suggesting that the heritable component is smaller in 
UC than in CD (Ananthakrishnan 2015).  
 
Several mutations and gene variants, many of which affecting loci containing 
genes involved in microbial handling and immune response, are associated with 
CD, UC, or both disease (Fig. 1.5) (Lees et al. 2011; Jostins et al. 2012; 
McGovern et al. 2015). A meta-analysis of genome-wide association studies 
(GWAS) and ImmunoChip data identified 163 loci associated with IBD, which 
explained 13.6% of CD and 7.5% of UC total disease variances (Jostins et al. 
2012), and a trans-ethnic analysis of genome-wide and ImmunoChip data 
identified 38 additional loci associated with CD and UC (Liu et al. 2015). The 
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majority of genetic variations are consistently found both in European and in non-
European cohorts, and are common to both forms of IBD (Jostins et al. 2012; Liu 
et al. 2015). On the other hand, not all loci are reported consistently between 
different GWAS, which underlines the heterogeneity of IBD (Baumgart et al. 
2007a). 
 
 
 
 
Figure 1.5. Heterogeneity of loci containing immune response genes 
associated with IBD. Some of the variants in the listed loci are specific for CD, 
few are specific for UC, and the majority, including several Th1- and Th17-related 
genes, are common to both forms of IBD. (Adapted from Lees et al. 2011). 
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NOD2 polymorphisms 
 
Three mutations in the gene encoding NOD2, also known as caspase recruitment 
domain-containing protein 15 (CARD15), on chromosome 16 are associated with 
a higher risk of CD (Hugot et al. 2001; Ogura et al. 2001), and studies from 
France, Germany, UK, and US have shown that up to 40% of patients with CD 
(compared with 14% of controls) have one or more of these mutations (Cho et al. 
2007a). Homozygous or compound heterozygous carriage of NOD2 risk alleles 
confers a 17-fold increased risk of CD, whereas heterozygous carriage of NOD2 
increases the risk of CD 2.4-fold (Cho et al. 2007b). NOD2 mutations are 
associated with ileal CD and with a higher likelihood of developing fibrostenosing 
complications (Abreu et al. 2002; Cho et al. 2007a). 
 
Several studies have been performed to clarify the functional link between NOD2 
mutations and susceptibility to CD. NOD2 plays an important role in microbial 
handling, as suggested by the observations that NOD2 stimulation by bacterial 
MDP induces the release of -defensins by Paneth cells, activates autophagy in 
DCs by intracellularly directing bacteria to the autophagosome, and promotes 
colonic IEC growth and survival (Cruickshank et al. 2008; Cooney et al. 2010; 
Tan et al. 2015). Mice with targeted NOD2 mutations show altered TLR signalling, 
leading to overproduction of pro-inflammatory cytokines and impaired -defensin 
release by Paneth cells (Watanabe et al. 2004; Kobayashi et al. 2005). 
Overexpression of NOD2 containing the fs1007 mutation associated with CD in 
transgenic mouse macrophages results in up-regulated IL-1 release following 
MDP stimulation (Maeda et al. 2005). Conversely, as compared to control 
subjects, peripheral blood mononuclear cells (PBMCs) from homozygous NOD2 
mutant CD patients fail to up-regulate IL-8 release upon stimulation with MDP, 
and do not show up-regulated TNF- and IL-1 release upon stimulation with 
TLR ligands (Van Heel et al. 2005). Overall, NOD2 mutations appear to promote 
a dysregulated mucosal immune response to microbial components, however the 
exact mechanisms are unknown, likely due to our incomplete understanding of 
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the interactions between the host immune system and the intestinal microbiota 
(Baumgart et al. 2007a). 
 
Polymorphisms in autophagy and in IL-23 receptor (IL23R) genes 
 
Variants in the autophagy genes ATG16L1 and ATG4B have been associated 
with CD (Hampe et al. 2007; Liu et al. 2015). In particular, the T300A ATG16L1 
polymorphism introduces a caspase-3 or caspase-7 cleavage sequence, 
resulting in more efficient degradation of the ATG16L1 allele, with consequent 
impaired autophagy (Lassen et al. 2014; Murthy et al. 2014). A study on Scottish 
population, which has high incidence of CD, the T300A ATG16L1 was found to 
be present in 61% adult-onset CD compared with 54% control subjects (Van 
Limbergen et al. 2008). Variants in IL23R gene are protective against CD (Duerr 
et al. 2006). In particular, the R381Q polymorphism, which is present in 
approximately 14% of the European population, is a loss-of-function allele which 
results in reduced IL-23 signalling (Sarin et al. 2011). It has been calculated by a 
meta-analysis of genetic association studies that the T300A ATG16L1 and the 
R381Q IL23R variants are associated with 38% increase and a 54% decrease in 
the risk for CD (Grigoras et al. 2015). 
 
Polymorphisms in other immune response and intestinal barrier function genes 
 
Single nucleotide polymorphisms (SNPs) in the HLA-DRA gene, encoding for the 
-chain of the MHC class II, are strongly associated with an increased risk of UC 
(McGovern et al. 2015). Variants in the gene encoding for IFN regulatory factor 
(IRF)5, which is a susceptibility gene for rheumatoid arthritis and systemic lupus 
erythematosus, and whose product induces cytokines such as IL-6, IL-12 and 
TNF- via TLR signalling, have been associated with UC (Anderson et al. 2011). 
A highly significant association with UC has also been observed for a common 
polymorphism in a region on chromosome 1q32 containing the IL10 gene, with 
only a very modest association observed in CD (Franke et al. 2008). However, it 
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has been found that the loss-of-function mutations in the IL-10 receptor gene 
results in early-onset IBD with a CD-like phenotype (Glocker et al. 2009; Kotlartz 
et al. 2012). GWAS have identified gene variants related to specific pathways of 
inflammation in IBD (Fig. 1.5). Variants in several genes centrally involved in Th1 
pro-inflammatory immune responses, namely STAT1, STAT4, IL12B, IFNG, and 
IL18RAP, are associated with increased susceptibility to CD and UC (McGovern 
et al. 2015). Polymorphisms in AHR, STAT3, RORC, and CCR6, a group of 
genes involved in Th17 immune response, are associated with a greater risk for 
both CD and UC (Duerr et al. 2006; McGovern et al. 2015). 
 
Finally, mutations in LAMB1, HNF4A, GNA12 and OSMR, which encode for 
important molecules for the intestinal barrier function, are associated with a 
higher risk of IBD (McGovern et al. 2015).  
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1.4.2 Environmental triggers in IBD 
 
There are important evidences that cigarette smoking and appendicectomy play 
a significant role in the aetiopathogenesis of IBD. Moreover, long-term intake of 
specific dietary factors is likely to influence the susceptibility to IBD, despite 
relatively few nutrients have been investigated so far, and some of the results 
have been inconstistent between different studies. 
 
Cigarette smoking 
 
Cigarette smoking is one of the most consistently replicated risk factors for CD 
(Ananthakrishnan 2015). Smoking is associated with a two-fold increase (odds 
ratio [OR] 1.76; 95% confidence interval [CI] 1.40-2.22) in the risk of CD and with 
a similar decrease (OR 0.58; 95% CI 0.45-0.75) in the risk of UC (Mahid et al. 
2006). Conversely, former smoking is associated with an increased (OR 1.79; 
95% CI 1.37-2.34) risk of UC, which remains persistently elevated over 20 years 
after smoking cessation (Mahid et al. 2006; Higuchi et al. 2012). Resumption of 
low dose smoking in a selected group of ex-smokers with treatment-resistant UC 
may ameliorate signs and symptoms (Calabrese et al. 2012). In CD, current 
smoking is associated with earlier age of onset and more frequent need for 
immunosuppression in women but not in men, worsens the disease course, 
favours fistula and stricture formation, and increases the number of flares and 
post-surgical relapses, whereas in UC current smoking is associated with later 
age of onset and lower risk of need for immunosuppression in men but not in 
women (Cosnes et al. 2004; van der Heide et al. 2009). Less than 40% CD 
patients are aware of the detrimental effects of smoking (De Bie et al. 2015). 
Current smoking is also associated with a reduced risk of primary sclerosing 
cholangitis in UC (van der Heide et al. 2009), which suggests that the effects of 
smoking may be systemic and not just limited to the colon. 
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Several hypotheses have been formulated to explain the reasons behind the 
complex relationship between smoking and IBD. Nicotine was believed to play an 
important role due to its ability to increase mucus production and to improve 
intestinal barrier function in experimental colitis (Cosnes 2004), however trials of 
nicotine patches or aenemas were not successful (McGrath et al. 2004; Ingram 
et al. 2005). PBMCs from smokers with CD, but not UC, show an impaired anti-
inflammatory protection against oxidative free radical stress because of lower 
levels of heat shock protein 70 (Bergeron et al. 2012). Polymorphisms in nicotine 
metabolising genes may influence the association between smoking and IBD 
(Ananthakrishnan et al. 2014b). Moreover, it has been shown that smoking is 
associated with changes in the intestinal microbiota composition in humans 
(Biedermann et al. 2014).  
 
Appendicectomy 
 
Appendicectomy appears to have a protective effect against the development of 
UC, since it has been shown to be associated with a 69% reduction in the 
subsequent risk of UC (Koutroubakis et al. 2002). Patients who develop UC after 
appendicectomy are diagnosed at an older age, are less likely to have recurrent 
symptoms, and have a reduced need for immunosuppression, however they 
have a higher risk of primary sclerosing cholangitis (Radford-Smith et al. 2002; 
Gardenbroek et al. 2012). As opposed to UC, a higher incidence of CD has been 
reported following appendicectomy, however it is not clear whether this results 
from diagnostic problems in patients with undiagnosed CD or whether it may 
relate to altered microbial handling by the mucosal immune system and failure to 
develop immune tolerance after appendicectomy (Baumgart et al. 2007a; Kaplan 
et al. 2008). The use of oral contraceptive agents is associated with an increased 
risk of CD, however this effect tends to disappear after suspension (Khalili et al. 
2013). 
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Dietary factors 
 
Currently, nutrients which have been investigated in prospective studies in IBD 
include polyunsaturated fatty acids (PUFAs), vitamin D, fibre, and protein. High 
dietary intake of the n-3 PUFA docosahexaenoic acid is associated to a reduced 
risk of developing CD (Chan et al. 2014). Another prospective study has shown 
that high intake of dietary long-chain n-3 PUFAs is associated with a reduced risk 
of UC, whereas high intake of trans-unsaturated fats appears to be associated 
with an increased risk of UC (Ananthakrishnan et al. 2014a). Higher predicted 
plasma levels of vitamin D, a micronutrient with anti-inflammatory properties, are 
associated with a reduced risk of developing CD (Ananthakrishnan et al. 2012). 
Interestingly, normalisation of plasma level of vitamin D is associated with a 
lower risk of surgery and hospitalisation in CD (Ananthakrishnan et al. 2013a). 
Long-term intake of dietary fibre, particularly from fruit, is associated with 
significantly lower risk of CD, but not UC (Ananthakrishnan et al. 2013b). Finally, 
in the French cohort of the EPIC-IBD study, a positive association between 
animal, but not vegetable, protein intake and risk of IBD has been reported 
(Jantchou et al. 2010), whereas in the whole European study no association 
between body mass index and risk of IBD has been reported (Chan et al. 2013). 
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1.4.3 The intestinal microbiota in IBD 
 
There is abundant evidence that the intestinal microbiota plays an important role 
in the pathogenesis of intestinal inflammation, and this is epitomised by the 
observation that, despite germ-free mice have increased susceptibility to 
infections, such as Salmonella, Shigella, Listeria and Leishmania, experimental 
colitis does not develop under germ-free conditions (Sartor 2004). 
 
Effects of intestinal microbiota alterations and constituents on experimental colitis 
 
It has been shown in various experimental models that, in genetically susceptible 
hosts, changes in the intestinal microbiota may be required for the development 
of intestinal inflammation. For example, Tbx21-/-Rag2-/- ulcerative colitis (TRUC) 
mice, which lack the transcription factor T-bet in the innate immune system and 
do not develop colitis spontaneously unless infected with the Proteobacterium 
species Helicobacter typhlonius (Powell et al. 2012). Mice with a mutation in 
ATG16L1 develop a dysfunction in Paneth cells and an altered response to DSS 
colitis resembling CD, which are both dependent on infection with Norovirus, and 
are prevented by broad-spectrum antibiotics (Cadwell et al. 2010). 
 
Conversely, a rational selection of Treg-inducing bacterial strains from the stool 
microbiota of a healthy volunteer has been shown to ameliorate TNBS-induced 
colitis (Atarashi et al. 2013). It has also been demonstrated that B. fragilis 
polysaccharide A, which can undergo processing by DCs and be presented to T 
cells despite being a polysaccharide, is responsible for protecting Rag-/- mice 
from T cell transfer colitis exacerbated by H. hepaticus (Mazmanian et al. 2008). 
B. fragilis polysaccharide A appears to exert its effect by promoting the 
differentiation of IL-10-producing Tregs and by inhibiting Th1 and Th17 response 
(Mazmanian et al. 2008). These observations suggest that targeted modulation 
of the intestinal microbiota may hold considerable therapeutic potential in IBD.  
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Alterations of the intestinal microbiota in IBD 
 
There are significant differences in the intestinal commensal microbiota 
composition between IBD patients and healthy individuals, and IBD patients have 
a reduced biodiversity of the intestinal microbial community compared to control 
subjects (Qin et al. 2010; Carding et al. 2015). Firmicutes and Bacteroidetes are 
underrepresented in the intestinal microbiota of CD patients, whereas 
Enterobacteriaceae and Proteobacteria are overrepresented (Kostic et al. 2014). 
In particular, the butyrate-producing Firmicutes species Faecalibacterium 
prausnitzii, which is less abundant in patients with IBD, appears to have a 
protective effect, as patients with high levels are less prone to recurrence 
following surgical resections (Sokol et al. 2008).  
 
High frequency of the pathogen Mycobacterium avium subspecies 
paratuberculosis has been reported in CD (Feller et al. 2007), and presentation 
of IBD occurs frequently after gastrointestinal infections (García Rodríguez et al. 
2006). AIEC has been found to preferentially colonise the ileal mucosa in CD 
patients (Darfeuille-Michaud et al. 2004). AIEC reduces levels of ATG16L1 in 
epithelial cells, and favours invasion both by inhibiting autophagy and by 
producing the mucin-degrading protease Vat-AIEC (Nguyen et al. 2014; Gibold et 
al. 2015). Finally, C. difficile infection is associated with a higher risk of mortality 
and morbidity in IBD patients (Ananthakrishnan et al. 2009). Dysbiosis in IBD is 
not limited to bacterial species. It has been shown that both CD and UC are 
associated with the expansion of Caudovirales, independently from bacterial 
dysbiosis (Norman et al. 2015), and aberrant immune response to indigenous 
fungi influences susceptibility to experimental colitis (Iliev et al. 2012). 
 
Evidences suggesting a contributing role of the intestinal microbiota in IBD 
 
Overall, IBD is more prevalent in the distal ileum and colon, consistent with the 
idea that they reflect aberrant inflammatory responses to the intestinal microbiota 
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(Knights et al. 2013). Remarkable differences in microbial composition between 
healthy control subjects and CD have been shown in a large cohort of paediatric 
new-onset and treatment-naïve CD patients, thereby minimising the influence of 
confounding factors, such as drugs and disease duration, on the intestinal 
microbiota and highlighting some important changes preceding the start of 
treatment (Gevers et al. 2014; Hall et al. 2014). In particular, in CD samples there 
was abundance of Pasteurellaceae, Veillonellaceae, Neisseriaceae, and 
Fusobacteriaceae, and depletion of Bacteroidetes, Faecalibacterium, and 
Bifidobacterium (Gevers et al. 2014). These differences were only revealed by 
analysis of mucosal tissue rather than faecal samples, suggesting that bacteria 
resident on the mucosal surface may be more relevant for disease development 
than those present in the lumen (Gevers et al. 2014; Hall et al. 2014). However, it 
is currently unclear whether changes in intestinal microbial composition observed 
in IBD contribute to, or rather are a consequence of the mucosal lesions (Carding 
et al. 2015). Moreover, it has been shown in a prospective study that serologic 
positivity for a combination of antibodies against E. coli outer membrane porin 
and flagellin, ASCA and pANCA predicts the development of IBD in a low-risk 
population (van Schaik et al. 2013). 
 
There is evidence to suggest that perturbation of the intestinal microbiota with 
antibiotics in early childhood may influence the mucosal immune response and 
confers high susceptibility to IBD. This is supported by the observations that, 
compared to 39% of the control subjects, 58% of paediatric patients with IBD 
received an antibiotic in their first year of life, and that the relative risk of CD in 
children who previously used antibiotics is 1.84 higher compared to non-users 
(Shaw et al. 2010; Hviid et al. 2011). Moreover, multiple antibiotic courses are 
associated with a higher risk of IBD than one single course (Kronman et al. 2012). 
On the other hand, antibiotics such as metronidazole and ciprofloxacine are 
effective in perianal disease and decrease the risk of post-operative recurrences 
in CD, and both probiotics and antibiotics are useful in the treatment of pouchitis 
(Mowat et al. 2011). 
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1.4.4 Inappropriate inflammatory reaction in IBD intestinal mucosa 
 
Dysregulation of the intestinal immune response in IBD involves several 
components of the mucosal immune system (Cader et al. 2013). This Section 
focuses on changes in intestinal barrier and epithelial function, on the aberrant 
mucosal B cell response, on the mucosal T cell response and the relative 
cytokines involved.
 
Impaired intestinal barrier and epithelial function in IBD 
 
One of the key initiating mucosal alterations in IBD is a defect in the intestinal 
barrier function. Multiple mouse models of colitis, such as IL-10-/- mice, TNFARE 
mice, and the CD45RBhi-adoptive transfer model, share a component of barrier 
loss and epithelial damage (Nalle et al. 2015). Interestingly, in IL-10-/- mice, 
barrier loss precedes the onset of colitis. Alterations in tight junction composition 
play an important role in inducing intestinal epithelial barrier dysfunction and in 
favouring inflammation. It has been observed that mice with constitutively 
activated MLCK and consequent increased paracellular permeability, when 
crossed with mice which spontaneously develop colitis, develop accelerated and 
more severe intestinal inflammation (Su et al. 2009). An important consequence 
of impaired intestinal barrier function is that it allows luminal antigens, including 
the microbiota, to interact with the components of the mucosal immune system 
directly and without regulation. It has been shown that, in IL-10-/- mice, before the 
onset of inflammation, the inner colonic mucus layer has a normal thickness but 
is penetrable to bacteria (Johansson et al. 2014). Moreover, it has been 
observed that conditional claudin 7 knock-out in IECs determines a selective loss 
of barrier function in the colon, which leads to the absorption of a bacterial 
chemoattractant for neutrophils, and to the consequent onset of intestinal 
inflammation (Tanaka et al. 2015). 
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Patients with IBD have increased intestinal permeability, not only in the inflamed 
mucosa, but also in non-inflamed areas (Söderholm et al. 2002; Hedin et al. 
2012). The defect in the intestinal barrier function in CD has a genetic component, 
as suggested by the observation that it occurs in healthy relatives of CD patients 
(May et al. 1993; Buhner et al. 2006). Moreover, intestinal barrier impairment has 
been shown to precede the onset of CD in a patient with positive family history 
(Irvine et al. 2000). Matriptase transcripts are significantly down-regulated in 
inflamed colonic mucosa of both CD and UC compared to control subjects, and 
this may promote the increase in intestinal permeability observed in IBD (Netzel-
Arnett et al. 2012). Finally, it has been shown that IBD patients in remission with 
intestinal barrier defect consequent to excessive IEC shedding and have a higher 
risk of relapse compared to those with an intact barrier (Kiesslich et al. 2012). 
 
IECs may contribute to the inflammatory process by releasing pro-inflammatory 
cytokines, such as IL-15 and IL-8, or by producing smaller amounts of the 
tolerogenic factor TSLP (Kaser et al. 2010). In the presence of pro-inflammatory 
cytokines such as IFN- and TNF-, IECs acquire overexpression of MHC 
molecules and may function as APCs and activate T cells (Cruickshank et al. 
2004). Co-culture of IECs from IBD patients has been shown to induce control 
CD4+ T cells to proliferate and produce IFN- (Dotan et al. 2007).Aberrant TLR 
signalling in IECs may contribute to the development of intestinal inflammation by 
altering the response to the intestinal microbiota, thereby facilitating tissue injury 
and pro-inflammatory responses (Cario 2010). It has been observed that, in the 
IL-2-/- mouse model of colitis, colonic IECs show decreased TLR4 
responsiveness and increased TLR2 responsiveness, with up-regulated 
production of IL-6 and IL-18 (Singh et al. 2005). PRR expression by IECs is 
dysregulated in IBD, with significant up-regulation of TLR4 in IBD, up-regulation 
of NOD2 in CD, and down-regulation of TLR3 in CD as compared to control 
subjects (Cario et al. 2000; Berrebi et al. 2003). Patients with UC show goblet 
cell and mucin depletion. Moreover, it has been shown that Paneth cells from 
ileal CD patients with NOD2 mutations express reduced levels of human -
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defensin 5 and human -defensin 6 (Wehkamp et al. 2005). Moreover, differently 
from PBMCs from control subjects, PBMCs from CD patients fail to restore 
defensin production by Paneth cells (Courth et al. 2015). CD patients who are 
homozygous for the T300A ATG16L1 polymorphism have marked abnormalities 
in the secretory apparatus of Paneth cells (Cadwell et al. 2008). Finally, features 
of unfolded protein response, which arises from endoplasmic reticulum stress in 
highly secretory cells such as Paneth cells, have been found to be present both 
in uninflamed and inflamed IBD epithelium, irrespective of genetic risk variants 
within this pathway (Kaser et al. 2011; Tréton et al. 2011). 
 
Aberrant mucosal B cell response in IBD 
 
There is evidence of dysregulated humoral immune response in IBD, and also 
this alteration may reflect aberrant handling of the intestinal microbiota by the 
mucosal immune system in this condition, as suggested by the frequent 
presence of antibodies directed against microbial components and ASCA in CD 
patients. Unlike CD, UC is often being regarded to as an autoimmune disease, 
and among the evidences quoted to support this concept are the frequent 
positivity of serum pANCA and anti-goblet cell autoantibodies, and the presence 
of genetic risk variants in the the HLA-DRA gene (Leiper et al. 2011). Moreover, 
the abnormal mucosal immune cell response in UC has been considered to be 
driven by B cell-promoting Th2 cells (Fuss et al. 2008). However, treatment with 
rituximab, a humanised antibody against the B cell surface marker CD20, has not 
been effective in a randomised clinical trial in UC (Leiper et al. 2011). 
 
The intestinal lamina propria in IBD is infiltrated by cytotoxic, granzyme B-
expressing CD19+ and IgA+ plasma cells, which may contribute to mucosal 
damage (Cupi et al. 2014). Mucosal production of pIgA, and J chain and pIgR 
expression are significantly decreased in IBD mucosa. Moreover, in this condition 
there is a substantial shift from IgA2 to IgA1 mucosal synthesis, which has 
important consequences as this latter subclass is less resistant to proteolytic 
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degradation. Impaired SIgA-mediated immune exclusion may contribute to the 
formation of autoantibodies and antibodies against microbial antigens commonly 
observed in IBD (Brandtzaeg et al. 2006). On a different line, it has been shown 
that faecal bacteria from IBD patients which are highly coated in SIgA confer a 
higher susceptibility to experimental colitis (Palm et al. 2014). Moreover, unlike 
uncoated microbial species, when SIgA-coated bacteria are transplanted into 
mice with DSS-induced colitis, they induce a substantial exacerbation of 
intestinal inflammation (Shapiro et al. 2015). 
 
Aberrant mucosal T cell response in IBD 
 
Several in vivo and in vitro evidences support the importance of both effector T 
cell overactivation and imbalance between effector T cells and Tregs in triggering 
and sustaining mucosal inflammation in IBD. A large number of mouse models of 
colitis, including TNBS-, DSS- and oxazolone-induced, T cell transfer, and IL-10-
deficient colitis, have been shown to be associated or dependent on an abnormal 
T cell response (Maynard et al. 2009). Furthermore, inflammatory lesions 
develop in small intestinal foetal explants cultured ex vivo with IL-12 and anti-
CD3 (Pender et al. 1996), and inhibition of T cell activation, for example upon 
selective blockade of calcium channels on T cell membrane, leads to a reduction 
in pro-inflammatory cytokine production both in vitro and ex vivo (Di Sabatino et 
al. 2009a).  
 
Excessive mucosal T cell activation in IBD may be promoted by the presence of 
an increased proportion of activated DCs in the lamina propria. Conversely, 
circulating immature DCs are depleted in active IBD, and display an aberrant 
response to bacterial CpG-DNA, suggesting a dysregulated interaction with the 
intestinal microbiota (Baumgart et al. 2005). Studies performed using KLH 
immunisation have shown that oral tolerance is defective in patients with IBD, 
and also in healthy family members, suggesting that this alteration may 
contribute to disease susceptibility (Kraus et al. 2006). A considerable effort has 
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been dedicated to the characterisation of the different mucosal effector T cell 
responses involved in CD and in UC. 
 
Th1 and Th2 cells and cytokines in IBD 
 
An abnormal mucosal Th1 immune response, triggered by increased mucosal 
levels of IL-18 and IL-12, is present in inflamed intestinal areas in CD 
(Monteleone et al. 1997; Monteleone et al. 1999; Podolsky 2002). Indeed, 
macrophage-derived IL-12 is overexpressed preferentially in CD (Monteleone et 
al. 1997). It has been observed that, while IFN- and IL-2 production by T-LPLs is 
undetectable in the majority of UC patients and control subjects, the proportion of 
IL-2- and IFN--producing T-LPLs ranges between 3 and 18% in CD patients. 
This was confirmed by Northern blot analysis, which showed the presence of 
IFN- mRNA in resected colonic mucosa of 5 out of 6 CD patients, as opposed to 
1 out of 5 UC patients, and none out of 9 control subjects (Breese et al. 1993). 
Accordingly, IFN- production by LPMCs measured by flow cytometry was 
significantly higher in CD patients compared to UC patients and control subjects 
(Noguchi et al. 1995). 
 
A few years later, it was demonstrated by LPMC isolation and culture and 
subsequent enzyme-linked immunosorbent assay (ELISA) assays that, upon 
activation via the CD2/CD28 pathway, CD4+ T-LPLs from CD patients release 
significantly higher IFN- concentrations (mean > 85000 pg/ml) than CD4+ T-
LPLs from UC patients (mean < 60000 pg/ml) or control subjects (mean < 60000 
pg/ml) (Fuss et al. 1996). Interestingly, upon activation via both the CD2/CD28 
and the CD3/CD28 pathways, CD4+ T-LPLs from both CD and UC patients 
produced significantly lower concentrations of IL-4 compared with CD4+ T-LPLs 
from control subjects, nevertheless the mean concentration was lower than 150 
ng/ml for all the groups studied (Fuss et al. 1996). Furthermore, upon activation 
of both the CD2/CD28 and the CD3/CD28 pathways, CD4+ T-LPLs from UC 
patients produced significantly higher levels of IL-5 than CD4+ T-LPLs from CD 
  
121 
patients and control subjects, nevertheless the mean concentration was lower 
than 300 ng/ml for all the groups studied (Fuss et al. 1996). These results were 
confirmed by subsequent studies from the same research group, showing that 
anti-CD2/CD28-activated LPMCs from CD patients produce significantly higher 
concentrations of IFN- (mean > 20000 pg/ml) than UC and control LPMCs 
(mean < 5000 pg/ml), significantly lower concentrations of IL-4 (mean < 20 pg/ml) 
than control LPMCs (mean > 60 pg/ml), and significantly lower concentrations of 
IL-5 (mean < 50 pg/ml) than UC LPMCs (mean > 150 pg/ml) (Fuss et al. 2004; 
Heller et al. 2005). 
 
It has been reported that anti-CD2/CD28-activated UC LPMCs release 
significantly higher concentrations of the Th2 cytokine IL-13 (mean > 900 pg/ml) 
compared to LPMCs from CD patients and control subjects (mean < 300 pg/ml) 
(Fuss et al. 2004; Heller et al. 2005). It has also been reported that the main 
source of IL-13 in UC mucosa is represented by non-invariant NKT cells, with up 
to 76% LPMCs being positive for IL-13 after anti-CD2/CD28 activation in UC, as 
opposed to less than 3% in CD patients and control subjects, and up to 24% 
being NKT cells, as opposed to 0.5% in CD patients and control subjects (Fuss 
et al. 2004). Subsequently, it has been reported that more than 30% LPMCs the 
colon of UC patients is constituted by non-invariant NKT cells which respond to 
stimulation with lyso-sulfatide glycolipid-loaded CD1d-tetramer by producing IL-
13 and by enhancing their cytotoxic effect on IECs (Fuss et al. 2014). 
Furthermore, IL-13 transcripts have been found to be detectable in 45% UC 
colonic samples, whereas they were undetectable in all samples from control 
subjects, and the frequency of UC samples positive for IL-13 mRNA was 
significantly higher in inflamed mucosa compared to uninflamed intestine 
(Kawashima et al. 2011). Finally, immunohistochemical characterisation of 
colonic mucosa showed that phosphorylated STAT6 is absent in paediatric CD 
patients and control subjects, whereas high expression levels are detectable in 
paediatric UC patients (Rosen et al. 2011). 
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Nevertheless, there have also been different observations about mucosal Th1 
and Th2 cytokines in IBD. Both inflamed CD and UC biopsies cultured ex vivo 
release significantly higher amounts of IFN- (mean 234 and 202 pg/ml, 
respectively) compared to control biopsies (mean 23 pg/ml), with no significant 
difference between CD and UC (Rovedatti et al. 2009). Similar observations have 
been reported by Bernardo et al. (Bernardo et al. 2012), who have described the 
presence of a mixed cytokine profile with predominance of IL-6 and absence of 
IL-13 in supernatants of UC biopsies cultured ex vivo. In another study, 
significantly lower levels of IL-13 were found in the colonic mucosa of UC 
patients (median 56 pg/mg of tissue) compared to CD patients and control 
subjects (82 pg/mg of tissue and 83 pg/mg of tissue, respectively) (Vainer et al. 
2000). Finally, evaluation of cytokine production by biopsies from paediatric 
patients with IBD cultured ex vivo revealed that IL-13 concentration were 
significantly lower in supernatants of UC biopsies compared to CD and control 
supernatants (Kadivar et al. 2004). 
 
IFN- is a potent pro-inflammatory cytokine produced by Th1 cells and by innate 
lymphoid cells (ILCs) (Neurath 2014). IFN- has been shown to play an important 
role in the pathogenesis of T cell transfer experimental colitis, and the 
administration of anti-IFN- antibodies to mice soon after T cell transfer prevents 
the onset of colitis (Powrie et al. 1994b). IFN- can activate a wide spectrum of 
immune cells, including endothelial cells, lymphocytes and macrophages, and 
stimulates macrophages to release TNF- (Boehm et al. 1997). Moreover, IFN- 
enhances the expression of MHC on APCs and promotes neutrophil migration by 
enhancing the expression of chemokines and their receptors (Colgan et al. 1993). 
 
IL-13 is a pleiotropic cytokine produced by T cells and NKT cells, with effects on 
many cell types, including macrophages, epithelial cells, smooth muscle cells 
and neurons (Wynn 2003). NKT cell-derived IL-13 has been implicated in the 
pathogenesis of an experimental model of colitis, namely oxazolone-induced 
colitis, in which disease can be prevented by treating mice with an IL-13 receptor 
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(IL-13R)2-Fc fusion protein (Heller et al. 2002). Interestingly, administration of 
neutralising antibodies against IL-17E, which is a potent inducer of Th2 cell 
development, before treatment with oxazolone ameliorates experimental colitis 
(Camelo et al. 2012). On the other hand, the observation that IL-13, in the 
absence of the decoy receptor IL-13R2, may suppress the development and 
function of Th1/Th17 cells in a murine model of colitis, does not support the pro-
inflammatory role of IL-13 in the intestine (Wilson et al. 2011). IL-13 activates the 
pro-apoptotic protease caspase-3 in mouse colonic IECs (Kawashima et al. 
2011). Moreover, IL-13 has a well-established role in enhancing epithelial 
permeability via the pore pathway by up-regulating claudin 2 expression within 
the tight junctions (Weber et al. 2010). 
 
Despite the contrasting observations regarding IL-13 expression and function in 
intestinal inflammation, CD has been thought to be characterised by a Th1 
immune response with predominant IFN- production, while UC has been 
considered as a Th2-mediated disease, with excessive production of IL-5 and IL-
13. In particular, based on data in experimental colitis, on the observations that 
IL-13 is up-regulated in UC, and on the in vitro establishment of plausible 
mechanisms of IL-13-mediated intestinal injury, neutralisation of this cytokine has 
been considered to be a promising therapeutic strategy in UC (Mannon et al. 
2012). 
 
Th17 cells and cytokines in IBD 
 
After the identification of genetic risk variants within the IL-23-Th17 pathway in 
IBD, the expression of Th17-associated cytokines has been studied in intestinal 
inflammation. Significantly higher transcript levels of IL-17A have been detected 
both in CD and UC mucosa in comparison to the normal intestine (Sugihara et al. 
2010). Moreover, T-LPLs from both CD and UC patients express significantly 
higher IL-17A transcript levels compared to those from control subjects 
(Kobayashi et al. 2008). It has been observed by immunohistochemistry that, 
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while IL-17A is undetectable in the lamina propria of control subjects, high levels 
of IL-17A are present in CD3+ and CD68+ cells in the lamina propria of IBD 
patients (Fujino et al. 2003). Moreover, inflamed mucosa from both CD and UC 
patients cultured ex vivo produces significantly higher levels of IL-17A (mean 188 
and 130 pg/ml, respectively) than control mucosa (mean 27 pg/ml) (Rovedatti et 
al. 2009). Moreover, the lamina propria of both CD and UC (mean 5.6% and 
6.7% of CD3+ LPMCs, respectively) patients contains significantly more Th17 
cells than the lamina propria of control subjects (mean 2.4% of CD3+ LPMCs) 
(Rovedatti et al. 2009). 
 
IL17A is a pleiotropic cytokine expressed mainly by T cells and ILCs, which acts 
on both immune and non-immune cells (Neurath 2014). IL17R is expressed on a 
wide range of cells, including fibroblasts, epithelial and endothelial cells (Toy et al. 
2006). It has been shown that IL-17A induces IL-6 and IL-8 production in vitro 
through mitogen-activated protein kinase (MAPK) pathways, thus favouring the 
recruitment of neutrophils at sites of inflammation, and triggers T cell proliferation 
and up-regulation of pro-inflammatory molecules, such as inducible nitric oxide 
synthase and IL-1 (Awane et al. 1999; Laan et al. 2001; Kolls et al. 2004). 
 
Th17 cells are also an important source of IL-21, an IL-2-related cytokine which 
is up-regulated in inflamed IBD mucosa (Monteleone et al. 2005; Sarra et al. 
2010). IL-21 enhances Th1 and Th17 immune responses in the intestine, as 
shown by the demonstration that IL-21-deficient mice are resistant to Th1/Th17 
cell-driven models of colitis and by the observation that IL-17A and IFN- 
production by activated LPMCs from IBD patients is inhibited when IL-21 is 
blocked (Monteleone et al. 2005; Fina et al. 2008). Finally, Th17 cells also 
produce IL-22, which regulates epithelial cell proliferation, wound healing 
processes, and expression of defensins and Reg3 (Pickert et al. 2009). It has 
been observed that IL-22-producing cells are significantly reduced in the inflamed 
mucosa of UC, but not CD, patients compared to control subjects (Leung et al. 
2014). 
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The importance of Th17 cells in intestinal inflammation has been demonstrated in 
vivo in T cell transfer colitis. In particular, it has been shown that, while transfer of 
T cells lacking the capacity to produce individual Th17 cytokines to RAG-deficient 
mice is sufficient to induce colitis, transfer of T cells from a RORt-deficient 
animal fails to induce colitis, indicating that at least one member of Th17 cytokine 
family is required for intestinal inflammation (Leppkes et al. 2009). The 
observation that blocking the p40 subunit, shared by IL-12 and IL-23, improves 
both murine colitis and active CD (Sandborn et al. 2008) has reinforced the 
hypothesis that not only the IL-12/Th1 axis, but also the IL-23/Th17 axis, may be 
playing an important pro-inflammatory role in IBD. However, secukinumab, a 
monoclonal antibody directed against IL-17A, has been ineffective in in active CD 
(Hueber et al. 2012). Indeed, neutralisation of IL-17A and IL-17F alone is 
ineffective or has a detrimental effect on T cell transfer experimental colitis 
(O'Connor et al. 2009), and treatment with IL-22 protects mice from T cell-
dependent colitis (Zenewicz et al. 2009). On the other hand, IL-21 deficiency 
significantly improves experimental colitis (Fina et al. 2008). These observations 
underline the complex effects of Th17 immune response in the intestinal mucosa, 
which can be pro- or anti-inflammatory depending on the model and the context 
considered, and on the predominant cytokine expression profile. 
 
Defective mucosal regulatory mechanisms in IBD 
 
Several mucosal immune regulatory mechanisms have been studied in IBD, 
including TGF- signalling, Tregs, and IL-17E expression and function. 
 
Both TNBS- and oxazolone-induced colitis are characterised by up-regulated 
expression of TGF- in inflamed tissue, associated with impaired TGF- 
signalling due to elevated levels of inhibitory Smad7, which in turn leads to 
reduced phosphorylated Smad3 (Boirivant et al. 2006). Moreover, Smad7 
overexpression in transgenic mice increases the severity of disease in DSS-
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induced colitis by inducing a prominent Th1 response (Rizzo et al. 2011). TGF- 
expression is increased in the inflamed colonic mucosa of IBD patients with 
active disease compared to control mucosa (Babyatsky et al. 1996). However, 
pre-incubation of IBD LPMCs with TGF- is unable to prevent TNF--induced 
NF-B activation, implying their resistance to TGF--mediated 
immunosuppression (Monteleone et al. 2004). Indeed, TGF- signalling pathway 
is defective in CD, as indicated by the reduced levels of phosphorylated Smad3 
and Smad3-bound Smad4 in inflamed CD intestinal mucosa (Monteleone et al. 
2001). This is due to the up-regulation of Smad7 in CD mucosa, where Smad7 is 
overexpressed by both T cells and non-T cells and critically impairs TGF- 
signalling (Monteleone et al. 2001). 
 
Transfer of CD4+ T cells depleted of Tregs into RAG-/- mice results in colitis, and 
Tregs suppress Th1-mediated experimental colitis (Powrie et al. 1994a; Fantini et 
al. 2006). The ability of Tregs to suppress intestinal inflammation in RAG-/- mice 
depends on their release of IL-10 and TGF- (Maloy et al. 2003). Tregs are 
depleted in peripheral blood of patients with active IBD compared to quiescent 
IBD patients and control subjects (Singh et al. 2001; Chamouard et al. 2009). 
Conversely, there is a higher number of Tregs in the intestinal mucosa of IBD 
patients compared to control subjects, and Tregs isolated from IBD intestinal 
mucosa display normal ability to suppress the proliferation of effector T cells in 
vitro (Maul et al. 2005; Saruta et al. 2007; Eastaff-Leung et al. 2010). An intact 
TGF- signalling, which is impaired in inflamed IBD mucosa because of up-
regulation of the inhibitory molecule Smad7, is required for Treg function 
(Monteleone et al. 2001; Fahlén et al. 2005). Effector T cells from IBD intestinal 
mucosa are hyporesponsive to Treg-mediated suppressive action, and this 
depends on defective TGF- signaling due to high Smad7 expression, as T cell 
responsiveness to Tregs is restored by the culture with Smad7 antisense 
oligonucleotide (Fantini et al. 2009). 
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IL-17E promotes Th2 cell differentiation and inhibits Th1 and Th17 responses 
(Monteleone et al. 2010). It has been showed that IL-17E, which in the human 
intestine is expressed mainly by subepithelial macrophages, is significantly 
reduced in the inflamed intestinal mucosa of subjects with IBD compared with 
control subjects (Caruso et al. 2009). Moreover, the addition of IL-17E to LPMCs 
isolated from inflamed IBD intestinal areas and stimulated with LPS or 
peptidoglycan significantly down-regulates the production of IL-12 and IL-23 
compared to the condition with LPS or peptidoglycan alone. The defect in the 
production of IL-17E in IBD could therefore be responsible for the upregulation of 
IL-12 and IL-23, with expansion of the mucosal Th1 and Th17 cells and 
consequent tissue damage (Caruso et al. 2009). 
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1.4.5 TNF- and TNF- neutralisation in IBD 
 
It is well established that TNF- expression, both at the transcript and protein 
levels, is markedly up-regulated in IBD inflamed intestinal mucosa compared to 
control mucosa (Dionne et al. 1997). Moreover, stool TNF- concentration has 
been shown to be significantly increased in paediatric CD and UC patients 
compared to control children (Braegger et al. 1992). Immunohistochemical 
staining has revealed that the median density of TNF--expressing cells in the 
lamina propria of CD and UC patients (148 and 145 cells/mm2, respectively) is 
significantly higher compared to control subjects (5.5. cells/mm2) (Murch et al. 
1993). It has been shown that a high proportion of CD14+ and CD4+ LPMCs from 
IBD patients express transmembrane TNF- and release soluble TNF- 
(Kamada et al. 2008; Atreya et al. 2011). 
 
TNF-, which signals via NF-B activation, is indeed produced by macrophages, 
DCs and T cells, and is biologically active as a homotrimeric transmembrane 
protein and as soluble TNF- after being cleaved by TACE (Scheller et al. 2011; 
Cabal-Hierro et al. 2014). TNF- receptor (TNFR)2 activation on T cells induces 
experimental colitis in vivo (Holtmann et al. 2002), and neutralisation of 
transmembrane, but not soluble, TNF- suppresses murine experimental colitis 
(Perrier et al. 2013). TNF- can exert a wide range of pro-inflammatory effects. In 
particular, TNF- induces intestinal barrier impairment by enhancing paracellular 
permeability via MLCK activation (Clayburgh et al. 2005), and by promoting IEC 
and Paneth cell necroptosis via receptor-interacting protein kinase (RIPK)3 
activation (Günther et al. 2011). TNF- also promotes the expression of 
MAdCAM-1 on endothelial cells in vitro (Oshima et al. 2001), thereby favouring 
the recruitment of T cells expressing 47 integrin to the intestinal mucosa. 
Moreover, TNF- may favour tissue damage by stimulating myofibroblasts to 
produce MMPs (Okuno et al. 2002). Finally, TNF- promotes macrophage 
activation in vitro (Wesemann et al. 2003). 
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The strongest evidence that TNF- plays a central role in the pathogenesis of 
IBD is provided by the therapeutic success of TNF- neutralisation in IBD. In 
particular, biologic therapies with agents which neutralise TNF- have 
revolutionised the treatment of human chronic inflammatory disease, including 
IBD (Kuek et al. 2007). Responsiveness, however, is difficult to predict, and there 
may be differences in efficacy and mode of action between different agents 
(Nesbitt et al. 2007; Tracey et al. 2008; Siegel et al. 2009). For example, 
infliximab and adalimumab are monoclonal IgG1 antibodies, whereas etanercept 
is a dimeric p75 TNF receptor-IgG Fc fusion protein (Sandborn et al. 2002; 
Rutgeerts et al. 2009). The fact that etanercept is not effective in CD (Sandborn 
et al. 2001), but is effective in rheumatoid arthritis and psoriasis (Weinblatt et al. 
1999; Leonardi et al. 2003), remains unexplained. 
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1.4.6 Proteases in IBD intestinal mucosa 
 
Excessive protease expression is a common feature of chronic inflammatory 
disorders, and elevated tissue levels of proteases are present in rheumatoid 
arthritis, asthma, chronic obstructive pulmonary disease, and IBD (Baugh et al. 
1999; Vandooren et al. 2004; Elkington et al. 2006; Shimshoni et al. 2015). In 
particular, during intestinal inflammation, several proteases are expressed at 
higher than normal levels, and dysregulated proteolysis leads to both structural 
and functional alterations in the intestinal barrier, which ultimately promote the 
development of intestinal lesions. 
 
Protease up-regulation in IBD inflamed mucosa 
 
Dysregulation of protease expression and activity in IBD mucosa has been 
repeatedly and consistently reported in several studies. MMP-1, MMP-2, MMP-3, 
MMP-7, MMP-8, MMP-9, MMP-10, MMP-12, collagenase 3 (MMP-13) and MMP-
14 are all up-regulated in IBD inflamed mucosa (Ravi et al. 2007; OʼShea et al. 
2014; O'Sullivan et al. 2015). Conversely, epilysin (MMP-28) is down-regulated in 
the inflamed mucosa of UC patients compared to control subjects (Rath et al. 
2010). 
 
Protein extracts from both inflamed and ulcerated intestinal mucosa of both CD 
and UC patients are characterised by an increased expression of MMP-1, MMP-
2, MMP-3, MMP-12, collagenase 3 (MMP-13) and MMP-14 compared to normal 
intestinal mucosa, and all these enzymes can be produced by stromal and 
immune cells in the lamina propria (Heuschkel et al. 2000; von Lampe et al. 
2000; Ravi et al. 2007). In situ hybridisation studies have shown high transcript 
levels of MMP-1, MMP-3 and MMP-12 in the granulation tissue around intestinal 
ulcerations of IBD patients, and myofibroblasts in these ulcers also express 
MMP-13 (Saarialho-Kere et al. 1996; Vaalamo et al. 1998; Di Sabatino et al. 
2009b). There is also evidence that another important source of MMP-3 in IBD 
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mucosa is represented by long-lived lamina propria IgG plasma cells (Gordon et 
al. 2008). MMP-9 is highly up-regulated in the inflamed mucosa of IBD patients, 
and mucosal MMP-9 levels correlate with disease activity in IBD (Baugh et al. 
1999). MMP-7 is also highly overexpressed in inflamed IBD mucosa, and its 
levels correlate with disease activity in UC (Matsuno et al. 2003; Salmela et al. 
2004). The epithelium at the edge of intestinal ulcers in IBD is strongly positive 
for MMP-7 and MMP-10 (Saarialho-Kere et al. 1996; Vaalamo et al. 1998). In 
particular, disruption of the basement membrane below the MMP-7-positive IECs 
has been reported in IBD (Saarialho-Kere et al. 1996), and immediately below 
MMP-10-expressing IECs there is loss of laminin staining, suggesting enzymatic 
degradation (Vaalamo et al. 1998). 
 
Proteases are dysregulated in IBD not only in terms of expression levels, but also 
in terms of main producing cell types. For example, in mucosal ulcers of IBD 
patients, MMP-1 is expressed by macrophages and myofibroblasts, but not by 
IECs (Arihiro et al. 2001). MMP-2 is highly up-regulated in IBD ulcers and is 
released in excess by IECs, lamina propria myofibroblasts, macrophages and 
lymphocytes (Kirkegaard et al. 2004). MMP-8 and MMP-9, which are essentially 
undetectable in the normal intestine, are produced in large amounts by IECs 
during active IBD (Pirilä et al. 2003; Ravi et al. 2007). 
 
The family of adamalysins is also involved in intestinal inflammation. ADAM15, a 
transmembrane metalloproteinase with chemotactic effects through its interaction 
with integrins on the surface of leukocytes, is highly overexpressed by IECs and 
endothelial cells in inflamed IBD intestine, and it is in close contact with cells 
expressing its integrin ligand 51, hence probably playing a role in inflammatory 
cell trafficking in this condition (Mosnier et al. 2006). Furthermore, the activity of 
ADAM17 has been reported to be up-regulated in UC but not in CD inflamed 
mucosa (Brynskov et al. 2002). Another study showed an increased ADAM17 
expression in inflamed CD mucosa and a correlation between ADAM17 levels 
and the intensity of neutrophil infiltration (Cesaro et al. 2009). The administration 
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of TNBS to rats stimulates ADAM17 expression and activity at the onset of colitis 
(Colón et al. 2001). Up-regulated ADAM17 activity may contribute to the excess 
of soluble TNF- that plays a crucial role in determining mucosal inflammation in 
IBD. Mucosal expression of TIMP-3, the endogenous inhibitor of ADAM17, is 
significantly down-regulated in CD patients compared to control subjects, while at 
the same time ADAM17 activity is up-regulated, resulting in increased shedding 
of TNF- from the cell membrane. Interestingly, TIMP-3 is a TGF--dependent 
gene, therefore its reduction in CD may be explained by the impairment in TGF- 
signaling present in this condition (Monteleone et al. 2012). While ADAM9 and 
ADAM10 mucosal expression is not different between IBD patients and control 
subjects, ADAM19 is significantly overexpressed in intestinal IBD biopsies 
compared to control biopsies (Franzè et al. 2013). 
 
Finally, elastinolytic activity is increased in mucosal samples from patients with 
IBD, and elafin is reduced in the intestinal epithelium (Motta et al. 2012). 
However, it has been reported that transcripts of the natural elastase inhibitor 
elafin are significantly up-regulated in IBD mucosa compared to control mucosa 
(Schmid et al. 2007), and that also serpin B1, another elastase inhibitor, is 
increased in the epithelium of IBD patients (Uchiyama et al. 2012). 
 
Functional consequences of protease dysregulation in intestinal inflammation 
 
Protease dysregulation contributes to the disruption of intestinal barrier and to 
the induction of intestinal lesions in IBD by multiple mechanisms (Fig. 1.6), which 
have been studied using several in vivo and in vitro experimental models. 
 
 
Figure 1.6 (see next page). Simplified representation of MMP-induced 
intestinal barrier damage in IBD. IECs, macrophages, LPMCs and 
myofibroblasts produce large and unbalanced amounts of MMPs in IBD inflamed 
intestinal mucosa. Once activated by proteolytic cleavage of their pro-domain, 
MMPs digest the ECM, causing tissue destruction and the development of 
ulcerations. The alteration of the epithelial barrier allows uncontrolled passage of 
luminal bacteria, amplifying their interactions with mucosal immune cells and 
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perpetuating the on-going pro-inflammatory immune response. (Adapted from 
Biancheri et al. 2013). 
 
 
The study of mice transgenic for MMPs has provided useful insights into the in 
vivo effect of MMPs in intestinal inflammation. Mucosal MMP-3 and MMP-10 up-
regulation precedes the onset of DSS-induced colitis, and RNA silencing of 
MMP-3 and MMP-10 reduces the severity of DSS-incuced colitis (Kobayashi et al. 
2006). Overexpression of MMP-9 results in reduced MUC2 expression and 
enhances susceptibility to DSS-induced colitis (Liu et al. 2013), whereas MMP-9 
deficiency protects mice from DSS- and S. typhimurium-induced colitis 
(Castaneda et al. 2005). Interestingly, MMP-9 is up-regulated and localises on 
the surface of colonic IECs in C. rodentium-induced colitis, however MMP-9 
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deficient mice are equally susceptible to colitis as wild-type mice in this particular 
model (Rodrigues et al. 2012). Fewer evidences are present on the functional 
role of MMP-12 in intestinal inflammation, however it has been observed that 
MMP-12-deficient mice are protected against TNBS-induced colitis (Pender et al. 
2006). Finally, MMP13-null mice are protected from DSS-induced colitis, and are 
resistant to LPS-induced shock. This appears to be due to the ADAM17-like 
ability of MMP-13 to cleave transmembrane TNF- into soluble TNF-, which 
damages the intestinal barrier (Vandenbroucke et al. 2013). Conversely, MMP-2- 
and MMP-10-deficient mice are more susceptible than wild-type mice to DSS-
induced colitis (Garg et al. 2006; Koller et al. 2012). Similar observations have 
been made in MMP-7-deficient mice, which are also more susceptible to DSS-
induced colitis, possibly due to defective wound healing or enhanced neutrophil 
migration (Shi et al. 2007; Swee et al. 2008). 
 
Neutrophil elastase-deficient mice are protected from DSS-induced colitis, 
treatment with neutrophil elastase inhibitors prevents DSS-induced colitis, and a 
similar effect is observed upon overexpression of elafin (Morohoshi et al. 2006; 
Motta et al. 2011). Likewise, feeding mice lactic acid bacteria engineered to 
overexpress elafin protects animals from both T cell transfer- and DSS-induced 
colitis (Motta et al. 2012). Neutrophil elastase plays an important role in leukocyte 
transmigration, and it has been shown that neutrophil elastase-deficient mice 
have defects in leukocyte adhesion and transmigration (Young et al. 2004). 
 
Several in vitro observations suggest that dysregulated protease expression has 
harmful effects on the integrity of the intestinal barrier and mucosa. Culture of 
human foetal intestinal explants with nanomolar concentrations of recombinant 
human (rh)MMP-3 causes tissue destruction in 24 hours, and can be prevented 
by the addition of an MMP-3 inhibitor to the culture (Pender et al. 1997). There is 
evidence that MMP-9 impairs re-epithelialisation, increases endothelial 
permeability, exerts a disruptive effect on the basement membrane and 
intercellular junction proteins, activates pro-inflammatory cytokines including IL-
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1 and IL-8 (Mohan et al. 2002; Van Den Steen et al. 2003; Ravi et al. 2007). 
Furthermore, the addition of MMP-2 and MMP-9 to Caco-2 cells worsens the 
damage induced by hypoxia in vitro (Zitta et al. 2012). MMP-12 effects have 
been studied mainly in atherosclerosis and chronic obstructive pulmonary 
disease, nevertheless it has been observed that ex vivo culture of IBD intestinal 
biopsies with rhMMP-12 induces epithelial and basement membrane destruction 
(Pender et al. 2006). The action of MMP-7 is complex, as on one hand it has 
been shown that MMP-7 ensures wound re-epithelisation and activates -
defensins (Wilson et al. 1999; Parks et al. 2004), whereas on the other hand 
MMP-7 can also disrupt the intestinal epithelium by degrading the epithelial 
adherens junction protein E-cadherin (Noë et al. 2001). PGP, which is generated 
by the combined action of MMP-8, MMP-9 and prolyl-endopeptidase, has 
chemoattractive effects on neutrophils and is up-regulated in IBD mucosa, and 
this suggests an additional mechanism by which MMPs can sustain the 
inflammatory infiltrate in this condition (Koelink et al. 2014). 
 
Pro-inflammatory cytokines involved in IBD pathogenesis have an important 
influence on MMP expression. In particular, TNF- promotes excessive release 
of a wide range of tissue-degrading MMPs by mucosal myofibroblasts cultured in 
vitro (Okuno et al. 2002). Moreover, both IL-21 and IL-17A induce a marked 
increase in MMP production by intestinal myofibroblasts in synergy with either 
TNF- or IL-1 (Bamba et al. 2003; Monteleone et al. 2006). Finally, TNF-, IL-
21 and IL-6 stimulate colonic IEC lines and normal colonic explants to 
overexpress ADAM19, which co-localises with zonula occludens-1, a tight 
junction-associated protein (Franzè et al. 2013).  
 
MMPs exert specific effects on IgG1. Interestingly, IgG1 has a Thr-His human 
neutrophil elastase cleavage site in the upper hinge, and there is a Pro-Glu 
scissile bond susceptible to cleavage by MMP-3 and MMP-12 in the lower hinge 
(Brezski et al. 2009; Brezski et al. 2010). Trastuzumab, a monoclonal antibody 
used in the treatment of breast cancer, can be degraded by several proteolytic 
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enzymes with consequent reduction of its immune effector functions (Fan et al. 
2012). Moreover, cleaved IgG have been detected within squamous cell 
carcinoma with a predominant localisation at the invasive front, a site particularly 
rich in proteases (Kinder et al. 2013). 
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1.4.7 Mechanisms of intestinal fibrogenesis in CD 
 
Fibrosis is a common end-stage of chronic inflammatory diseases in various 
tissues, and involves excessive accumulation of ECM components, including 
collagen and fibronectin, in the damaged tissue, leading to scarring and organ 
malfunction (Wynn et al. 2012). In CD, where inflammation is transmural, 
subsequent damage and repair processes may ultimately cause architectural 
distortion and thickening of all layers of the intestinal wall, thus leading to 
intestinal fibrosis and stricture development (Burke et al. 2007). This represents a 
significant clinical problem in CD, and patients with fibrostenosing disease may 
require surgical removal of the affected tract (Rieder et al. 2011). 
 
Chronic TNBS-induced murine colitis, which is accompanied by intestinal fibrosis, 
is characterised by the development of TGF--dependent intestinal fibrosis, as 
shown by the observation that chronic intrarectal TNBS-induced colonic fibrosis, 
marked by increased mucosal transcripts of TGF-1 (Lawrance et al. 2003), is 
effectively prevented by a TGF-1 peptide-based vaccine, able to suppress 
excessive TGF-1 activity (Ma et al. 2010). 
 
Collagen levels are increased in CD intestinal strictures compared to non-
strictured CD and control intestine (Graham et al. 1988). In the mucosa overlying 
CD strictures, MMP-3 and MMP-12 are down-regulated, whereas TIMP-1 is up-
regulated, and this may also contribute to the abnormal ECM accumulation 
observed in CD intestinal fibrosis (Di Sabatino et al. 2009b). In a murine model of 
intestinal fibrosis, TIMP-1, which is up-regulated, effectively inhibits ECM 
degradation by MMPs (Lawrance et al. 2003), and TIMP-1 has been found to be 
increased in collagenous colitis (Gunther et al. 1999). Moreover, in the 
uninflamed mucosa overlying intestinal strictures of CD patients, expression of 
the potent pro-fibrotic cytokine TGF- is higher compared to uninflamed mucosa 
overlying non-strictured areas (Di Sabatino et al. 2009b). 
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Intestinal myofibroblasts in CD fibrosis 
 
Intestinal myofibroblasts are primarily involved in modulating tissue remodelling 
through the production of proteases, and play an important role in fibrogenesis 
and stricture development in CD (Regan et al. 2000; Andoh et al. 2007; Rieder et 
al. 2009). Myofibroblasts isolated from the mucosa overlying intestinal strictures 
of CD patients show significantly higher collagen and TIMP-1 production (Fig. 
1.7), and have reduced migratory ability compared to those isolated from non-
strictured areas of CD patients or from control subjects, suggesting that this cell 
population exerts a pro-fibrogenic action in CD. Moreover, myofibroblasts 
isolated from the mucosa overlying CD strictures express increased TGF- 
transcripts, and release higher TGF- protein levels compared to myofibroblasts 
from uninflamed non-strictured CD and control areas (Di Sabatino et al. 2009b). 
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Figure 1.7 (see previous page). TGF- in CD intestinal fibrosis. The right part 
of the diagram represents an intestinal CD stricture, preceded by a pre-stenotic 
dilatation of an uninflamed non-strictured tract (left part of the diagram). In CD 
intestinal strictures, myofibroblasts produce excessive amounts of TGF-. 
Stricture development in CD is characterised by excessive synthesis and 
accumulation of collagen and other ECM components by intestinal 
myofibroblasts, by the reduction of tissue-degrading proteolytic enzymes, such 
as MMP-3 and MMP-12, and by the increase in TIMPs, including TIMP-1. TGF- 
enhances TIMP-1 secretion and reduces MMP-12 production by intestinal 
myofibroblasts. (Adapted from Biancheri et al. 2014). 
 
Within the normal intestinal mucosa, TGF- plays a pivotal role in the 
maintenance of immune homeostasis by preventing abnormal and harmful pro-
inflammatory responses against the normal constituents of the intestinal flora 
(Konkel et al. 2011), and it is centrally implicated in the physiologic processes of 
intestinal remodelling and wound healing (Iizuka et al. 2011). In fibrostenosing 
CD, however, TGF- plays a prominent pro-fibrogenic role by increasing TIMP-1 
production by myofibroblasts isolated from strictured, uninflamed non-strictured 
CD and control mucosa, and by reducing MMP-12 release by myofibroblasts 
isolated from uninflamed mucosa overlying non-strictured CD and control areas 
(McKaig et al. 2003; Di Sabatino et al. 2009b). 
 
In addition to TGF-, a number of cytokines can modulate myofibroblast function, 
including IL-1 and TNF- (Okuno et al. 2002), and those belonging to the IL-17 
family (Wynn 2004; Gaffen 2011). 
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Involvement of IL-17A and IL-17E in tissue fibrosis 
 
IL-17A, which is up-regulated in the intestinal mucosa of patients affected by IBD, 
has been shown in experimental studies to play an important role in tissue 
remodelling and fibrosis in a number of different tissues. In particular, IL-1-
induced and bleomycin-induced lung fibrosis seems to depend on the action of 
IL-17A, and IL-17A−/− mice show reduced susceptibility to experimental skin 
fibrosis (Okamoto et al. 2012; Wilson et al. 2010). IL-17A stimulates proliferation 
and migration of cardiac fibroblasts (Valente et al. 2012), promotes hepatic 
stellate cell activation into fibrogenic myofibroblasts (Meng et al. 2012; Tan et al. 
2013), induces collagen production by skin fibroblasts (Okamoto et al. 2012), and 
promotes epithelial-mesenchymal transition of lung epithelial cells (Mi et al. 2011). 
Unlike acute experimental colitis, chronic TNBS-induced murine colitis is driven 
predominantly by IL-17A-producing Th17 cells (Guan et al. 2011). The 
observation that targeting IL-23 (a key cytokine in Th17 cell development) with a 
p40 peptide-based vaccine ameliorates chronic TNBS-induced colitis, and 
reduces IL-17A, TGF- levels, and collagen deposition in the intestine (Guan et 
al. 2011), highlights the importance of IL-17A in intestinal experimental fibrosis. 
 
IL-17E exerts two distinct immunological functions: it promotes Th2 response in 
allergic diseases including asthma (Sharkhuu et al. 2006), and it dampens the 
inflammatory process in immune-mediated disorders, including IBD (Monteleone 
et al. 2010). It has been shown that IL-17E exerts a pro-fibrogenic role in 
experimental fibrotic disorders. Moreover, IL-17E up-regulates pro-inflammatory 
cytokine expression and collagen production by lung fibroblasts (Létuvé et al. 
2006; Gregory et al. 2013). IL-17E mediates pulmonary collagen deposition in 
mice exposed to house dust mite (Gregory et al. 2013), and intestinal TNBS-
induced fibrosis has been found to be associated in the early phase by a marked 
increase in IL-17E (Fichtner-Feigl et al. 2008a). 
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Involvement of IL-13 in lung and intestinal fibrosis 
 
IL-13 has been implicated in experimental lung and intestinal fibrosis. Treating 
mice with bleomycin induces IL-13-dependent pulmonary fibrosis (Fichtner-Feigl 
et al. 2006), and inhibition of IL-13 activity ameliorates TNBS-induced chronic 
colitis-associated fibrosis (Fichtner-Feigl et al. 2008b). IL-13 signalling through 
IL-13R2induces monocytes and macrophages to release TGF- (Lee et al. 
2001; Fichtner-Feigl et al. 2006; Fichtner-Feigl et al. 2008b), which in turn 
promotes collagen production (Feagins 2010). Interestingly, Akiho et al. (Akiho et 
al. 2005) showed that IL-13 enhances the contractility of smooth muscle cells 
isolated from the intestine of CD patients, and the study by Bailey et al. (Bailey et 
al. 2012) reported higher IL-13 transcripts in the intestinal muscle layer of fibrotic 
CD. 
 
  
142 
1.5 Hypotheses 
 
The roles of IL-17, IL-13, MMPs, and ADAM17 are not completely understood in 
IBD. I shall therefore test the following hypotheses in this Thesis. 
 
IL-17 
 
IL-17A and IL-17E expression in human intestinal fibrosis is not clear. Moreover, 
no information is available on IL-17R expression in the intestinal mucosa, or on 
the effect of IL-17A and IL-17E on the release of pro-fibrogenic mediators by 
intestinal myofibroblasts in vitro. 
 
In Chapter 3 of the present Thesis, we therefore tested the following hypotheses: 
- “IL-17A and IL-17E expression is dysregulated in fibrostenosing CD intestine”. 
 
- “IL-17A and IL-17E may contribute to intestinal fibrosis in CD”. 
 
IL-13  
 
IL-13 has been reported to be up-regulated in UC intestinal mucosa, and to play 
an important role in oxazolone-induced colitis and in intestinal experimental 
fibrosis. However, contrasting observations exist on the levels and the role of IL-
13 in inflamed IBD mucosa, and limited information is available on the role of IL-
13 in CD intestinal fibrosis. 
 
In Chapter 4 of the present Thesis, we therefore tested the following hypotheses: 
- “IL-13 expression is up-regulated in UC intestinal mucosa, and may play a 
functional role in the mucosal pro-inflammatory response in UC”. 
 
- “IL-13 is up-regulated in CD intestinal strictures, and may contribute to 
intestinal fibrosis in this condition”. 
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MMP-3, MMP-9 and MMP-12 
 
Information on the bioavailability of anti-TNF- agents in inflamed tissues, where 
they are expected to exert their effect, is lacking. MMPs are up-regulated in IBD 
inflamed mucosa, and can cleave human IgG1 near the hinge region. Anti-TNF- 
agents in use in clinical practice are IgG1 or have part of the amino acid 
sequence in common with Ig. 
 
In Chapter 5 of the present Thesis, we therefore tested the following hypotheses: 
- “MMPs and protein extracts from inflamed IBD mucosa impair the integrity 
and function of anti-TNF- agents”. 
 
- “Serum levels of cleaved anti-TNF- agents correlate with primary non-
responsiveness to biologic therapy in IBD”. 
 
ADAM17 
 
We performed genetic studies in a family of consanguineous parents and their 
three children, two of whom had the same clinical features, with skin and small 
intestine inflammatory lesions, and we identified a deletion in ADAM17. 
 
In Chapter 6 of the present Thesis, we therefore tested the following hypotheses: 
- “ADAM17 expression is reduced in the skin and small intestine of the 
affected siblings compared to the unaffected parents and control subjects”. 
 
- “Soluble TNF- release by PBMCs of the affected siblings is reduced 
compared to the unaffected parents and control subjects”. 
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Chapter 2: Materials and Methods 
 
Note: Materials and Methods common to all or most experimental Chapters have 
been pulled together into this Chapter. Each experimental Chapter is preceded 
by a Materials and Methods section that is specific for that Chapter alone. 
 
2.1 Patients and tissues 
 
In order to study the role of IL-17 in CD intestinal fibrosis, surgical specimens 
from ileum or colon of CD patients and control subjects were collected. The role 
of IL-13 in IBD was studied upon collecting biopsies or surgical specimens from 
the ileum or colon of IBD patients and control subjects. The effect of proteolytic 
cleavage on the integrity and the function of anti-TNF- agents was investigated 
using colonic biopsies and sera of IBD patients and control subjects. Finally, the 
disease and immunologic features associated to the deletion in ADAM17 in two 
affected siblings of consanguineous parents were studied on skin and duodenal 
biopsies collected from the family members and control subjects, and on PBMCs 
from the family members and control subjects. Detailed information on patients, 
samples and Ethics is reported in the Chapter-specific Patients and tissues 
paragraph of each experimental Chapter. 
 
2.2 Organ culture 
 
In order to evaluate the ex vivo production of IL-17A, IL-17E, IL-6, TNF-, IL-13, 
IL-1 and collagen, and the levels of TGF-1 transcripts, intestinal tissue 
explants (1 mm3 in size) from uninflamed areas of strictured and non-strictured 
ileum of patients with fibrostenosing CD and from normal ileum of control 
subjects were placed in 12-well tissue culture plates (BD Biosciences, Oxford, 
UK; one explant per well) and cultured at 37°C and 5% CO2 in 800 l serum-free 
HL-1 medium (Cambrex Bioscience, Wokingham, UK) supplemented with 100 
U/ml penicillin and 100 g/ml streptomycin. After 24 hour ex vivo culture, 
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supernatants were collected and stored at -70°C until used for cytokine 
measurement by ELISA or for collagen measurement by Sircol collagen assay, 
and intestinal explants were homogenised for subsequent evaluation of TGF-1 
expression by quantitative reverse transcription (qRT)-polymerase chain reaction 
(PCR). 
 
In order to evaluate the ex vivo production of IL-13, IL-17A, IFN-, IL-4 and IL-5 
by biopsies from inflamed and uninflamed colonic mucosa of CD and UC patients 
and control subjects, perendoscopic mucosal biopsies were placed in 24-well 
tissue culture plates (VWR International, Lutterworth, UK; one biopsy per well) in 
300 l serum-free HL-1 medium (Cambrex BioScience) supplemented with 100 
U/ml penicillin and 100 g/ml streptomycin, and cultured at 37°C and 5% CO2. 
After 24 hour ex vivo culture, supernatants were collected and stored at -70°C 
until used for cytokine measurement by ELISA. 
 
2.3 Myofibroblast isolation and culture 
 
Intestinal submucosal myofibroblasts were isolated as follows. The mucosa, 
muscle and serosa were dissected away from full thickness samples of bowel 
and discarded. The remaining tissue was cut into 1 mm-sized samples and 
cultured at 37°C in a humidified CO2 incubator in Dulbecco’s modified Eagle’s 
medium (DMEM; Sigma-Aldrich, Poole, UK) supplemented with 20% foetal 
bovine serum (FBS), 1% non-essential amino acids (Invitrogen Ltd, Paisley, UK), 
100 U/ml penicillin, 100 g/ml streptomycin, 50 g/ml gentamycin, and 1 g/ml 
amphotericin (Sigma-Aldrich). Myofibroblasts migrated out of the tissue after a 
few days. Established colonies of myofibroblasts were seeded into 25-cm2 
culture flasks and cultured in DMEM supplemented with 20% FBS and antibiotics. 
At confluence, the cells were passaged using trypsin-ethylenediaminetetraacetic 
acid (EDTA) in a 1:2 to 1:3 split ratio. Cells were grown to at least passage 4 
before there were enough to use in stimulation experiments. 
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In order to assess the effect of IL-17A and IL-17E on the production of MMP-3, 
MMP-12, TIMP-1 and collagen, and the effect of IL-13 on the production of 
collagen, subconfluent monolayers of myofibroblasts seeded in 12-well plates 
(BD Biosciences; 3x 105 cells/well) were starved in serum-free medium for 24 
hours at 37°C and 5% CO2 before being cultured for 24 hours at 37°C and 5% 
CO2 with DMEM containing antibiotics in the absence or presence of 10 ng/ml of 
rhIL-17A, or 10 ng/ml rhIL-17E, or 10 ng/ml rhTNF- (all from R&D Systems, 
Abingdon, UK), or 20 ng/ml rhIL-13 (PeproTech EC), or 20 ng/ml rhIL-13 plus 20 
ng/ml rhTNF-. 
 
2.4 ELISA 
 
Concentrations of IL-17A and IL-17E in tissue sample homogenates were 
measured using specific ELISA kits (all from R&D Systems), in accordance with 
the manufacturer’s instructions, and were normalized to the total protein 
concentration, determined by a protein assay (Bio-Rad Laboratories, Hemel 
Hempstead, UK). Concentrations of IL-17A, IL-17E, IL-6, TNF-, IL-13, IFN-, IL-
4, IL-5 and IL-1 in culture supernatants and tissue homogenates were assessed 
using specific ELISA kits (all from R&D Systems), in accordance with the 
manufacturer’s instructions. With regards to the sensitivity of the ELISA kits, the 
detection range of each kit is as follows: IL-17A, 15.6-1000 pg/ml; IL-17E, 46.9-
3000 pg/ml; IL-6, 9.4-600 pg/ml; TNF-, 15.6-1000 pg/ml; IL-13, 15.6-1000 
pg/ml; IFN-, 15.6-1000 pg/ml; IL-4, 31.2-2000 pg/ml; IL-5, 23.4-1500 pg/ml; IL-
1, 3.9-250 pg/ml. Since IL-13 measurements were central to my study, I also 
repeated the measurement of IL-13 in culture supernatants using a different 
ELISA kit (eBioscience, San Diego, CA), with higher sensitivity (detection range 
4-500 pg/ml) compared to the correspondent R&D Systems kit. 
 
2.5 Collagen assay 
 
Total soluble forms of collagen were measured in supernatants of tissue explants 
  
147 
and myofibroblasts using the Sircol Collagen Assay Kit (Biocolor Ltd, Belfast, UK), 
in accordance with the manufacturer’s instructions. The collagen content in each 
sample was calculated as an average of three readings. 
 
2.6 RNA extraction and analysis of mRNA expression by qRT-PCR 
 
In order to assess the expression of IL-13, IL-5, IL-17A and IFN- in IBD and 
control mucosa, and in order to evaluate the expression of TGF-1 in CD and 
control explants, RNA was extracted from snap-frozen mucosa of UC, CD and 
control subjects, and from cultured tissue explants. cDNAs were synthesized 
(Improm-II RT system; Promega, Southampton, UK) using random hexamers 
and 1 g of RNA in a final volume of 20 l. RT reactions were performed using 
the Improm-II reverse transcriptase enzyme from the kit. An RT reaction without 
reverse transcriptase enzyme was performed for each tissue type as a negative 
control for qPCR. IL-13, IL-5, IL-17A, IFN- and TGF-1 primers and probe sets 
were validated for use with the ∆∆CT method of quantification. The probe was 
labeled with a 59-reporter dye FAM (6-carboxy-fluorescein) and the 39-quencher 
dye TAMRA (6-carboxy-N,N,N’,N9-tetramethyl-rhodamine). RT reactions were 
diluted 1 in 10 in distilled water, and 5 l of template was added to 6.5 l of 2x 
master mix (Eurogentech, Seraing, Belgium) containing 1.2 mol/l forward and 
reverse primers and 0.248 mol/l of probe in a total volume of 12.5 l. The PCR 
protocol was as follows: 50°C for 2 minutes and 95°C for 10 minutes, followed by 
40 cycles of denaturation at 95°C for 15 seconds, and annealing/extension at 
60°C for 1 minute. Thermocycling and real-time detection of PCR products were 
performed on a sequence detection system (iCycler iQ; Bio-Rad Laboratories). 
Expression levels were normalized against 18S, -actin, and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH), and values were calculated using the ∆∆CT 
method. 
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2.7 Western blotting 
 
In order to assess IL-17A, IL-17E, IL-17RB and IL-17RC expression in CD and 
control mucosa, in order to determine MMP-3, MMP-12 and TIMP-1 release by 
IL-17-stimulated CD and control myofibroblasts, in order to evaluate claudin 2 
expression by IL-13-stimulated T84 cells, and in order to study ADAM17, 
ADAM10 and DSG1/2 expression by keratinocytes, tissue samples or 
myofibroblasts or T84 cell monolayers or keratinocytes were homogenised in ice-
cold lysis buffer, and the amount of protein was determined by the DC Protein 
Assay (Bio-Rad Laboratories). Equal amounts of protein or 15 l of cell culture 
supernatants were loaded into each lane and run in 10% sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis gels under reducing conditions. After 
electrophoresis, protein was transferred onto nitrocellulose membranes (Bio-Rad 
Laboratories). Membranes were blocked with 5% non-fat dry milk, followed by 
incubation for 16 hours at 4°C with the following antibodies: goat anti-human IL-
17A (1 g/ml), goat anti-human IL-17E (0.1 g/ml) (both from R&D Systems), 
mouse anti-human IL-17RB (1:500 dilution; LifeSpan Biosciences, Seattle, WA), 
mouse anti-human IL-17RC (1:750 dilution), rabbit anti-human MMP-3 (1:200 
dilution), rabbit anti-human MMP-12 (1:1000 dilution) (all three from Abcam, 
Cambridge, UK), mouse anti-human TIMP-1 (1 μg/ml; Oncogene Research, 
Nottingham, UK), rabbit anti-human ADAM17 (1/500; Abcam), rabbit anti-human 
ADAM10 (1:500; Millipore, Bedford, MA), or mouse anti-human DSG1/2 (1 g/ml; 
Zymed, Cambridge, UK). Appropriate antibodies conjugated to horseradish 
peroxidase (Dako, High Wycombe, UK) were used as secondary antibodies. For 
the detection of claudin 2 expression by T84 cells, rabbit anti-human claudin 2 
antibody (2 g/ml; Invitrogen Ltd) and a goat anti-rabbit IgG antibody conjugated 
to horseradish peroxidase (Dako) were used as primary and secondary 
antibodies, respectively. Reactions were developed with enhanced 
chemiluminescence (ECL Plus Kit; Amersham Biosciences, Little Chalfont, UK). 
Blots were then stripped and analysed for -actin, as an internal loading control, 
using a rabbit anti--actin antibody (1:5000 dilution; Abcam). Blots on T84 cell 
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lysates were stripped and analysed for cytokeratin 19 as a loading control for 
epithelial proteins, using a mouse anti-human cytokeratin 19 antibody (1:1000 
dilution; Abcam). Bands were quantified by scanning densitometry using an LKB 
Ultrascan XL Laser Densitometer (Kodak Ltd, Hemel Hempstead, UK). 
 
The effect of proteases on the integrity of TNF- neutralising agents was 
assessed by immunoblotting under denaturing conditions. After co-incubation 
with active rhMMP-3 or rhMMP-12 or rhMMP-9 or IBD mucosal homogenates or 
control mucosal homogenates, TNF- neutralising agents were run on 10% 
sodium dodecyl sulphate-polyacrylamide gel electrophoresis gels under reducing 
or non-reducing conditions. After electrophoresis, proteins were transferred onto 
nitrocellulose membranes (Bio-Rad Laboratories). Membranes were then 
incubated with a rabbit anti-human Ig Fc antibody (1:3000 dilution; Fisher 
Scientific UK, Loughborough, UK), or a rabbit anti-human Ig  light chain 
antibody (1:2000 dilution; Abcam) followed by a horseradish peroxidase-
conjugated goat anti-rabbit Ig secondary antibody (Dako). Bands were quantified 
by scanning densitometry using ImageJ software program (NIH, Bethesda, MD). 
 
2.8 PBMC isolation 
 
PBMCs were isolated from heparinised peripheral venous blood within 10 
minutes from collection by Ficoll-Hypaque (Sigma-Aldrich) density-gradient 
centrifugation. Sample was centrifuged (1500 rpm, 30 minutes) and the resultant 
‘buffy coat’ containing the PBMCs collected. After further centrifugation (1500 
rpm, 10 minutes) and washing in 10 ml PBS containing  EDTA (2 mM), the final 
cell pellet was resuspended in 10 ml PBS containing EDTA (2 mM). Cells were 
counted and the final concentration adjusted to 1 x 106 cells/ml by resuspension 
in RPMI-1640 medium containing 10% FBS, 100 U/ml penicillin and 100 g/ml 
streptomycin, and kept on ice until used. The total processing time from 
collection to culture was less than 1 hour. 
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2.9 Statistical analysis 
 
Data were analysed by the GraphPad Prism statistical PC program (GraphPad 
Software, San Diego, CA) using the paired or unpaired t test, the Mann-Whitney 
U-test, or using the ANOVA One way analysis of variance followed by the 
Tukey’s multiple comparison test or by the Dunnett's multiple comparison test. 
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Chapter 3: The role of IL-17A and IL-17E in CD intestinal fibrosis 
 
Note: The wound-healing scratch assay on intestinal myofibroblasts and the 
analysis of the data (Paragraph 3.3.7) have been performed by Professor 
Antonio Di Sabatino’s group in the Laboratory of the First Department of Internal 
Medicine, St Matteo Hospital, University of Pavia, Pavia, Italy, and primary data 
are not available. These results have been published in the following paper, on 
which I am first Author (Biancheri P, Pender SL, Ammoscato F, Giuffrida P, 
Sampietro G, Ardizzone S, Ghanbari A, Curciarello R, Pasini A, Monteleone G, 
Corazza GR, MacDonald TT, Di Sabatino A. The role of interleukin 17 in Crohn's 
disease-associated intestinal fibrosis. Fibrogenesis Tissue Repair 2013;6:13). 
 
IL-17A and IL-17E expression in human intestinal fibrosis is not clear. Moreover, 
no information is available on IL-17R expression in the intestinal mucosa, or on 
the effect of IL-17A and IL-17E on the release of pro-fibrogenic mediators by 
intestinal myofibroblasts in vitro. Further information on the background to this 
Chapter is present in Section “1.4.7 Mechanisms of intestinal fibrogenesis in CD”. 
 
3.1 Aims of the study 
 
This study aims to explore the possible involvement of IL-17A and IL-17E in CD 
intestinal fibrosis using the following approach: 
1. Assessment of the expression of IL-17A and IL-17E in the intestine of 
patients with fibrostenosing CD and in the normal intestine of control subjects. 
2. Investigation of IL-17A and IL-17E production by intestinal tissue explants 
from CD strictured areas cultured ex vivo. 
3. Assessment of IL-17R (IL-17RC for IL-17A and IL-17RB for IL-17E, 
respectively) expression in the intestinal tissue and myofibroblasts from 
patients with fibrostenosing CD and from normal intestine of control subjects. 
4. Evaluation of the in vitro effects of IL-17A and IL-17E on CD and control 
intestinal myofibroblasts. 
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3.2 Chapter-specific Materials and Methods 
 
3.2.1 Patients and tissues 
 
Surgical specimens were collected from uninflamed areas of strictured and non-
strictured ileum or colon of 29 patients with fibrostenosing CD (Table 3.1). 
Diagnosis of CD was ascertained by standard clinical criteria (Van Assche et al. 
2010), and strictured areas were identified by colonoscopy, entero-magnetic 
resonance imaging (MRI), or enteroclysis (Maglinte et al. 2005). None of the 
patients with CD had been treated previously with ciclosporin, tacrolimus, 
methotrexate, or anti-TNF- antibodies. Intestinal samples were also collected 
from macroscopically and microscopically unaffected (at least 500 mm from the 
tumour mass) ileum or colon of 27 patients undergoing intestinal resection for 
colon cancer (Table 3.2), who were considered as control subjects. CD patients 
and control subjects were sex-matched, whereas control subjects were 
significantly (p<0.0001) older than CD patients, most likely due to differences in 
the age of clinical presentation between CD and colon cancer. This study was 
approved by the NRES Committee London - City & East (REC reference: 
10/H0704/74), and informed consent was obtained from all patients and control 
subjects. 
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Table 3.1. Clinical features of patients with fibrostenosing CD (n=29) 
Characteristics and parameters N. Median (range) 
Age (years) 
Sex (M/F) 
First attack 
Intestinal location 
        Small bowel and colon 
        Small bowel only 
        Colon only 
Duration of disease (months) 
Number of recurrences 
CDAI 
Treatment 
        Mesalazine 
        Topical steroids 
        Antibiotics 
        Azathioprine/6-MP/methotrexate 
 
16/13 
6 
 
15 
9 
5 
 
 
 
 
13 
3 
9 
14 
35.8 (23-61) 
 
 
 
 
 
 
81.2 (7-196) 
4 (0-9) 
223 (155-426) 
 
 6-MP, 6-mercaptopurine. 
 
Table 3.2. Clinical features of control subjects (n=27) 
Characteristics and parameters N. Median (range) 
Age (years) 
Sex (M/F) 
Comorbidities 
        Ischaemic heart disease 
        Hypertension 
        Hyperlipaemia 
        Diabetes 
        Chronic kidney disease         
        None 
Current medications 
        Anti-hypertensive 
        Diuretics 
        Anti-coagulants 
        Aspirin 
        Statins 
        Metformin 
        Proton pump inhibitors 
        Anti-depressants 
        None 
 
13/14 
 
4 
7 
6 
6 
2 
14 
 
7 
5 
1 
4 
6 
6 
8 
2 
9 
53.4 (45-71) 
 
 
 
 
 
 F, female; M, male. 
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3.2.2 Study design 
 
Since the excessive collagen deposition occurs in the submucosa and outer 
muscle layers, the mucosa was discarded upon dissection, and the muscle-
enriched fraction was used. Tissue from the ileum and colon of 12 CD patients 
and 11 control subjects was homogenised in order to study in vivo IL-17A, IL-17E, 
IL-17RC and IL-17RB tissue expression (Fig. 3.1, Fig. 3.2). The ex vivo tissue 
production of IL-17A, IL-17E and pro-fibrogenic mediators was evaluated in the 
supernatants of cultured tissue explants from the ileum of further six CD patients 
and seven control subjects (Fig. 3.3). Intestinal myofibroblasts were isolated from 
the ileum and colon of further 11 CD patients and nine control subjects, and used 
for experiments aimed at determining IL-17RC and IL-17RB expression (Fig. 3.4), 
MMP, TIMP and collagen production (Fig. 3.5, Fig. 3.6), and migration (Fig. 3.7) 
upon stimulation with IL-17A or IL-17E. 
 
3.2.3 Wound-healing scratch assay 
 
Myofibroblast migration was assessed in accordance with the modified method of 
Rodriguez et al. (Rodriguez et al. 2005; Di Sabatino et al. 2009b). Briefly, cells (2 
x 105) were seeded into cell culture dishes (Nalge Nunc International, Rochester, 
NY, USA) with 2 mm grids, size 35 x 10 mm, in 2 ml of DMEM supplemented 
with 20% FBS and antibiotics. The cells were maintained at 37°C and 5% CO2 
until confluent. Once confluent, each dish of monolayer cells was given a 
mechanical wound by scoring with a 200 l pipette tip, parallel to the grid bars 
along the central grid line. This permitted easy viewing of the cells growing back 
together, and ensured that the 2 mm grid could be used as a reference, so that 
the wound areas could be measured and compared. Wound placement was 
checked with an inverted microscope (CK2; Olympus UK Ltd, London, UK). The 
medium was then removed, and the cells were washed five times with HL-1 
serum-free medium (Cambrex Bioscience) supplemented with antibiotics, and 
then replaced with 1.5 ml HL-1 medium with or without 10 ng/ml rhIL-17A or rhIL-
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17E (both from R&D Systems). Photographs of the cells in each grid along the 
induced wound were taken at 0, 2, 4, 8, 16 and 24 hours, using a digital camera 
(Camedia; Olympus UK Ltd) with 34 to 40 zoom, and 20x magnification, attached 
to a light microscope. The computer program Image J was used to measure the 
area of initial damage (images taken at time 0) and of the remaining damage at 
subsequent time points. Each grid image was observed separately, and two 
points per grid at the same position at every time point were measured using 
imaging software at the same magnification. The percentage of wound repair 
was then calculated. 
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3.3 Results 
 
3.3.1 In vivo IL-17A and IL-17E tissue expression 
 
IL-17A and IL-17E levels were analysed by immunoblotting in tissue samples 
collected from uninflamed areas of strictured and non-strictured ileum and colon 
of 12 patients with fibrostenosing CD and from normal ileum and colon of 11 
control subjects (Fig. 3.1A). IL-17A expression was significantly (p<0.001) up-
regulated in strictured CD areas compared with non-strictured CD areas and 
control ileum and colon. No significant difference in IL-17A expression was found 
between non-strictured CD areas and control ileum and colon. IL-17E levels did 
not differ significantly between strictured and non-strictured CD areas and control 
ileum and colon. 
 
In parallel, IL-17A and IL-17E expression was analysed by ELISA in the same 
samples (Fig. 3.1B). IL-17A was significantly up-regulated in strictured CD (mean 
98.5  13.7 pg/g total protein) compared with non-strictured CD (mean 42.3  
11.0 pg/μg total protein, p<0.001) and control (mean 46.5  8.3 pg/g total 
protein, p<0.001) areas. There was no significant difference in IL-17A expression 
between non-strictured CD and control areas. IL-17E did not significantly differ 
between strictured CD (mean 222.5  32.4 pg/g total protein), non-strictured CD 
(mean 178.1  30.3 pg/g total protein), and control areas (mean 188.2  35.3 
pg/g total protein). 
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Figure 3.1. In vivo expression of IL-17A and IL-17E. IL-17A and IL-17E were 
detected by both (A) immunoblotting and (B) ELISA in uninflamed strictured 
(Strict uninfl) and non-strictured (Non-strict uninfl) ileum and colon of 12 patients 
with fibrostenosing CD and from normal ileum and colon of 11 control subjects 
(HCs). (A) Each blot shown in the upper panel displays IL-17A and IL-17E 
expression in uninflamed strictured and non-strictured ileum of one patient with 
fibrostenosing CD and from normal ileum of one HC, and is representative of 
experiments performed in 12 patients with CD and 11 HCs. Blots were stripped 
and analysed for -actin as an internal loading control. In the lower panel, 
densitometry of IL-17A and IL-17E expression normalised for -actin is shown. 
Results are mean  SEM. au, Arbitrary units. (B) Results, expressed as pg/100 
g of total protein, are mean  SEM. Data were analysed by ANOVA One way 
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analysis of variance followed by the Tukey’s multiple comparison test. *p<0.001 
versus Non-strict uninfl and HC tissue samples.  
 
 
3.3.2 In vivo IL-17RC and IL-17RB tissue expression 
 
IL-17RC and IL-17RB expression was then analysed by immunoblotting in the 
same tissue samples (Fig. 3.2). IL-17RC expression was not significantly 
different between CD strictured, CD non-strictured, and control ileum and colon 
(Fig. 3.2A). Similarly, IL-17RB expression did not differ between CD strictured, 
CD non-strictured and control ileum and colon (Fig. 3.2B). 
 
 
Figure 3.2. In vivo expression of IL-17RC and IL-17RB. (A) IL-17RC and (B) 
IL-17RB were detected by immunoblotting in uninflamed areas of strictured 
(Strict uninfl) and non-strictured (Non-strict uninfl) ileum and colon of 12 patients 
with fibrostenosing CD and from normal ileum and colon of 11 control subjects 
(HCs). Each blot shown in the left panels displays IL-17RC and IL-17RB 
expression in uninflamed strictured and non-strictured ileum of one patient with 
fibrostenosing CD and from normal ileum of one HC, and is representative of 
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experiments performed in all patients with CD and all HC subjects. Blots were 
stripped and analysed for -actin as an internal loading control. In the right 
panels, densitometry of IL-17RC and IL-17RB expression normalized for -actin 
is shown. Results are mean  SEM. Data were analysed by ANOVA One way 
analysis of variance followed by the Tukey’s multiple comparison test. au, 
Arbitrary units. 
 
 
3.3.3 Ex vivo tissue production of IL-17A, IL-17E, IL-6, TNF-, collagen and 
TGF-1 
 
Tissue explants (1 mm3 in size) from uninflamed areas of strictured and non-
strictured ileum of six patients with fibrostenosing CD and from normal ileum of 
seven control subjects were cultured ex vivo for 24 hours, and IL-17A, IL-17E, IL-
6, TNF-, and collagen concentration in the culture supernatant and TGF-1 
transcripts in the cultured tissue were measured (Fig. 3.3). IL-17A was 
significantly higher in the organ culture supernatants of strictured CD (mean 
110.0  23.8 pg/ml) than in those of non-strictured CD (mean 55.9  8.8 pg/ml, 
p<0.05) or normal ileum (mean 51.1  8.9 pg/ml, p<0.05). Concentrations of IL-
17E, IL-6, and TNF- did not differ significantly between the supernatants of 
strictured CD (mean 653.3  283.5 pg/ml, 26553  6647 pg/ml, and 43.4  7.6 
pg/ml, respectively), non-strictured CD (mean 1028.0  202.5 pg/ml, 31740  
3944 pg/ml, and 40.8  7.7 pg/ml, respectively), and normal ileum (mean 1068.0 
 282.8 pg/ml, 36784  2516 pg/ml, and 30.0  7.9 pg/ml, respectively). Collagen 
concentration was significantly higher in the supernatants of strictured CD (mean 
979.0  108.6 g/ml, respectively) than in those of non-strictured CD (mean 
604.6  97.5 g/ml, p<0.05) and normal ileal areas (mean 523.6  77.9 g/ml, 
p<0.01). TGF-1 transcripts were significantly higher in the cultured tissue 
explants from strictured CD than in those from non-strictured CD (p<0.01) and 
normal ileum (p<0.001). 
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Figure 3.3. Levels of cytokines and pro-fibrogenic mediators in tissue 
explant culture supernatants. Levels of IL-17A, IL-17E, IL-6, and TNF-, 
expressed as pg/ml, and collagen, expressed as g/ml, in the supernatants of 
tissue explants from uninflamed areas of strictured (Strict uninfl) and non-
strictured (Non-strict uninfl) ileum of six patients with fibrostenosing CD and from 
normal ileum of seven control subjects (HCs), cultured for 24 hours in the 
absence of stimuli, and levels of TGF-1, expressed as relative units compared 
with the median expression in HCs (which was assigned the value 1), in the 
same cultured tissue explants. Values are mean  SEM. Data were analysed by 
ANOVA One way analysis of variance followed by the Tukey’s multiple 
comparison test. r.u., Relative units. 
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3.3.4 IL-17RC and IL-17RB expression on myofibroblasts 
 
IL-17RC and IL-17RB expression was then studied by immunoblotting in lysates 
of myofibroblasts isolated from uninflamed areas of strictured and non-strictured 
ileum and colon of six patients with fibrostenosing CD, and from normal ileum 
and colon of seven control subjects (Fig. 3.4). Myofibroblasts isolated from 
strictured CD areas, non-strictured CD areas, and control ileum and colon 
expressed both IL-17RC (Fig. 3.4A) and IL-17RB (Fig. 3.4B). However, no 
significant difference in IL-17RC and IL-17RB expression was found between 
strictured, non-strictured CD, and control myofibroblasts. 
 
Figure 3.4. Expression of IL-17RC and IL-17RB on intestinal myofibroblasts. 
(A) IL-17RC and (B) IL-17RB were detected by immunoblotting on lysates of 
myofibroblasts isolated from uninflamed areas of strictured (Strict uninfl) and 
non-strictured (Non-strict uninfl) ileum and colon of six patients with 
fibrostenosing CD and from normal ileum and colon of seven control subjects 
(HCs). Each blot shown in the left panels displays IL-17RC and IL-17RB 
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expression in myofibroblasts from uninflamed strictured and non-strictured colon 
of one patient with fibrostenosing CD and from normal colon of one HC, and is 
representative of experiments performed in all patients with CD and all HC 
subjects. Blots were stripped and analysed for -actin as an internal loading 
control. In the right panels, densitometry of IL-17RC and IL-17RB expression 
normalized for -actin is shown. Results are mean  SEM. Data were analysed 
by ANOVA One way analysis of variance followed by the Tukey’s multiple 
comparison test. au, Arbitrary units. 
 
 
3.3.5 In vitro effect of rhIL-17A and rhIL-17E on MMP-3, MMP-12, and TIMP-
1 production by myofibroblasts 
 
The production of MMP-3, MMP-12, and TIMP-1 was evaluated by 
immunoblotting in supernatants of myofibroblasts from strictured or non-strictured 
ileum and colon of six patients with fibrostenosing CD, and from normal ileum 
and colon of six control subjects, stimulated with rhTNF-, rhIL-17A, or rhIL-17E 
(Fig. 3.5). Stimulation with rhIL-17A and rhIL-17E induced a significant (p<0.05) 
increase in MMP-3 and MMP-12 production by CD myofibroblasts from strictured 
and non-strictured areas and by control myofibroblasts. Stimulation with rhTNF- 
induced a significant (p<0.05) increase in both MMP-3 and MMP-12 production 
compared to control (myofibroblasts from the same group of patients cultured 
with medium alone). No significant difference in MMP-3 or MMP-12 production 
was found between rhTNF-, rhIL-17A, and rhIL-17E stimulation (Fig. 3.5A,B). 
Myofibroblasts from CD strictured areas showed a significantly (p<0.05) lower 
spontaneous release of MMP-12 than myofibroblasts from CD non-strictured 
areas or control ileum and colon (Fig. 3.5B). Myofibroblast stimulation with rhIL-
17A induced a significant (p<0.05) increase in TIMP-1 production compared with 
unstimulated cells. Stimulation with rhIL-17E did not induce any significant 
change in TIMP-1 production compared to control (myofibroblasts from the same 
group of patients cultured with medium alone). Stimulation with rhTNF- induced 
a significant (p<0.05) increase in TIMP-1 production compared to control 
(myofibroblasts from the same group of patients cultured with medium alone). No 
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significant difference in TIMP-1 production was found between rhTNF- and rhIL-
17A stimulation (Fig. 3.5C). 
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Figure 3.5 (see previous page). Effect of rhIL-17A and rhIL-17E on the 
production of MMP-3, MMP-12, and TIMP-1 by intestinal myofibroblasts. (A) 
MMP-3, (B) MMP-12, and (C) TIMP-1 in culture supernatants of myofibroblasts 
isolated from uninflamed areas of strictured (Strict uninfl) and non-strictured 
(Non-strict uninfl) ileum and colon of six patients with fibrostenosing CD and from 
normal ileum and colon of six control subjects (HCs), cultured for 24 hours with 
medium alone or rhTNF-, or rhIL-17A, or rhIL-17E. Each blot displays one 
experiment, and is representative of experiments performed in all patients with 
CD and HCs. Lower panels show densitometry of Western blots. Values are 
mean  SEM. Data were analysed by ANOVA One way analysis of variance 
followed by the Tukey’s multiple comparison test. *p<0.05 versus unstimulated 
myofibroblasts. §p<0.05 versus unstimulated Non-strict uninfl CD and HC 
myofibroblasts. 
 
 
3.3.6 In vitro effect of rhIL-17A and rhIL-17E on myofibroblast collagen 
production 
 
Myofibroblasts isolated from uninflamed areas of strictured and non-strictured 
ileum and colon of six patients with fibrostenosing CD, and from normal ileum 
and colon of six control subjects were cultured in the presence or absence of 
rhTNF-, rhIL-17A, or rhIL-17E, and measured collagen in the culture 
supernatants (Fig. 3.6). CD myofibroblast stimulation with rhIL-17A induced a 
significant (p<0.05) increase in mean collagen production (strictured CD 
myofibroblasts: 412  57 g/ml; non-strictured CD myofibroblasts: 154  17 
g/ml) compared to control (myofibroblasts from the same group of patients 
cultured with medium alone) (strictured CD myofibroblasts: 155  23 g/ml; non-
strictured CD myofibroblasts: 76  15 g/ml). Conversely, stimulation with rhIL-
17A did not induce a significant increase in collagen production by control 
myofibroblasts compared to culture with medium alone (114  12 g/ml and 67  
7 g/ml, respectively). Stimulation with rhIL-17E did not induce any significant 
change in mean collagen production by strictured CD myofibroblasts (181  37 
g/ml), non-strictured CD myofibroblasts (83  7 g/ml) or control myofibroblasts 
(61  10 g/ml) compared to myofibroblasts from the same group of patients 
cultured with medium alone. Stimulation with rhTNF- induced a significant 
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(p<0.05) increase in mean collagen production by strictured CD myofibroblasts 
(399  62 g/ml), non-strictured CD myofibroblasts (175  22 g/ml) and control 
myofibroblasts (124  18 g/ml) compared with unstimulated cells from the same 
group of patients. No significant difference in collagen production was found 
between cells cultured with rhTNF- and rhIL-17A. Strictured CD myofibroblasts 
produced significantly (p<0.05) higher amounts of collagen than did non-
strictured CD and control myofibroblasts cultured under the same conditions. No 
significant difference in collagen production was found between non-strictured 
CD and control myofibroblasts cultured under the same conditions. 
 
 
Figure 3.6. Effect of rhIL-17A and rhIL-17E on the production of collagen by 
intestinal myofibroblasts. Levels of collagen, expressed as g/ml, in the 
supernatants of myofibroblasts isolated from uninflamed areas of strictured (Strict 
uninfl) and non-strictured (Non-strict uninfl) ileum and colon of six patients with 
fibrostenosing CD and from normal ileum and colon of six control subjects (HCs), 
cultured for 24 hours with medium alone or rhTNF-, or rhIL-17A, or rhIL-17E. 
Values are mean  SEM. Data were analysed by ANOVA One way analysis of 
variance followed by the Tukey’s multiple comparison test. *p<0.05 versus 
unstimulated myofibroblasts. §p<0.05 versus Non-strict uninfl CD and HC 
myofibroblasts cultured with medium only. 
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3.3.7 In vitro effect of rhIL-17A and rhIL-17E on myofibroblast migration 
 
To evaluate the role of IL-17A and IL-17E on myofibroblast migration, a wound-
healing scratch assay was performed using subconfluent monolayers of 
myofibroblasts isolated from uninflamed areas of strictured and non-strictured 
ileum and colon of six patients with fibrostenosing CD, and from normal ileum 
and colon of seven control subjects. Cell migration was measured as the 
percentage of wound repair and results were expressed as mean percentage of 
wound repair (Fig. 3.7). rhIL-17A significantly (p<0.05) reduced migration of 
strictured CD, non-strictured CD and control myofibroblasts at 8 hours (3.2  
1.1%, 4.6  1.0%, and 6.4  1.6%, respectively), 16 hours (5.8  1.7%, 8.4  
1.8%, and 10.6  1.9%, respectively) and 24 hours (8.8  1.9%, 23.2  2.3%, and 
29.7  2.0%, respectively) compared with myofibroblasts from the same three 
groups cultured with medium alone and evaluated at the same time points (8 
hours 9.8  1.3%, 13.7  1.8%, and 14.6  1.7%, respectively; 16 hours: 15.6  
1.6%, 25.3  2.3%, and 20.3  1.1%, respectively; and 24 hours: 30.6  2.3%, 
49.1  1.9%, and 48.4  1.8%, respectively). Compared with medium alone, rhIL-
17E did not induce any significant change in strictured CD, non-strictured CD, 
and control myofibroblast migration (8 hours: 11.2  1.2%, 15.4  1.4%, 12.9  
1.5%, respectively; 16 hours: 16.2  1.4%, 28.2  1.7%, 25.1  1.1%, 
respectively; and 24 hours: 26.3  1.9%, 41.3  2.2%, 43.4  2.2%, respectively). 
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Figure 3.7. Effect of rhIL-17A and rhIL-17E on intestinal myofibroblast 
migration. Effect of rhIL-17A and rhIL-17E on the migration, assessed by an in 
vitro wound-healing scratch assay, of myofibroblasts isolated from uninflamed 
areas of strictured (Strict uninfl) and non-strictured (Non-strict uninfl) ileum and 
colon of six patients with fibrostenosing CD and from normal ileum and colon of 
seven control subjects (HCs). Myofibroblasts were cultured with rhIL-17A or rhIL-
17E or medium alone. Results, expressed as percentage of wound repair, are 
mean  SEM. *p<0.05 versus myofibroblasts cultured with medium only at 8, 16, 
and 24 hours. 
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3.4 Results summary 
 
In the current study, we found that: 
1. IL-17A, but not IL-17E, is overexpressed in strictured CD ileum and colon 
compared with non-strictured CD and control ileum and colon. 
2. Intestinal tissue explants from strictured CD ileum cultured ex vivo release 
significantly more IL-17A, but not IL-17E, compared with intestinal tissue 
explants from non-strictured CD and control ileum. 
3. Strictured CD, non-strictured CD, and control ileum and colon, and intestinal 
myofibroblasts from CD and control ileum and colon express both IL-17RC 
and IL-17RB, without significant differences between the groups studied. 
4. Stimulation with IL-17A significantly up-regulates MMP-3, MMP-12, TIMP-1 
and collagen release by intestinal myofibroblasts from CD and control ileum 
and colon cultured in vitro, whereas it significantly down-regulates the 
migratory ability of intestinal myofibroblasts from CD and control ileum and 
colon cultured in vitro. Stimulation with IL-17E significantly up-regulates 
MMP-3 and MMP-12, but not TIMP-1 and collagen release by intestinal 
myofibroblasts from CD and control ileum and colon cultured in vitro, and it 
has no significant effect on the migratory ability of intestinal myofibroblasts 
from CD and control ileum and colon cultured in vitro. 
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3.5 Discussion 
 
Our findings indicate that IL-17A, but not IL-17E, expression is up-regulated in 
fibrostenosing CD intestine, and that IL-17A, but not IL-17E, may contribute to 
intestinal fibrosis in CD. This Section focuses on the interpretation of our results 
in the context of the existing literature, on the limitations of our study, and on 
possible future experiments aimed at clarifying further the role of IL-17 in CD 
intestinal fibrosis. 
 
IL-17A and IL-17E expression in intestinal fibrosis 
 
IL-17A, which is produced by several cell types including T cells, NKT cells and 
neutrophils, can exert several pro-fibrogenic actions (Meng et al. 2012; Okamoto 
et al. 2012; Valente et al. 2012). In particular, it has been shown that in vitro 
stimulation with IL-17A enhances the expression of pro-fibrogenic mediators, 
such as TGF- and type I collagen, by pulmonary fibroblasts in bleomycin-
induced systemic sclerosis, and this effect is inhibited by anti-IL-17 treatment (Lei 
et al. 2016). Moreover, IL-17A produced by T cells is required for inflammation 
and destruction of the biliary system in a mouse model of virus-induced biliary 
atresia (Klemann et al. 2016). IL-17A plays an important role in liver fibrosis by 
promoting hepatic stellate cell activation, and defective IL-17 signalling has a 
protective effect on experimental cholestatic liver fibrosis (Meng et al. 2012; Hara 
et al. 2013; Tan et al. 2013). It has also been shown that treatment with an anti-
IL-17A monoclonal antibody attenuates liver fibrosis following bile duct ligation 
(Zhang et al. 2016). 
 
IL-17E is produced by various cell types, including T cells, epithelial cells and 
eosinophils, and has a well-established role in allergic diseases including asthma, 
and in the prevention of helminth infections (Iwakura et al. 2011). In the human 
intestinal mucosa, IL-17E is produced by subepithelial macrophages (Caruso et 
al. 2009), which may be involved in intestinal fibrosis. IL-17E has been shown to 
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promote Th2 and to suppress Th1 and Th17 immune responses, possibly by 
inhibiting the expression of IL-12 and IL-23 (Sharkhuu et al. 2006; Caruso et al. 
2009). IL-17E has known pro-fibrogenic properties, especially in the context of 
experimental pulmonary fibrosis (Létuvé et al. 2006; Gregory et al. 2013). On the 
other hand, the administration of IL-17E has been shown to ameliorate bile duct 
ligation-induced liver fibrosis in mice (Meng et al. 2012), suggesting that the 
inhibitory effect of IL-17E on Th17 cell development is predominant in this model. 
 
In the present study, we observed that IL-17A, but not IL-17E, is overexpressed 
in strictured CD ileum and colon compared with non-strictured CD and control 
ileum and colon. We collected samples from uninflamed areas of patients with 
fibrostenosing CD, in order to minimise any confounding effect of inflammation 
on IL-17A. It has been observed that IL-17A expression is higher in long-standing 
CD mucosa compared with early mucosal lesions (Zorzi et al. 2013), which is 
compatible with the possible involvement of IL-17A in CD intestinal fibrosis, as 
this latter is a late-stage process in CD. 
 
While ours is the first report on mucosal levels of IL-17 in fibrostenosing CD, 
there are data in the literature on intestinal IL-17 expression in experimental 
intestinal fibrosis. Mucosal up-regulation of both IL-17A and IL-17E has been 
reported to occur approximately 21 days after the first TNBS administration in 
chronic TNBS-induced colitis, which is associated to the development of 
intestinal fibrosis. Interestingly, mucosal IL-17E production continued to increase 
even after the levels of IL-17A reached a plateau, and was associated with the 
up-regulation of IL-13. In this particular model, collagen up-regulation occurs 
between day 35 and day 42, therefore both IL-17A and IL-17E overexpression 
appear to precede the onset of fibrosis (Fichtner-Feigl et al. 2008b). The 
functional relevance of the data on IL-17 family members in experimental 
intestinal fibrosis is still unclear. However, when considering the time of onset of 
the up-regulation of the different cytokines, one possible interpretation is that IL-
17E, which does not appear to influence the simultaneous IL-17A 
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overexpression, may contribute to Th2 cell development with consequent 
overexpression of IL-13, and that IL-17A up-regulation may exert a pro-fibrogenic 
action via an independent pathway. 
 
Functional role of IL-17A and IL-17E in intestinal fibrosis 
 
It is difficult to determine whether the IL-17A up-regulation that we observed in 
CD strictures is an epiphenomenon due to the persistence of a pre-existing 
inflammatory infiltrate, and therefore IL-17A is a by-stander in the process of 
fibrosis, or whether this cytokine plays a functional role in stricture formation in 
vivo. It is difficult to solve this problem using human tissue, since intestinal 
strictures in CD are the end-stage product of a long-standing process. 
Furthermore, there are no clear predictors of intestinal fibrosis in CD (Rieder et al. 
2014), which would allow the selection of a subset of patients to be studied 
prospectively in order to elucidate the relative contribution of different types of 
immune response and cytokines in the early phases of stricture development. 
 
The ideal tool to study the early phases of intestinal fibrosis would be an animal 
model with similar features to CD. Unfortunately, however, currently existing 
mouse models of intestinal fibrosis, such as chronic TNBS- and DSS-induced 
colitis, have few similarities to CD. One of the most relevant differences is that in 
the experimental model, unlike in CD, the causative agent of fibrosis is a pre-
determined chemical agent. Novel models are emerging, which are more similar 
to CD. One of them is the AIEC-induced colitis, in which mice, upon pre-
treatment with streptomycin, receive by gavage the AIEC NRG857 strain, 
isolated from the intestinal microbiota of CD patients, and as a result, they 
develop Th1-/Th17-mediated intestinal fibrosis (Small et al. 2013). This model 
has the advantage of using a microbial strain which has been found preferentially 
in the intestine of CD patients, however the degree of intestinal fibrosis is only 
mild. Another interesting mouse model to study the development and progression 
of intestinal fibrosis is represented by the SAMP mice, which spontaneously 
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develop terminal ileitis and subsequently fibrosis, and are characterised by 
impaired migration of DCs to MLNs, suggesting a defect in immunologic 
tolerance (Mikulski et al. 2015). It has been shown that the mucosal immune 
response in the early phases of intestinal inflammation in SAMP mice is 
characterised predominantly by a Th1 profile, which is subsequently replaced by 
a Th2 profile when fibrosis is established, however the role of IL-17 in this model 
has never been investigated (Ray et al. 2014). 
 
We have attempted to investigate the possible functional role of IL-17A in 
intestinal fibrosis by means of in vitro experiments using intestinal myofibroblasts. 
In keeping with the study of Bamba et al. (Bamba et al. 2003), we found that IL-
17A stimulation in vitro increases MMP-3 and MMP-12 production by 
myofibroblasts from strictured CD, non-strictured CD and control ileum and colon. 
In parallel, we observed that IL-17A up-regulates TIMP-1 and collagen release, 
and reduces the migration ability of CD and control myofibroblasts. Our results 
have been confirmed by Honzawa et al. (Honzawa et al. 2014), who showed that 
IL-17A promotes collagen I expression by intestinal subepithelial myofibroblasts 
from IBD patients via heat shock protein (HSP)47, and that HSP47 knock-down 
by mRNA interference in intestinal subepithelial myofibroblasts abrogates IL-17A-
induced collagen I up-regulation. Collectively, our in vitro data suggest that IL-
17A has a complex effect on the process of intestinal fibrosis, as the up-
regulation in tissue-degrading MMP-3 and MMP-12 is counterbalanced by the 
up-regulation of TIMP-1. Based on our in vitro data, however, the overall effect of 
IL-17A is more likely to be pro-fibrogenic, as suggested by the up-regulation of 
collagen release and the reduction in the migratory ability. The stimulation with 
IL-17E increases MMP-3 and MMP-12 production by myofibroblasts from CD and 
control ileum and colon, however we did not observe any influence of IL-17E on 
collagen or TIMP-1 production by CD myofibroblasts, or on their migratory ability. 
Based on the expression data and on the in vitro results, it is therefore difficult to 
imagine a prominent role of IL-17E in CD intestinal fibrosis. 
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Collectively, both the data present in the literature and our data suggest that IL-
17 family member, and more generally Th17 cells, play a complex role in 
intestinal inflammation and fibrosis. An example of this is represented by the 
observations that in vitro stimulation of CD myofibroblasts with an agonist of aryl 
hydrocarbon receptor (AhR), which is essential for Th17 cell differentiation and 
activation, induces the down-regulation of collagen synthesis, and that treatment 
with the same AhR agonist ameliorates TNBS-induced intestinal fibrosis 
(Monteleone et al. 2016). 
 
Limitations of our study 
 
In our study, we analysed the intestinal expression of IL-17 family members and 
IL-17Rs using Western blotting and ELISA assays, however other methods such 
as qRT-PCR and immunohistochemistry would be useful to corroborate our data, 
and should be used in the first part of a validation study. Moreover, the 
magnitude of IL-17A up-regulation which we observed in CD strictures compared 
with non-strictured CD areas and control intestine is in the range of a 2-3 fold 
factor, which raises the question whether this statistically significant difference 
has a biological relevance in CD intestinal fibrosis. 
 
Another limitation of our study is represented by the choice of ECM components 
and tissue remodelling enzymes which we used as read-outs to assess the pro-
fibrogenic potential in our in vitro experiments. We chose to evaluate the 
production of MMP-3, MMP-12 and TIMP-1 by intestinal myofibroblasts because 
of the prominent and established involvement in IBD pathogenesis, or because of 
existing data in the same context and experimental model, or because of the 
availability of the reagents and of an optimised detection protocol (Di Sabatino et 
al. 2009a). It would be appropriate to study the effects of IL-17A and IL-17E on 
the production of other proteases and their inhibitors, such as MMP-9, MMP-13 
and TIMP-3, however we decided not to study MMP-7 as fibrosis occurs in the 
submucosal and muscle layers, and we focused on these layers upon discarding 
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the mucosa of the intestinal samples. Nevertheless, the measurement of total 
collagen concentration in myofibroblast supernatants and myofibroblast migratory 
ability provides the evaluation of downstream events in the fibrogenic cascade, 
which may be more representative of the in vivo conditions than upstream 
mediators such as proteases and their inhibitors. 
 
Future experiments 
 
In addition to the experiments mentioned in the paragraph about study limitations, 
such as the measurement of intestinal IL-17 family member expression by qRT-
PCR and immunohistochemistry, and the evaluation of other pro-fibrogenic 
mediators, among which fibronectin and collagen subtypes appear to be 
particularly relevant, it would be important to assess the expression of other IL-17 
family members and Th17 cytokines, including IL-17F and IL-22, in the context of 
CD intestinal fibrosis. 
 
An important point still to be clarified is the evaluation of the mucosal expression 
levels and the contribution of different IL-17 family members to intestinal fibrosis 
during the phases that precede the onset of CD strictures. The first step in order 
to address this question could involve using AIEC-induced colitis and SAMP mice, 
which are currently the experimental models of intestinal fibrosis most closely 
related to CD. 
 
It has been shown that cathelicidin, an anti-microbial peptide with anti-
inflammatory properties, can reverse TNBS-induced intestinal fibrosis by 
inhibiting collagen production by colonic fibroblasts via a MAPK-dependent 
mechanism (Yoo et al. 2015). Additionally, cathelicidin down-regulates IL-17A 
and up-regulates TGF- production by monocyte-derived macrophages infected 
with M. tuberculosis (Torres-Juarez et al. 2015). It is known that AIEC NRG857 
strain has a pro-fibrogenic effect in experimental colitis, that anti-microbial 
peptides, albeit via their anti-inflammatory action, have an anti-fibrogenic effect, 
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and that components of the intestinal microbiota such as SFB have important 
effects on Th17 cells. Hence, it would be particularly interesting to investigate the 
effects of specific components of the intestinal microbiota and anti-microbial 
peptides on the mechanisms of intestinal fibrosis, with particular reference to the 
Th17 immune response. In the first instance, this could be done by characterising 
the intestinal microbiota of patients with fibrostenosing CD compared to non-
fibrostenosing CD patients, and subsequently by studying the in vitro effects of 
differentially represented species on the mechanisms of intestinal fibrosis. 
 
Finally, it will be important to clarify which cell types are the main responsible for 
the overproduction of specific Th17-related cytokines at different time points 
during intestinal stricture development in CD. A starting point to address this 
question will be to perform intracellular flow cytometry on freshly isolated cells 
from fibrostenosing CD patients, and to determine which cell types are 
responsible for the overproduction of IL-17A in this condition. Interestingly, it has 
been shown that, among Th17 cells, upon TCR stimulation, only a sub-
population with stable expression of multi-drug resistance type 1 (MDR1), but not 
their MDR1- counterparts, can produce IL-17A and IFN-, and no IL-10 or other 
anti-inflammatory molecules. MDR1+ Th17 cells are enriched in the intestinal 
mucosa of CD patients (Ramesh et al. 2014), hence in a subsequent validation 
study it would be appropriate to assess whether this cell population is involved in 
CD intestinal fibrosis. 
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Chapter 4: The role of IL-13 in IBD 
 
Note: The quantification of NKT, iNKT and Th2 cells within intestinal lamina 
propria and the evaluation of IL-13 production by mucosal NKT cells (Paragraphs 
4.3.2-4) have been performed by Dr F Facciotti in the Laboratories of the Istituto 
Nazionale di Genetica Molecolare, Milan, Italy. Primary data of the experiment 
are not available, therefore I could not repeat the statistical analysis using a 
different and more appropriate test, such as the ANOVA One way analysis of 
variance. These results have been published in the following paper, on which I 
am first Author (Biancheri P, Di Sabatino A, Ammoscato F, Facciotti F, Caprioli F, 
Curciarello R, Hoque SS, Ghanbari A, Joe-Njoku I, Giuffrida P, Rovedatti L, 
Geginat J, Corazza GR, MacDonald TT. Absence of a role for interleukin-13 in 
inflammatory bowel disease. Eur J Immunol 2014;44:370-85). Substantial help in 
the study of IL-4R and IL-13R expression by intestinal T cells, macrophages and 
myofibroblasts (Paragraphs 4.3.9-12) has been provided by Ms F Ammoscato in 
the Centre for Immunobiology Laboratory, Blizard Institute, Barts and The 
London School of Medicine and Dentistry, London, UK. 
 
IL-13 has been reported to be up-regulated in UC intestinal mucosa, and to play 
an important role in oxazolone-induced colitis and in intestinal experimental 
fibrosis. However, contrasting observations exist on the levels and the role of IL-
13 in inflamed IBD mucosa, and limited information is available on the role of IL-
13 in CD intestinal fibrosis. Further information on the background to this Chapter 
is reported in Sections “1.4.4 Inappropriate inflammatory reaction in IBD intestinal 
mucosa” and “1.4.7 Mechanisms of intestinal fibrogenesis in CD”. 
 
4.1 Aims of the study 
 
This study aims to explore the role of IL-13 in UC mucosal inflammation and in 
CD intestinal fibrosis using the following approach: 
5. Assessment of IL-13 production by mucosal intestinal explants and LPMCs 
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from UC patients, CD patients and control subjects. 
6. Evaluation of IL-13-producing cells in the intestinal mucosa of UC patients, 
CD patients and control subjects. 
7. Assessment of IL-13 production by intestinal tissue explants from 
fibrostenosing CD patients and control subjects. 
8. Assessment of IL-13R expression on mucosal T cells and macrophages from 
UC patients, CD patients and control subjects. 
9. Assessment of IL-13R expression on submucosal myofibroblasts of CD 
patients and control subjects. 
10. Study of the in vitro effects of IL-13 on UC LPMCs. 
11. Study of the in vitro effects of IL-13 on CD and control intestinal 
myofibroblasts. 
  
178 
4.2 Chapter-specific Materials and Methods 
 
4.2.1 Patients and tissues 
 
Colonic biopsies or surgical specimens were taken from macroscopically and 
microscopically inflamed or uninflamed mucosa of 44 patients affected by CD 
(Table 4.1) and 51 patients affected by UC (Table 4.2). Surgical specimens were 
also taken from uninflamed areas of strictured and non-strictured ileum of 13 
patients with fibrostenosing CD (Table 4.1). CD and UC patients were enrolled 
consecutively. Diagnosis of CD and UC was made according to standard clinical 
criteria (Van Assche et al. 2010), and the site and extent of the disease were 
confirmed by endoscopy. In CD patients, disease activity was assessed by 
Crohn’s Disease Activity Index (Best et al. 1976). Patients with scores below 150 
were classified as being in remission, whereas those with scores over 450 had 
severe disease (Best et al. 1976). In UC patients, disease activity was assessed 
according to the Clinical Activity Index (Rachmilewitz 1989). Clinical remission 
was defined as a score below 4. None of the IBD patients had been ever treated 
with cyclosporine, tacrolimus, methotrexate or anti-TNF- antibodies. Mucosal 
samples were collected perendoscopically from the ileum or the colon of 22 
subjects who had functional diarrhoea at the end of their diagnostic work-up 
(Table 4.3), who were considered as control subjects. Intestinal samples were 
also collected from macroscopically and microscopically unaffected (at least 500 
mm far from the tumour mass) ileal or colonic areas of 17 patients undergoing 
intestinal resection for colon cancer (Table 4.4), who were considered as control 
subjects. CD, UC patients and control subjects who provided intestinal 
perendoscopic biopsies were sex-matched, whereas control subjects subjects 
who underwent intestinal resection were significantly (p<0.001) older than CD 
and UC patients and than control subjects who provided intestinal perendoscopic 
biopsies. This study was approved by the NRES Committee London - City & East 
(REC reference: 10/H0704/74), and informed consent was obtained from all 
patients and control subjects. 
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Table 4.1. Clinical features of patients with CD (n=57) 
Characteristics and parameters N. Median (range) 
Age (years) 
Sex (M/F) 
First attack 
Intestinal location 
        Small bowel and colon 
        Colon only 
Disease behaviour 
        Fistulising 
        Fibrostenosing 
        Luminal 
Duration of disease (months) 
Number of recurrences 
CDAI 
Treatment 
        Mesalazine 
        Topical steroids 
        Antibiotics 
        Azathioprine/6-MP 
 
31/26 
14 
 
41 
16 
 
8 
13 
36 
 
 
 
 
42 
15 
12 
16 
32.5 (18-61) 
 
 
 
 
 
 
 
 
 
47.3 (1-188) 
3 (0-9) 
215 (73-412) 
 
 6-MP, 6-mercaptopurine. 
 
Table 4.2. Clinical features of patients with UC (n=51) 
Characteristics and parameters N. Median (range) 
Age (years) 
Sex (M/F) 
First attack 
Intestinal location 
        Pancolitis 
        Left-sided colitis 
Duration of disease (months) 
Number of recurrences 
CAI 
Treatment 
        Mesalazine 
        Mesalazine + topical steroids 
        Mesalazine + azathioprine/6-MP 
 
24/27 
6 
 
21 
30 
 
 
 
  
10 
22 
12 
34.5 (17-56) 
 
 
 
 
 
48.8 (1-173) 
3.5 (0-6) 
8 (5-13) 
 
 6-MP, 6-mercaptopurine; CAI, Clinical activity index. 
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Table 4.3. Clinical features of control subjects who provided intestinal 
perendoscopic biopsies (n=22) 
Characteristics and parameters N. Median (range) 
Age (years) 
Sex (M/F) 
Comorbidities 
        Hypertension 
        Hyperlipaemia 
        Diabetes 
        Chronic obstructive lung disease 
        Chronic kidney disease         
        None 
Current medications 
        Anti-hypertensive 
        Diuretics 
        Aspirin 
        Statins 
        Metformin 
        Bronchodilators 
        None 
 
12/10 
 
4 
4 
3 
1 
1 
13 
 
4 
2 
2 
3 
3 
1 
10 
38 (25-62) 
 
 
 
 
 
 F, female; M, male. 
 
 
Table 4.4. Clinical features of control subjects who underwent intestinal 
resection (n=17) 
Characteristics and parameters N. Median (range) 
Age (years) 
Sex (M/F) 
Comorbidities 
        Ischaemic heart disease 
        Hypertension 
        Hyperlipaemia 
        Diabetes 
        None 
Current medications 
        Anti-hypertensive 
        Diuretics 
        Aspirin 
        Statins 
        Metformin 
        None 
 
9/8 
 
3 
6 
8 
2 
13 
 
6 
1 
3 
5 
2 
8 
57 (42-72) 
 
 
 
 
 
 F, female; M, male. 
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4.2.2 Study design 
 
In order to study the involvement of IL-13 in intestinal inflammation, spontaneous 
IL-13 and pro-inflammatory cytokine production by intestinal biopsies from 10 CD 
patients, 13 UC patients and 10 control subjects cultured ex vivo was evaluated 
(Fig. 4.1, Fig. 4.2). Additionally, the production of IL-13 and pro-inflammatory 
cytokines by unstimulated or activated intestinal LPMCs isolated from additional 
15 CD patients, 15 UC patients and 15 control subjects was studied (Fig. 4.9, Fig. 
4.10, Fig.4.11, Table 4.5). The expression of IL-13 and other pro-inflammatory 
cytokines was studied in biopsy homogenates from additional nine CD patients, 
additional seven UC patients and 16 of the aforementioned control subjects (Fig. 
4.12). The distribution of NKT cells and their production of IL-13 were evaluated 
in LPMCs from the inflamed intestinal mucosa of additional four CD patients, 
seven UC patients, and in the normal intestinal mucosa of additional three control 
subjects (Fig. 4.4, Fig. 4.8). Moreover, the distribution of iNKT and Th2 cells was 
evaluated in LPMCs from the inflamed intestinal mucosa of additional three CD 
patients and three UC patients, and from the normal intestinal mucosa of 
additional three control subjects (Fig. 4.6). The expression of IL-13Rs and IL-4R 
by LPMCs isolated from the inflamed colon of additional three CD patients and 
three UC patients, and from the normal colon of additional three control subjects 
was then characterised (Fig. 4.15, Fig. 4.16, Fig. 4.18, Fig. 4.19). Finally, the 
effects of IL-13 or IL-13R blockade on LPMCs isolated from the inflamed colon of 
three additional UC patients were evaluated (Fig. 4.22, Fig. 4.24). 
 
In order to study the role of IL-13 in CD fibrosis, spontaneous IL-13 and pro-
fibrogenic mediator production by muscle layer explants from the ileum of six 
fibrostenosing CD patients, five additional control subjects and two of the 
aforementioned control subjects was evaluated (Fig. 4.13). The expression of IL-
13Rs and IL-4R by LPMCs isolated from the ileum of three additional 
fibrostenosing CD patients was then characterised (Fig. 4.15, Fig. 4.16, Fig. 4.18, 
Fig. 4.19). Ileal submucosal myofibroblasts from four additional fibrostenosing 
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CD patients, from one of the aforementioned fibrostenosing CD patients and from 
five of the aforementioned control subjects were isolated and, after characterising 
the expression of IL-13Rs and IL-4R (Fig. 4.21), were cultured with IL-13 and 
the production of collagen in the supernatant was measured (Fig. 4.25). 
 
4.2.3 LPMC isolation and culture 
 
LPMCs were isolated as follows within 30 minutes from biopsy/specimen 
collection. The epithelial layer was removed from the lamina propria with 1 mM 
EDTA (Sigma-Aldrich) treatment. After stirring for 1 hour at 37°C, the supernatant 
was removed and the remaining tissue was treated with type 1A collagenase (1 
mg/ml; Sigma-Aldrich) for 1 hour with stirring at 37°C. The crude cell suspension 
was allowed to stand for 5 minutes to permit debris sedimentation. Cells from the 
supernatant were washed twice, resuspended in 1 ml RPMI-1640 medium 
(Sigma-Aldrich) containing 10% FBS, 100 U/ml penicillin and 100 g/ml 
streptomycin, and kept on ice until used. Cells were not used if viability, as 
assessed by flow cytometry after propidium iodide staining, did not exceed 90%. 
Freshly isolated LPMCs were cultured (2 x 105 cells/well, in duplicate) in RPMI-
1640 medium (Sigma-Aldrich) supplemented with 10% FBS, 100 U/ml penicillin 
and 100 g/ml streptomycin, at 37°C, 5% CO2 for 48 hours in 96-well plates 
(VWR International) with medium alone or with rhIL-13 (PeproTech EC, London, 
UK), or in anti-CD3-coated 96-well plates (BD Biosciences) with soluble anti-
CD28 antibody (1 g/ml; eBioscience), in the absence or presence of the 
following stimuli: rhIL-13, polyclonal goat anti-IL-13R2 neutralising antibody 
(R&D Systems, goat IgG), monoclonal mouse anti-IL-4 receptor (IL-4R) 
neutralising antibody (R&D Systems, Mouse IgG2a), goat IgG (Sigma-Aldrich), 
mouse IgG2a (R&D Systems), soluble anti-CD2 (1 g/ml; BioLegend, Cambridge, 
UK) and soluble anti-CD28 antibody (1 g/ml; eBioscience). All the above 
mentioned antibodies and control IgG were used at a concentration of 10 g/ml, 
while rhIL-13 was used at 20 ng/ml. The total processing time from collection to 
cell resuspension was less than 3 hours. After culture, LPMC supernatants were 
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collected and stored at -70°C. For the purposes of analysis of IL-13 production by 
flow cytometry, LPMCs were cultured with immobilised anti-CD3 antibodies (2 
g/ml) in the presence of 2 g/ml anti-CD28 antibodies (BD Biosciences) for 44 
hours before addition for 4 hours of brefeldin A (Sigma-Aldrich). 
 
4.2.4 Flow cytometry 
 
LPMCs and myofibroblasts were stained with the following antibodies (or 
corresponding isotype control antibodies): FITC-anti-human CD3 (UCHT1, BD 
Biosciences; Mouse IgG1() isotype control), APC-anti-human CD4 (RPA-T4, BD 
Biosciences, Mouse IgG1() isotype control; VIT4, Miltenyi Biotec, Mouse 
IgG2a() isotype control), PE-anti-human CD294 (CRTH2) (BM16, Miltenyi Biotec, 
Rat IgG2a() isotype control), APC-anti-human CD161 (DX12, BD Biosciences, 
Mouse IgG1() isotype control), APC-anti-human CXCR3 (1C6, BD Biosciences, 
Mouse IgG1() isotype control), PE/Cy7-anti-human CD127 (HTK888, BioLegend, 
Rat IgG2a() isotype control), FITC-anti-human lineage cocktail (UCHT1, 
BioLegend, Mouse IgG1() isotype control), PE-anti-human V24 (6B11, 
BioLegend, Mouse IgG1() isotype control), APC-anti-human V11 (C21, Becton 
Dickinson, Mouse IgG2a() isotype control), APC-anti-human IL-4R (FAB230A, 
R&D Systems, Mouse IgG2a() isotype control), Alexa Fluor
® 700-anti-human IL-
13R1 (FAB1462N, R&D Systems, Mouse IgG2a() isotype control), fluorescein-
anti-human IL-13R2 (FAB614F, R&D Systems, Mouse IgG2b() isotype control), 
biotinylated anti-human CD68 (Y1/82A, BioLegend, Mouse IgG2b() isotype 
control), PE-anti-human IL-13 (JES10-5A2, BD Biosciences, Rat IgG1 isotype 
control). Biotinylated monoclonal antibodies were revealed with Streptavidin-
APC-Cy7 (BD Biosciences). Samples were passed on a FACSCanto II flow 
cytometer (BD Biosciences). A minimum of 30,000 events/test tube for LPMC 
stainings, and a minimum of 10,000 events/test tube for myofibroblasts were 
collected. The doublets corresponding to cell aggregates were excluded by 
gating, and single cells were further analysed. Events were also gated to exclude 
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nonviable cells on the basis of light scatter, and to eliminate artefacts caused by 
poor flow. Gates were set up according to the isotype staining profiles, and 
differences in setting the gates for the same staining between different samples 
analysed are attributable to interindividual variability. Data were analysed using 
FlowJo software (Treestar, Ashland, OR). 
 
4.2.5 T84 cell culture 
 
Subconfluent monolayers of T84 cells were cultured in 24-well plates (VWR 
International) for 72 hours at 37°C, 5% CO2, with DMEM/Hams Nutrient F12 Mix 
(Invitrogen Ltd), supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 
100 g/ml streptomycin and 2 mM glutamine (Invitrogen Ltd), in the absence or 
presence of the following stimuli: rhIL-13 (PeproTech EC), polyclonal goat IL-
13R2 neutralising antibody (R&D Systems), monoclonal mouse anti-IL-4R 
neutralising antibody (R&D Systems), goat IgG (Sigma-Aldrich), mouse IgG2a 
(R&D Systems). All the above mentioned antibodies and control IgG were used 
at a concentration of 10 g/ml, while rhIL-13 was used at 20 ng/ml. 
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4.3 Results  
 
4.3.1 Ex vivo production of IL-13, IFN-, IL-17A, IL-4 and IL-5 by mucosal 
biopsies 
 
The spontaneous production of IL-13, IL-17A, IFN-, IL-4 and IL-5 by biopsies in 
organ culture from inflamed and uninflamed mucosa of 23 IBD patients (10 with 
CD and 13 with UC) and 10 control subjects was determined (Fig. 4.1 and 4.2). 
 
The concentration of IL-13 was the same in organ culture supernatants of IBD 
inflamed mucosa (CD: median 44 pg/ml, range 18-77; UC: median 37 pg/ml, 
range 0-96), IBD uninflamed mucosa (CD: median 39 pg/ml, range 15-62; UC: 
median 35 pg/ml, range 12-72), and control mucosa (median 31 pg/ml, range 10-
71) (Fig. 4.1). IL-13 measurement on the same supernatants was repeated using 
a different and more sensitive kit, and in this case IL-13 was actually 
undetectable in all the supernatants tested. 
 
Since it is well known that IL-17A and IFN- are elevated in CD and UC, these 
cytokines were also measured in the same supernatants (Fig. 4.1). IFN- was 
significantly higher in the supernatants of inflamed CD (median 235 pg/ml, range 
72-465; p<0.001) and inflamed UC (median 210 pg/ml, range 37-370; p<0.01) 
biopsies compared with those of control subjects (median 59 pg/ml, range 25-82). 
The concentration of IL-17A was significantly higher in the supernatants of 
inflamed CD (median 164 pg/ml, range 52-467; p<0.001) and inflamed UC 
(median 171 pg/ml, range 68-434; p<0.01) organ culture biopsies in comparison 
with those of uninflamed areas (CD: median 44 pg/ml, range 20-98; UC: median 
72 pg/ml, range 38-150) and control subjects (median 55 pg/ml, range 31-93; 
p<0.01). 
 
IL-4 and IL-5 were not detectable in all supernatants of inflamed and uninflamed 
IBD and control mucosa (Fig. 4.2). 
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Figure 4.1. Ex vivo production of IL-13, IFN- and IL-17A by intestinal 
biopsies. Levels of IL-13, IFN- and IL-17A expressed in pg/ml, in the 
supernatants of intestinal biopsies taken from the inflamed and uninflamed 
mucosa of 10 CD patients and 13 UC patients, and from the mucosa of 10 
control subjects (HC), and cultured for 24 hours in the absence of stimuli. Each 
point represents one patient. Horizontal bars are median values. Data were 
analysed by ANOVA One way analysis of variance followed by the Tukey’s 
multiple comparison test. 
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Figure 4.2. Ex vivo production of IL-4 and IL-5 by intestinal biopsies. Levels 
of IL-4 and IL-5 expressed in pg/ml, in the supernatants of intestinal biopsies 
taken from the inflamed and uninflamed mucosa of 10 CD patients and 13 UC 
patients, and from the mucosa of 10 control subjects (HC), and cultured for 24 
hours in the absence of stimuli. Each point represents one patient. Data were 
analysed by ANOVA One way analysis of variance followed by the Tukey’s 
multiple comparison test. 
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4.3.2 Relative distribution of NKT cells among T-LPLs 
 
Previous studies showed that NKT cells, iNKT cells and Th2 lymphocytes are 
among the most relevant producers of IL-13 in humans (van Dieren et al. 2007). 
Flow cytometry was used to determine the distribution of NKT cells, defined as 
CD3+ cells expressing CD161 (please see gating strategy in Fig. 4.3), among 
sorted T-LPLs from normal intestinal mucosa of three control subjects and from 
inflamed intestinal mucosa of four clinically active patients with CD and seven 
clinically active patients with UC (Fig. 4.4). NKT cells were significantly (p<0.01) 
reduced in UC (mean 12.02  4.39%) compared with control (mean 69.33  
4.90%) and CD T-LPLs (mean 38.00  16.19%). The percentage of NKT cells did 
not differ significantly between control and CD T-LPLs. 
 
 
Figure 4.3. Gating strategy used for the evaluation of NKT cell distribution 
in the intestinal lamina propria. LPMCs were isolated from the intestinal 
mucosa of IBD patients and control subjects, and were stained with FITC-anti-
human CD3 and APC-anti-human CD161. Subsequently, cells were analysed by 
flow cytometry. NKT cells were identified as CD161+ (gated on viable CD3+ cells). 
The dot plot displays one experiment, and is representative of experiments 
performed in all patients with IBD and control subjects. 
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Figure 4.4. NKT cell distribution in the intestinal lamina propria. Relative 
distribution of NKT cells in T-LPLs of control subjects (HC, n=3) and patients with 
CD (n=4) and UC (n=7). NKT cells were identified as CD161+ (gated on viable 
CD3+ cells). Each dot plot displays one experiment, and is representative of 
experiments performed in all patients with IBD and control subjects. Right 
histogram bar graph: mean percentage of NKT cells out of total viable T-LPLs 
from HC subjects and CD and UC patients. Bars represent mean  SEM. The 
Mann-Whitney U test was applied. *p<0.01 versus HC and CD T-LPLs. 
 
 
4.3.3 Relative distribution of iNKT and Th2 cells among T-LPLs 
 
Similarly, the percentage of iNKT cells, defined as CD3+ cells that express a 
semi-invariant TCR composed in humans by the V24 and V11 rearrangement, 
and of Th2 cells, defined as CD294 (CRTH2)+CD3+ cells was determined by flow 
cytometry (please see gating strategy in Fig. 4.5), among sorted T-LPLs from 
normal intestinal mucosa of three control subjects and from inflamed intestinal 
mucosa of three clinically active patients with CD and three clinically active 
patients with UC (Fig. 4.6). The percentage of iNKT did not differ statistically 
between control, CD and UC T-LPLs (mean 0.23  0.18%; mean 0.34  0.10%; 
mean 0.05  0.04%, respectively). Finally, the mean percentage of Th2 cells was 
comparable between control, CD and UC T-LPLs (1.43  0.50%; 1.14  0.20%; 
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0.80  0.14%, respectively). The mean percentage of V24+V11- T cells which 
we observed were the following: control T-LPLs: 7.32  2.13%; CD T-LPLs: 
22.31  22.64%; UC T-LPLs: 2.92  1.10%. 

 
Figure 4.5. Gating strategy used for the evaluation of iNKT and Th2 cell 
distribution in the intestinal lamina propria. LPMCs were isolated from the 
intestinal mucosa of IBD patients and control subjects, and were stained with 
FITC-anti-human CD3, APC-anti-human CD4, PE-anti-human CD294 (CRTH2), 
PE-anti-human V24, APC -anti-human V11. Subsequently, cells were 
analysed by flow cytometry. iNKT cells (upper panels) were identified as 
V24+V11+ cells (gated on viable CD3+ cells), whereas Th2 cells (lower 
panels) were identified as CD294 (CRTH2)+CD3+ cells (gated on viable CD4+ 
cells). The dot plots display one experiment, and are representative of 
experiments performed in all patients with IBD and control subjects. 
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Figure 4.6. iNKT and Th2 cell distribution in the intestinal lamina propria. 
Relative distribution of iNKT cells (upper panels) and Th2 cells (lower panels) 
in T-LPLs of control subjects (HC, n=3) and patients with CD (n=3) and UC (n=3). 
Each dot plot displays one experiment, and is representative of experiments 
performed in all patients with IBD and control subjects. Right histogram bar 
graphs: mean percentage of iNKT cells (upper panel) or Th2 cells (lower panel) 
out of total viable T-LPLs from HC subjects, CD and UC patients. Bars represent 
mean  SEM. The Mann-Whitney U test was applied. 
 
 
4.3.4 Percentage of IL-13-producing NKT cells after anti-CD3/CD28 
stimulation 

To determine the percentage of mucosal IL-13-producing cells in NKT cells after 
T cell activation, LPMCs from normal intestinal mucosa of three control subjects 
and from inflamed intestinal mucosa of four clinically active patients with CD and 
seven clinically active patients with UC were cultured in the presence of anti-
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CD3/CD28 antibodies, subsequently evaluating the production of IL-13 by 
intracellular flow cytometry (please see gating strategy in Fig. 4.7). Basal IL-13 
production by mucosal NKT cells was undetectable (data not shown). The 
percentage of IL-13+ NKT cells did not differ between control, CD and UC T-LPLs 
(mean 1.90  0.81%; mean 3.19  0.97%; mean 3.74  1.71%, respectively) (Fig. 
4.8). 
 
Figure 4.7. Gating strategy used for the evaluation of IL-13-producing NKT 
cells in the intestinal lamina propria. LPMCs were isolated from the intestinal 
mucosa of IBD patients and control subjects, and were stimulated for 48 hours 
with immobilised anti-CD3/CD28 monoclonal antibodies, with the addition of 
brefeldin A for the last 4 hours of culture. Intracellular IL-13 was measured on 
NKT cells. In particular, LPMCs were stained with FITC-anti-human CD3, APC-
anti-human CD161 and, after permeabilisation, with PE-anti-human IL-13. 
Subsequently, cells were analysed by flow cytometry. NKT cells were identified 
as CD161+ (gated on viable CD3+ cells). The dot plots display one experiment, 
and are representative of experiments performed in all patients with IBD and 
control subjects. 
  
193 
 
Figure 4.8. IL-13 production by NKT cells in the intestinal lamina propria. 
LPMCs isolated from intestinal mucosa of control subjects (HC, n=3) and from 
inflamed intestinal mucosa of clinically active patients with CD (n=4) and UC 
(n=7) were stimulated for 48 hours with immobilised anti-CD3/CD28 monoclonal 
antibodies, and intracellular IL-13 was subsequently measured on NKT cells. 
Each dot plot displays one experiment, and is representative of experiments 
performed in all patients with IBD and control subjects. Right histogram bar 
graph: mean percentage of IL-13-producing NKT cells out of total viable T-LPLs 
from HC subjects and CD and UC patients. Data are shown as mean  SEM. 
The Mann-Whitney U test was applied. 
 
 
4.3.5 In vitro production of IL-13, IFN-, IL-17A, IL-4 and IL-5 by LPMCs 
after activation with anti-CD3/CD28 antibodies  
 
The production of IL-13, IL-17A, IFN-, IL-4 and IL-5 by unstimulated and anti-
CD3/CD28-stimulated LPMCs from the inflamed mucosa of 22 IBD patients (11 
with CD and 11 with UC) and the normal mucosa of 11 control subjects was then 
evaluated by ELISA (Fig. 4.9, Fig. 4.10 and Fig. 4.11). 
 
No significant difference was found between control, CD and UC LPMCs in the 
production of IL-13 in unstimulated conditions (control subjects: median 12 pg/ml, 
range 0-40; CD: median 27 pg/ml, range 0-78; UC: median 30 pg/ml, range 0-72) 
(Fig. 4.9). In unstimulated conditions, LPMCs from CD and UC patients produced 
significantly (p<0.05) higher amounts of IFN- (median 547 pg/ml, range 170-
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832; UC: median 373 pg/ml, range 210-902) in comparison with control LPMCs 
(median 134 pg/ml, range 27-321). In unstimulated conditions, LPMCs from CD 
and UC patients produced significantly (p<0.05) higher amounts of IL-17A 
(median 392 pg/ml, range 120-1330; UC: median 436 pg/ml, range 138-532) in 
comparison with control LPMCs (median 59 pg/ml, range 19-242). No difference 
in IFN- and IL-17A production was found between unstimulated CD and UC 
LPMCs (Fig. 4.9). 
 
Figure 4.9. In vitro production of IL-13, IFN- and IL-17A by unstimulated 
LPMCs. Levels of IL-13, IFN- and IL-17A, expressed in pg/ml, in the 
supernatants of unstimulated LPMCs isolated from the inflamed intestinal 
mucosa of 11 CD patients and 11 UC patients, and from the mucosa of 11 
control subjects (HC), and cultured for 48 hours. Horizontal bars are median 
values. Data were analysed by ANOVA One way analysis of variance followed by 
the Tukey’s multiple comparison test. *p<0.05 versus concentration of the same 
cytokine in culture supernatants from HC LPMCs. 
 
Stimulation with anti-CD3/CD28 antibodies induced a significant (p<0.05) 
increase in IL-13 production by both CD and UC LPMCs, but did not influence 
significantly the release of IL-13 by control LPMCs (control subjects: median 40 
pg/ml, range 0-141; CD: median 38 pg/ml, range 0-190; UC: median 63 pg/ml, 
range 0-143) (Fig. 4.10). No significant difference in IL-13 production by anti-
CD3/CD28-stimulated LPMCs was found between control, CD and UC LPMCs. 
Of note, IL-13 levels in culture supernatants were never greater than 200 pg/ml. 
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After stimulation with anti-CD3/CD28 antibodies, IFN- production was 
significantly (p<0.0005) enhanced in comparison with unstimulated conditions in 
CD, UC and control subjects (CD: median 7281 pg/ml, range 4351-12210; UC: 
median 5432 pg/ml, range 2203-12302; control subjects: median 2026 pg/ml, 
range 951-6149). Of note, in three out of 11 CD and two out of 11 UC patients 
IFN- production exceeded 10000 pg/ml. Activation with anti-CD3/CD28 
antibodies also significantly enhanced also the production of IL-17A in CD, UC 
and control subjects (CD: median 6332 pg/ml, range 2079-12900, p<0.0005; UC: 
median 4232 pg/ml, range 2018-11200, p<0.0005; control subjects: median 1730 
pg/ml, range 830-5555, p<0.005). In three out of 11 CD and two out of 11 UC 
patients IL-17A concentration exceeded 10000 pg/ml. Anti-CD3/CD28 stimulation 
markedly increased IFN- and IL-17A release by LPMCs from all 11 CD, 11 UC 
patients and 11 control subjects. Conversely, the overall increase in IL-13 
production observed in CD and UC LPMCs upon anti-CD3/CD28 stimulation was 
mostly due to a subset of six out of 11 CD patients and five out of 11 UC patients 
who responded to anti-CD3/CD28 stimulation. Culture with anti-CD3/CD28 
antibodies enhanced IL-13 production by LPMCs from only four out of 11 control 
subjects. 
 
Figure 4.10. In vitro production of IL-13, IFN- and IL-17A by activated 
LPMCs. Levels of IL-13, IFN- and IL-17A, expressed in pg/ml, in the 
supernatants of unstimulated (-) and anti- ()CD3/CD28-stimulated (+) LPMCs 
isolated from the inflamed intestinal mucosa of 11 CD patients and 11 UC 
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patients, and from the mucosa of 11 control subjects (HC), and cultured for 48 
hours. Each set of connected points represents data from one patient. Horizontal 
bars are median values. The paired two-tailed t test was applied to compare 
between unstimulated and stimulated conditions, and the ANOVA One way 
analysis of variance followed by the Tukey’s multiple comparison test was 
applied to compare the same condition of culture in different patient populations. 
*p<0.05 versus unstimulated LPMCs of the respective group of patients; 
**p<0.005 versus unstimulated LPMCs of the respective group of patients; 
***p<0.0005 versus unstimulated LPMCs of the respective group of patients; 
§p<0.05 versus CD3/CD28-stimulated HC LPMCs. 
 
 
IL-4 and IL-5 were undetectable in all the supernatants of unstimulated or anti-
CD3/CD28-stimulated LPMCs from both IBD and control mucosa (Fig. 4.11). 
 
 
 
Figure 4.11. In vitro production of IL-4 and IL-5 by LPMCs. Levels of IL-4 and 
IL-5, expressed in pg/ml, in the supernatants of unstimulated (-) and anti- 
()CD3/CD28-stimulated (+) LPMCs isolated from the inflamed intestinal mucosa 
of 11 CD patients and 11 UC patients, and from the mucosa of 11 control 
subjects (HC), and cultured for 48 hours. Each set of connected points 
represents data from one patient. Horizontal bars are median values. The paired 
two-tailed t test was applied to compare between unstimulated and stimulated 
conditions, and the ANOVA One way analysis of variance followed by the 
Tukey’s multiple comparison test was applied to compare the same condition of 
culture in different patient populations. 
 
 
4.3.6 In vitro production of IL-13, IFN-, IL-17A, IL-4 and IL-5 by LPMCs 
after activation with anti-CD2/CD28 antibodies 
 
The production of IL-13, IL-17A, IFN-, IL-4 and IL-5 by anti-CD2/CD28-
stimulated LPMCs isolated from the inflamed mucosa of eight different IBD 
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patients (four with CD and four with UC) and the normal mucosa of four different 
control subjects was also investigated (Table 4.5). No significant difference was 
found in IL-13 production between control, CD and UC LPMCs in unstimulated 
and anti-CD2/CD28-stimulated conditions. In contrast, anti-CD2/CD28 
stimulation significantly enhanced IFN- and IL-17A production by CD and UC 
LPMCs, although IFN- and IL-17A in culture supernatants of anti-CD2/28-
stimulated LPMCs was 2-3 fold lower than in supernatants of anti-CD3/CD28-
stimulated LPMCs. Anti-CD2/CD28 stimulation led to a marked increase in IFN- 
and IL-17A production by control LPMCs, however this was not statistically 
significant after applying the paired two-tailed t test. IL-4 and IL-5 were 
undetectable in all the supernatants of unstimulated or anti-CD2/CD28-stimulated 
LPMCs from both IBD and control mucosa. 
 
Table 4.5. IL-13, IFN-, IL-17A, IL-4 and IL-5 production by anti- 
()CD2/CD28-stimulated LPMCs. IL-13, IFN-, IL-17A, IL-4 and IL-5 levels 
(pg/ml) in the supernatants of unstimulated and CD2/CD28-stimulated LPMCs 
isolated from the inflamed intestinal mucosa of four CD and four UC patients, and 
from the intestinal mucosa of four control subjects (HC), and cultured for 48 
hours. Results are shown as mean  SEM. The paired two-tailed t test was 
applied to compare between unstimulated and stimulated conditions, and the 
ANOVA One way analysis of variance followed by the Tukey’s multiple 
comparison test was applied to compare the same condition of culture in different 
patient populations. *p<0.05 versus unstimulated LPMCs of the respective group 
of patients; §p<0.05 versus CD3/CD28-stimulated HC LPMCs. 
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
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IL-4 
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0 
 
0 
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IL-5 
 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
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4.3.7 In vivo expression of IL-13 and IL-5 transcripts in intestinal mucosa 
 
We thought it important to use another methodology to analyse IL-13, IL-5, IFN- 
and IL-17A in IBD mucosa so we measured cytokine transcripts by qRT-PCR in 
snap frozen fresh intestinal biopsies from inflamed mucosa of seven patients with 
UC, nine patients with CD and from normal mucosa of 16 control subjects (Fig. 
4.12). The mean expression of IL-13 was uniformly low in all groups studied, and 
IL-5 expression was not significantly different in UC, CD and control mucosa. 
IFN- transcripts were significantly higher in CD patients in comparison with 
control subjects. As previously described (Fujino et al. 2003), IL-17A transcripts 
were also up-regulated in CD mucosa. 
 
Figure 4.12. In vivo mucosal expression of IL-13 and IL-5. Expression of IL-
13, IL-5, IFN- and IL-17A in inflamed intestinal mucosa of seven patients with 
UC, nine patients with CD, and from normal mucosa of 16 control subjects (HC). 
Levels were normalised to the mean expression of 18S, -actin and GAPDH. 
Data are shown as mean  SEM of the indicated number of donors, each 
examined once. Data were analysed by ANOVA One way analysis of variance 
followed by the Tukey’s multiple comparison test. r.u., relative units. 
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4.3.8 Ex vivo production of IL-13, IL-1, collagen and TGF-1 in strictured 
CD tissue 
 
Intestinal muscle layer explants (1mm3 in size) were then cultured ex vivo for 24 
hours from uninflamed areas of strictured and non-strictured ileum of 6 patients 
with fibrostenosing CD and from normal ileum of 7 control subjects, and IL-13, IL-
1 and collagen concentration in the culture supernatant and TGF-1 transcripts 
in the cultured tissue were measured (Fig. 4.13). The concentrations of IL-13 
were uniformly low in all samples (strictured CD ileum: median 24 pg/ml, range 
15-30; non-strictured CD ileum: median 19 pg/ml, range 9-28; normal ileum of 
control subjects: median 22 pg/ml, range 16-35). 
 
In contrast, both IL-1 and collagen were significantly higher in the organ culture 
supernatants of strictured CD ileum (median 372 pg/ml, range 226-595; median 
1159 g/ml, range 603-1429, respectively) compared with those of non-strictured 
CD ileum (median 188 pg/ml, range 95-255, p<0.01; median 508 g/ml, range 
248-958, p<0.05, respectively) and normal ileum of control subjects (median 111 
pg/ml, range 52-320, p<0.01; median 495 g/ml, range 325-933; p<0.01, 
respectively). Similarly, TGF-1 mRNA was significantly (p<0.001) higher in the 
cultured muscle layer tissue from strictured CD ileum compared with that in non-
strictured CD ileum and normal ileum of control subjects. 
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Figure 4.13. Ex vivo production of IL-13 by strictured CD tissue. Levels of IL-
13 and IL-1, expressed as pg/ml, and collagen, expressed as g/ml, in the 
supernatants of muscle layer explants from uninflamed areas of strictured (Strict) 
and non-strictured (Non-strict) ileum of 6 patients with fibrostenosing CD and 
from normal ileum of 7 control subjects (HC), cultured for 24 hours in the 
absence of stimuli, and levels of TGF-1 mRNA, expressed as relative units 
compared with the median expression in HCs that was assigned the value 1 in 
the same cultured tissue explants. Horizontal bars are median values. Data were 
analysed by ANOVA One way analysis of variance followed by the Tukey’s 
multiple comparison test. r.u., relative units. 
 
 
4.3.9 Surface expression of IL-4R, IL-13R1 and IL-13R2 on intestinal T 
cells and macrophages 
 
In parallel to the evaluation of IL-13 expression in normal and inflamed intestinal 
mucosa, we aimed to characterise which cell types may respond to IL-13 in the 
intestinal lamina propria of IBD patients and control subjects. In order to do so, 
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we used flow cytometry to measure IL-4R, IL-13R1 and IL-13R2 expression 
on the surface of both CD3+ and CD68+ LPMCs (please see gating strategy in 
Fig. 4.14) from three control subjects, from inflamed colonic mucosa of three UC 
patients, from inflamed colonic mucosa of three CD patients and from uninflamed 
ileal mucosa overlying strictured and non-strictured areas of three CD patients 
(Fig. 4.15, Fig. 4.16). Surface expression of IL-4, IL-13R1 and IL-13R2 by 
LPMCs isolated from normal mucosa of control subjects, from inflamed UC and 
CD mucosa and from the mucosa overlying CD strictures and CD mucosa above 
non-strictured areas was very low or not detectable, with no significant difference 
between all the groups of patients studied, in both T cells (Fig. 4.15) and 
macrophages (Fig. 4.16). 
 
 
Figure 4.14. Gating strategy used for the evaluation of surface expression 
of IL-4R, IL-13R1 and IL-13R2 on intestinal T cells and macrophages. 
LPMCs were isolated from the intestinal mucosa of IBD patients and control 
subjects, and were stained with FITC-anti-human CD3, APC-anti-human IL-4R, 
Alexa Fluor® 700-anti-human IL-13R1, fluorescein-anti-human IL-13R2, and, 
after permeabilisation, with biotinylated anti-human CD68. Subsequently, cells 
were analysed by flow cytometry. The doublets corresponding to cell aggregates 
were excluded by gating, and single cells were further analysed. Events were 
also gated to exclude nonviable cells on the basis of light scatter, and to 
eliminate artefacts caused by poor flow. T cells (upper panels) were identified as 
CD3+ cells, whereas macrophages (lower panels) were identified as CD68+ cells. 
The dot plots display one experiment, and are representative of experiments 
performed in all IBD patients and control subjects. 
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Figure 4.15 (see next page). Surface expression of IL-4R, IL-13R1 and IL-
13R2 on intestinal T cells. The expression of IL-4R, IL-13R1 and IL-13R2 
on the surface of CD3-gated LPMCs from the normal colon of a control subject 
(HC), from inflamed colonic mucosa of a UC patient, from inflamed colonic 
mucosa of a CD patient, and from uninflamed ileal mucosa overlying strictured 
and non-strictured areas of a fibrostenosing CD patient was determined by flow 
cytometry. Dashed line histograms display isotype control, while solid line 
histograms correspond to the receptor expression. Each histogram corresponds 
to one representative sample per group of independent experimental repeats 
(one for each patient analysed). The example is representative of independent 
experiments performed in three HC subjects, three UC patients, three luminal CD 
patients and three fibrostenosing CD patients. Data were analysed by ANOVA 
One way analysis of variance followed by the Tukey’s multiple comparison test. 
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Figure 4.16 (see previous page). Surface expression of IL-4R, IL-13R1 and 
IL-13R2 on intestinal macrophages. The expression of IL-4R, IL-13R1 and 
IL-13R2 on the surface of CD68-gated LPMCs from the normal colon of a 
control subject (HC), from inflamed colonic mucosa of a UC patient, from 
inflamed colonic mucosa of a CD patient, and from uninflamed ileal mucosa 
overlying strictured and non-strictured areas of a fibrostenosing CD patient was 
determined by flow cytometry. Dashed line histograms display isotype control, 
while solid line histograms correspond to the receptor expression. Each 
histogram corresponds to one representative sample per group of independent 
experimental repeats (one for each patient analysed). The example is 
representative of independent experiments performed in three HC subjects, three 
UC patients, three luminal CD patients and three fibrostenosing CD patients. 
Data were analysed by ANOVA One way analysis of variance followed by the 
Tukey’s multiple comparison test. 
 
 
4.3.10 Cytoplasmic expression of IL-4R, IL-13R1 and IL-13R2 in 
intestinal T cells 
 
Alongside the detection of IL-13R expression on the cell surface, we used part of 
the same LPMCs from IBD patients and control subjects for the assessment of 
intracellular expression of IL-4R, IL-13R1 and IL-13R2. In particular, we 
assessed by flow cytometry IL-4R, IL-13R1 and IL-13R2 expression in the 
cytoplasm of CD3+ LPMCs (please see gating strategy in Fig. 4.17) from three 
control subjects, from inflamed colonic mucosa of three UC patients, from 
inflamed colonic mucosa of three CD patients and from uninflamed ileal mucosa 
overlying strictured and non-strictured areas of three CD patients (Fig. 4.18). The 
intracellular expression of IL-4R and IL-13R2 by CD3+ LPMCs isolated from 
normal mucosa of control subjects, from inflamed UC and CD mucosa and from 
the mucosa overlying CD strictures and CD mucosa above non-strictured areas 
was very low or not detectable. Conversely, CD3+ LPMCs from inflamed CD 
mucosa expressed significantly (p<0.001) higher intracellular levels of IL-13R1 
(mean 33.5  12.5%) than CD3+ LPMCs from normal mucosa of control subjects 
(mean 1.2  0.3%), from inflamed UC mucosa (mean 1.4  0.7%) and from the 
mucosa overlying CD strictures (mean 0.8  0.3%) and CD mucosa above non-
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strictured areas (mean 1.1  0.6%). 
 
Figure 4.17. Gating strategy used for the evaluation of intracellular 
expression of IL-4R, IL-13R1 and IL-13R2 in intestinal T cells and 
macrophages. LPMCs were isolated from the intestinal mucosa of IBD patients 
and control subjects, and were stained with FITC-anti-human CD3 and, after 
permeabilisation, with APC-anti-human IL-4R, Alexa Fluor® 700-anti-human IL-
13R1, fluorescein-anti-human IL-13R2 and biotinylated anti-human CD68. 
Subsequently, cells were analysed by flow cytometry. The doublets 
corresponding to cell aggregates were excluded by gating, and single cells were 
further analysed. Events were also gated to exclude nonviable cells on the basis 
of light scatter, and to eliminate artefacts caused by poor flow. T cells (upper 
panels) were identified as CD3+ cells, whereas macrophages (lower panels) 
were identified as CD68+ cells. The dot plots display one experiment, and are 
representative of experiments performed in all IBD patients and control subjects. 
 
 
Figure 4.18 (see next page). Intracellular expression of IL-4R, IL-13R1 and 
IL-13R2 in intestinal T cells. The intracellular expression of IL-4R, IL-13R1 
and IL-13R2 by CD3-gated LPMCs from the normal colon of a control subject 
(HC), from inflamed colonic mucosa of a UC patient, from inflamed colonic 
mucosa of a CD patient, and from uninflamed ileal mucosa overlying strictured 
and non-strictured areas of a fibrostenosing CD patient was determined by flow 
cytometry. Dashed line histograms display isotype control, while solid line 
histograms correspond to the receptor expression. Each histogram corresponds 
to one representative sample per group of independent experimental repeats 
(one for each patient analysed). The example is representative of independent 
experiments performed in three HC subjects, three UC patients, three luminal CD 
patients and three fibrostenosing CD patients. Data were analysed by ANOVA 
One way analysis of variance followed by the Tukey’s multiple comparison test. 
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4.3.11 Cytoplasmic expression of IL-4R, IL-13R1 and IL-13R2 in 
intestinal macrophages 
 
In parallel, on the same LPMCs used for assessing intracellular IL-13R 
expression in T cells, we assessed by flow cytometry intracellular expression of 
IL-13Rs in CD68+ cells. In particular, we assessed by flow cytometry IL-4R, IL-
13R1 and IL-13R2 expression in the cytoplasm of CD68+ LPMCs (please see 
gating strategy in Fig. 4.17) from three control subjects, from inflamed colonic 
mucosa of three UC patients, from inflamed colonic mucosa of three CD patients 
and from uninflamed ileal mucosa overlying strictured and non-strictured areas of 
three CD patients (Fig. 4.19). The intracellular expression of IL-4R and IL-
13R2 by CD68+ LPMCs isolated from normal mucosa of control subjects, from 
inflamed UC and CD mucosa and from the mucosa overlying CD strictures and 
CD mucosa above non-strictured areas was very low or not detectable. 
Conversely, CD68+ LPMCs from inflamed CD mucosa expressed significantly 
(p<0.001) higher intracellular levels of IL-13R1 (mean 52.3  21.7%) than 
CD68+ LPMCs from normal mucosa of control subjects (mean 0.9  0.6%), from 
inflamed UC mucosa (mean 1.6  0.4%) and from the mucosa overlying CD 
strictures (mean 0.7  0.5%) and CD mucosa above non-strictured areas (mean 
0.9  0.3%). 
 
Figure 4.19 (see next page). Intracellular expression of IL-4R, IL-13R1 and 
IL-13R2 in intestinal macrophages. The intracellular expression of IL-4R, IL-
13R1 and IL-13R2 by CD68-gated LPMCs from the normal colon of a control 
subject (HC), from inflamed colonic mucosa of a UC patient, from inflamed 
colonic mucosa of a CD patient, and from uninflamed ileal mucosa overlying 
strictured and non-strictured areas of a fibrostenosing CD patient was 
determined by flow cytometry. Dashed line histograms display isotype control, 
while solid line histograms correspond to the receptor expression. Each 
histogram corresponds to one representative sample per group of independent 
experimental repeats (one for each patient analysed). The example is 
representative of independent experiments performed in three HC subjects, three 
UC patients, three luminal CD patients and three fibrostenosing CD patients. 
Data were analysed by ANOVA One way analysis of variance followed by the 
Tukey’s multiple comparison test. 
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4.3.12 Expression of IL-4R, IL-13R1 and IL-13R2 by intestinal 
myofibroblasts 
 
We also investigated by flow cytometry the expression of IL-4R, IL-13R1 and 
IL-13R2 on the surface and in the cytoplasm of submucosal myofibroblasts 
(please see gating strategy in Fig. 4.20) isolated from uninflamed areas of 
strictured and non-strictured ileum of three patients with fibrostenosing CD, and 
from normal ileum of three control subjects (Fig. 4.21). Surface expression of IL-
4R, IL-13R1 and IL-13R2 by myofibroblasts isolated from uninflamed areas 
of strictured and non-strictured CD ileum and from control ileum was very low or 
not detectable (Fig. 4.21A). 
 
Myofibroblasts isolated from uninflamed areas of strictured CD ileum expressed 
significantly (p<0.05) higher intracellular levels of IL-4R (mean 6.2  2.7%) than 
myofibroblasts isolated from uninflamed areas of non-strictured CD ileum (mean 
0.6  0.4%) and from control ileum (mean 0.4  0.3%) (Fig. 4.21B). 
Myofibroblasts isolated from uninflamed areas of both strictured and non-
strictured CD ileum expressed significantly (p<0.05) higher intracellular levels of 
IL-13R1 (mean 21.5  8.6%; mean 18.3  5.5%, respectively) and IL-13R2 
(mean 61.2  21.1%; mean 52.6  16.2%, respectively) than myofibroblasts 
isolated from control ileum (IL-13R1: mean 6.9  2.8%; IL-13R2: mean 11.2  
4.7%). 
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Figure 4.20 (see previous page). Gating strategy used for the evaluation of 
IL-4R, IL-13R1 and IL-13R2 expression by intestinal myofibroblasts. 
Submucosal intestinal myofibroblasts were isolated from CD patients and control 
subjects, and were then stained, before or after permeabilisation, with APC-anti-
human IL-4R, Alexa Fluor® 700-anti-human IL-13R1 and fluorescein-anti-
human IL-13R2. Subsequently, cells were analysed by flow cytometry. The dot 
plot displays one experiment, and is representative of experiments performed in 
all CD patients and control subjects. 
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Figure 4.21 (see previous page). IL-4R, IL-13R1 and IL-13R2 expression 
by intestinal myofibroblasts. (A) Surface or (B) intracellular expression of IL-
4R, IL-13R1 and IL-13R2 by submucosal myofibroblasts isolated from 
uninflamed areas of strictured and non-strictured ileum of a patient with 
fibrostenosing CD, and from normal ileum of a control subject (HC) was 
determined by flow cytometry. Dashed line histograms display isotype control, 
while solid line histograms correspond to the receptor expression. Each 
histogram corresponds to one representative sample per group of independent 
experimental repeats (one for each patient analysed). The example is 
representative of independent experiments performed in three fibrostenosing CD 
patients and three HC. Data were analysed by ANOVA One way analysis of 
variance followed by the Tukey’s multiple comparison test. 
 
 
4.3.13 Effect of IL-13R2 and IL-4R neutralisation on IL-13 production in 
UC 
 
Concentrations of cytokines in supernatants reflect both production and 
consumption. Since IL-13 can bind both to IL-13R2 and to the heterodimer 
formed by IL-13R1 and IL-4R (Rahaman et al. 2002; LaPorte et al. 2008), 
LPMCs from inflamed UC with anti-CD3/CD28 or anti-CD2/CD28 antibodies were 
cultured in the absence or presence of anti-IL-13R2 and anti-IL-4R 
neutralising antibodies or their control IgG, and IL-13 in the culture supernatants 
was measured by ELISA (Fig. 4.22). IL-13, IFN- and IL-17A concentrations in 
the supernatants of anti-CD3/CD28-stimulated UC LPMCs cultured with anti-IL-
13R2 and anti-IL-4R antibodies were not significantly different than those in 
the supernatants of anti-CD3/CD28-stimulated UC LPMCs cultured with the 
controls (Fig. 4.22). Similar results were observed in the supernatants of anti-
CD2/CD28-stimulated LPMCs (data not shown). These experiments suggest that 
consumption of IL-13 by LPMCs is not the reason for the low levels I observed in 
IBD. 
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Figure 4.22. Effect of IL-13R and IL-4R blockade on cytokine production by 
UC LPMCs. Levels of IL-13, IFN- and IL-17A, expressed in pg/ml, in the 
supernatants of LPMCs isolated from the inflamed colon of three UC patients and 
cultured for 48 hours with medium alone (-) or with anti-()CD3/CD28 antibodies 
(+), in the absence or presence of a polyclonal goat IL-13R2 neutralising 
antibody and a monoclonal mouse IL-4R neutralising antibody or their control 
IgG (goat IgG and mouse IgG2a). Bars represent mean  SEM. Data were 
analysed by ANOVA One way analysis of variance followed by the Tukey’s 
multiple comparison test. *p<0.05 versus unstimulated LPMCs. 
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4.3.14 Bioassay for the functional evaluation of rhIL-13, anti-IL-13R2 and 
anti-IL-4R antibodies 
 
IL-13 increases claudin 2 expression in T84 epithelial cells (Prasad et al. 2005). 
On this basis, in order to assess whether rhIL-13 and the IL-13R2 and IL-4R 
neutralising antibodies used in our in vitro assays were functionally active, T84 
cells were cultured with rhIL-13 in the presence of a polyclonal goat anti-IL-
13R2 neutralising antibody and a monoclonal mouse anti-IL-4R neutralising 
antibody or their respective control IgG, and we evaluated the expression of 
claudin 2 in the T84 cell lysates by immunoblotting (Fig. 4.23). Culture with rhIL-
13 induced a significant (p<0.05) increase in claudin 2 expression compared to 
culture with medium alone. The addition of anti-IL-13R2 and anti-IL-4R 
neutralising antibodies significantly (p<0.01) reduced the expression of claudin 2 
in rhIL-13-stimulated T84 cells, whereas the addition of the control IgG did not 
affect the expression of claudin 2 in rhIL-13-stimulated T84 cells. 
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Figure 4.23 (see previous page). Functional evaluation of rhIL-13, anti- ()IL-
13R2 and IL-4R antibodies. Expression of claudin 2, detected by 
immunoblotting on the lysates of T84 cells cultured for 72 hours with medium 
alone or with rhIL-13, in the absence or presence of a polyclonal goat IL-13R2 
neutralising antibody and a monoclonal mouse IL-4R neutralising antibody or 
the respective control IgG (goat IgG and mouse IgG2a). The example shown in 
the upper panel is representative of three separate experiments. Membranes 
were analyzed for cytokeratin 19 as a loading control for epithelial proteins. In the 
lower panel, densitometry of claudin 2 expression normalised for cytokeratin 19 is 
shown. Three independent repeats of the experiment were performed. Bars 
represent mean  SEM. au, arbitrary units. Data were analysed by ANOVA One 
way analysis of variance followed by the Tukey’s multiple comparison test. 
*p<0.05 versus T84 cells cultured with medium alone. §p<0.01 versus T84 cells 
cultured with rhIL-13 and versus T84 cells cultured with rhIL-13 + control IgG. 
 
 
4.3.15 Effect of IL-13 on pro-inflammatory cytokine production in UC 
 
In order to assess the potential effects of IL-13 on the pro-inflammatory immune 
response observed in UC, unstimulated or anti-CD3/CD28-stimulated LPMCs 
from inflamed UC were cultured with rhIL-13, and the production of TNF-, IFN- 
and IL-17A was measured by ELISA (Fig. 4.24). Stimulation with anti-CD3/CD28 
antibodies significantly (p<0.05) enhanced TNF-, IFN- and IL-17A production 
by UC LPMCs (mean 4263  705 pg/ml; mean 3977  1030 pg/ml; mean 4983  
1236 pg/ml, respectively) compared to unstimulated conditions (mean 95  14 
pg/ml; mean 268  92 pg/ml; mean 489  129 pg/ml, respectively). The addition 
of rhIL-13 did not have any significant effect on TNF-, IFN- and IL-17A 
production by both unstimulated (mean 97  24 pg/ml; mean 254  67 pg/ml; 
mean 413  112 pg/ml, respectively) and anti-CD3/CD28-stimulated LPMCs 
(mean 4327  292 pg/ml; mean 4537  778 pg/ml; mean 5243  1539 pg/ml, 
respectively). 
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Figure 4.24. Effect of rhIL-13 on cytokine production by UC LPMCs. Levels 
of TNF-, IFN- and IL-17A, expressed in pg/ml, in the supernatants of LPMCs 
isolated from the inflamed colon of three UC patients and cultured for 48 hours 
with medium only (-) or with anti- ()CD3/CD28 antibodies (+), in the absence or 
presence of 20 ng/ml rhIL-13. Bars represent mean  SEM. Data were analysed 
by ANOVA One way analysis of variance followed by the Tukey’s multiple 
comparison test. *p<0.05 versus LPMCs cultured with medium only or with rhIL-
13. 
  
217 
4.3.16 Effect of IL-13 on collagen production in CD 
 
Finally, submucosal myofibroblasts isolated from uninflamed areas of strictured 
and non-strictured ileum of 5 patients with fibrostenosing CD, and from normal 
ileum of 5 control subjects, were cultured with rhIL-13, rhTNF- or rhIL-13 + 
rhTNF-, and collagen was measured in the culture supernatants (Fig. 4.25). 
Myofibroblast stimulation with rhIL-13 did not induce any significant change in 
mean collagen production compared to culture with medium alone (control 
myofibroblasts: 153  38 g/ml versus 144  26 g/ml, respectively; non-
strictured CD myofibroblasts: 200  55 g/ml versus 175  47 g/ml, respectively; 
strictured CD myofibroblasts: 374  115 g/ml versus 336  124 g/ml, 
respectively). Compared to culture with medium alone, stimulation of strictured 
CD myofibroblasts with both rhTNF- or rhIL-13 + rhTNF- induced a significant 
increase in mean collagen production (804  154 g/ml and 814  153 g/ml, 
respectively). Compared to culture with medium alone, stimulation of control and 
non-strictured CD myofibroblast with both rhTNF- or rhIL-13 + rhTNF- induced 
an increase in mean collagen production (control myofibroblasts: 310  63 g/ml 
and 335  70 g/ml, respectively; non-strictured CD myofibroblasts: 390  70 
g/ml and 389  74 g/ml, respectively), which however did not reach statistical 
significance. No significant difference in collagen production was found between 
myofibroblasts cultured with rhTNF- and rhIL-13 + rhTNF-. Strictured CD 
myofibroblasts cultured with rhTNF- or rhIL-13 + rhTNF- produced significantly 
(p<0.05) more collagen than control myofibroblasts cultured in the same 
conditions. 
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Figure 4.25. Effect of rhIL-13 on collagen production by intestinal 
myofibroblasts. Levels of collagen, expressed as g/ml, in the supernatants of 
submucosal myofibroblasts isolated from uninflamed areas of strictured (Strict) 
and non-strictured (Non-strict) ileum of 5 patients with fibrostenosing CD, and 
from normal ileum of 5 control subjects (HC), cultured for 24 hours with medium 
alone or 20 ng/ml rhIL-13 or 20 ng/ml rhTNF-, or 20 ng/ml rhIL-13 + 20 ng/ml 
rhTNF-. Bars represent mean  SEM. Data were analysed by ANOVA One way 
analysis of variance followed by the Tukey’s multiple comparison test. *p<0.05 
versus Strict myofibroblasts cultured with medium alone; §p<0.05 versus HC 
myofibroblasts cultured in the same condition. 
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4.4 Results summary 
 
In the current study, we found that: 
1. IL-13 is not produced in excess by both mucosal explants and LPMCs from 
inflamed colon of UC patients in comparison to inflamed colon of CD patients 
and normal colon of control subjects. 
2. NKT cells are reduced in the inflamed colonic mucosa of clinically active UC 
patients compared with NKT cells found in CD and control subjects, and their 
production of IL-13 is not up-regulated in UC inflamed colon. 
3. Explants from strictured CD ileum produce small amounts of IL-13, not 
different from non-strictured CD or normal ileum. 
4. Surface expression of IL-4R, IL-13R1 and IL-13R2 on IBD and control 
CD3+ and CD68+ LPMCs is very low or not detectable. CD3+ and CD68+ 
LPMCs from inflamed CD mucosa contain high levels of IL-13R1. 
5. Surface expression of IL-4R, IL-13R1 and IL-13R2 on CD and control 
submucosal ileal myofibroblasts is very low or not detectable. Myofibroblasts 
from strictured CD ileum express significantly higher intracellular levels of IL-
4R, IL-13R1 and IL-13R2 than myofibroblasts isolated from control ileum. 
6. IL-13 has no significant effects on the production of pro-inflammatory 
cytokines by colonic UC LPMCs. 
7. IL-13 has no significant effects on the production of collagen by ileal CD and 
control myofibroblasts. 
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4.5 Discussion 
 
Our findings indicate that IL-13 is not up-regulated in UC intestinal mucosa, and it 
is unlikely to play a functional role in the mucosal pro-inflammatory response in 
UC. Moreover, our results indicate that IL-13 is not up-regulated in CD intestinal 
strictures, and it is unlikely to contribute to intestinal fibrosis in this condition. This 
Section focuses on the interpretation of our findings in the context of the existing 
literature, on the limitations of our study, and on possible future experiments 
aimed at clarifying the involvement of IL-13 in disease processes in IBD patients. 
 
IL-13 expression and production in intestinal inflammation 
 
IL-13, which has 25% homology with IL-4, is released by Th2 and NKT cells and 
can also be expressed by innate cells including ILCs, eosinophils, basophils, and 
mast cells (van Dieren et al. 2007; Mannon et al. 2012). IL-13 expression is 
regulated at the transcriptional level by the classical Th2 transcription factor 
GATA3, and its production can be stimulated by epithelial-derived molecules 
including IL-33, IL-17E and TSLP (Brandt et al. 2011). IL-13 signals upon binding 
two transmembrane receptors, namely IL-13R2 or the heterodimer formed by 
IL-13R1 and IL-4R (Rahaman et al. 2002; LaPorte et al. 2008). Upon binding 
the IL-13R1/IL-4Rheterodimer, IL-13 signals mostly through STAT6 
activation, although other pathways may be activated, such as MAPK and 
phosphatidylinositol 3-kinase (PI3K). Following IL-13R2 binding, it has been 
considered that no intracellular signalling occurs, however it has been shown that 
STAT3 and MAPK activation can take place (Mannon et al. 2012). Interestingly, 
IL-13 binds IL-13R2 with higher affinity compared to the IL-13R1/IL-
4Rheterodimer, and it is then rapidly internalised, therefore IL-13R2 has been 
traditionally considered as a scavenger or a decoy receptor for IL-13 (Kasaian et 
al. 2011). Moreover, IL-13R2 is mostly expressed as an intracellular protein and 
can be rapidly mobilised on the cell surface by IFN-, suggesting that Th1 
immune response can negatively regulate IL-13 signalling (Konstantinidis et al. 
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2008). It has been shown that a soluble form of IL-13R2 exists, which can be 
generated by alternative splicing in mice, and by MMP-8 cleavage of the 
extracellular domain in humans (Chen et al. 2009).
 
IL-13 is part of type 2 immunity and plays an important role in counteracting 
helminth infections, in suppressing Th1-mediated autoimmunity, and in regulating 
wound repair mechanisms (Wynn 2015). Dysregulated IL-13 expression has 
been shown to play an important role in the pathogenesis of airway and skin 
disease, especially in asthma and atopic dermatitis (Ong 2014; Gour et al. 2015). 
The most important effects of IL-13 in asthma include goblet cell hyperplasia and 
hypersecretion, fibroblast activation, bronchial hyperresponsiveness and IgE 
class switch (Corren 2013). It has been shown that both recruitment of 
eosinophils and, more importantly, aeroallergen-induced airway resistance 
depend on IL-13R1 signalling in mice exposed to Aspergillus (Rothenberg et al. 
2011). Excessive serum IL-13 has been reported in a subgroup of patients with 
atopic dermatitis associated with bronchial hyperresponsiveness (Lee et al. 
2016).
 
In the gastrointestinal tract, IL-13 plays an important role in mediating the 
immune response against helminth infections (Grencis et al. 2004). In particular, 
clearance of nematodes from the intestine is dependent on IL-13R1 signalling 
(Sun et al. 2016). Excessive oesophageal expression of IL-5, IL-13 and IL-13-
induced chemokines such as eotaxin-3 has been reported in patients with 
eosinophilic oesophagitis (Blanchard et al. 2011). Moreover, IL-5 and IL-13 are 
up-regulated in plasma of children with eosinophilic oesophagitis and food allergy 
(Frischmeyer-Guerrerio et al. 2011). Based mainly on results obtained on 
oxazolone-induced colitis, on the observation that IL-13-producing NKT cells are 
markedly increased in UC but not in CD inflamed mucosa, and on the existence 
of biologically plausible effects exerted in vitro by IL-13, such as the pro-apoptotic 
effect on IECs and the enhancement of epithelial permeability, IL-13 has been 
implicated in the pathogenesis of mucosal inflammation in UC (Heller et al. 2002; 
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Fuss et al. 2004; Heller et al. 2005). In particular, UC mucosal inflammation has 
been considered to be mediated by an atypical Th2 response, characterised by 
selective up-regulation of IL-13 and IL-5 in the absence of IL-4 up-regulation. 
This is consistent with an innate cell source of IL-13 and IL-5, as opposed to a 
classical Th2 response with overexpression of IL-4 (Mannon et al. 2012). There 
are, however, contrasting evidences on the role of IL-13 in intestinal immunity 
and inflammation. It has been shown in mice that both IL-4 and IL-13 play an 
important role in inducing intestinal goblet cell hyperplasia and mucin secretion, 
thereby promoting protective immunity against gastrointestinal helminths (Oeser 
et al. 2015), and goblet cell depletion is a classical histologic feature in inflamed 
UC mucosa. Furthermore, IL-13 plays a protective role in the IL10-/- model of 
experimental colitis by suppressing Th1 and Th17 immune response via IL-
13R1 signalling (Wilson et al. 2011). Finally, IL-13 stimulates epithelial cells to 
produce the anti-microbial RELM, thereby protecting from nematode infections 
(Herbert et al. 2009). 
 
In the present study, we found that the spontaneous production of IL-13 both by 
inflamed UC colonic biopsies cultured ex vivo for 24 hours and by unstimulated 
UC LPMCs cultured for 48 hours is low and not significantly different compared 
to that of CD patients and control subjects. Moreover, both IL-4 and IL-5 
concentrations in our experiments were uniformly undetectable. Our findings are 
in keeping with those of Bernardo et al. (Bernardo et al. 2012), who observed 
nearly no production of IL-13 by both inflamed and uninflamed UC mucosa. In 
particular, it has been reported that organ culture supernatants from UC patients 
contain concentrations of IL-13 below the limit of detection in the majority of 
cases (10 out of 11 from uninflamed mucosa and 6 out of 11 from inflamed 
biopsies), and these did not correlate with clinical severity. IL-13 concentrations 
in inflamed UC organ culture supernatants were similar in our study (range 0-96 
pg/ml) and in the study by Bernardo et al. (Bernardo et al. 2012) (range 0-
approximately 85 pg/ml). Previous studies have also found significantly lower 
concentrations of IL-13 in intestinal organ culture supernatants and biopsy 
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homogenates of UC patients compared to CD patients (Vainer et al. 2000; 
Kadivar et al. 2004). Finally, it has been shown by immunohistochemistry that IL-
13 expression is low or undetectable in active UC and control subjects, and it is 
low and limited to IECs in luminal CD (Scharl et al. 2013). 
 
We observed that IL-13 transcripts in inflamed UC and CD mucosa were not 
significantly different from control mucosa. Polymorphisms in IL-13 gene which 
alter the affinity for IL-13Rs have been reported in other diseases. In particular, 
the IL-13 variant Arg130Gln, which produces an IL-13 peptide with lower affinity 
for the IL-13R2, has been found to be associated with asthma, atopy and 
systemic sclerosis (Vladich et al. 2005; Granel et al. 2006). However, the 
presence of this polymorphism has not been reported in UC (Waterman et al. 
2006). It has been shown that intestinal IL-13 transcript levels are significantly 
lower in UC patients compared to control subjects (Verma et al. 2013). On the 
other hand, another study has reported that IL-13 mucosal transcripts are 
undetectable in control subjects, whereas 45% UC colonic samples tested are 
positive for IL-13 transcripts (Kawashima et al. 2011). Finally, mucosal transcripts 
for Th1, Th2 and Th17 cytokines have been investigated in inflamed ileal or 
colonic biopsies from UC and CD patients, and it has been shown that IL-21 and 
IL-13 display the largest difference in expression levels between the two 
diseases. However, the 5-marker set which has the highest discriminative power 
includes IL-21, IFN-, IL-12 p35, T-bet and GATA3, but does not include IL-13 
(Iboshi et al. 2014). 
 
Up-regulated expression of IL-4, IL-13 and IL-13R2 in CRC-derived cells is 
associated with liver invasion, metastasis and poor prognosis (Barderas et al. 
2012). Moreover, tumour-infiltrating lymphocytes isolated from patients with colon 
cancer express both IL-4 and IL-13, which may play a role in invasive properties 
of cancer cells by down-regulating the expression of adhesion molecules (Kanai 
et al. 2000). It may be hypothesised that the overall lack of difference in IL-13 
production between IBD patients and control subjects observed in our study may 
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derive from IL-13 up-regulation in samples from patients who underwent surgery 
for colon cancer. However, only part of the mucosal explants in our control group 
were collected from patients who underwent an intestinal resection for colon 
cancer, and samples were taken at least 50 cm far from the tumoral mass, which 
makes the possibility of collecting tumour-infiltrating lymphocytes unlikely. 
Moreover, samples used for the analysis of IL-13 transcript levels did not include 
patients undergoing surgery for colon cancer, and the results confirmed the 
absence of significant differences in IL-13 expression between control subjects 
and IBD patients. 
 
Internalisation upon binding to IL-13R2 is an established mechanism 
responsible for the rapid clearance of IL-13, and exposure to IL-13 induces the 
up-regulation of IL-13R2, thereby amplifying its effects (Kawakami et al. 2001; 
Kasaian et al. 2011). We hypothesised that the low levels of IL-13 observed in 
our culture supernatants might depend on its binding to IL-13Rs and subsequent 
internalisation by LPMCs. We therefore performed anti-CD2/CD28 and anti-
CD3/CD28-stimulations of UC LPMCs in the presence of blocking antibodies to 
IL-13R2 and IL-4R, however this did not induce any significant change in IL-13 
concentration in culture supernatants. 
 
Both anti-CD2/CD28 and anti-CD3/CD28 stimulations of LPMCs from inflamed 
UC and CD or normal colon, despite inducing a marked increase in both IFN- 
and IL-17A, overall had no significant effect on IL-13 release, without significant 
differences in the levels of this cytokine between the three groups studied. 
Despite the conditions of our experiments being similar, particularly regarding 
anti-CD2/CD28 stimulation, in the present study we could not replicate the 
findings of Fuss et al. (Fuss et al. 2004) and Heller et al. (Heller et al. 2005). In 
particular, compared to the previous studies, while anti-CD2/CD28 stimulation 
resulted in a significant increase in IFN- production, without significant difference 
between CD and UC LPMCs, we did not observe an increase in IL-13 
concentration in the supernatants of UC LPMCs cultured in the same conditions. 
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It is important to underline that, while anti-CD3/CD28 stimulation induced a clear 
up-regulation of IFN- and IL-17A production by LPMCs in all CD and UC 
patients and control subjects, the same stimulation largely failed to induce IL-13 
release. However, a small, but clear increase in IL-13 production after anti-
CD3/CD28 stimulation was present in LPMC supernatants from five out of 11 CD 
patients, five out of 11 UC patients and three out of 11 control subjects, 
suggesting that, upon T cell activation, IL-13 production may be up-regulated in a 
subset of IBD patients and control subjects. Nevertheless, when considering 
LPMCs which produced higher concentrations of IL-13 following anti-CD3/CD28 
stimulation, the up-regulation reached a maximum concentration of <200 pg/ml, 
as opposed to a mean concentration around 1000 pg/ml measured in 
supernatants of LPMCs cultured with anti-CD2/CD28 antibodies in the previous 
studies (Fuss et al. 2004; Heller et al. 2005). Unfortunately, in the previous 
studies, cytokine concentrations in the supernatants of stimulated LPMCs were 
presented as means  SEM, therefore it is not possible to determine the relative 
contribution of each sample to the overall results, and to evaluate the 
heterogeneity between different patients (Fuss et al. 2004; Heller et al. 2005). 
 
We can only speculate why we were not able to show enhanced IL-13 and IL-5 
expression and production in UC compared to other studies (Del Zotto et al. 
2003; Fuss et al. 2004; Heller et al. 2005; Kawashima et al. 2011). In particular, 
we believe that our experimental settings were adequate and appropriately 
sensitive in order to detect differential production of the cytokines examined in 
the different groups of patients studied. We were able to detect high production 
of IL-17A (>400 pg/ml in some IBD patients) and IFN-(>300 pg/ml in some IBD 
patients) in our 24 hour ex vivo organ cultures, and we observed high levels of 
IFN- (never <2000 pg/ml in IBD patients) and IL-17A (never <2000 pg/ml in IBD 
patients) in our 48 hour in vitro LPMC cultures. It should be noted that, when 
intestinal samples were collected, the large majority of CD and UC patients in our 
study were not on treatment with immunosuppressants, which profoundly 
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dampen cytokine secretion and may deplete T cell subsets by the induction of 
apoptosis. Conversely, immunosuppressants may have influenced the findings 
reported in other investigations. It has been shown that cyclosporine A, which is 
used intravenously as a rescue therapy in order to avoid colectomy in ASUC, 
induces T cell apoptosis and down-regulates IL-13 production by PBMCs isolated 
from UC, but not CD, patients (Steiner et al. 2015). In our study, however, none 
of the patients were on treatment or had been previously treated with 
cyclosporine A. Mucosal transcripts for IL-4, IL-5, and IL-13, have been reported 
to be increased compared to control subjects during all stages of CD (Zorzi et al. 
2013). We included patients with both early- and late-stage disease, and, while 
IFN- production by LPMCs seemed more prominent in early CD, we did not find 
any correlation or trend between disease duration and IL-13 production. 
 
Biopsies, unstimulated LPMCs and stimulated LPMCs from inflamed colon of 
both CD and UC patients produced significantly higher amounts of IFN- and IL-
17A than those from uninflamed UC, CD and control subjects, with no significant 
differences between CD and UC. This is a major discrepancy between our study 
and previous ones, which showed high IFN- expression and production by 
activated CD LPMCs, as opposed to significantly lower IFN- expression and 
release by activated UC and control LPMCs (Fuss et al. 2004; Heller et al. 2005; 
Sarra et al. 2010). Nonetheless, also in previous studies IFN- concentration in 
supernatants of anti-CD2/CD28-stimulated UC LPMCs was around 2000 pg/ml, 
whereas that of IL-5 was 150-200 pg/ml and that of IL-13 around 1000 pg/ml, 
highlighting the relative importance of IFN- compared to Th2 cytokines (Fuss et 
al. 2004; Heller et al. 2005). While differences between ours and the findings by 
Fuss et al. (Fuss et al. 2004) and Heller et al. (Heller et al. 2005) are difficult to 
explain since the experimental conditions are very similar, PMA plus ionomycin 
stimulation used in the study by Sarra et al. (Sarra et al. 2010) may induce 
different T cell responses. Moreover, we previously reported no difference 
between CD and UC in terms of IFN--producing T-LPLs after stimulation with 
PMA plus ionomycin (Rovedatti et al. 2009). Determinations performed using 
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different methods may lead to different results, and indeed in our qRT-PCR 
determination we could observe that IFN- expression is higher in CD than in UC 
and control subjects, however post-transcriptional modifications exist and may 
lead to discrepancy between mRNA and protein levels (Washburn et al. 2003; 
Laloo et al. 2009), which in turn may be responsible for the lack of difference in 
IFN- protein levels between CD and UC patients. 
 
Unlike IFN-, we found IL-17A to be similarly up-regulated in CD and UC as in 
the previous studies (Rovedatti et al. 2009; Sarra et al. 2010). Nevertheless, the 
magnitude of IL-17A up-regulation which we observed in supernatants from CD 
and UC inflamed colonic biopsies compared to those from uninflamed IBD 
biopsies was less than 2 folds, which raises the question whether this statistically 
significant difference has a biological relevance in IBD. In the study by Bernardo 
et al. (Bernardo et al. 2012), IFN-, IL-4, IL-6, IL-7 and TNF-, but not IL-17A, 
concentrations were all significantly higher in organ culture supernatants from 
inflamed UC mucosa compared to uninflamed UC mucosa, however IL-4 
concentrations were below 7.5 pg/ml in all cases tested, and the only cytokine 
which correlated with the endoscopic Mayo score was IL-6. Interestingly, it has 
been shown that serum IL-17A, TNF- and IL-6, but not IFN-, correlate both 
with CAI and with the endoscopic Mayo score in UC (Mańkowska-Wierzbicka et 
al. 2015). 
 
IL-13-producing cells in intestinal inflammation 
 
We observed a significantly reduced percentage of NKT cells, defined as 
CD3+CD161+ cells, among T-LPLs from the inflamed colon of UC patients 
compared to the inflamed colon of CD patients and to the normal colon of control 
subjects. Our observation confirms the findings by Shimamoto et al. (Shimamoto 
et al. 2007), who also observed that CD161+ T cells are significantly decreased in 
the inflamed mucosa of UC patients compared to control subjects. Even upon 
stimulation with anti-CD3/CD28, the intracellular production of IL-13 by mucosal 
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NKT cells was low in all the groups studied. This is different from the studies by 
Fuss et al. (Fuss et al. 2004; Fuss et al. 2014), who reported that up to 24% 
lamina propria NKT cells in UC release IL-13, and that more than 30% LPMCs in 
UC is constituted by non-invariant NKT cells which produce IL-13 upon 
stimulation with lyso-sulfatide-loaded CD1d-tetramer. 
 
In keeping with Fuss et al. (Fuss et al. 2004), we observed that there are no 
mucosal iNKT (CD3+V24+V11+) cells in UC. Conversely, in contrast to Fuss et 
al. (Fuss et al. 2004), who could not detect any lamina propria CD3+V24+V11- 
cells, we report the presence of a small but definite population of CD3+ LPMCs 
expressing V24, as would be expected for a commonly used  chain, which 
was not significantly increased in UC patients compared to CD patients and 
control subjects. Since we were mostly interested in iNKT cells, we chose the 
plots with the most representative iNKT cell populations, and since iNKT in UC 
were very low (<0.1% CD3+ LPMCs) we acquired more events (>50,000), hence 
CD3+V24+V11- LPMCs seem more frequent in UC, but percentage-wise this is 
not the case. The mean percentage of CD3+V24+V11- LPMCs in CD was 
higher, although not significantly, compared to UC and control LPMCs, however 
we only evaluated this on three patients per group, which limits the possibility to 
draw any conclusion, particularly with regards to positive observations. Moreover, 
the high mean percentage of CD3+V24+V11- LPMCs observed in CD was due 
to a single patient with 47% CD3+V24+V11- LPMCs, probably because of the 
random oligoclonality seen in intestinal T cells, where only a few clones make up 
the repertoire, in whom a dominant clone expressed V24. 
 
In vitro effects of IL-13 in intestinal inflammation 
 
The previous experiments are descriptive and suggest that IL-13 is not up-
regulated in the inflamed mucosa of the majority of UC patients, and that IL-13-
producing cells are a small proportion of mucosal immune cells in UC, at least in 
the patients examined. It is nevertheless important to remember that IL-13 has 
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important in vitro effects in the intestine. It has been shown in vitro using HT-29 
cells that IL-13 induces epithelial cell apoptosis, inhibitis restitution of epithelial 
cell monolayers, and disrupts epithelial permeability (Heller et al. 2005). 
Furthermore, it has been observed that IL-13 activates the pro-apoptotic 
protease caspase-3 in mouse colonic IECs (Kawashima et al. 2011), and that IL-
13 enhances epithelial permeability by up-regulating claudin 2 expression within 
the tight junctions (Weber et al. 2010). We performed functional experiments on 
LPMCs from inflamed UC mucosa. In particular, the addition of rhIL-13 to 
unstimulated or anti-CD3/CD28-stimulated LPMCs from inflamed colonic UC 
mucosa did not have any influence on their production of classical pro-
inflammatory cytokines such as TNF-, IFN- and IL-17A. In accordance with our 
results, it has been shown that culturing for 24 hours ex vivo UC biopsies from 
inflamed colon with anti-IL-13 antibody, or UC biopsies from uninflamed colon 
with rhIL-13 does not induce any significant difference on pro-inflammatory and 
regulatory cytokine concentration in culture supernatants (Bernardo et al. 2012). 
This observation is particularly interesting, since in the same study it has been 
reported that organ culture of uninflamed or inflamed UC intestinal biopsies with 
rhIL-6 or anti-IL-6 antibody, respectively, does influence the cytokines released in 
the supernatants, promoting a pro-inflammatory or an anti-inflammatory 
microenvironment, respectively. This suggests that the organ culture model used 
is responsive to exogenous stimuli and provides the opportunity to detect the 
effects of one specific cytokine or its neutralisation. One possible reason to 
explain our results is that rhIL-13, IL-13R2 and IL-4R neutralising antibodies 
used in our in vitro experiments were not biologically active, however this is not 
the case, as shown by the ability of anti-IL-13R2 and anti-IL-4R antibodies to 
inhibit rhIL-13-induced claudin 2 up-regulation in T84 cells. 
 
IL-13R expression in intestinal inflammation 
 
It has been shown that both IL-13R1 and IL-4R are expressed on the surface 
of HT-29 cells and IECs of UC patients and control subjects, and are responsible 
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for the effects of IL-13 on epithelial apoptosis and permeability (Heller et al. 
2005). It has subsequently been observed that lamina propria NKT cells in UC 
express high levels of IL-13R2 (Fuss et al. 2014). We therefore studied IL-13R 
expression by different LPMC subtypes in inflamed IBD and control mucosa. In 
particular, we assessed the expression of IL-4R, IL-13R1 and IL-13R2 by T 
cells (CD3+ LPMCs) and macrophages (CD68+ LPMCs) from normal mucosa of 
control subjects and from inflamed UC and CD mucosa. We observed that IL-
4R, IL-13R1 and IL-13R2 expression profile is similar between intestinal 
mucosal T cells and macrophages. Surface expression of IL-4R, IL-13R1 and 
IL-13R2 by both T cells and macrophages from normal mucosa of control 
subjects and from inflamed UC and CD mucosa was low or not detectable. We 
hypothesised that the low surface expression of IL-13Rs by LPMCs could derive 
from the removal of receptors by collagenase digestion during LPMC isolation. In 
order to investigate this, we repeated the same staining after overnight culture of 
freshly isolated LPMCs within low-adherence tissue culture plates, however the 
expression of IL-13Rs was not modified. 
 
Since IL-13R2 is present mostly within the cytoplasm (Konstantinidis et al. 
2008), we evaluated the levels of IL-13Rs in mucosal immune cells in IBD and 
control subjects by flow cytometry upon intracellular staining. We added the anti-
IL-4R, anti-IL-13R1 and anti-IL-13R2 antibodies after LPMC 
permeabilisation, and, since the surface expression of the receptors on the same 
cells was low or not detectable, we considered any positive signal as being the 
result of intracellular expression. The intracellular expression of IL-4R, IL-
13R1 and IL-13R2 by intestinal T cells and macrophages from normal mucosa 
of control subjects and from inflamed UC mucosa was low or not detectable. 
Intestinal T cells and macrophages from inflamed CD mucosa, which expressed 
low levels of IL-4R and IL-13R2, contained high levels of IL-13R1. It has 
been shown that non-responsiveness to infliximab treatment in UC, defined as 
lack of endoscopic and histologic healing, is associated to significantly higher 
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mucosal expression of IL-13R2 (Arijs et al. 2009), which is difficult to interpret, 
since TNF- is an inducer of IL-13R2, and higher IL-13R2 expression should 
dampen the effects of IL-13. Collectively, our data on IL-13R expression in UC 
are in keeping with our results showing the lack of pro-inflammatory effects of 
rhIL-13 on UC LPMCs. 
 
IL-13 and IL-13Rs in intestinal fibrosis 
 
IL-13 has an important role in experimental fibrosis and in diseases characterised 
by tissue fibrosis (Lee et al. 2001; Fichtner-Feigl et al. 2008a; Fichtner-Feigl et al. 
2008b). In particular, IL-13 has been shown to play an important pro-fibrogenic 
role in systemic sclerosis, asthma, and idiopathic pulmonary fibrosis (Wilson et 
al. 2009; Fuschiotti 2011; Agrawal et al. 2014). IL-13 is thought to exert its pro-
fibrogenic effects by stimulating the production of TGF- by macrophages via IL-
13R2 activation, and this mechanism has been shown to be responsible for 
intestinal fibrosis in oxazolone- and in chronic TNBS-induced colitis (Fichtner-
Feigl et al. 2006; Fichtner-Feigl et al. 2008b). However, intestinal stricture 
formation is rare in UC, and the involvement of IL-13 in CD intestinal fibrosis is 
unclear. 
 
We observed that muscle layer explants from strictured CD ileum release small 
amounts of IL-13, not significantly different from non-strictured CD or normal 
ileum. Conversely, IL-1and collagen levels in the supernatants and TGF-1 
transcripts in the homogenates of cultured explants were significantly higher in 
strictured CD compared to non-strictured CD or normal ileum. Our data are in 
contrast with Bailey et al. (Bailey et al. 2012), who observed that IL-13 mRNA is 
overexpressed in the lysates of fibrotic intestinal muscle of CD patients 
compared to control subjects. Post-transcriptional modifications may explain, at 
least in part, this discrepancy (Washburn et al. 2003; Laloo et al. 2009). 
Interestingly, it has been shown that IL-13 is highly expressed by transitional 
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cells lining fistulae in CD, and that IL-13 induces genes involved in cell invasion, 
which are likely to contribute to the formation of fistulae (Scharl et al. 2013). 
 
We observed that the surface and intracellular expression of IL-4R, IL-13R1 
and IL-13R2 by both T cells and macrophages from the mucosa overlying CD 
strictures and CD mucosa above non-strictured areas is low or not detectable. 
Furthermore, surface expression of IL-4R, IL-13R1 and IL-13R2 on 
submucosal myofibroblasts isolated from uninflamed areas of strictured and non-
strictured ileum of patients with fibrostenosing CD, and from normal ileum of 
control subjects was low or not detectable. In order to exclude that the low 
surface expression of IL-13Rs by submucosal myofibroblasts could derive from 
the removal of receptors by trypsin during the passage of cells, we repeated the 
same staining after overnight culture of freshly passaged myofibroblasts within 
low-adherence tissue culture plates, and we observed that the expression of IL-
13Rs was not modified. Conversely, compared to myofibroblasts isolated from 
control ileum, myofibroblasts isolated from uninflamed areas of strictured CD 
ileum expressed detectable and significantly higher intracellular levels of IL-4R, 
IL-13R1 and IL-13R2, and myofibroblasts isolated from uninflamed areas of 
non-strictured CD ileum expressed detectable and significantly higher 
intracellular levels of IL-13R1 and IL-13R2. It has been shown that 
myofibroblast-like transitional cells lining CD fistulae and epithelial-like cells close 
to the fistulae express high levels of IL-13R1 (Scharl et al. 2013). Another study 
has reported that IL-13R1, but not IL-13R2, is highly expressed by smooth 
muscle cells and ILCs infiltrating CD intestinal strictures (Bailey et al. 2012).  
 
Functional data on experimental intestinal fibrosis support an important role for 
IL-13, and there are several evidences that blocking IL-13 signalling at different 
levels improves intestinal fibrosis in mice. It has been shown that the PPAR 
activator GED-0507-34 Levo ameliorates chronic DSS-induced intestinal fibrosis, 
and this is associated with a significant down-regulation of mucosal IL-13 (Speca 
et al. 2016). However, it is unclear whether IL-13 down-regulation plays an active 
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role in the improvement of fibrosis. Indeed, it has been shown that the small 
molecule HSc025, which antagonises TGF- signalling, improves TNBS-induced 
intestinal fibrosis despite not having any effects on the mucosal levels of IL-13 
and TNF- (Imai et al. 2015). 
 
Since IL-13 and TNF- can exert a synergistic effect on the expression of IL-
13R2, and TNF- has a known pro-fibrogenic action (Fichtner-Feigl et al. 2006), 
we finally performed a functional experiment in vitro by testing the effect of 
exogenous rhIL-13 and/or rhTNF- on submucosal myofibroblasts isolated from 
strictured CD ileum and control ileum. As opposed to TNF-, which indeed 
increased the production of collagen, no direct effect was exerted by IL-13 on 
collagen release by CD and control myofibroblasts, in keeping with existing data 
(Bailey et al. 2012). It has to be noted that Bailey et al. performed in vitro 
experiments on fibroblasts isolated from the muscle layer (Bailey et al. 2012), 
whereas we studied submucosal myofibroblasts. This may provide a possible 
explanation for the different effect of TNF- on collagen production which we 
observed in our experiments. 
 
Limitations of the study 
 
Unfortunately, when working with human tissue, sample size can often be a 
relevant limitation. In our study, this affected mainly the experiments regarding 
IL-13R expression in intestinal cells from IBD patients and control subjects, and 
in vitro effects of IL-13 on UC LPMCs, for which only very few samples could be 
analysed (n=3). This needs to be taken into account in the interpretation of the 
results, particularly in the case of the up-regulated IL-13R1 expression in T cells 
and macrophages from inflamed CD mucosa, and in the case of the higher 
intracellular levels of IL-4R, IL-13R1 and IL-13R2 in CD myofibroblasts 
compared to myofibroblasts isolated from control ileum. With a very small sample 
size, particularly the positive results need to be interpreted with caution, as both 
interindividual and intraindividual variability are more likely to have a relevant 
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impact on the data, and should be validated in a larger cohort of patients before 
any conclusion can be made. 
 
Organ culture of intestinal biopsies has not been formally validated, however it 
has been recognised as a useful technique to investigate the abnormal immune 
response in IBD, as it recapitulates the architecture and organisation of the 
intestinal mucosa with the use of human tissue. Relevant shortcomings of the 
organ culture approach, particularly when compared to organoid generation and 
culture, are the limited time (maximum 36 hours) during which the tissue remains 
viable, and sample availability. One possible limitation of the organ culture 
system is that, in addition to the interindividual variability in the severity of 
mucosal inflammation and to the intraindividual variability due to heterogeneity in 
the severity of mucosal inflammation in different sections of the colon or the small 
intestine, there is additional variability due to the different size of biopsy samples. 
This, however, can be minimised by normalising the results by weight. As an 
example of the potential validity and predictive value of the organ culture model, 
the Smad7 antisense oligonucleotide inhibitor mongersen, which has been 
shown promising efficacy data in CD, was first tested on CD biopsies using the 
organ culture system (Monteleone et al. 2001; Monteleone et al. 2015). We are 
currently assessing the potential efficacy of novel molecules for the treatment of 
IBD using the organ culture system. In addition to organ culture, in our study we 
have assessed IL-13 expression and production in IBD inflamed mucosa using 
other methods, including qRT-PCR and LPMC isolation and culture, and the 
results were consistent with those obtained using organ culture. 
 
For the in vitro experiments, when available, we used reagents at concentrations 
based upon previous data existing in the literature (e.g. we used rhIL-13 and 
rhTNF- at 20 ng/ml, which is the same concentration used by Fichtner-Feigl et 
al. 2006). When no previous results were available, we decided the 
concentrations of the reagents based on the reagent data sheet, as in the case of 
anti-IL-4R and anti-IL-13R2 antibodies. The concentration of rhIL-13 that we 
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used in our in vitro experiments (20 ng/ml) is ten-fold higher than that reported to 
induce changes in epithelial permeability, and the same described to exert pro-
fibrogenic effects, so we have no doubt that we added active doses to the 
LPMCs (Kadivar et al. 2004; Prasad et al. 2005), and this is confirmed by the up-
regulation of claudin 2 expression induced by rhIL-13 in T84 cells. However, we 
are unable to draw any conclusion on the physiological relevance of this 
concentration in vivo, and there is the possibility that this is excessive compared 
to the in vivo levels in the intestinal mucosa, especially as IL-13 concentrations in 
culture supernatants were never >200 pg/ml. However, it is important to note that 
cytokines act locally, therefore the physiologically relevant concentration is the 
one present in close proximity of the target cells, and our data are not informative 
regarding this.  
 
Future experiments 
 
There is evidence of the importance of IL-13 in experimental models of colitis and 
intestinal fibrosis, however there is poor correlation between murine and human 
genomic response to acute inflammatory stress (Seok et al. 2013). Indeed, our 
results suggest that it is hard to envisage a prominent role for this cytokine in the 
overall population of patients with UC and fibrostenosing CD. Several 
experiments are needed to address specific aspects of IL-13 involvement in the 
gastrointestinal mucosal immune response, and to investigate the possibility that 
IL-13 contributes to the disease process in a subset of IBD patients.  
 
Our results on IL-13 expression and production in the intestinal mucosa were 
obtained using qRT-PCR and ELISA, however other methods such as 
immunohistochemical characterisation would be useful to corroborate the data, 
and should be used in a future validation study. Immunohistochemical 
characterisation of IL-13Rs would also be needed to draw more informative 
conclusions on the expression levels in the intestinal mucosa of the different 
groups studied, particularly considering the previous studies on this aspect 
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(Bailey et al. 2012; Scharl et al. 2013). 
 
It has been shown that a specific subset of ILCs, namely type 2 ILCs (ILC2), 
depend on GATA3 for their development and display a cytokine production 
profile characterised by the release of high amounts of IL-5, IL-13, and relatively 
small amounts of IL-4 (Zhu 2015). ILC2 are involved in the early disease phase 
in allergic skin and lung inflammation (Monticelli et al. 2011; Roediger et al. 
2013). The atypical Th2 cytokine profile expressed by ILC2 makes them a 
particularly interesting cell type to study in IBD, particularly in the early disease 
phase and in treatment-naïve patients. 
 
Regarding the involvement of IL-13 in CD intestinal fibrosis, we did not study the 
effects of IL-13 on the production of tissue remodelling enzymes such as MMPs 
and TIMPs by intestinal cells contributing to the process of stricture formation. 
This would be particularly important, as it has been shown that in vitro culture 
with IL-13 down-regulates spontaneous MMP-2 expression and TNF--induced 
MMP-1 and MMP-9 synthesis by intestinal smooth muscle CD fibroblasts (Bailey 
et al. 2012). On the other hand, it would be particularly interesting to explore the 
effects of MMPs on IL-13 signalling in the intestinal mucosa, as MMP-8 cleavage 
of the extracellular domain is responsible for the generation of soluble IL-13R2 
in humans (Chen et al. 2009).
 
Finally, using the IMPACT IL-13 assay, which has high sensitivity – in the range 
of fg/ml – and specificity, it has been reported that sera of patients with asthma, 
atopic dermatitis and idiopathic pulmonary fibrosis, have significantly higher 
concentrations of IL-13 compared to control sera (Cai et al. 2016). It would be 
interesting to study whether mucosal expression of IL-13 correlates with serum 
concentrations of IL-13 in UC, in order to identify by means of a simple biomarker 
test the subset of patients in whom this cytokine is more likely to play a 
pathogenic role. 
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Chapter 5: Effects of MMP-3, MMP-9 and MMP-12 on the integrity and 
function of anti-TNF- agents in IBD 
 
Information on the bioavailability of anti-TNF- agents in inflamed tissues, where 
they are expected to exert their effect, is lacking. MMPs are up-regulated in IBD 
inflamed mucosa, and can cleave human IgG1 near the hinge region. Anti-TNF- 
agents in use in clinical practice are IgG1 or have part of the amino acid 
sequence in common with Ig. Further information on the background to this 
Chapter is reported in Sections “1.4.5 TNF- and TNF- neutralisation in IBD” 
and “1.4.6 Proteases in IBD intestinal mucosa”. 
 
We have studied MMP-3 and MMP-12 due to their up-regulation in intestinal 
inflammation and to the fact that they can specifically cleave IgG1 at the same 
point in the lower hinge, and MMP-9 as it is one of the main proteolytic enzymes 
associated to intestinal inflammation. 
 
5.1 Aims of the study 
  
This study aims to explore the effects of MMPs on the integrity and function of 
anti-TNF- agents in the context of IBD, and to evaluate whether MMP 
degradation may be relevant in primary non-responsiveness to biologic therapy 
in IBD. We have used the following approach: 
1. Evaluation of the effects of MMP-3, MMP-9 and MMP-12 on the integrity and 
TNF- neutralisation function of anti-TNF- agents. 
2. Assessment of the effects of protein extracts from inflamed IBD mucosa on 
the integrity and TNF- neutralisation function of anti-TNF- agents. 
3. Study of serum levels of MMP-3-/MMP-12-cleaved anti-TNF- agents in IBD 
patients. 
4. Study of serum levels of MMP-3-/MMP-12-cleaved endogenous IgG and anti-
hinge autoantibodies in IBD patients and control subjects. 
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5.2 Chapter-specific Materials and Methods 
 
5.2.1 Patients and tissues 
 
In order to assess the effect of proteins from human intestinal mucosa on the 
integrity and function of TNF- neutralising agents, perendoscopic biopsies from 
the inflamed colon of eight CD and eight UC patients (Table 5.1) and from the 
normal colon of eight control subjects (Table 5.2) were collected and processed 
for protein extraction. Sera from 29 active CD and 33 active UC patients before 
and after infliximab treatment, and from 20 control subjects were collected. 
Responsiveness to infliximab treatment was defined as the concomitant 
presence of clinical remission and complete mucosal healing (Levesque et al. 
2015) at the first endoscopic examination after the treatment start. This study 
was approved by the NRES Committee London - City & East (REC reference: 
10/H0704/74), and informed consent was obtained from all IBD patients and 
control subjects from whom biopsies were collected. IBD sera were obtained 
from Professor Severine Vermeire’s clinic (Department of Gastroenterology, 
University Hospital Gasthuisberg, Leuven, Belgium). 
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Table 5.1. Clinical features of IBD patients (n=16) 
 
 
 
CD 
(n=8) 
 
 
 
UC 
(n=8) 
 
Median age – years (range) 
 
28 (20-55) 
 
30.5 (22-63) 
 
Male/Female (%) 
 
5/3 (62.5/37.5) 
 
4/4 (50/50) 
 
Median duration of disease – years (range) 
 
4 (0.5-11) 
 
3 (0-15) 
 
Extent of disease 
  
 Ileocolon – CD (%) 4 (50) NA 
 Colon – CD (%) 4 (50) NA 
 Left-sided colitis – UC (%) NA 5 (62.5) 
 Pancolitis – UC (%) NA 3 (37.5) 
 
Disease behaviour 
  
 Non-stricturing non-penetrating – CD (%) 8 (100) NA 
 Stricturing – CD (%) 0 (0) NA 
 Penetrating – CD (%) 0 (0) NA 
 
Clinical disease activity 
  
 Mild (%) 0 (0) 0 (0) 
 Moderate (%) 3 (37.5) 2 (25) 
 Severe (%) 5 (62.5) 6 (75) 
 
Grading of histologic inflammation 
  
 Mild (%) 0 (0) 0 (0) 
 Moderate (%) 0 (0) 1 (12.5) 
 Severe (%) 8 (100) 7 (87.5) 
 
Treatment 
  
 None 1 (12.5) 2 (25) 
 5-aminosalicylates (%) 2 (25) 4 (50) 
 Corticosteroids (%) 3 (37.5) 4 (50) 
 Immunosuppressants   
  Azathioprine/6-mercaptopurine (%) 2 (25) 3 (37.5) 
  Methotrexate (%) 1 (12.5) 0 (0) 
 Corticosteroids + immunosuppressants (%) 3 (37.5) 3 (37.5) 
 
 
CD, Crohn’s disease; NA, not applicable; UC, ulcerative colitis. 
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Table 5.2. Clinical features of control subjects (n=8) 
Characteristics and parameters N. Median (range) 
Age (years) 
Sex (M/F) 
Comorbidities 
        Hypertension         
        None 
Current medications 
        Anti-hypertensive 
        Proton pump inhibitors 
        None 
 
4/4 
 
2 
6 
 
2 
2 
5 
34 (26-45) 
 
 
 
 
 
 F, female; M, male. 
 
5.2.2 Study design 
 
First, cleavage reactions with rhMMP-3, rhMMP-12, rhMMP-9 and infliximab, 
adalimumab, etanercept were performed in order to study the effect of MMPs on 
the integrity and soluble TNF- neutralisation function of anti-TNF- agents. 
Then, the possibility to prevent the effect of rhMMP-3 and rhMMP-12 on anti-
TNF- agents using MMP inhibitors was investigated. Protein extracts from 
normal colonic biopsies of eight control subjects and from inflamed colonic 
biopsies of 16 IBD patients were subsequently prepared and, upon measuring 
MMP-3/MMP-12 activity, cleavage reactions were performed in the absence or 
presence of MMP inhibitors in order to study the effect of protein extracts on the 
integrity and soluble TNF- neutralisation function of anti-TNF- agents. Then, 
experiments were performed in order to assess whether cleaved antibodies could 
be identified in the sera of IBD patients and control subjects. In particular, ELISA 
assays aimed at detecting MMP-3-/MMP-12-cleaved anti-TNF- agents, MMP-3-
/MMP-12-cleaved endogenous IgG and anti-hinge autoantibodies were 
developed by testing sera of 29 active CD and 33 active UC patients either 
before (MMP-3-/MMP-12-cleaved endogenous IgG and anti-hinge 
autoantibodies) or after (MMP-3-/MMP-12-cleaved anti-TNF- agents) infliximab 
therapy, and sera of 20 control subjects.
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5.2.3 Protein extraction 
 
Biopsies were placed in PBS (Oxoid Ltd, Basingstoke, UK) and homogenised by 
sonication. Endogenous IgG were removed from the mucosal protein extracts by 
two cycles of Protein G SpinTrap (GE Healthcare, Little Chalfont, UK), and total 
protein concentration was normalised to 2 mg/ml by dilution in PBS. 
 
5.2.4 MMP activity assay 
 
MMP-3/MMP-12 activity in IBD and control mucosal protein extracts was 
measured using the fluorescence resonance energy transfer (FRET)-based 
Sensolyte® 520 MMP-12 assay kit from AnaSpec Inc. (Fremont, CA, USA). This 
kit uses a 5-FAM (fluorophore)- and QXL520™ (quencher)-labeled FRET peptide. 
In an intact FRET peptide, the fluorescence of 5-FAM is quenched by QXL520™. 
Upon cleavage of the FRET peptide by MMP-3 or MMP-12 (the FRET peptide 
provided with this kit is cleaved by both MMP-3 and MMP-12), the fluorescence 
of 5-FAM is recovered. Protein extracts were incubated with the FRET peptide at 
37°C for 1 hour and fluorescence was subsequently measured using 
(fluorescence detection mode, 490 nm/520 nm excitation/emission wavelengths) 
the Bio-tek Synergy™ HT Multi-Detection Microplate Reader (BioTek). Active 
rhMMP-3 and rhMMP-12, each one at the concentration of 1 g/ml, were used as 
positive controls. 
 
5.2.5 Cleavage reactions 
 
Upon activation, rhMMP-3 and rhMMP-12 were co-incubated with TNF- 
neutralising agents in order to subsequently evaluate their effect on the drug 
integrity and function. In particular, rhpro-MMP-3 and rhpro-MMP-9 (both from 
R&D Systems), at a concentration of 50 g/ml, were activated by 24 hour 
incubation at 37°C with p-aminophenylmercuric acetate (p-APMA; Sigma-Aldrich) 
1 mM in 50 mM Tris, 10 mM CaCl2, 150 mM NaCl, 0.05% Brij 35 (Sigma-Aldrich) 
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(TCNB) buffer, whereas rhpro-MMP-12 (R&D Systems) 50 g/ml was auto-
activated by 30 hour incubation at 37°C in TCNB buffer, following manufacturers’ 
instructions. Infliximab (Remicade®, Merck & Co., Inc., Whitehouse Station, NJ) 
or adalimumab (Humira®, Abbott Immunology, Chicago, IL) or etanercept 
(Enbrel®, Wyeth, Philadelphia, PA), each one at the concentration of 1 g/ml, 
were incubated for 24 hours at 37°C with either active MMP-3 or active MMP-12 
(0.001-1 g/ml) or active MMP-9 (1 g/ml) or p-APMA 0.02 mM in TCNB buffer or 
TCNB buffer alone. In parallel, infliximab or adalimumab or etanercept, each one 
at the concentration of 1 g/ml, were incubated for 24 hours at 37°C with 1 g/ml 
active MMP-3 or MMP-12 or p-APMA 0.2 mM in TCNB buffer or TCNB buffer 
alone, and the reaction was stopped at fixed time points (3, 6, 10 and 24 hours). 
In parallel, increasing concentrations (0.01-10 g/ml) of infliximab or adalimumab 
or etanercept were co-incubated for 24 hours with p-APMA 0.02 mM in TCNB 
buffer or 1 g/ml active MMP-3 or MMP-12. In parallel, etanercept 0.1 g/ml was 
incubated for 24 hours at 37°C with 1 g/ml active MMP-3 or MMP-12 or p-APMA 
0.2 mM in TCNB buffer or TCNB buffer alone, in the absence or presence of 
increasing concentrations (0.001-1 M) of the broad-spectrum MMP inhibitor 
marimastat (Sigma-Aldrich) or the selective MMP-3/MMP-12 inhibitor UK370106 
(Santa Cruz Biotechnology, Dallas, TX). Moreover, to assess the effect of 
mucosal protein extracts on TNF neutralizing agents, infliximab, adalimumab and 
etanercept, all at the concentration of 1 g/ml, were co-incubated for 24 hours 
with either PBS only or with mucosal protein extracts. In parallel, increasing 
concentrations (0.01-10 g/ml) of infliximab or adalimumab or etanercept were 
co-incubated for 24h with either PBS only or with mucosal protein extracts. In 
parallel, infliximab, adalimumab and etanercept, all at the concentration of 0.1 
g/ml, were incubated for 24h at 37°C with either PBS only or with IBD mucosal 
protein extracts, in the absence or presence of increasing concentrations (0.001-
1 M) of marimastat (Sigma-Aldrich) or UK370106 (Santa Cruz Biotechnology). 
Cleavage reaction products were then stored at -70°C until further analysis. 
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5.2.6 Protein G binding assay 
 
The effect of proteases on the Fc region of TNF- neutralising agents was 
assessed by means of a protein G binding assay. Untreated or MMP-3-/MMP-12-
treated TNF- neutralising agents were added to the wells of a protein G-coated 
plate (Fisher Scientific UK). While human IgG can bind to protein G through their 
Fc region, chicken antibodies are unable to bind to protein G. Therefore, chicken 
anti-human p75 TNF receptor antibody (Abcam) which had been previously 
conjugated with horseradish peroxidase using a commercial kit (Abcam), or 
horseradish peroxidase-conjugated chicken anti-human F(ab’)2 (Fisher Scientific 
UK) were then added to the plate as a method to detect, respectively, the amount 
of etanercept or infliximab and adalimumab bound to the plate. 
Tetramethylbenzidine was then added and after stopping the reaction the optical 
density was measured (absorbance detection mode, 450 nm wavelength) on the 
Bio-tek Synergy™ HT Multi-Detection Microplate Reader (BioTek, Swindon, UK). 
 
5.2.7 Luciferase assay 
 
The effect of proteases on the TNF--neutralising function of anti-TNF- agents 
was assessed by means of a HeLa cell line which had been stably transfected 
with the luciferase reporter gene under the control of NF-B enhancer elements 
(Kabouridis et al. 2002). HeLa cells were cultured for 6 hours in the absence or 
presence of 10 ng/ml rhTNF- (R&D Systems), with or without 1 g/ml active 
MMP-3 or MMP-12 or increasing concentrations (0.01-10 g/ml) of infliximab or 
adalimumab or etanercept, all pre-treated for 24 hours with either p-APMA 0.02 
mM in TCNB buffer or 1 g/ml active MMP-3 or MMP-12. In parallel, HeLa cells 
were cultured in the absence or presence of 10 ng/ml rhTNF-, with 0.1 g/ml 
etanercept, pre-incubated for 24 hours with TCNB or 1 g/ml active MMP-3 or 
MMP-12, in the absence or presence of increasing concentrations (0.001-1 M) 
of marimastat (Sigma-Aldrich) or UK370106 (Santa Cruz Biotechnology). In 
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parallel, HeLa cells were cultured with 10 ng/ml rhTNF-, with or without 
increasing concentrations (0.01-10 g/ml) of infliximab or adalimumab or 
etanercept, all pre-treated for 24 hours with either PBS or mucosal protein 
extracts prepared in PBS. In parallel, HeLa cells were cultured for 6 hours in the 
absence or presence of 10 ng/ml rhTNF-, with or without 0.1 g/ml of infliximab, 
adalimumab or etanercept, all pre-treated for 24 hours with either PBS or 
mucosal proteins from IBD patients, in the absence or presence of increasing 
concentrations (0.001-1 M) of marimastat (Sigma-Aldrich) or UK370106 (Santa 
Cruz Biotechnology). The direct effect of IBD protein extracts and MMP inhibitors 
on the production of luciferase by HeLa cells was also assessed. HeLa cells were 
cultured for 6 hours in the absence or presence of 10 ng/ml rhTNF- (R&D 
Systems), with or without IBD mucosal protein extracts prepared in PBS, in the 
absence or presence of 1 M marimastat (Sigma-Aldrich) or 1 M UK370106 
(Santa Cruz Biotechnology). After culture, HeLa cells were lysated and assayed 
for luciferase activity with a commercial kit (Promega UK), following the 
manufacturers’ instructions, using (luminescence detection mode, filters set in 
open position) the Bio-tek Synergy™ HT Multi-Detection Microplate Reader 
(BioTek). 
 
5.2.8 Cleaved anti-TNF- agent detection 
 
The presence of clipped infliximab or adalimumab in human sera of IBD patients 
was investigated by a newly set-up ELISA assay. rhTNF- (R&D Systems) 10 
g/ml was added to Nunc Clear Maxisorp 96-well plates (Sigma-Aldrich). After 16 
hour incubation at +4°C, plates were blocked for 30 minutes at 20-26°C in 3% 
bovine serum albumine (Sigma-Aldrich) in PBS. Three-fold serial dilutions of IBD 
sera, and of MMP-3- and MMP-12-cleaved infliximab (kindly provided by our 
collaborator R.J. Brezski – starting from 2 g/ml), which I used as standard, were 
added to the plates. After 1 hour at 20-26°C, 2.5 g/ml biotinylated rabbit anti-
human MMP-3/MMP-12 IgG hinge cleavage site monoclonal antibody (kindly 
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provided by R.J. Brezski) were added. After 1 hour at 20-26°C, horseradish 
peroxidase-conjugated streptavidin (R&D Systems) 1:10000 was added to the 
plates. After 1 hour and thorough washing, tetramethylbenzidine was added and 
after stopping the reaction the optical density was measured (absorbance 
detection mode, 450 nm wavelength) on the Bio-tek Synergy™ HT Multi-
Detection Microplate Reader (BioTek). 
 
5.2.9 Cleaved endogenous IgG detection 
 
The presence of clipped endogenous IgG in human sera of IBD patients and 
control subjects was studied by a newly set-up ELISA assay. Streptavidin 
(Sigma-Aldrich) 10 g/ml was added to Nunc Clear Maxisorp 96-well plates 
(Sigma-Aldrich). After 16 hour incubation at +4°C, plates were blocked for 30 
minutes at 20-26°C in 3% bovine serum albumine (Sigma-Aldrich) in PBS, then 
incubated for 1 hour at 20-26°C with 15 g/ml biotinylated rabbit anti-human 
MMP-3/MMP-12 IgG hinge cleavage site monoclonal antibody (kindly provided 
by our collaborator R.J. Brezski, Biologics Research, Janssen Research & 
Development, Spring House, PA). Plates were then incubated for 1 hour at 20-
26°C with three-fold serial dilutions of IBD and control sera, followed by an 
horseradish peroxidase-conjugated donkey anti-human IgG heavy and light chain 
antibody 1:10000 (Jackson ImmunoResearch, West Grove, PA), that has 
minimum cross-reactivity with rabbit IgG. After 1 hour and thorough washing, 
tetramethylbenzidine was added and after stopping the reaction the optical 
density was measured (absorbance detection mode, 450 nm wavelength) on the 
Bio-tek Synergy™ HT Multi-Detection Microplate Reader (BioTek). 
 
5.2.10 Anti-hinge autoantibody detection 
 
Finally, anti-hinge autoantibodies against the immunogenic neo-epitopes 
generated by the proteolytic cleavage of endogenous IgG in human sera of IBD 
patients and control subjects were measured by a newly set-up ELISA assay. 
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Streptavidin (Sigma-Aldrich) 10 g/ml was added to Nunc Clear Maxisorp 96-well 
plates (Sigma-Aldrich). After 16 hour incubation at +4°C, plates were blocked for 
30 minutes at 20-26°C in 3% bovine serum albumine (Sigma-Aldrich) in PBS, 
then incubated for 1 hour at 20-26°C with 1 M biotinylated 14mer peptide 
analogue of the human IgG1 hinge with a C-terminal amino acid corresponding 
to the MMP-3/MMP-12 cleavage site (kindly provided by our collaborator R.J. 
Brezski). Plates were then incubated for 1 hour at 20-26°C with three-fold serial 
dilutions of a chimaeric rabbit/human anti-human MMP-3/MMP-12 IgG hinge 
cleavage site monoclonal antibody – which I used as a standard – or sera from 
62 active IBD patients and from 20 control subjects, followed by an horseradish 
peroxidase-conjugated goat anti-human IgG Fc antibody 1:10000 (Jackson 
ImmunoResearch). After 1 hour and thorough washing, tetramethylbenzidine was 
added and after stopping the reaction the optical density was measured 
(absorbance detection mode, 450 nm wavelength) on the Bio-tek Synergy™ HT 
Multi-Detection Microplate Reader (BioTek). Similarly to a commercial ELISA, a 
concentration curve was constructed based on the optical densities recorded for 
the standard (which was added to the plate with two-fold serial dilutions starting 
from 10 ng/ml), and the corresponding equation (optical density = 
0.5143*concentration + 0.1344) allowed to convert serum anti-hinge 
autoantibody optical density into concentration (ng/ml). 
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5.3 Results 
 
5.3.1  Effect of MMP-3, MMP-12 and MMP-9 on the integrity of anti-TNF- 
agents 
 
Increasing concentrations (0.001-1 g/ml) of MMP-3 or MMP-12 were co-
incubated for 24 hours with 1 g/ml (therapeutic serum levels in patients) (Tracey 
et al. 2008) infliximab, adalimumab and etanercept, and cleavage patterns were 
analysed in reducing gels by immunoblotting using an anti-human IgG Fc 
antibody (Fig. 5.1). Infliximab, adalimumab and etanercept were clipped in a 
concentration-dependent manner by both MMP-3 and MMP-12, with the 
formation of a 32 kDa fragment, which likely corresponds to the Fc monomer 
observed after MMP digestion of native human IgG1 (Brezski et al. 2009) (Fig. 
5.1A). An additional 50 kDa etanercept fragment appeared at low MMP 
concentrations, which was not predicted based on the known MMP-3/MMP-12 
cleavage site on the lower hinge of human IgG1. Densitometry of the percentage 
of intact anti-TNF- agents remaining at each MMP concentration showed that 
etanercept is markedly more susceptible to clipping than infliximab and 
adalimumab (Fig. 5.1B). In parallel, 1 g/ml MMP-9 was co-incubated for 24 
hours with 1 g/ml infliximab, adalimumab and etanercept, and cleavage patterns 
were analysed in non-reducing gels by immunoblotting using an anti-human IgG 
Fc antibody (Fig. 5.2). Infliximab, adalimumab and etanercept were not cleaved 
by MMP-9. 
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Figure 5.1. Degradation of anti-TNF- agents by MMP-3 and MMP-12. (A) 
Infliximab, adalimumab and etanercept (1 g/ml) were co-incubated at 37°C for 
24 hours with increasing concentrations (0.001-1 g/ml) of p-APMA-activated 
rhMMP-3 or rhMMP-12, and were visualised by immunoblotting in reducing 
conditions using an anti-human IgG Fc primary antibody. The heavy chains of 
infliximab and adalimumab appeared as a single band of 55 kDa and the 
monomers of etanercept appeared as a single band of 75 kDa, and remained 
intact after 24 hour co-incubation with or without p-APMA alone (0h, 24h on the 
left of each blot). All TNF- neutralising agents were cleaved by MMP-3 or MMP-
12 with the formation of a 32 kDa band, likely to correspond to the Fc monomer 
observed after MMP digestion of native human IgG1. Cleavage occurred in a 
concentration-dependent manner, as shown by the increasing intensity of the 32 
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kDa band at higher MMP concentrations and the decreasing intensity of the 
bands correspondent to the intact heavy chain of infliximab and adalimumab and 
to the intact etanercept monomer. At the lowest MMP concentrations, another 
50 kDa etanercept fragment appeared. Blots are representative of six separate 
experiments. (B) Densitometric analysis of the intact infliximab and adalimumab 
heavy chain, and of the intact etanercept monomer, after co-incubation with 
increasing concentrations of activated rhMMP-3 or rhMMP-12. Etanercept was 
more susceptible to MMP degradation than infliximab and adalimumab, and the 
band corresponding to the intact etanercept monomer totally disappeared after 
co-incubation with 0.1 g/ml MMP-3 and MMP-12. Results are expressed as 
mean percentage of the intact anti-TNF- agent after MMP treatment compared 
to the correspondent untreated TNF- neutralising agent after 24 hour co-
incubation with or without p-APMA ± s.d. (n=6). Data were analysed by ANOVA 
One way analysis of variance followed by the Tukey’s multiple comparison test. 
*p<0.001 versus MMP-3-/MMP-12-treated etanercept at the correspondent MMP 
concentration. 
 
 
 
 
 
Figure 5.2. Effect of MMP-9 on the integrity of anti-TNF- agents. Infliximab, 
adalimumab and etanercept (1 g/ml) were co-incubated at 37°C for 24 hours 
with 1 g/ml activated rhMMP-9, and were visualised by immunoblotting in 
reducing conditions using an anti-human IgG Fc primary antibody. Infliximab, 
adalimumab and etanercept were not cleaved by MMP-9. Blots are 
representative of six separate experiments. 
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5.3.2  Sequential cleavage of anti-TNF- agents by MMP-3 and MMP-12 
 
Each anti-TNF- agent (1 g/ml) was also co-incubated with a fixed 
concentration (1 g/ml) of MMP-3 or MMP-12. Subsequent immunoblotting in 
non-reducing gels with anti-human Ig  light chain showed that degradation of 
infliximab and adalimumab occurs in a time-dependent sequential manner, with 
the formation of single-cleaved – upon removal of one Fc monomer – and, 
subsequently, double-cleaved – F(ab’)2 – intermediate products (Figure 5.3). 
Etanercept could not be visualised using anti-human Ig  primary antibody. 
 
 
 
Figure 5.3 Sequential cleavage of infliximab and adalimumab by MMP-3 and 
MMP-12. Infliximab and adalimumab (1 g/ml) were co-incubated at 37°C with 1 
g/ml activated rhMMP-3 or rhMMP-12. The incubation was interrupted at fixed 
time points (3, 6, 10 and 24 hours), and the anti-TNF- agents were visualised by 
immunoblotting in non-reducing conditions using an anti-human Ig  light chain 
antibody. Infliximab and adalimumab were cleaved in a time-dependent manner 
by either MMP-3 or MMP-12 with the sequential formation of two additional 130 
and 100 kDa bands, which likely correspond to single-cleaved Ig intermediate 
(scIg) and F(ab')2 fragments, respectively, and increased in intensity over time. 
Of note, the bands corresponding to intact infliximab and adalimumab decreased 
in intensity over time. 
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5.3.3 Effect of MMP-3 and MMP-12 on protein G binding capacity of anti-
TNF- agents 
 
To confirm that MMP-3 and MMP-12 had indeed removed the Fc region, an 
ELISA using protein G-coated plates was performed on samples of TNF- 
neutralising agents pre-incubated with increasing concentrations of activated 
MMP-3 and MMP-12, using chicken secondary antibodies against F(ab’)2 or p75 
TNFR (Fig. 5.4). In this experiment, only intact anti-TNF- agents can bind to the 
protein G-coated plate, are then recognised by secondary antibodies and give a 
positive signal, therefore the optical density can be considered as an indication of 
the amount of residual intact anti-TNF- agent. Untreated TNF- neutralising 
agents bound strongly to protein G, but after 24 hour of incubation with MMP-3 or 
MMP-12, binding decreased in a dose-dependent fashion. The kinetics of the 
loss of protein G binding were faster for etanercept than for the other agents 
tested. After pre-incubation with 0.1 g/ml of either MMP-3 or MMP-12, there was 
still substantial binding with infliximab and adalimumab, but etanercept binding 
was minimal. 
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Figure 5.4 (see previous page). Effect of MMP-3 and MMP-12 on protein G 
binding capacity of anti-TNF- agents. TNF- neutralising agents, all at the 
concentration of 1 g/ml, were co-incubated for 24 hours with increasing 
concentrations (0.001-1 g/ml) of active rhMMP-3 or rhMMP-12. Untreated or 
MMP-3- and MMP-12-treated TNF- neutralising agents were added to the wells 
of protein G-coated plates. Horseradish peroxidase-conjugated chicken anti-
human F(ab’)2 or anti-human TNF receptor II antibodies, which do not bind to 
protein G, were used to detect and quantify protein G binding to TNF- 
neutralising agents. Values, expressed as optical density (OD), are mean  s.d. 
of six separate experiments. Data were analysed by ANOVA One way analysis of 
variance followed by the Tukey’s multiple comparison test. *p<0.05 versus 
etanercept at the correspondent MMP concentration; **p<0.01 versus etanercept 
at the correspondent MMP concentration; #p<0.001 versus etanercept at the 
correspondent MMP concentration. 
 
 
5.3.4 Effect of MMP-3 and MMP-12 on TNF- neutralisation ability of anti-
TNF- agents 
 
A nuclear factor-B reporter cell line was then used to investigate the effect of 
MMP-3 and MMP-12 on the ability of each biologic agent to neutralise soluble 
TNF- (Fig. 5.5). In the absence of MMPs, infliximab, adalimumab and 
etanercept effectively inhibited TNF--induced luciferase activity. Neutralisation 
of TNF- by infliximab and adalimumab did not change after overnight incubation 
with MMP-3/MMP-12, whereas etanercept showed a significant reduction in its 
ability to neutralise TNF-. Collectively, these results show that the removal of 
the Fc region by MMP-3 and MMP-12 does not affect the ability of infliximab and 
adalimumab to neutralise soluble TNF- as F(ab’)2 fragments, even at the lowest 
anti-TNF/MMP concentration ratio of 1:10, but does compromise significantly the 
TNF- neutralising function of etanercept.  
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Figure 5.5. Effect of MMP-3 and MMP-12 on TNF- neutralising function of 
anti-TNF- agents. NF-B reporter HeLa cells were cultured for 6 hours in the 
absence or presence of 10 ng/ml rhTNF-, with increasing concentrations (0.01-
10 g/ml) of infliximab, adalimumab or etanercept, all pre-treated for 24 hours 
with p-APMA; w/o MMPs) or 1 g/ml active MMP-3 or MMP-12. After culture, 
HeLa cell lysates were assayed for luciferase activity. Values, expressed as 
arbitrary units (a.u.), are means  s.d. of six separate experiments. Data were 
analysed by ANOVA One way analysis of variance followed by the Tukey’s 
multiple comparison test. *p<0.001 versus TNF- plus p-APMA-treated 
etanercept at the correspondent concentration. 
 
 
5.3.5 Effect of MMP-3 and MMP-12 inhibition on TNF- neutralisation 
ability of MMP-exposed etanercept 
 
Subsequently, the ability of the broad-spectrum MMP inhibitor marimastat (which 
however has no inhibitory effect on MMP-12) or the selective MMP-3/MMP-12 
inhibitor UK370106 to prevent the loss of function of MMP-exposed etanercept 
was investigated (Fig. 5.6). In particular, based on my results showing maximal 
loss of TNF- neutralising ability when 0.1 g/ml etanercept was pre-incubated 
with 1 g/ml MMPs, I tested the effect of 1 g/ml active rhMMP-3 or MMP-12 on 
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0.1 g/ml etanercept in the absence or presence of increasing concentrations 
(0.001-1 M) of marimastat or UK370106. The addition of UK370106 to the 
cleavage reactions with either MMP-3 or MMP-12 effectively restored TNF- 
neutralising function of etanercept in a dose-dependent manner. Conversely, 
marimastat was able to prevent only MMP-3- but not MMP-12-induced loss of 
TNF- neutralising ability of etanercept. This shows that the loss of TNF- 
neutralising function of etanercept induced by MMP-3 and MMP-12 can be 
specifically prevented by the MMP inhibitors. 
 
 
 
Figure 5.6. Effect of MMP inhibitors on TNF- neutralising function of MMP-
exposed etanercept. Nuclear factor-B reporter HeLa cells were cultured for 6 
hours in the absence or presence of 10 ng/ml rhTNF-, with 0.1 g/ml 
etanercept, pre-incubated for 24 hours with 1 g/ml active rhMMP-3 or rhMMP-
12 in the absence or presence of increasing concentrations (0.001-1 M) of 
marimastat or UK370106. After culture, HeLa cell lysates were assayed for 
luciferase activity. Values, expressed as arbitrary units (a.u.), are means  s.d. of 
six separate experiments. Data were analysed by ANOVA One way analysis of 
variance followed by the Dunnett’s multiple comparison test. #p<0.01 versus 
TNF- plus MMP-treated etanercept; *p<0.001 versus TNF- plus MMP-treated 
etanercept.  
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5.3.6 MMP-3/MMP-12 activity in IBD and control protein extracts 
 
Subsequently, protein extracts from normal colonic biopsies of control subjects 
and from inflamed colonic biopsies of IBD patients were prepared, and 
differences in the amounts of tissue-extracted proteins from the different patient 
samples were controlled by measuring total protein concentration, then 
normalising it to 2 mg/ml by dilution in PBS. MMP-3/MMP-12 activity was then 
measured by a FRET assay, using rhMMP-3 and rhMMP-12 as positive controls 
(Fig. 5.7). IBD protein extracts showed a significantly higher MMP-3 and MMP-12 
activity compared to control protein extracts. No difference between CD and UC 
protein extracts was observed. Interestingly, MMP-3/MMP-12 activity in IBD 
protein extracts was significantly lower than rhMMP-3 and rhMMP-12, each one 
at the concentration of 1 g/ml. 
 
 
Figure 5.7. MMP-3/MMP-12 activity in IBD and control protein extracts. 
MMP-3/MMP-12 activity in the protein extracts of normal colonic biopsies of eight 
control subjects (HC) and in inflamed colonic biopsies of 16 IBD patients. Active 
rhMMP-3 and rhMMP-12 have been used as positive controls. Bars, expressed 
as arbitrary units (a.u.), are means  s.d. Data were analysed by ANOVA One 
way analysis of variance followed by the Tukey’s multiple comparison test. 
*p<0.01 versus HC biopsies. §p<0.05 versus rhMMP-3 and rhMMP-12. 
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5.3.7 Effect of mucosal protein extracts on the integrity of anti-TNF- 
agents 
 
Subsequently, the protein extracts from control subjects and inflamed IBD colonic 
mucosa were co-incubated with TNF- neutralising agents, and cleavage 
patterns were analysed in reducing gels by immunoblotting using an anti-human 
IgG Fc antibody (Fig. 5.8). No cleavage by control protein extracts was detected, 
whereas infliximab, adalimumab and etanercept were cleaved by IBD proteins, 
suggesting that the increased proteolytic activity present in chronically inflamed 
tissues may affect drug stability. While infliximab and adalimumab were partially 
cleaved, intact etanercept was completely lost after co-incubation with IBD 
protein extracts. In some cases the 32 kDa fragment, indicative of lower hinge 
cleavage by MMP-3/MMP-12 (Fig. 5.8 – patient #2), could be observed, 
nevertheless the heterogeneous clipping profile between different patients 
suggests that the tissue proteolytic profile varies among individuals and other 
proteases may also contribute to IgG cleavage. 
 
Figure 5.8. Effect of IBD mucosal protein extracts on anti-TNF- agent 
integrity. Infliximab, adalimumab and etanercept, all at the concentration of 1 
g/ml, were co-incubated for 24 hours with PBS only or with protein extracts from 
the colon of control subjects (HC) or from the colon of IBD patients. Infliximab, 
adalimumab and etanercept were visualised by immunoblotting in reducing 
conditions using an anti-human IgG Fc primary antibody. The heavy chains of 
infliximab and adalimumab appeared as a single band of 55 kDa, remained 
intact after 24 hour co-incubation with PBS or HC protein extracts, and were 
partially cleaved by IBD mucosal proteins with the appearance of 32, 35 and 
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40 kDa fragments. Etanercept, which was minimally cleaved by HC mucosal 
proteins, was completely cleaved by inflamed IBD mucosal proteins with the 
formation of 32, 35 and 40, 45 and 50 kDa fragments. The 32 kDa band is 
consistent with lower hinge cleavage. Blots are representative of experiments 
performed with colonic mucosal proteins from eight HC subjects and eight IBD 
patients. 
 
 
5.3.8 Effect of IBD mucosal protein extracts on TNF- neutralisation ability 
of anti-TNF- agents 
 
Additionally, the effect of tissue extracts from normal and IBD colonic mucosa on 
the ability of each agent to neutralise soluble TNF- was investigated (Fig. 5.9). 
The ability to neutralise TNF- by the three agents was not altered after 24 hour 
co-incubation with proteins from control colonic mucosa. At low concentration 
(0.1 g/ml), infliximab and adalimumab showed a reduction in their ability to 
neutralise soluble TNF- after co-incubation with IBD mucosal tissue extracts. 
Etanercept significantly lost its ability to neutralise TNF- after co-incubation with 
proteins from inflamed IBD mucosa. 
 
Figure 5.9 (see next page). Effect of mucosal protein extracts on TNF- 
neutralisation capacity of anti-TNF- agents. NF-B reporter HeLa cells were 
cultured for 6 hours in the absence or presence of 10 ng/ml rhTNF-, with or 
without increasing concentrations (0.01-10 g/ml) of infliximab, adalimumab or 
etanercept, all pre-treated for 24 hours with either PBS or mucosal proteins from 
eight control subjects (HC) or eight IBD patients. After culture, HeLa cell lysates 
were assayed for luciferase activity. Values, expressed as arbitrary units (a.u.), 
are means  s.d. of eight separate experiments. Data were analysed by ANOVA 
One way analysis of variance followed by the Tukey’s multiple comparison test. 
*p<0.001 versus TNF- plus PBS/HC-treated infliximab or adalimumab or 
etanercept at the correspondent concentration. 
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5.3.9 Effect of MMP-3 and MMP-12 inhibition on TNF- neutralisation 
ability of anti-TNF- agents exposed to IBD protein extracts 
 
The ability of marimastat or the selective MMP-3/MMP-12 inhibitor UK370106 to 
prevent the loss of function of anti-TNF- agents exposed to IBD mucosal protein 
extracts was then assessed (Fig. 5.10). In particular, based on my results 
showing maximal loss of TNF- neutralising ability when 0.1 g/ml etanercept 
was pre-incubated with IBD mucosal protein extracts, I tested the effect of IBD 
tissue extracts on 0.1 g/ml of each anti-TNF- agent in the absence or 
presence of increasing concentrations (0.001-1 M) of marimastat or UK370106. 
Marimastat, but not UK370106, was able to restore the ability of infliximab and 
adalimumab to neutralise soluble TNF- upon exposure to IBD tissue extracts. 
Both marimastat and, to a lesser extent, UK370106 were able to restore the 
ability of etanercept to neutralise soluble TNF- upon exposure to IBD tissue 
extracts. These findings suggest that, in addition to MMP-3 and MMP-12, other 
proteolytic enzymes may contribute significantly to the loss of TNF- neutralising 
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function of anti-TNF- agents exposed to IBD mucosal protein extracts. 
 
 
 
Figure 5.10. Effect of MMP inhibitors on TNF- neutralising function of anti-
TNF- agents exposed to IBD protein extracts. Nuclear factor-B reporter 
HeLa cells were cultured for 6 hours in the absence or presence of 10 ng/ml 
rhTNF-, with 0.1 g/ml infliximab, adalimumab or etanercept, all pre-treated for 
24h with either PBS or mucosal tissue extracts from eight IBD patients in the 
absence or presence of increasing concentrations (0.001-1 M) of marimastat or 
UK370106. After culture, HeLa cell lysates were assayed for luciferase activity. 
Values, expressed as arbitrary units (a.u.), are means  s.d. of eight separate 
experiments. Data were analysed by ANOVA One way analysis of variance 
followed by the Dunnett’s multiple comparison test. *p<0.05 versus TNF- plus 
the corresponding IBD tissue extract-treated anti-TNF- agent; #p<0.001 versus 
TNF- plus the corresponding IBD tissue extract-treated anti-TNF- agent.  
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5.3.10 Detection of MMP-3-/MMP-12-cleaved anti-TNF- agents in IBD sera 
 
In order to measure the concentration of clipped anti-TNF- agents in the serum 
of IBD patients, sera collected at the time of cannulation a few minutes before the 
following infliximab infusion were collected (i.e. at least two weeks after the 
previous one). Subsequently, an ELISA assay was developed in which sera were 
incubated on a TNF--coated plate, then a biotinylated antibody specific for the 
MMP-3 and MMP-12 cleavage sites on the hinge region of human IgG was used 
to reveal the presence of any clipped infliximab in the serum. Clipped infliximab 
was undetectable (data not shown), and this could be due to a number of 
reasons. The first could be that clipped anti-TNF- agents may not have the 
same affinity as intact anti-TNF- agents for TNF- absorbed on the plate. One 
further explanation may be the catabolism of degraded IgG in the samples 
collected immediately before the following administration. 
 
5.3.11 Detection of MMP-3-/MMP-12-cleaved endogenous IgG in IBD and 
control sera 
 
In order to test whether proteolytic cleavage occurs in vivo and has clinical 
relevance in IBD patients, we hypothesised that we could detect clipped 
endogenous IgG in patients’ sera. Indeed, the ELISA assay which was performed 
by absorbing on the plate the biotinylated antibody specific for the MMP-3 and 
MMP-12 cleavage sites on the hinge region of human IgG revealed that sera 
from active IBD patients contained significantly higher levels of MMP-3-/MMP-12-
cleaved endogenous IgG compared to control subjects (Fig. 5.11A). IBD patients 
were then stratified according to their subsequent response to biologic therapy, 
and, among patients who did not respond to infliximab or adalimumab therapy, a 
subset of patients had significantly higher serum levels of MMP-3-/-12-cleaved 
IgG than responders (Fig. 5.11B). 
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Figure 5.11. Levels of MMP-3-/MMP-12-cleaved endogenous IgG in IBD and 
control sera. (A) ELISA plates were coated with streptavidin, followed by a 
biotinylated rabbit anti-human MMP-3/MMP-12 IgG hinge cleavage site 
monoclonal antibody. Sera from 62 active IBD patients who were going to 
receive the first infliximab infusion, and from 20 control subjects (HC) were 
serially diluted and added to the plate, then a horseradish peroxidase-conjugated 
donkey anti-human IgG heavy and light chain antibody was used to detect bound 
cleaved IgG. Levels of clipped endogenous IgG are expressed as optical 
densities (OD). The horizontal bar indicates the mean OD. Data shown here refer 
to the highest serum dilution (1:12150) at which I could detect significantly 
different signals between HC and IBD sera. (B) Levels of clipped endogenous 
IgG in the serum of IBD patients were stratified as IBD responder patients (IBD 
resp; n=46) and IBD non-resp (n=16; 6 CD and 10 UC patients) according to 
their subsequent response to infliximab treatment. No difference in disease 
severity and/or CRP serum levels were present at baseline between IBD resp 
and IBD non-resp patients. Levels are expressed as OD. The horizontal bar 
indicates the mean OD. Data shown here were obtained at a 1:1350 dilution of 
the sera, which is the highest serum dilution at which I could detect significantly 
different signals between IBD resp and IBD non-resp sera. The unpaired two-
tailed t test was applied to compare between HC and IBD sera, and between IBD 
resp and IBD non-resp sera. *p<0.005 versus HC sera. **p<0.05 versus IBD resp 
sera. 
 
 
5.3.12 Detection of anti-hinge autoantibodies in IBD and control sera 
 
The IgG F(ab’)2 fragments generated as a result of proteolytic cleavage become 
self-antigens that lead to the formation of autoantibodies in the human population 
(Brezski et al. 2008), and serum anti-hinge autoantibodies are more frequent in 
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patients with rheumatoid arthritis compared to control subjects (Rispens et al. 
2012). An additional cause of the inability to detect clipped anti-TNF- agents 
could be the presence of anti-hinge autoantibodies bound to the drug, which may 
render the epitope inaccessible to the detection antibody. Therefore, an ELISA 
assay was developed and tested on the same IBD patient and control sera by 
coating the plate with the peptide sequence on the IgG hinge region generated 
by MMP-3/MMP-12 cleavage (Fig. 5.12). Sera from active IBD patients contained 
significantly higher concentrations of anti-hinge autoantibodies compared to 
control subjects (Fig. 5.12A). Moreover, among patients who subsequently did 
not respond to infliximab therapy, a subset of patients had significantly higher 
serum levels of anti-hinge autoantibodies compared to responders (Fig. 5.12B). 
 
 
 
Figure 5.12. Levels of anti-hinge autoantibodies in IBD and control sera. (A) 
ELISA plates were coated with streptavidin, followed by the biotinylated 14mer 
peptide analogue of the human IgG1 hinge with a C-terminal amino acid 
corresponding to the MMP-3/MMP-12 cleavage site. A chimaeric rabbit/human 
anti-human MMP-3/MMP-12 IgG hinge cleavage site monoclonal antibody, used 
as a standard, or sera from 62 active IBD patients who were going to receive the 
first infliximab infusion, and from 20 control subjects (HC) were serially diluted 
and added to the plate, then a horseradish peroxidase-conjugated goat anti-
human IgG Fc antibody was used as detection antibody. A concentration curve 
was constructed based on the OD recorded for the standard, and the 
corresponding equation allowed to convert serum anti-hinge autoantibody OD 
into ng/ml. The horizontal bar indicates the mean concentration. (B) Levels of 
anti-hinge autoantibodies in the serum of IBD patients were stratified as IBD resp 
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(n=46) and IBD non-resp (n=16; 6 CD and 10 UC patients) according to their 
response to infliximab treatment. The horizontal bar indicates the mean 
concentration. Data shown here were obtained at a 1:1350 dilution of the sera, 
which is the highest serum dilution at which I could detect significantly different 
signals between HC and IBD sera, and between IBD resp and IBD non-resp sera. 
The unpaired two-tailed t test was applied to compare between HC and IBD sera, 
and between IBD resp and IBD non-resp sera. *p<0.05 versus HC sera. **p<0.05 
versus IBD resp sera. 
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5.4 Results summary 
 
In the current study, we found that: 
8. MMP-3 and MMP-12, but not MMP-9, cleave infliximab, adalimumab and 
etanercept in vitro in a dose-dependent manner. As a result of MMP 
degradation, only etanercept loses its TNF- neutralisation ability. 
9. None of the anti-TNF- agents studied are degraded by proteins from control 
colonic mucosa. Protein extracts from inflamed IBD colonic mucosa impair 
the integrity of infliximab, adalimumab, and etanercept. At low concentration, 
infliximab, adalimumab, and etanercept lose TNF- neutralisation ability after 
co-incubation with protein extracts from inflamed IBD colonic mucosa. 
10. We were unable to detect MMP-3-/MMP-12-cleaved infliximab in IBD sera. 
11. Overall, sera from active IBD patients and from IBD patients who 
subsequently do not respond to biologic therapy contain significantly higher 
levels of MMP-3-/MMP-12-cleaved endogenous IgG and anti-hinge 
autoantibodies compared to control subjects and to IBD patients who 
subsequently respond to biologic therapy. It needs to be noted, however, that 
there is a high degree of overlap between the groups considered. 
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5.5 Discussion 
 
Our findings indicate that MMP-3, MMP-12, and protein extracts from inflamed 
IBD mucosa degrade infliximab, adalimumab and etanercept in vitro, however 
etanercept shows a higher susceptibility than infliximab and adalimumab. 
Furthermore, sera from active IBD patients contained higher levels of MMP-3-
/MMP-12-cleaved endogenous IgG and anti-hinge autoantibodies compared to 
control subjects. This Section focuses on the interpretation of our findings in the 
context of the existing literature, on the limitations of our study, and on possible 
future experiments aimed at clarifying the relevance of MMP degradation as a 
mechanism of primary non-responsiveness to biologic therapy in IBD. 
 
Effects of MMPs and IBD mucosal protein extracts on anti-TNF- agents 
 
Anti-TNF- agents, despite being a powerful tool in the management of IBD, are 
burdened with high costs and relevant risks, and a significant percentage of 
patients do not respond to treatment. Non-responsiveness can be defined as 
primary, when patients do not show any improvement after the treatment start, or 
secondary, when patients initially improve and subsequently lose response to 
treatment (Komaki et al. 2016). 
 
Multiple factors contribute to non-responsiveness to anti-TNF- agents in IBD. 
One important factor may be represented by the high degree of disease 
heterogeneity present in IBD. Insufficient dosing may represent an alternative to 
disease heterogeneity in explaining primary non-responsiveness. As an example, 
a high body mass index may influence responsiveness to adalimumab, which, 
unlike infliximab, is administered at a fixed dose rather than based on the 
patient’s weight (Travis et al. 2012a). The formation of anti-drug antibodies, 
especially against infliximab, exerts a profound influence on the persistence of 
functional TNF- neutralising agents in the circulation and, more importantly, in 
the inflamed mucosa (Nanda et al. 2013). However, anti-drug antibodies are 
  
266 
important in the late induction phase, and are unlikely to play a role in primary 
non-responsiveness. The application of treatment algorithms based on serum 
trough levels of anti-TNF- agents, and on the presence or absence of anti-drug 
antibodies, has shown promising results in IBD (Afif et al. 2010; Vande Casteele 
et al. 2014).
 
One of the mechanisms mediating the pro-inflammatory effects of T cell-derived 
cytokines in the inflamed IBD mucosa is represented by the overexpression of 
proteolytic enzymes, which can degrade ECM components and promote the 
formation of intestinal ulcers (Ravi et al. 2007). Proteolytic enzymes cleave 
human IgG1 at different points on the amino acid sequence. In particular, 
proteases that cleave IgG1 in the lower hinge region include MMP-3 and MMP-
12; MMP-7, that has the same cleavage site as pepsin; and cathepsin G. As a 
result of the exposure to these proteases, F(ab’)2 fragments are released. 
Conversely, neutrophil elastase cleaves IgG1  in the upper hinge region, between 
the plasmin and the papain cleavage sites, thereby generating single F(ab’) 
fragments (Brezski et al. 2010). After MMP-3, MMP-12 and MMP-7 cleavage, a 
32 kDa single-chain fragment is released, which is part of the Fc portion (Brezski 
et al. 2009). TNF- neutralising biologic agents have at least part of their amino 
acid sequence in common with IgG1 (Rutgeerts et al. 2009). 
 
We observed that MMP-3 and MMP-12, but not MMP-9, cleave infliximab, 
adalimumab and etanercept in vitro in a dose-dependent, time-dependent, and 
sequential manner. MMP-3 and MMP-12 are capable of cleaving human IgG1 
exactly at the same point in the hinge region (Brezski et al. 2010). This explains 
why the analysis of anti-TNF- integrity after digestion with these two MMPs 
displays very similar profiles. IBD mucosal protein extracts, which showed up-
regulated MMP-3/MMP-12 activity compared to control mucosal protein extracts, 
were able to cleave infliximab and adalimumab. However, the degradation profile 
was heterogeneous, with evidence of several different fragments, suggesting that 
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various proteolytic enzymes present in IBD mucosa may degrade IgG1 also in 
other points on the amino acid sequence than in the hinge region.
 
Anti-TNF- agents may exert their therapeutic action via multiple mechanisms, 
including induction of apoptosis of activated immune cells, antibody-dependent 
cell-mediated cytotoxicity, and complement activation (Nesbitt et al. 2007). 
Similarly to what had been demonstrated for the monoclonal antibodies 
trastuzumab and rituximab (Clynes et al. 2000), the presence of the Fc region is 
necessary for antibody-dependent cell-mediated cytotoxicity and complement 
activation. A genetic polymorphism in IgG Fc receptor (FcR)IIIa that enhances 
its affinity for IgG1 is associated to increased biological response to infliximab in 
CD (Louis et al. 2004). Moreover, Vos et al. (Vos et al. 2011) have shown that 
the Fc region is required for the ability of anti-TNF- monoclonal antibodies to 
promote the development of regulatory M2 macrophages, which are induced by 
infliximab in responder, but not in non-responder, IBD patients (Vos et al. 2012). 
 
Proteolytic digestion by MMP-3 and MMP-12 leads to the complete removal of 
the Fc region of anti-TNF- agents. Following exposure to MMP-3 or MMP-12, 
infliximab and adalimumab are still able to neutralise soluble TNF- as F(ab’)2 
fragments, even at the lowest anti-TNF-/MMP concentration ratio of 1:10. 
However, proteolytic degradation of anti-TNF- agents may be clinically relevant 
in IBD patients due to the consequent impairment of Fc-mediated properties. 
Moreover, since binding of the IgG to the FcRn has been shown to protect them 
from catabolism (Akilesh et al. 2007), the removal of the Fc region from anti-TNF-
 agents operated by MMP-3 and MMP-12 may result in decreased serum 
trough levels of these drugs. Upon exposure to IBD mucosal protein extracts, 
infliximab and adalimumab, at low concentration, display an impaired ability to 
neutralise soluble TNF-. 
 
Human IgG2 are resistant to proteolytic cleavage by MMPs, however their Fc-
dependent immunologic functions are weak (Brezski et al. 2011). Specific 
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mutations can be incorporated into the Fc region of protease-resistant 
monoclonal IgG1 antibodies, resulting in enhanced cell killing properties (Kinder 
et al. 2013). Therefore, it may be possible to apply the same strategy in order to 
generate anti-TNF- agents resistant to proteolytic cleavage, without 
compromising their immunologic properties. 
 
Our findings provide an explanation for the failure in CD of etanercept (Sandborn 
et al. 2001), which is highly susceptible to proteolytic cleavage. Etanercept is the 
only anti-TNF- agent, among those studied, that loses its TNF- neutralisation 
ability after Fc removal by MMP-3 and MMP-12, and that, even at high 
concentrations, loses its TNF- neutralisation ability after exposure to IBD 
mucosal protein extracts. The effect of MMP-3 and MMP-12 on the ability of 
etanercept to neutralise TNF- may be related to a conformational change in the 
p75 TNF receptor when cleaved from the IgG Fc. Conversely, the effect of IBD 
mucosal protein extracts on the ability of etanercept to neutralise TNF- may 
depend on the possible degradation of the p75 TNF receptor itself by different 
proteolytic enzymes present in IBD mucosa. 
 
Nevertheless, etanercept is clinically useful in rheumatoid arthritis (Weinblatt et al. 
1999), and there are many reports showing that MMP-3 is elevated in the 
rheumatoid joint (Vandooren et al. 2004). However, concentration and activity of 
MMPs and their natural inhibitors in the affected tissues may be different in 
different diseases affecting different tissues, therefore local quantification of 
proteolytic activity would be important for interpretation of our results and 
translation into practical consequences. Nevertheless, in diseases such as IBD, 
cleavage and loss of function of biologic agents may be quantitatively greater 
than in the rheumatoid joint. The high susceptibility of etanercept to proteolytic 
cleavage suggests that there may be an inherent problem with Fc receptor fusion 
proteins at sites of inflammation rich in proteases. The failure of the cytotoxic T 
lymphocyte antigen (CTLA)-4-IgG fusion protein abatacept both in CD and in UC 
(Sandborn et al. 2012a) supports this idea. 
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The addition of the specific MMP-3/MMP-12 inhibitor UK370106 to the cleavage 
reactions prevented both MMP-3- and MMP-12-induced loss of TNF- 
neutralisation ability of etanercept. Conversely, the broad-spectrum MMP 
inhibitor marimastat was able to restore TNF- neutralisation ability of etanercept 
following exposure to MMP-3, but not MMP-12, in keeping with its known activity 
profile. On the other hand, marimastat showed a stronger effect than UK370106 
in restoring TNF- neutralisation ability of anti-TNF- agents exposed to IBD 
mucosal protein extracts, supporting the view that multiple proteases contribute 
to the cleavage process in the inflamed mucosa. 
 
Biomarker studies on IgG cleavage in IBD sera 
 
In our study, we were particularly interested in exploring proteolytic degradation 
as a possible mechanism underlying lack of response to anti-TNF- therapy in 
IBD. However, the demonstration that this mechanism is biologically plausible 
was the starting point for investigating the possibility to develop a biomarker, 
which may ultimately help identify the subset of IBD patients with the highest 
likelihood of responding to anti-TNF- agents. 

Different IBD patients are characterised by extensive disease heterogeneity, 
which involves genetic, immunologic, and clinical aspects. There are 
considerable ongoing efforts in order to develop biomarkers involving different 
clinical aspects of IBD. As an example, gene array profiling has been used to 
identify IBD patients with poor prognosis. In particular, based on transcriptional 
signatures of circulating CD8+ T cells, it is possible to identify at diagnosis, both 
in CD and in UC, the subgroup of patients with higher incidence of relapses (Lee 
et al. 2011). Regarding anti-TNF- therapy in IBD, biomarkers capable of 
predicting patients who will or will not respond to treatment are not currently 
available in the clinical practice. Patients with high serum concentrations of CRP 
show significantly higher responsiveness and remission rates compared to those 
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with normal CRP (Jürgens et al. 2011). A decrease in faecal calprotectin early 
after the start of infliximab treatment predicts remission in UC patients (De Vos et 
al. 2012), however this can only be evaluated after the start of anti-TNF- 
treatment. One gene array profiling study in UC has identified a mucosal gene 
expression panel able to distinguish responders from non-responders to 
infliximab (Arijs et al. 2009), and another gene expression profiling study based 
on TNF- signalling has allowed discrimination between responders and non-
responders, both in UC and in CD (Westra et al. 2013). 
 
In order to evaluate whether signs of anti-TNF- degradation in IBD could be 
detected in the serum of patients, we tried to measure clipped infliximab in IBD 
patients’ sera collected immediately after the first or before the second infusion, 
however these experiments were uniformly negative. This may be due to the low 
ratio of clipped versus intact drug within the sera collected one hour after the 
infusion, or to the catabolism of degraded IgG in the samples collected before the 
following administration. An additional reason may be the fact that the F(ab’)2 
fragments generated as a result of proteolytic cleavage become self-antigens 
that are recognised by autoantibodies (Brezski et al. 2008). This may prevent the 
possibility to detect clipped infliximab with an immunoassay directed against the 
same epitope. Interestingly, patients with rheumatoid arthritis have a higher 
incidence of serum anti-hinge autoantibodies compared to control subjects 
(Rispens et al. 2012). We performed an ELISA on IBD and control sera upon 
coating the plate with the peptide sequence on the IgG hinge region generated 
by MMP-3/MMP-12 cleavage. We observed that sera from active IBD patients 
contain significantly higher concentrations of anti-hinge autoantibodies compared 
to control subjects, and that, overall, IBD patients who subsequently did not 
respond to treatment with anti-TNF- agents have significantly higher levels of 
anti-hinge autoantibodies than responders. 
 
Finally, we also hypothesised that, in parallel to exogenous IgG, as it is the case 
with anti-TNF- agents, cleavage of higher quantities of endogenous IgG occurs 
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in the inflamed IBD intestinal mucosa compared to the normal mucosa of control 
subjects, and that this is reflected in the serum. We therefore performed an 
ELISA on IBD and control sera after absorbing on the plate the biotinylated 
antibody specific for the MMP-3 and MMP-12 cleavage sites on the hinge region 
of human IgG, and we observed that sera from active IBD patients contain 
significantly higher serum levels of MMP-3-/MMP-12-cleaved endogenous IgG 
than control subjects. We then stratified IBD patients according to their response 
to biologic therapy, and we observed that, overall, those who subsequently did 
not respond to treatment have significantly higher levels of MMP-3-/MMP-12-
cleaved endogenous IgG than responders. 
 
Limitations of the study and possible confounding factors 
 
In our in vitro experiments we have only studied LPMC-derived MMP-3, MMP-12 
and MMP-9, and we have not assessed the effects of a range of other proteases 
with known ability to cleave IgG, including IEC-derived MMP-7, MMP-13 or the 
serine proteases neutrophil elastase and cathepsin G (Brezski et al. 2009; 
Brezski et al. 2010), which may play a relevant role in biologic agent clipping in 
vivo. Moreover, in our experiments we used single doses of MMPs added at a 
single time and we do not know if these reflect the in vivo situation, where it is 
likely that there is continuous production of MMPs by myofibroblasts and 
inflammatory cells into the pericellular spaces. 
 
The highest concentration of rhMMP-3 and rhMMP-12 (1 g/ml) that we used in 
our in vitro experiments when we tested them as positive controls on the MMP-
3/MMP-12 activity assay had a higher activity than IBD protein extracts. 
Nevertheless, in the MMP-3 and MMP-12 cleavage reactions for the integrity 
analysis and the protein G assay we used a range of rhMMP concentrations 
(0.001-1 g/ml), which most likely include physiologically relevant activity levels 
in IBD inflamed mucosa. Moreover, in some of the Western blots of anti-TNF- 
agents after incubation with MMP-3 and MMP-12, we observed a disparity 
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between the intensity of intact anti-TNF- agents and the cumulative intensity of 
the fragments produced after MMP-3 and MMP-12 cleavage. We are unable to 
exclude that this could be due to additional cleavage at different sites than the 
known cleavage sequence in the hinge region of IgG1, with consequent formation 
of fragments which may not be recognised by the anti-Fc antibody used as a 
primary antibody for immunoblotting. 
 
In the protein G assay, only intact anti-TNF- agents can bind to the protein G-
coated plate, are then recognised by secondary antibodies against F(ab’)2 or p75 
TNFR (chicken antibodies, which are unable to bind to protein G) and give a 
positive signal, therefore the optical density can be considered as an indication of 
the amount of intact anti-TNF- agent. The reduction of positive signal observed 
upon MMP cleavage of anti-TNF- agents suggests that the Fc region has been 
removed by MMP-3 and MMP-12. Based on our experiments, we cannot exclude 
that free/cleaved Fc fragments may interfere/compete with intact anti-TNF- 
agents for binding to the plates, and a possible way to evaluate this would be to 
perform the protein G assay with Fc fragments (commercially available) plus 
intact anti-TNF- agents at different concentrations. Nevertheless, if present, 
interference/competition by free/cleaved Fc fragments in the cleavage reaction 
product would amplify, rather than diminish, the possibility to detect and quantify 
Fc removal by MMPs in the protein G assay. 
 
There is considerable heterogeneity in the MMP mucosal expression profile in 
different IBD patients, which requires further investigation. Moreover, the multiple 
bands detected after incubation of adalimumab and infliximab with IBD mucosal 
protein extracts do not correspond to the 32 kDa band seen with recombinant 
MMP-3 and MMP-12, suggesting that, in the complex situation of inflammation, 
clipping of biologic agents may be variable in different patients. The interpretation 
of the clinical relevance of our data regarding the effect of inflamed IBD mucosal 
protein extracts on anti-TNF- agents may be confounded by the fact that we do 
not exactly know what proportion of systemically administered anti-TNF- agents 
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access the intestinal mucosa. However, an indirect suggestion that anti-TNF- 
agents exert their action in the intestinal mucosa is provided by the study by 
Atreya et al. (Atreya et al. 2014), who showed by confocal laser endomicroscopy 
that CD patients with high numbers of transmembrane TNF-+ cells in the colonic 
mucosa have a substantially better response rate to adalimumab compared to 
patients with low numbers of transmembrane TNF-+ cells in the colonic mucosa. 
Moreover, we do know that IBD mucosal protein extracts have a significantly 
higher MMP-3/MMP-12 activity compared to control protein extracts, without any 
difference between CD and UC patients, and that several other proteases are up-
regulated in IBD inflamed mucosa. Further studies on the effects of proteolysis 
on the function of anti-TNF- agents in IBD mucosa seem therefore appropriate. 
 
Our data on serum levels of cleaved IgG and anti-hinge autoantibodies need to 
be interpreted with caution, as there is a high degree of overlap between the 
groups considered. At the same time, there is also a high degree of 
heterogeneity in the serum levels of both MMP-3-/MMP-12-cleaved endogenous 
IgG and anti-hinge autoantibodies within the same patient group, especially 
among IBD patients. Moreover, the sample size in our analysis, particularly with 
regards to the comparison between responder and non-responder IBD patients, 
is considerably small. Nevertheless, even among a small number of non-
responder IBD patients, there is a subgroup with high levels of MMP-3-/MMP-12-
cleaved endogenous IgG, which may be the biomarker of high mucosal 
proteolytic activity contributing to non-responsiveness to treatment. Moreover, it 
should be pointed out that there are multiple factors which can contribute to 
primary non-responsiveness to biologic therapy, and that ours was a pilot study 
on a small cohort of patients. 
 
Future experiments 
 
While our study has provided evidence that proteolytic degradation is a 
biologically plausible mechanism which may contribute to primary non-
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responsiveness to anti-TNF- agents in IBD by affecting their bioavailability in 
the intestinal mucosa, it forms the starting point for a number of future 
investigations. 
 
In the present study we have not examined the possibility that proteolytic 
cleavage by inflamed IBD protein extracts may influence the efficacy of anti-TNF-
 agents by means of in vivo experiments. This could instead be the focus of a 
future preclinical interventional study on the treatment of experimental colitis with 
anti-TNF- antibodies combined with the broad-spectrum MMP inhibitor 
marimastat. Although this approach would not provide clear evidence that MMP-
3 and MMP-12 are the key enzymes involved in proteolytic degradation, it will be 
useful in order to evaluate whether MMP inhibition may enhance the efficacy of 
anti-TNF- therapy. 
 
Furthermore, we will clarify the effects of other proteases with known ability to 
cleave IgG1, including MMP-7, MMP-13, the serine proteases neutrophil elastase 
and cathepsin G, which may play a relevant role in biologic agent degradation in 
vivo, on the integrity and function of anti-TNF- agents. Furthermore, we will 
investigate the effects of proteases on biologic agents with different mechanism 
of action that are becoming increasingly relevant in the treatment of IBD, such as 
the anti-47 integrin monoclonal antibody vedolizumab (Feagan et al. 2013; 
Sandborn et al. 2013b), the anti-7 integrin monoclonal antibody etrolizumab 
(Vermeire et al. 2014), and the anti-p40 monoclonal antibody ustekinumab 
(Sandborn et al. 2012b). We are also going to clarify the presence of a class-
specific increased susceptibility of Ig Fc fusion proteins, such as etanercept and 
the CTLA-Ig abatacept, to proteolytic degradation. 
 
In addition to soluble TNF- neutralisation, anti-TNF- agents are supposed to 
exert their therapeutic effect by inducing immune cell apoptosis by reverse 
signalling upon binding transmembrane TNF- (Tracey et al. 2008). Although this 
is not an Fc-dependent property, it would be important to evaluate the effect of 
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MMP-3, MMP-12, and of other proteases with the potential ability to degrade also 
the F(ab’), on the ability of anti-TNF- agents to induce apoptosis of immune 
cells. Moreover, in addition to the ability to promote the development of 
regulatory M2 macrophages (Vos et al. 2011), anti-TNF- agents have been 
shown, at least in vitro, to exert important effects on immune cells by two other 
Fc-dependent properties, namely antibody-dependent cell-mediated cytotoxicity 
upon binding the IgG Fc receptor, and complement-dependent cytotoxicity 
(Nesbitt et al. 2007). We will investigate the effects of proteolytic cleavage on 
these properties of anti-TNF- agents, which we have not evaluated in the 
present study, in a future confirmation study. 
 
In our study we focused on serum markers of IgG proteolytic cleavage, and we 
did not perform in situ analysis of cleaved anti-TNF- agents – or cleaved 
endogenous IgG – on colonic biopsy sections from responder and non-responder 
IBD patients. This, which can be performed by immunofluorescence using the 
same biotinylated antibody specific for the MMP-3 and MMP-12 cleavage sites 
on the hinge region of human IgG that we used to measure MMP-3-/MMP-12-
cleaved endogenous IgG by ELISA, should be assessed in a future validation 
study. Moreover, since it is likely that, in addition to MMP-3 and MMP-12, other 
proteases with different cleavage site specificity contribute to anti-TNF- and IgG 
cleavage in the inflamed intestinal mucosa, it would be important to characterise 
further and to quantify anti-TNF- and IgG fragments in IBD inflamed mucosa 
and serum. It has been shown that faecal loss of infliximab through the ulcerated 
intestinal mucosa is associated with primary non-responsiveness in UC (Brandse 
et al. 2015), and it will be interesting to investigate the proportion of intact and 
cleaved anti-TNF- in the stool of IBD patients, and to assess whether it 
correlates with response to biologic therapy. 
 
Finally, therapeutic drug monitoring by serial measurement of serum trough 
levels of anti-TNF- agents and anti-drug antibodies is a valuable strategy for 
optimising the management of non-responsiveness to biologic therapy in IBD 
  
276 
(Afif et al. 2010; Ben-Horin et al. 2014; Vande Casteele et al. 2015). However, 
there is a strong need to develop biomarkers able to stratify IBD patients 
according to their subsequent possibility to respond to biologic therapy. For this 
purpose, a large, prospective validation study is needed to explore the possibility 
to use the quantification of serum levels of cleaved IgG and anti-hinge 
autoantibodies as biomarkers of responsiveness to biologic therapy in IBD.  
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Chapter 6: Inflammatory skin and bowel disease linked to a deletion in 
ADAM17 
 
Note: Genetic analysis, ADAM17 and ADAM10 expression studies in patients’ 
skin and small intestine, and DSG expression and immune cell quantification in 
patient’s skin (Paragraphs 6.4.1-3) have been performed by Professor David P 
Kelsell’s group in the Centre for Cell Biology and Cutaneous Research laboratory, 
Blizard Institute, Barts and the London School of Medicine and Dentistry, London, 
UK. Primary data of these experiments are not available, therefore I could not 
show scale bars and magnification values on all micrographs, and I could not 
include immunohistochemical characterisation of B cells, natural killer cells, 
neutrophils and dendritic cells in the skin of the affected boy, as well as isotype 
control antibody stainings, which were however performed for all experiments. 
These results have been published in the following paper, on which I am second 
Author (Blaydon DC, Biancheri P, Di WL, Plagnol V, Cabral RM, Brooke MA, van 
Heel DA, Ruschendorf F, Toynbee M, Walne A, O'Toole EA, Martin JE, Lindley K, 
Vulliamy T, Abrams DJ, MacDonald TT, Harper JI, Kelsell DP. Inflammatory skin 
and bowel disease linked to ADAM17 deletion. N Engl J Med 2011;365:1502-8). 
 
We performed genetic studies in a family of consanguineous parents and their 
three children, two of whom had the same clinical features, with skin and small 
intestine inflammatory lesions, and we identified a deletion in ADAM17. Further 
information on the background to this Chapter is reported in Paragraph “1.2 
Proteases and their inhibitors” and in Section “1.4.6 Proteases in IBD intestinal 
mucosa”. 
 
6.1 Aims of the study 
 
This study aims to explore the consequences of a deletion in ADAM17, identified 
in a family of consanguineous parents and their three children, on skin barrier 
function and pro-inflammatory immune response. We have used the following 
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approach: 
5. Evaluation of ADAM17 expression in the skin and keratinocytes from the 
affected boy and control subjects, and in duodenal biopsy sections from the 
affected siblings and control subjects. 
6. Assessment of pro-inflammatory cytokine production by PBMCs from the 
affected boy, the unaffected mother and control subjects. 
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6.2 Case report 
 
Two out of three children born to consanguineous parents (first cousins) of 
Lebanese origin had the same clinical features involving the skin, hair, and small 
intestine. Both skin lesions and diarrhoea developed from the second day of life. 
Professor David P Kelsell and his research group are interested in cutaneous 
syndromes, and particularly those with a phenotypic indication of a desmosomal 
disorder, such as the hair phenotype. Moreover, they are also interested in 
helping to deliver a genetic diagnosis in difficult and rare cases. The skin, hair, 
and small bowel disorder affecting the boy could not be defined with a specific 
diagnosis, neither did the similar disorder of the affected girl. Thus, when 
approached by the Great Ormond Street Hospital, Professor David P Kelsell and 
his research group took on the challenge. The unknown diagnosis, together with 
the similarity between the disorder affecting the two siblings, and the 
consanguinity of the parents prompted to hypothesise that a genetic mutation 
could contribute to the syndrome. 
 
The affected girl had died at 12 years of age from fulminant Parvovirus B19-
associated myocarditis, and, on subsequent investigation, the affected boy was 
found to have left ventricular dilatation (end diastolic dimension 60 mm) with 
borderline systolic function (ejection fraction 55%). 
 
The skin lesions were perioral and perianal erythemas with fissuring and a 
generalised pustular rash that developed into psoriasiform erythroderma, with 
flares of erythema, scaling, and widespread pustules (Fig. 6.1A, B). The skin of 
the affected siblings, in the first years of life, was prone to infection with S. 
aureus, resulting in recurrent blepharitis and otitis externa. Their hair was short or 
broken, and their eyelashes and eyebrows were wiry and disorganised (Fig. 
6.1A). They had thickened nails, with frequent paronychia caused by Candida 
and Pseudomonas infections (Fig. 6.1C). Microscopic examination of the affected 
siblings’ hair showed an unusual hair shaft abnormality with severe weathering 
  
280 
and a markedly damaged cuticle. A skin biopsy showed patchy vacuolation of the 
basal layer over much of the biopsy and pigment incontinence, with a 
perivascular lymphocytic infiltrate involving vessels of the papillary dermis. 
 
 
Figure 6.1. Clinical features of the syndrome. The affected boy is shown at 
five years of age, with (A) facial erythema and scaling, short scalp hair, and 
disorganised, wiry eyebrows; (B) widespread pustules and erythema; and (C) 
swelling of the distal phalanges, abnormal nails, and a susceptibility to 
paronychia. 
 
 
The chronic diarrhoea in the affected girl was associated, at four months of age, 
with failure to thrive. The diarrhoea was predominantly bloody with malabsorptive 
characteristics, worsening in parallel with increases in the severity of the skin 
disease and exacerbated by intercurrent gastrointestinal infections. The affected 
girl underwent gastroscopy at the age of three years and the duodenal biopsies 
revealed a plasma cell duodenitis and chronic gastritis. The affected boy 
underwent gastroscopy and colonoscopy at the age of six years, and duodenal 
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biopsies revealed a plasma cell duodenitis with crypt hyperplasia, villous atrophy 
and mucosal eosinophilia. 
 
Both affected siblings had extensive immunological investigations, including IgG, 
IgA and IgM, Ig subclasses, vaccine responses (Haemophilus influenzae B, 
tetanus and pneumococcus), which were all normal with no evidence of an 
immunodeficiency. Both affected siblings did have moderately raised IgE levels. 
 
Treatments included acitretin, ciclosporin, methotrexate and adalimumab, none 
of which produced a significant sustained improvement in the skin or bowel 
disease. The skin infections initially responded best to systemic antibiotics, but 
this has become problematic because of increased resistance and a limited 
choice of antibiotics. 
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6.3 Chapter-specific Materials and Methods 
 
6.3.1 Patients and tissues 
 
Skin samples were obtained from family members as well as control subjects 
undergoing cosmetic (facelift or “tummy tuck”) surgery, and blood specimens for 
collection of PBMCs were obtained from family members and control subjects. 
This study was approved by the NRES Committee London - City & East (REC 
reference: 08/H1102/73), and informed consent was obtained from the family 
members and control subjects. None of the control subjects were age- or sex-
matched. It was not possible to study matched control subjects due to the age of 
the affected boy. 
 
6.3.2 Study design 
 
All family members (both parents, the affected boy, the affected girl and the 
unaffected boy) were genotyped and analysed by SNP-homozygosity mapping 
and targeted next-generation sequencing of the regions of linkage on the 
genome. Upon the identification of a deletion in ADAM17, the protein expression 
levels of ADAM17 were studied in the skin and keratinocytes from the affected 
boy and control subjects, and in duodenal biopsy sections from the affected 
siblings and control subjects. Moreover, the expression of desmogleins was 
investigated in the skin and keratinocytes from the affected boy and control 
subjects, and the distribution of immune cells was studied in the skin of the 
affected boy. Finally, peripheral venous blood was collected once from the 
affected boy and three male control subjects of the same age as the affected boy, 
and another time from the affected boy, the unaffected mother and three control 
subjects. PBMCs were isolated from peripheral blood samples and cultured with 
various stimuli, and subsequently pro-inflammatory cytokine levels were 
measured in culture supernatants. Unfortunately, the affected girl died before the 
start of this study, therefore it was only possible to study the expression of 
  
283 
ADAM17 in her duodenum on paraffin-embedded tissue sections of duodenal 
biopsies. 
 
6.3.3 SNP mapping, targeted sequence capture and sequencing 
 
Due to the consanguinity within the family, homozygosity mapping using 
Affymetrix 10K SNP arrays (Affymetrix, Santa Clara, CA, USA) was performed. 
All five family members (both parents, the affected boy, the affected girl and the 
unaffected boy) were genotyped and analysed using Allegro software 
(Gudbjartsson et al. 2005). Quality control and data conversion of the SNP array 
data was made with the software ALOHOMORA (Rüschendorf et al. 2005). All 
exons within regions of putative linkage (identified via UCSC and Ensembl) were 
then included on a sequence capture array (Roche Nimblegen Inc., Madison, WI). 
The DNA from the affected male was pooled with the DNA extracted from four 
irrelevant other individuals (from unrelated projects) and hybridised to the array. 
The subsequent DNA “library” was then sequenced by next generation 
sequencing on a GAII sequencer (Illumina Inc., San Diego, CA). Raw 76bp 
paired end fastq reads were aligned to the human reference sequence (hg19) 
using novoalign (www.novocraft.com), including the soft clipping, adapter 
trimming, and quality calibration options. Filtering for clonal reads, pileup 
generation and SNP calling were performed using in-house perl/C++ scripts. 
SNP calling used a Bayesian approach adapted to deal with the presence of 
multiple haplotypes in the pool. Insertion/deletion (indels) calls were based 
directly on the novoalign output and were filtered. Indels likely to be true events 
were called if found in at least three independent reads. 
 
6.3.4 Immunofluorescence 
 
Primary keratinocytes were isolated from skin biopsies for Western blotting and 
immunofluorescence staining was performed on frozen or paraffin-embedded 
tissue sections collected from skin and duodenal biopsies from the affected 
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siblings and control subjects. Immunofluorescence and Western blotting studies 
were performed using antibodies against ADAM17 (skin immunofluorescence: 
ab39161, Abcam Ltd; small intestine immunofluorescence: ab39163, Abcam Ltd; 
Western blotting: ab2051, Abcam Ltd), ADAM10 (AB19026, Millipore, Bedford, 
MA) and DSG1/2 (DG3.10, Zymed, Cambridge, UK). For ADAM17 staining, 
paraffin sections were de-waxed, antigen retrieved and blocked with 3% serum in 
PBS and avidin/biotin blocking solution (Vector Laboratories, Burlingame, CA). 
The sections were then incubated with rabbit anti-ADAM17 antibody in 1:150 
dilutions for 16 hours at 4°C. Sections were further incubated with biotinylated 
anti-rabbit IgG antibody for 1 hour and FITC-streptavidin conjugates for 30 
minutes. For DSG staining, frozen sections were fixed in 1:1 methanol:acetone 
incubated with the relevant antibody in 1:250 dilution for 16 hours at 4°C followed 
by incubation of anti-mouse or anti-rabbit IgG conjugated with FITC. Stained 
tissues were imaged using a Zeiss laser confocal microscopy 710 (Carl Zeiss, 
Welwyn Garden City, UK) and images were processed using Adobe Photoshop 
CS (Adobe Systems Inc, San Jose, CA). 
 
6.3.5 PBMC culture 
 
PBMCs were isolated and cultured at 37°C for 24 hours in 96-well plates (BD 
Biosciences) (2x105 cells/well), in the presence or absence of 0.1-1000 ng/ml 
LPS (InvivoGen, San Diego, CA), or 100 ng/ml phorbol 12-myristate 13-acetate 
(PMA; Sigma-Aldrich) plus 500 ng/ml ionomycin (Sigma-Aldrich), or in anti-CD3-
coated 96-well plates (BD Biosciences) with 1g/ml anti-CD28 antibody 
(eBioscience). In particular, in one first experiment PBMCs from the affected boy 
and three control subjects were cultured with 10-1000 ng/ml LPS or with anti-
CD3/anti-CD28 antibodies, and another time, in a separate experiment, PBMCs 
from the affected boy, the unaffected mother and three control subjects were 
cultured with 0.1-1000 ng/ml LPS or with anti-CD3/anti-CD28 antibodies or PMA 
plus ionomycin. Subsequently, TNF-, IL-1, IL-6 and IFN- concentrations were 
measured by ELISA in cell culture supernatants. 
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6.4 Results 
 
6.4.1  Genetic analyses 
 
Analysis of the SNP array data revealed putative linkage (maximum lod score of 
1.8) to three large stretches of SNP homozygosity, seen in DNA from both 
affected siblings, on chromosomes 2, 5, and 21 (Fig. 6.2A). After ruling out nine 
plausible candidate genes by using standard Sanger sequencing (data not 
shown), we included probes for all exons from these three regions of the genome 
on a capture array. A total of 1468 exons corresponding to 439 kb of DNA were 
captured in the affected boy and sequenced. After ruling out known SNPs 
(accessing dbSNP and 1000 Genome project via the Seattle SNP website url: 
http://pga.gs.washington.edu/), we identified 22 nonsynonymous single-
nucleotide variants in coding regions. In parallel, we assessed the sequence data 
for insertion-deletion variations and discovered a new deletion of 4 bp in exon 5 
of ADAM17 (c.603-606delCAGA) on chromosome 2 that segregated with the 
disease in this family (Fig. 6.2B, Fig. 6.3). The unaffected boy lacked this deletion. 
We were unable to find rare variants, predicted to result in loss of function, within 
ADAM17 in the dbSNP database or the 1000 Genomes database. Bioinformatic 
analysis predicted that the mutation would introduce a frameshift and a 
premature stop codon (p.Asp201GlufsX11) separated by 10 codons. Thus, the 
mutation predicts a severely truncated protein consisting of the signal peptide 
and pro-domain of ADAM17 and lacking the catalytic domain, disintegrin domain, 
transmembrane segment, and cytosolic tail (Fig. 6.4). Given the likely deleterious 
nature of the 4 bp deletion identified in ADAM17 and the role of ADAM17 in 
processing TNF-, this was likely to be the disease-associated mutation and the 
rest of the study focussed on ADAM17. 
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Figure 6.2. Genetic studies. (A) Due to the consanguinity within the family, 
homozygosity mapping using Affymetrix 10K SNP arrays was performed. All five 
family members (both parents, the affected boy, the affected girl and the 
unaffected boy) were genotyped and analysed using Allegro software Linkage 
analysis performed on SNP array data using Allegro revealed three regions of 
linkage on chromosomes 2, 5 and 21. (B) All exons within regions of putative 
linkage were then included on a sequence capture array. Sanger sequence 
traces showing a new homozygous deletion of 4 bp in exon 5 of ADAM17 (c.603-
606delCAGA) on chromosome 2 that segregated with the disease in this family. 
The parents are both heterozygous carriers and the unaffected boy is wild-type. 
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Figure 6.3. Family pedigree. The family pedigree shows the two affected 
siblings and the unaffected boy from a consanguineous marriage of first cousins; 
segregation of the c.603-606delCAGA ADAM17 mutation is also shown. Squares 
and circles represent male and female family members, respectively; double 
horizontal lines indicate consanguinity; solid symbols and open symbols indicate 
affected and unaffected family members, respectively; and the slash indicates 
the deceased affected girl. 
 
 
 
 
Figure 6.4. Predicted structure of wild-type and mutant ADAM17. Schematic 
illustrating the domain structure of wild-type ADAM17 protein (SP, signal peptide; 
Pro, pro-domain; catalytic domain; disintegrin domain; TM, transmembrane 
region; cytosolic tail) and the predicted structure of the p.Asp201GlufsX11 mutant 
protein if expressed. 
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6.4.2 ADAM17 expression studies in the affected boy’s skin and in the 
affected siblings’ duodenum 
 
Immunofluorescence of control skin using an ADAM17 antibody which reacts 
with the pro-domain revealed expression throughout the epidermis with a 
cytoplasmic distribution (Fig. 6.5A). However, in the skin from the affected boy 
there was a marked reduction of ADAM17 expression (Fig. 6.5B).  
  
Figure 6.5. Expression of ADAM17 in the skin. Immunofluorescence staining 
with an ADAM17 antibody (green) that reacts with an epitope in the active site of 
ADAM17 (consisting of a cysteine switch and furin cleavage sites) was 
performed in paraffin-embedded sections of skin biopsies from the affected boy 
and one control subject. (A) In control skin ADAM17 is expressed throughout the 
epidermis, with a cytoplasmic staining pattern, whereas (B) ADAM17 expression 
is clearly reduced in the affected boy’s skin. Control staining of the nuclei with 
4’,6-diamidino-2-phenylindole (DAPI; blue), without the addition of the ADAM17 
antibody, is shown for (C) a section of control skin and (D) the affected boy’s skin. 
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Histologic analysis and immunofluorescence for ADAM17 on duodenal biopsies 
from both affected siblings was performed. Compared with the normal findings in 
the control subject (Fig. 6.6A), in the affected girl there was evidence of a 
mononuclear cell infiltrate, villus blunting, and lengthening of crypts (Fig. 6.6B); 
although the findings were more variable, also in the duodenum of the affected 
boy there was evidence of a mononuclear cell infiltrate and villus blunting (Fig. 
6.6C). ADAM17 was expressed in the enterocytes of the small intestine in a 
control subject (Fig. 6.6D), but was absent in the small intestine of the affected 
girl (Fig. 6.6E) and the affected boy (Fig. 6.6F). 
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Figure 6.6 (see previous page). Expression of ADAM17 in the duodenal 
mucosa. (A-C) Haematoxylin and eosin staining of duodenal biopsies was 
performed in a control subject and in the two affected siblings. (D-I) 
Immunofluorescence staining with an ADAM17 antibody (green) that reacts with 
an epitope in the active site of ADAM17 (consisting of a cysteine switch and furin 
cleavage sites) was performed on duodenal biopsies from a control subject and 
the two affected siblings. (G-I) Control staining of the nuclei with 4’,6-diamidino-2-
phenylindole (DAPI; blue), without the addition of the ADAM17 antibody, is 
shown. (A-C) Scale bar = 250 m. (D-I) Scale bar = 20 m. 
 
Furthermore, Western blotting of both PBMCs and keratinocyte lysates obtained 
from the affected boy showed an absence of ADAM17 expression, in contrast 
with the findings in control subjects and the unaffected mother (Fig. 6.7A). Of 
note, PBMCs from the unaffected mother showed lower ADAM17 expression, 
which may reflect her being heterozygous carrier of the ADAM17 mutation, 
however it is not possible to exclude that it is the result of interindividual 
variability. The expression of ADAM10, whose substrates overlap with those of 
ADAM17, was similar in keratinocytes from the affected boy and from a control 
patient undergoing cosmetic surgery (Fig. 6.7B). 
 
Figure 6.7. ADAM17 and ADAM10 expression in keratinocytes. (A) Western 
blotting for ADAM17, with the use of an antibody that reacts with the C-terminal 
of ADAM17, on lysates of PBMCs from three control subjects (HC), from the 
affected boy (AB) and the unaffected mother (UM), and on lysates of primary 
human keratinocytes (hKs) from one HC and the AB. Blots were stripped and 
analysed for GAPDH as an internal loading control. (B) Western blotting for 
ADAM10 on lysates of primary hKs from one HC and the AB. Blots were stripped 
and analysed for -actin as an internal loading control. 
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6.4.3 Epidermal barrier and immune cell investigations on the affected 
boy’s skin 
 
ADAM17 functions as a sheddase with the ability to cleave and thereby release a 
multitude of different membrane-bound substrates, including desmogleins 
(DSGs), from the cell surface. Immunofluorescence analysis of skin sections and 
Western blotting of primary keratinocytes showed that expression of DSG (DSG1, 
DSG2, or both) is greater in the affected boy than in one control subject (Fig. 6.8). 
suggesting that DSG is retained on the plasma membrane in the control subject 
studied. 
 
 
Figure 6.8. DSG expression in the skin. Immunofluorescence staining for 
DSG1 and DSG2 (green) was performed on frozen skin sections obtained from 
(A) a control subject and (B) the affected boy. Nuclei were stained with propidium 
iodide (red). (C) Western blotting for DSG1 and DSG2 on protein lysates of 
primary human keratinocytes from one control subject (HC) and the affected boy 
(AB). Blots were stripped and analysed for -actin as an internal loading control. 
 
Further immunohistochemical characterisation of the affected boy showed an 
infiltrate of T cells (CD3+) around the skin follicles and in the epidermis. We 
observed CD4+ T cells in the perifollicular region and CD8+ T cells in the 
epidermis at the neck of the follicle (Fig. 6.9). There were some B cells (CD20+), 
natural killer cells (CD56+), or neutrophils (elastase+) present, and levels of 
dendritic cells (S100+) were normal (negative data not shown). 
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Figure 6.9. Expression of T cell markers in the skin of the affected boy. 
Immunohistochemistry revealed (A) anti-CD3-stained, (B) anti-CD4-stained and 
(C) anti-CD8-stained cells in the skin of the affected boy. Continuous arrows 
indicate the epidermis, dashed arrows indicate skin follicles. 
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6.4.4 Cytokine production by PBMCs 
 
ADAM17 converts membrane-bound TNF- into soluble TNF-. Bearing in mind 
the inflammatory aspect of the disease phenotype, cytokine production by 
PBMCs isolated from the affected boy, his unaffected mother and three control 
subjects was investigated (Fig. 6.10). Due to limited availability of blood samples 
from the affected patient and the unaffected mother, only a total of two cell 
stimulations could be performed, with the second one being more extensive, with 
additional conditions of culture. Due to the low number of replicates (n=1 or n=2) 
of stimulation performed on PBMCs from the affected boy and the unaffected 
mother, statistical analysis could not be done. For the conditions with more than 
one experimental replicate, the mean cytokine concentration in pg/ml  SEM is 
reported below, whereas in case a condition was tested only once, the cytokine 
concentration in pg/ml was reported. TNF- concentrations in the supernatants of 
PBMCs from the affected boy cultured with 0.1, 1, 10, 100 or 1000 ng/ml LPS 
were 168; 184; 399  128; 386  148; 405  119, respectively. TNF- 
concentrations in the supernatants of control PBMCs cultured with 0.1, 1, 10, 100 
or 1000 ng/ml LPS were 785  59; 956  72; 1128  86; 1381  85; 1465  92, 
respectively. TNF- concentrations in the supernatants of PBMCs from the 
unaffected mother cultured with 0.1, 1, 10, 100 or 1000 ng/ml LPS were 580; 
1256; 1452; 1693; 1843, respectively. TNF- concentrations in the supernatants 
of PBMCs from the affected boy, the unaffected mother and control subjects 
cultured with medium alone were 0 pg/ml. IL-1 concentrations in the 
supernatants of PBMCs from the affected boy cultured with 0.1, 1, 10, 100 or 
1000 ng/ml LPS were 1418; 2503; 4620  1433; 4788  1610; 4875  1298, 
respectively. IL-1 concentrations in the supernatants of control PBMCs cultured 
with 0.1, 1, 10, 100 or 1000 ng/ml LPS were 1213  262; 1436  334; 1599  
282; 2050  365; 2214  369, respectively. IL-1 concentrations in the 
supernatants of PBMCs from the unaffected mother cultured with 0.1, 1, 10, 100 
or 1000 ng/ml LPS were 2733; 3138; 3264; 3749; 3870, respectively. IL-1 
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concentration in the supernatants of PBMCs from the affected boy cultured with 
medium alone was 141  141 pg/ml. IL-1 concentrations in the supernatants of 
PBMCs from the unaffected mother and control subjects cultured with medium 
alone were 0 pg/ml. IL-6 concentrations in the supernatants of PBMCs from the 
affected boy cultured with 0.1, 1, 10, 100 or 1000 ng/ml LPS were 5556; 6390; 
9315  1219; 11440  864.0; 14270  1650, respectively. IL-6 concentrations in 
the supernatants of control PBMCs cultured with 0.1, 1, 10, 100 or 1000 ng/ml 
LPS were 2095  447; 3159  573; 2347  792; 3505  850; 4671 ± 1137, 
respectively. IL-6 concentrations in the supernatants of PBMCs from the 
unaffected mother cultured with 0.1, 1, 10, 100 or 1000 ng/ml LPS were 5711; 
7043; 9260; 9532; 10532, respectively. IL-6 concentrations in the supernatants of 
PBMCs from the affected boy cultured with medium alone were 2926  2926 
pg/ml. IL-6 concentrations in the supernatants of PBMCs from the unaffected 
mother and control subjects cultured with medium alone were 0 pg/ml.In 
summary, stimulation with LPS induced a strong and concentration-dependent 
increase in TNF- production in PMBCs from controls and from the unaffected 
mother, whereas the increase in TNF-production elicited by LPS in PBMCs 
from the affected boy was at least three-fold smaller. PBMCs from all samples 
showed similarly increased production of IL-1 and IL-6 after LPS stimulation 
(Fig. 6.10A).
 
TNF- concentrations in the supernatants of PBMCs from the affected boy, his 
unaffected mother and control subjects cultured with anti-CD3/CD28 antibodies 
were 1180  343, 10581 and 8809  911, respectively. IFN- concentrations in 
the supernatants of PBMCs from the affected boy, his unaffected mother and 
control subjects cultured with anti-CD3/CD28 antibodies were 9774  654, 12920 
and 7458  532, respectively. TNF- concentrations in the supernatants of 
PBMCs from the affected boy, his unaffected mother and control subjects 
cultured with PMA plus ionomycin were 639, 8695 and 5725  1055, respectively. 
IFN- concentrations in the supernatants of PBMCs from the affected boy, his 
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unaffected mother and control subjects cultured with PMA plus ionomycin were 
5320, 9293 and 5149  894, respectively. In summary, stimulation with anti-
CD3/CD28 antibodies evoked strong TNF- production in PMBCs from controls 
and from the unaffected mother, whereas the increase in TNF-production 
elicited by LPS in PBMCs from the affected boy was more than seven times 
smaller. PBMCs from all samples showed similarly high levels of IFN- 
production after stimulation with anti-CD3/CD28 antibodies (Fig. 6.10B). 
Shedding of transmembrane proteins including TNF- on immune cells has been 
shown to be stimulated by activators of protein kinase C, such as PMA (Peschon 
et al. 1998). In response to PMA and ionomycin, similarly high amounts of IFN- 
were secreted by PBMCs from all samples, whereas TNF- production by 
PBMCs was more tha eight times smaller in the affected boy than in the control 
subjects and the unaffected mother (Fig. 6.10C). 
 
 
  
296 
Figure 6.10 (see previous page). Cytokine production by PBMCs. Pro-
inflammatory cytokine production by PBMCs from the affected boy, his 
unaffected mother, and three control subjects (HC) was evaluated. (A) 
Production of TNF-, IL-1 and IL-6 by PBMCs cultured for 24 hours in medium 
alone or LPS at concentrations of 0.1 to 1000 ng/ml. (B) Production of TNF- 
and IFN- by PBMCs cultured for 24 hours with medium alone (Control) or in the 
presence of anti-CD3/CD28 antibodies. (C) Production of TNF- and IFN- by 
PBMCs cultured for 24 hours with medium alone (Control) or in the presence of 
PMA plus ionomycin. Cytokine levels were measured in cell culture supernatants 
by ELISA. A total of two cell stimulations were performed due to limited 
availability of blood samples from the affected patient and the unaffected mother. 
All conditions of culture were tested in duplicate. Data displayed here, expressed 
as pg/ml, are those of the second experiment, and are representative of data 
relative to the same condition of culture (medium alone, 10-1000 ng/ml LPS and 
anti-CD3/anti-CD28 antibodies) performed in the first experiment on PBMCs from 
the affected boy and HC. 
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6.5 Results summary 
 
In the current study, we found that: 
12. Compared to the unaffected mother and control subjects, ADAM17 
expression is down-regulated in the skin and keratinocytes from the affected 
boy, and in duodenal biopsy sections from the affected siblings. 
13. After LPS stimulation, PBMCs from the affected boy produced comparable 
amounts of IL-1 and IL-6, but substantially less soluble TNF- compared to 
the unaffected mother and control subjects. After stimulation with anti-
CD3/CD28 antibodies or PMA plus ionomycin, PBMCs from the affected boy 
produced comparable amounts of IFN-, but substantially less soluble TNF- 
compared to the unaffected mother and control subjects. 
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6.6 Discussion 
 
Our findings indicate that homozygous deletion in ADAM17 gene in humans is 
associated with a complex, neonatal-onset, multi-organ syndrome affecting 
mainly the intestine, the skin, and the cardiovascular system. In this condition, 
ADAM17 expression is down-regulated in the skin and in duodenal biopsy 
sections, and soluble TNF- release by PBMCs is substantially reduced 
compared to control subjects. This Section focuses on the interpretation of our 
findings in the context of the existing literature, on the limitations of our study, 
and on possible future studies to be performed on newly identified humans with 
genetic ADAM17 deficiency, in order to better understand the consequences of 
ADAM17 dysregulation, both at the systemic and the mucosal levels. 
 
ADAM17 homozygous mutations in humans and mice 
 
Inflammatory disorders of the skin and the intestine, including eczema, psoriasis 
and IBD have been linked to changes in barrier function and immune responses, 
by means of genetic and functional studies. Large case-control studies combined 
with GWAS have identified common genetic risk factors, with low penetrance, for 
a plethora of human disorders. Such studies have also identified numerous SNPs 
in some of the genes linked to the regulation of immunity and inflammation 
affecting epithelial tissues (Liu et al. 2008; Dubois et al. 2010). High-throughput 
sequence technology can be used to identify rare but penetrant disease-
associated mutations in affected members of families with Mendelian conditions 
(Ng et al. 2010; Rehman et al. 2010; Volpi et al. 2010; Kahrizi et al. 2011). 
 
We combined high-throughput sequence technology with SNP-homozygosity 
mapping and targeted sequence capture to investigate likely causative genes in 
a syndrome of neonatal-onset inflammatory skin and bowel disease in two 
affected siblings born from consanguineous parents, and we identified the first 
described human mutation in the ADAM17 gene. The mutation is predicted to 
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lead to a truncated protein that lacks all functional domains, including the 
catalytic domain required for the sheddase function of ADAM17. We suggest that 
the deletion mutation in ADAM17 present in the homozygous state in both 
affected siblings is a major contributor to their disease. The existence of the 
syndrome has been confirmed by the study by Bandsma et al. (Bandsma et al. 
2015), who reported the case of a child born from non consanguineous parents, 
who presented with severe diarrhoea, skin rash, and recurrent episodes of sepsis, 
eventually leading to her death at the age of 10 months. In this case, a different 
homozygous frameshift mutation in ADAM17, leading to a premature stop codon, 
has been identified. Also in this case the mutation has been predicted to lead to a 
truncated ADAM17 or to the absence of ADAM17 protein as a consequence of 
nonsense-mediated mRNA decay (Bandsma et al. 2015). 
 
ADAM17 is a transmembrane metalloproteinase that exerts an important 
influence on development and disease via its effects on the EGF receptor 
(EGFR) and the TNF- signalling pathways. In particular, ADAM17 converts 
transmembrane TNF- into soluble TNF-, but it can also cleave both TNFR1 
and TNFR2 (Bell et al. 2007). Moreover, a substantial proportion of substrates on 
which ADAM17 exerts its sheddase activity are molecules with important immune 
functions (Scheller et al. 2011). ADAM17 cleaves adhesion molecules, including 
intercellular adhesion molecule (ICAM)-1, vascular cell adhesion molecule 
(VCAM)-1, and L-selectin, thereby limiting the adhesion of immune cells to the 
endothelium, and it has been shown that leukocyte recruitment in the inflamed 
peritoneum is up-regulated in mice expressing non-cleavable L-selectin (Venturi 
et al. 2003). ADAM17 can cleave MHC class I-related chain A/B and B7-H6, 
which are ligands for receptors expressed on NK, NKT and cytotoxic T cells, 
thereby possibly contributing to the escape from immunosurveillance by cancer 
cells (Schlecker et al. 2014). Finally, IL-6 receptor (IL-6R) is another important 
substrate of ADAM17 sheddase activity (Boutet et al. 2009; Schumacher et al. 
2015). In particular, IL-6R is only expressed on hepatocytes and leukocytes, 
whereas the transmembrane protein gp130 is ubiquitously expressed. Upon 
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cleavage, soluble IL-6R can bind IL-6, and this complex may subsequently bind 
gp130 and promote intracellular signalling in cell types that otherwise would not 
respond to IL-6 (Rose-John 2012). This process is known as trans-signalling, and 
it is particularly important for the pleiotropic functions of IL-6. 
 
Mice with a homozygous mutation in the zinc-binding sequence of 
ADAM17/TACE (taceZn/Zn mice), which is essential for its metalloproteinase 
action, display a severely impaired survival rate. In particular, evaluation of the 
genetic composition of the mouse population between two-three weeks of age 
revealed that live mice with homozygous taceZn/Zn mutation are only 1.3% of 
total mice, as opposed to the expected Mendelian ratio of 25%, with the majority 
of homozygous taceZn/Zn mice dying between embryonic day 17.5 and the first 
day after birth (Peschon et al. 1998). All taceZn/Zn mutant fetuses at embryonic 
day 17.5 have open eyelids, resulting from a failure of eyelid fusion, and lack a 
conjunctival sac. The few taceZn/Zn mice which survive for several weeks show 
a 20-40% reduction in body weight compared to wild-type littermates, and display 
corneal inflammation, perturbed hair coats, and curly vibrissae (Peschon et al. 
1998). Histologic sections of taceZn/Zn skin show disorganised distribution and 
structures of hair follicles, and histologic analysis of taceZn/Zn mutant fetuses at 
embryonic day 17.5 shows delayed or impaired maturation in multiple organs. In 
particular, the proximal small intestinal epithelium displays blunted villi and a 
hypercellular, pseudostratified mucosal epithelium, with altered cell polarity 
(Peschon et al. 1998). Lethality in taceZn/Zn mutant mice can not be attributed to 
soluble TNF- deficiency, as mice lacking TNF- show a normal development 
(Pasparakis et al. 1996). The taceZn/Zn mutation is also lethal in TNFR-deficient 
mice, indicating that the survival impairment is not due to inappropriate signalling 
by uncleaved transmembrane TNF-. Indeed, this extensively abnormal 
phenotype has been attributed to the effects of TACE on a plethora of other 
molecules, including TGF- and EGF (Peschon et al. 1998). 
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The hair, skin and eye defects observed in mice with taceZn/Zn mutation are 
similar to those reported in mice lacking TGF-. In particular, ADAM17 cleaves 
transmembrane TGF- to soluble TGF-, which appears to be essential for hair 
follicle development and eyelid fusion in vivo (Luetteke et al. 1993; Mann et al. 
1993). The epithelial maturation defects observed in mice with taceZn/Zn 
mutation are similar to those of mice lacking EGFR (Miettinen et al. 1995), which 
is the obligate receptor for several ligands cleaved by ADAM17, including EGF, 
TGF- and amphiregulin (Scheller et al. 2011). In particular, EGFR-/- mice suffer 
from impaired development in several organs, including the skin, the lungs, and 
the gastrointestinal tract (Miettinen et al. 1995). 
 
Using exon-induced translational stop strategy, mice with a marked reduction, 
but not complete deficiency, of ADAM17 in all tissues (ADAM17ex/ex mice) have 
been developed (Chalaris et al. 2010). ADAM17ex/ex mice are viable, and have 
skin, hair and eye defects similar to those of TGF--deficient mice. Despite not 
showing overt histologic intestinal abnormalities, ADAM17ex/ex mice are more 
susceptible to DSS-induced colitis than wild-type mice (Chalaris et al. 2010). 
Mice with an N-ethyl-N-nitrosourea-induced mutation in ADAM17 (wavedX mice) 
have also been developed, and express predominantly immature ADAM17, with 
impaired sheddase activity. Intestinal histology of wavedX mice is normal, 
however, similarly to ADAM17ex/ex mice, they also have a higher susceptibility to 
DSS-induced colitis than wild-type mice (Brandl et al. 2010). 
 
Association of human ADAM17 mutations with a multi-organ syndrome 
 
When considering the affected siblings described in our study, it would appear 
that, differently from mice, in humans homozygous ADAM17 deficiency is 
compatible with survival. However, the affected girl in our study died at 12 years 
of age, and in the case reported by Bandsma et al. (Bandsma et al. 2015) the 
affected child, despite showing considerable similarities with the cases described 
in our study, died at the age of 10 months for respiratory insufficiency related to a 
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respiratory syncytial virus infection. This suggests that it is premature to draw any 
conclusion on the probability of long-term survival in this syndrome on the basis 
of the three cases described so far. 
 
Both the affected siblings in our study had diarrhoea from the second day of life, 
which later spontaneously resolved, and also in the study by Bandsma et al. 
(Bandsma et al. 2015) the affected child developed watery diarrhoea during the 
first week of life, which did not disappear after discontinuation of feeding. It has 
been suggested that, similarly to DSS-induced colitis in ADAM17ex/ex and 
wavedX mice, a trigger may have been necessary to induce diarrhoea in early 
childhood in the affected siblings described in our study (Brandl et al. 2012). 
However, diarrhoea in the homozygous ADAM17 mutant children studied started 
very early in life and, unlike for ADAM17 mutant mice, the triggering event is 
unclear. Furthermore, it needs to be noted that multiple reasons, unrelated to 
ADAM17 deficiency, exist for early-onset diarrhoea with resolution later in life, 
and that changes in gastrointestinal tract physiology and function during 
development, with particular regards to the composition of the intestinal 
microbiota, may account for or contribute to episodes of acute diarrhoea. 
Duodenal biopsies, collected from the affected boy and the affected girl at the 
age of six and three years, respectively, showed only mild inflammatory changes, 
and the presence of villous atrophy. In the study by Bandsma et al. (Bandsma et 
al. 2015), a duodenal biopsy of the affected child showed mild focal villous 
atrophy and crypt hyperplasia without intraepithelial lymphocytosis. These 
alterations are similar to those observed in the small intestine of mice with 
taceZn/Zn mutation (Peschon et al. 1998), and may be related at least in part to a 
maturation defect in the intestinal epithelium, however the cause of the intestinal 
problems in both affected siblings has not been satisfactorily resolved and 
requires more investigation. 
 
ADAM17 deficiency in humans has important immunologic consequences on the 
systemic immune response. PMA induces protein kinase C activation, which, in 
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turn, activates ADAM17 (Xu et al. 2010). Bandsma et al. (Bandsma et al. 2015) 
reported that both CD4+ and CD8+ peripheral blood T cells from the affected child 
showed normal activation following stimulation with PMA, phytohaemagglutinin, 
or staphylococcal enterotoxin B. It has been observed that TACE inhibition 
promotes IL-1 and IFN- production by PBMCs (Sharma et al. 2013). However, 
in our study, levels of LPS-induced production of IL-1 and levels of PMA- or 
anti-CD3/CD28-induced production of IFN- by PBMCs isolated from the affected 
boy at 17 years of age were comparable to those of the unaffected mother and 
control subjects. Interestingly, in the same experiments, levels of LPS-induced 
production of IL-6 by PBMCs from the affected boy were higher than those of 
control subjects. Conversely, levels of LPS-, PMA-, and anti-CD3/CD28-induced 
soluble TNF- produced by PBMCs isolated from the affected boy were 
substantially impaired compared to those of the unaffected mother and control 
subjects, and this is likely to be a consequence of reduced TACE activity due to 
ADAM17 mutation. Using intracellular staining and flow cytometry, Bandsma et al. 
(Bandsma et al. 2015) reported that peripheral blood T cells from the affected 
child in their study displayed up-regulated IFN- and down-regulated IL-2 and 
TNF-. It is difficult to explain their result on TNF- production, as ADAM17 is 
known to exert its TACE activity on transmembrane, rather than intracellular, 
TNF-. Other molecules with TACE activity, such as ADAM9, ADAM10, and 
ADAM19, may contribute to the residual production of soluble TNF- by PBMCs 
from humans with ADAM17 deficiency. Conditional knock-out mice lacking 
ADAM17 in myeloid cells are protected from TNF--mediated endotoxin shock 
(Horiuchi et al. 2007). On the other hand, the impaired production of soluble 
TNF- might have contributed to the increased susceptibility of the affected boy 
to opportunistic infections of the skin, such as otitis externa from S. aureus and 
paronychia from Candida.  
 
The affected boy in our study presented with a generalised pustular rash with 
flares of erythema and scaling. The skin of both affected siblings, in the first 
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years of life, was prone to infection with S. aureus. Also, in the study by 
Bandsma et al. (Bandsma et al. 2015) the affected child developed skin lesions, 
including pustular rash and erythema, and skin biopsies revealed parakeratosis, 
neutrophil infiltration, and spongiosis, with bacterial swabs of the skin being 
positive for S. aureus on multiple occasions. Keratinocytes from the affected boy 
in our study expressed ADAM10, which has substrates in common with ADAM17 
(Le Gall et al. 2009). The desmosomal cadherin DSG2, expressed in the less 
differentiated layers of the epidermis and hair follicle, has been shown to be a 
substrate of both ADAM17 and ADAM10 (Bech-Serra et al. 2006). The up-
regulation in DSG2 expression that we observed in skin and keratinocytes of the 
affected boy suggests that ADAM17-mediated regulation of DSG2 availability at 
intercellular junctions is important in the skin (Klessner et al. 2009). 
 
Finally, both the affected siblings in our study showed cardiac abnormalities. In 
particular, the affected girl died from fulminant Parvovirus B19-associated 
myocarditis, and the affected boy had left ventricular dilatation, with end diastolic 
dimension of 60 mm. Interestingly, in the study by Bandsma et al. (Bandsma et al. 
2015), the affected child developed systolic hypertension and had mild 
pulmonary valve stenosis and a small atrial septum defect. DSG2 is the 
predominant DSG expressed in cardiac myocytes, and DSG2 mutations are 
associated with arrhythmogenic and dilated cardiomyopathies (Syrris et al. 2007; 
Posch et al. 2008). The relationship between myocarditis and possible early-
onset arrhythmogenic cardiomyopathy is well recognised (Delmar et al. 2010), 
and impaired DSG2 regulation by ADAM17 may be responsible for the cardiac 
manifestations in the affected siblings. In addition, the lack of TNF- may have 
been, at least in part, responsible for the affected girl’s death, given the 
cardioprotective role of TNF- in acute myocarditis (Wada et al. 2001). 
 
Relevant similarities with the clinical features present in the humans with 
ADAM17 deficiency have been reported in a patient with inherited homozygous 
loss-of-function missense mutation in EGFR gene. In particular, this patient 
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showed dry skin and alopecia during his first year of life. Subsequently, pustules 
and papules were present, similar to those described among the side effects of 
EGFR inhibitors (Lacouture 2006), associated with dysregulated differentiation of 
keratinocytes. The patient died at 2.5 years of age due to extensive skin and 
chest infections and electrolyte imbalance (Campbell et al. 2014). 
 
Both our observations and the findings by Bandsma et al. (Bandsma et al. 2015) 
suggest that ADAM17 deficiency in humans is associated with down-regulated 
TNF- signalling. Interestingly, the affected boy in our study had been previously 
treated with the anti-TNF- agent adalimumab, and this did not induce any 
significant improvement, which would not be surprising given the impairment in 
TNF- production. It has been reported that almost 5% IBD patients treated with 
anti-TNF- agents develop psoriasiform skin lesions. These are characterised by 
infiltrates of IL-17A/IL-22-expressing Th17 cells and IFN--expressing Th1 cells, 
and show a high response rate to the anti-IL-12/IL-23 monoclonal antibody 
ustekinumab (Tillack et al. 2014). The mechanism proposed to explain the 
paradoxical skin inflammation induced by anti-TNF- agents involves the binding 
of the anti-TNF- Fc region to the FcRI of macrophages, and the subsequent 
activation and production of IL-23 (Niess et al. 2014). In genetic ADAM17 
deficiency in humans, it does not seem likely that the skin lesions, which 
represent one of the predominant clinical features in all three cases described so 
far, derive directly from the impairment in TNF- signalling. Nevertheless, the 
multiple effects of ADAM17 on the immune response may influence Th1 and 
Th17 cell development in specific tissues, including the skin.
 
Limitations of the study 
 
Both in our study and in that of Bandsma et al. (Bandsma et al. 2015), patients 
showed features compatible with functional ablation of ADAM17, however we 
have not formally proved that the predicted truncated version of ADAM17 is 
expressed in humans with genetic ADAM17 deficiency, and whether residual or 
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truncated forms of ADAM17 are non-functional. It needs to be noted that 
mutations at different sites on the ADAM17 gene produce specific alterations in 
ADAM17 protein. Therefore, comparing transgenic mice that express no 
ADAM17 with patients that may have some residual and potentially active protein 
may prove to be misleading and requires caution. Nevertheless, there are 
similarities between the phenotypes of taceZn/Zn mutant mice and humans with 
genetic ADAM17 deficiency. ADAM17ex/ex mutant mice, which have a marked 
reduction, but not a complete deficiency, of ADAM17 also present with skin and 
hair alterations (Chalaris et al. 2010). 
 
One of the main limitations in our study was the availability of a small number of 
samples to analyse, which made it difficult to draw definitive conclusions 
regarding the consequences of ADAM17 deletion. Unfortunately, the affected girl 
died before the start of our study, therefore it was not possible to perform the 
same investigations as in the affected boy, and it was also not possible to study 
matched control subjects due to the age of the affected boy. An example of the 
consequences of the limited number of samples and experiments is our 
observation that PBMCs from the unaffected mother showed down-regulated 
ADAM17 expression. This may reflect her being heterozygous carrier of the 
ADAM17 mutation, however it is not possible to exclude that this is the effect of 
interindividual variability, and it has to be noted that this is the result of a single 
experiment. Nevertheless, the production of soluble TNF- by PBMCs from the 
unaffected mother was comparable to control subjects. 
 
Future studies 
 
Unfortunately, due to the limited availability of samples from the affected boy and 
the unaffected relatives, we could only perform basic assays on cytokine release 
by PBMCs from the affected boy and the unaffected mother. In a future study on 
newly identified humans with genetic ADAM17 deficiency, it will be important to 
study the effects of ADAM17 mutation on other important substrates, including 
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EGF, TGF- amphiregulin, IL-6R and L-selectin. Furthermore, it will be 
interesting to characterise the type of immune response driving the onset of 
cutaneous lesions, with particular focus on Th1 and Th17 cells and cytokines. 
 
In parallel to impaired soluble TNF- release by immune cells, ADAM17 
deficiency could be associated to up-regulated transmembrane TNF- 
expression due to defective cleavage. Transmembrane TNF- accumulation, in 
turn, would have important consequences on intestinal inflammation (Mitoma et 
al. 2005). Despite being possible to assess the expression of the transmembrane 
form of TNF- by flow cytometry using a commercially available antibody specific 
for transmembrane TNF-, in the present study we could not perform this 
experiment due to the limited availability of samples. Hence, in a future study on 
newly identified humans with genetic ADAM17 deficiency, it will be important not 
only to confirm the down-regulation of intracellular TNF- reported by Bandsma 
et al. (Bandsma et al. 2015), but also to explore the expression of 
transmembrane TNF- on immune cells and the consequences on the systemic 
and mucosal immune response. 
 
Inactive Rhomboid (iRhom)1 and iRhom2 are catalytically inactive intracellular 
serine proteases expressed in the endoplasmic reticulum that have emerged as 
important upstream regulators of ADAM17 (Lemberg et al. 2007; McIlwain et al. 
2012). In particular, iRhom2, which is preferentially expressed in immune cells, 
promotes furin-mediated maturation and trafficking of ADAM17 to the cell 
membrane (Adrain et al. 2012). Moreover, iRhom2 has been shown to be the 
main regulator of ADAM17 in the skin (Brooke et al. 2014). Both iRhom2-/- mice, 
which display defective TNF- signalling, and iRhom1-/- mice do not show any 
developmental abnormalities (Issuree et al. 2013; Li et al. 2015). Interestingly, 
iRhom2-/- mice are protected from experimental arthritis, similarly to mice lacking 
ADAM17 in myeloid cells or TNF--deficient mice (Issuree et al. 2013). 
Conversely, iRhom1/2 double knock-out mice display a severely impaired 
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survival rate and multi-organ abnormalities which resemble those of ADAM17-/- 
and EGFR-/- mice (Li et al. 2015). On the other hand, it has been shown that 
deletions in the cytoplasmic domain of iRhom1 and iRhom2 enhance ADAM17 
activity in vitro in fibrosarcoma cells, thereby stimulating TNFR shedding (Maney 
et al. 2015). Furthermore, it has been reported that iRhom2 expression is up-
regulated by TNF- signalling (Adrain et al. 2012). In a future study on newly 
identified humans with genetic ADAM17 deficiency, it will be interesting to study 
whether there is any consequence on the expression of iRhom1 and iRhom2, 
such as a compensatory up-regulation, or a down-regulation consequent to 
impaired TNF- signalling. More generally, it would be particularly intriguing to 
investigate iRhom1 and iRhom2 expression in IBD inflamed mucosa, where 
ADAM17 activity has been reported to be up-regulated (Monteleone et al. 2012), 
and to be a possible factor contributing to the excessive production of soluble 
TNF-. 
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Chapter 7: General discussion and future directions 
 
In this Thesis, we investigated aspects of disease pathogenesis and 
responsiveness to treatment in chronic intestinal inflammation using human 
tissue and various model systems. Experiments performed using human 
intestinal tissue, although not formally validated and not allowing mechanistic 
evaluations, may represent an informative tool to study the mucosal immune 
response in IBD. 
 
Advances in the pathogenesis of human intestinal inflammation 
 
Our results on the role of IL-17 and IL-13 in CD intestinal fibrosis, and of IL-13 in 
IBD inflamed mucosa, overall, suggest a pro-fibrogenic action of IL-17A in CD 
intestinal fibrosis. Moreover, our observations point towards the absence of a role 
for IL-17E and IL-13 in CD intestinal fibrosis, and suggest that IL-13 does not 
play an important role in IBD intestinal inflammation. A substantial proportion of 
our data derives from descriptive, cross-sectional observations and experiments. 
When evaluating the relevance of a certain pathway in IBD, results which report 
the up-regulation or down-regulation of specific molecules in the intestinal 
mucosa of CD and UC patients have often been used as supportive evidence, in 
addition to data obtained in experimental models of intestinal inflammation. 
Nevertheless, the rationale underlying the first application of anti-TNF- agents in 
CD was based on the observation of up-regulated concentrations of TNF- in the 
intestinal mucosa, stool and serum of patients compared to control subjects 
(Kaser 2014). We also performed in vitro functional experiments on the role of IL-
17 and IL-13 in IBD. For this purpose, we used cells isolated from CD and UC 
patients instead of cell lines derived from CRC, and our results were in 
agreement with our descriptive observations, supporting the biologic plausibility 
of the pro-fibrogenic role of IL-17A in CD, the absence of effects of IL-17E in CD 
intestinal fibrosis, and the lack of involvement of IL-13 in UC inflammation. 
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Investigations on the pathogenesis of IBD have largely involved the use of animal 
models of intestinal inflammation. One of the main advantages of this approach 
is the possibility to perform mechanistic in vivo experiments, and to obtain direct 
information on the immunologic processes underlying the onset of intestinal 
lesions. Nevertheless, several murine models of colitis, including DSS-induced, 
oxazolone-induced and TNBS-induced colitis, differ considerably from IBD, as 
they are triggered by the administration of a single, specific chemical agent to 
animals with a wild-type genetic background. While disease mechanisms 
underlying several experimental models of colitis have been dissected, animal 
models have shown limited ability to predict the efficacy of novel molecules for 
the treatment of intestinal inflammation, and numerous biologic agents that were 
successful in improving murine colitis have not been effective when subsequently 
tested in clinical trials in IBD (MacDonald 2010; Chang et al. 2014).  
 
In addition to animal models, in vitro experiments, and observations using human 
tissue, the critical analysis of data from clinical trials – especially those with 
immunotherapies – is an important method to evaluate the relevance of a certain 
pathway or molecule in IBD (Auer et al. 2014; Kaser 2014). In particular, our 
observations on the absence of a role for IL-13 in the overall population of UC 
patients are in keeping with the results of the two phase IIa clinical trials with 
monoclonal antibodies against IL-13, anrukinzumab and tralokinumab, in active 
UC (Reinisch et al. 2015; Danese et al. 2015; Tilg et al. 2015). Treatment with 
anrukinzumab did not result in any significant change in faecal calprotectin at 
week 14 compared to baseline in UC, and at the highest dose an increase in this 
biomarker of intestinal inflammation has been observed, reflecting disease 
deterioration (Reinisch et al. 2015). Despite showing a significant effect in 
inducing clinical remission (18% in the tralokinumab group compared to 6% in 
the placebo group), tralokinumab has been ineffective in achieving the primary 
endpoint, which was defined as clinical response at week 8, in moderate-to-
severe UC (Danese et al. 2015). 
 
  
311 
Another indirect indication that intestinal inflammation in the overall population of 
UC patients is not driven by IL-13 is represented by the results of two 
randomised clinical trials on the effects of the nematode T. suis in active UC and 
CD, respectively (Summers et al. 2005; Sandborn et al. 2013a). The study 
performed in UC showed a significantly higher clinical efficacy of T. suis 
compared to placebo (Summers et al. 2005). Although the quality of these 
studies was not sufficient to draw any conclusion regarding the efficacy of T. suis 
in IBD (Garg et al. 2014), this treatment, which should by definition trigger a Th2 
mucosal immune response, was not associated with significantly more adverse 
events compared to placebo. 
 
The anti-IL-17A monoclonal antibody secukinumab has been ineffective in a 
clinical trial in active CD (Hueber et al. 2012). This is not in disagreement with 
our results on the involvement of IL-17A in CD intestinal fibrosis, since patients 
with strictures causing obstructive symptoms were excluded from the clinical trial 
with secukinumab (Hueber et al. 2012). While ours and other groups’ results 
suggest that IL-17A is indeed involved in CD intestinal fibrosis, they need to be 
validated with in situ analyses and on larger numbers of patients before this 
cytokine can be considered as a promising therapeutic target in fibrostenosing 
CD. 
 
Finally, we cannot exclude that intestinal inflammation in humans with ADAM17 
deficiency may be related to their genetic mutation. This would highlight the 
heterogeneity of the possible mechanisms underlying intestinal inflammation, 
which would therefore develop regardless of the impaired ability to produce 
soluble TNF-. Due to its TACE activity, ADAM17 is an attractive target for the 
treatment of chronic inflammatory diseases characterised by excessive TNF- 
production (Arribas et al. 2009; Saftig et al. 2011), including IBD, psoriasis and 
rheumatoid arthritis. However, ADAM17 has a multitude of different substrates, 
including molecules playing an important role in tissue development and 
maturation, epithelial barrier function, and immune response, and this is reflected 
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by the alterations affecting the intestine, eyes, skin and hair observed in mice 
with ADAM17 deficiency. Also humans with genetic ADAM17 deficiency develop 
lesions involving the intestine, the skin, and the cardiovascular system. These 
aspects need to be carefully taken into account when considering ADAM17 as a 
therapeutic target. Finally, the long-term survival rate in humans with ADAM17 
deficiency is currently unknown, and further studies are needed to establish 
whether short-term inhibition of the ADAM17 pathway has similar effects to those 
observed in homozygous ADAM17 mutations. 
 
Biomarker development in IBD 
 
In our study on the proteolytic degradation of anti-TNF- agents and its 
correlation with response to biologic treatment in IBD, we initially performed 
functional in vitro experiments that demonstrated the biologic plausibility of this 
mechanism in the context of IBD inflamed mucosa. Subsequently, we studied 
whether we could detect signs of proteolytic degradation in the mucosa and in 
the serum of IBD patients, and we observed that there was overall correlation 
between response to anti-TNF- therapy and serum levels of MMP-3-/MMP-12-
cleaved endogenous IgG and anti-hinge autoantibodies.
 
In addition to their significance towards gaining a better understanding of the 
immunologic mechanisms underlying intestinal lesions and responsiveness to 
treatment in IBD, our results are potentially relevant for disease biomarker 
development in this condition. In particular, as it is often the case when 
performing studies on human tissues, the most important feature emerging from 
our findings is the considerable degree of heterogeneity between different 
patients in IBD. Our findings on levels of IL-17A and IL-13 in IBD intestinal tissue 
show that there is a high degree of heterogeneity in mucosal cytokine expression 
between different patients. This is consistent with previous studies, which 
showed that IL-13 transcripts are not always detectable in samples from UC 
inflamed mucosa (Kawashima et al. 2011), and that IFN- and IL-17A expression 
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in IBD inflamed mucosa is variable across different patients (Kobayashi et al. 
2008). We observed that there is also a high level of heterogeneity in MMP 
mucosal expression profile in different IBD patients, and that among IBD patients 
there are substantial differences in serum levels of MMP-3-/MMP-12-cleaved 
endogenous IgG and anti-hinge autoantibodies. 
 
The high degree of immunologic heterogeneity present in IBD may have 
important diagnostic and therapeutic implications. Both IL-13 and IL-17A 
blockade have been ineffective in unselected groups of active CD and UC 
patients. The lack of efficacy of anti-IL-13 and anti-IL17A antibodies in IBD may 
not be due to the absence of involvement of these cytokines in the majority of 
patients, but rather to the fact that they may play a pro-inflammatory or pro-
fibrogenic role only in a specific subset of patients. Furthermore, even in the case 
that IL-17A may play a role in the majority of patients with fibrostenosing CD, it is 
conceivable that its neutralisation would be effective only in the early phase of 
stricture development. Hence, the development of a biomarker capable to predict 
the onset of intestinal fibrosis, which is currently not available (Rieder et al. 2014), 
would be important for patient stratification and consequent therapeutic 
management in CD.
 
A similar approach has been developed and successfully applied in asthma. 
Based on the molecular mechanisms and the main cytokines involved, asthmatic 
patients have stratified in different “endotypes”, and response to specific biologic 
treatments varies accordingly (Kau et al. 2014; Agusti et al. 2016). In particular, it 
has been shown that therapies targeting IL-4, IL-5 and IL-13 are highly effective 
in patients with “type 2 high” asthma (Fajt et al. 2015). Furthermore, treatment 
with the anti-IL-13 monoclonal antibody lebrikizumab in asthma is more effective 
when patients are stratified according to molecular biomarkers, such as serum 
levels of periostin (Corren et al. 2011; Durham et al. 2016; Izuhara et al. 2016).  
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It has been shown that the humanised anti-7 integrin monoclonal antibody 
etrolizumab, that selectively binds the heterodimeric 47 and E7 integrins, is 
significantly more effective than placebo in inducing clinical remission in 
moderate to severe active UC (Vermeire et al. 2014). In UC patients treated with 
etrolizumab, high colonic expression of granzyme A and E integrin is associated 
to significantly higher rates of clinical remission and mucosal healing (Tew et al. 
2016). Regarding anti-TNF- therapy, it has been shown that CD patients with 
higher levels of transmembrane TNF-+ cells in the colon respond better to 
adalimumab than patients with low numbers of transmembrane TNF-+ cells in 
the colonic mucosa (Atreya et al. 2014). Interestingly, a subgroup analysis 
revealed that, differently from placebo, secukinumab induced a significant 
decrease in faecal calprotectin in CD patients with a specific polymorphism 
(rs4263839) in the TNF-like ligand 1A (TL1A) gene, which plays a role in Th17 
differentiation (Hueber et al. 2012). Further clinical trials on IL-17A and IL-13 
blockade in CD and UC, designed using strategies of patient stratification based 
on data from ours and future immunological studies, may prove to be more 
successful than unselective blockade of these cytokines in IBD. 
 
Our results may contribute to clarifying the mechanisms underlying primary non-
response to TNF- neutralising agents, especially in severely active IBD patients 
who are likely to have a high mucosal proteolytic activity and therefore may 
benefit from a higher anti-TNF-a loading dose (Gibson et al. 2015). It has been 
reported in a pharmacokinetic study that UC patients have a faster clearance of 
the anti-IL-13 monoclonal antibody anrukinzumab compared to control subjects 
and patients with asthma (Hua et al. 2015). It will be interesting to investigate 
whether this derives from general metabolic differences, or whether proteolytic 
cleavage may influence half-life and effectiveness of monoclonal antibodies 
against IL-13 and IL-17A in IBD. Finally, our preliminary observations that serum 
levels of cleaved IgG and anti-hinge autoantibodies against cleaved IgG are 
particularly high in a subgroup of IBD patients who do not respond to anti-TNF- 
agents may form the basis for subsequent, prospective studies, with the aim to 
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identify accurate serum biomarkers of responsiveness to biologic therapy, and 
ultimately to develop effective strategies of patient stratification in IBD. 
 
In conclusion, we believe that results from ours and other studies underline the 
complexity and the high degree of disease heterogeneity in human intestinal 
inflammation. Future studies should aim to achieve a better definition of the 
different immunologic components involved in individual IBD patients, which is 
necessary in order to develop a pathway-based approach to the treatment of IBD 
(Bamias et al. 2016). This will involve the development of reliable biomarkers and 
predictors of disease progression, and the formulation of stratification strategies 
and treatment algorithms that will form the basis for personalised, precision 
medicine in IBD. 
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